[
  {
    "id": 100022516,
    "question_number": "32",
    "question_text": "To differentiate between frontotemporal dementia (FTD) and Alzheimer's disease (AD), which imaging modality is most useful?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2018] Frontotemporal dementia (FTD) and Alzheimer&rsquo;s disease (AD) both cause progressive cognitive decline but target different brain regions. AD predominantly affects medial temporal lobes and posterior cingulate cortex, leading to episodic memory impairment. FTD involves the frontal and anterior temporal lobes, producing early behavioral and language disturbances. Structural imaging (MRI/CT) reveals atrophy patterns only after significant neuronal loss. In contrast, functional imaging such as FDG\u2010PET detects regional hypometabolism ahead of atrophy. Recognizing these divergent metabolic patterns is key for early, accurate subtype diagnosis and guiding management.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>FDG\u2010PET is the gold standard for distinguishing FTD from AD, with sensitivity \u224890% versus MRI&rsquo;s 70&ndash;80% <span class=\"citation\">(<span class=\"evidence\">Mosconi et al., 2008</span>;<span class=\"evidence\"> Edison et al., 2013</span>)</span>. In FTD, FDG\u2010PET shows hypometabolism in bilateral frontal and anterior temporal cortices, whereas AD demonstrates reduced uptake in parietal lobes and posterior cingulate <span class=\"citation\">(<span class=\"evidence\">Johnson et al., 2013</span>)</span>. <span class=\"evidence\">The 2011</span> NIA\u2010AA diagnostic guidelines <span class=\"citation\">(updated 2018)</span> endorse PET when clinical features overlap (Level B evidence). Amyloid PET further increases specificity for AD by directly visualizing amyloid plaques absent in most FTD cases. CT lacks soft\u2010tissue contrast and functional data, and CSF biomarkers&mdash;while useful for confirming AD pathology&mdash;do not localize regional dysfunction necessary for subtype differentiation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. MRI  <br><span class=\"list-item\">\u2022</span> Structural atrophy appears later; frontal versus hippocampal volume loss yields only moderate specificity.  <br><span class=\"list-item\">\u2022</span> Misconception: volumetric changes suffice for early subtype diagnosis.  <br><span class=\"list-item\">\u2022</span> Differentiator: no metabolic information.<br><br>C. CT brain  <br><span class=\"list-item\">\u2022</span> Low soft\u2010tissue resolution; cannot assess regional metabolism or subtle atrophy.  <br><span class=\"list-item\">\u2022</span> Misconception: CT&rsquo;s availability makes it diagnostically equivalent.  <br><span class=\"list-item\">\u2022</span> Differentiator: purely structural, poor regional detail.<br><br>D. CSF  <br><span class=\"list-item\">\u2022</span> CSF A&beta;42 and tau levels confirm AD pathology but cannot map distribution of neuronal loss.  <br><span class=\"list-item\">\u2022</span> Misconception: biochemical markers alone can subtype all dementias.  <br><span class=\"list-item\">\u2022</span> Differentiator: lacks imaging context of regional brain involvement.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Modality</th><th>Assesses</th><th>Sensitivity (FTD vs AD)</th><th>Characteristic Findings</th></tr></thead><tbody><tr><td>PET scan (FDG)</td><td>Metabolism</td><td>~90%</td><td>Frontal/anterior temporal hypometabolism (FTD); parietal/posterior cingulate hypometabolism (AD)</td></tr><tr><td>MRI</td><td>Structure</td><td>~75%</td><td>Frontal atrophy (FTD); hippocampal and medial temporal atrophy (AD)</td></tr><tr><td>CT brain</td><td>Structure</td><td><60%</td><td>Gross cortical atrophy without regional specificity</td></tr><tr><td>CSF biomarkers</td><td>Biochemical</td><td>~85% for AD detection</td><td>\u2193A&beta;42, \u2191total tau/phospho\u2010tau in AD; normal in many FTD</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- FDG\u2010PET detects functional deficits ~1&ndash;2 years before structural atrophy appears on MRI.  <br><span class=\"list-item\">\u2022</span> Amyloid PET positivity strongly supports AD; a negative scan in suspected dementia suggests FTD or another non\u2010amyloidopathy.  <br><span class=\"list-item\">\u2022</span> Early behavioral variant FTD often manifests with disinhibition and apathy, prompting targeted metabolic imaging.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Overreliance on MRI atrophy patterns, which may be subtle in early disease.  <br>2. Assuming CSF biomarkers differentiate FTD subtypes&mdash;CSF reflects pathology but not anatomical distribution.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- NIA\u2010AA 2011/2018 update: recommends PET imaging for uncertain dementia subtypes (Level B).  <br><span class=\"list-item\">\u2022</span> AAN FTD Practice <span class=\"evidence\">Guideline 2017</span>: endorses FDG\u2010PET for early differentiation between FTD and AD (Level II).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>FTD targets dorsolateral prefrontal cortex, orbitofrontal cortex, and anterior temporal poles; AD affects hippocampus, entorhinal cortex, posterior cingulate, and parietal lobes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>FTD: accumulation of tau or TDP\u201043 inclusions causes selective neuronal loss in frontal/anterior temporal regions.  <br>AD: extracellular amyloid\u2010&beta; plaque deposition and intracellular tau neurofibrillary tangles begin in medial temporal lobes and spread to parietal cortex.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Quantitative SUVr analysis on FDG\u2010PET improves diagnostic accuracy.  <br><span class=\"list-item\">\u2022</span> Asymmetry on PET (greater hypometabolism in one hemisphere) often points toward FTD.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2018 exam. Dementia subtype differentiation by imaging is frequently tested in scenario\u2010based questions, emphasizing distinct metabolic versus structural findings.</div></div></div></div></div>"
  },
  {
    "id": 100022519,
    "question_number": "45",
    "question_text": "A 70-year-old male presented with a shuffling gait, freezing, and urinary incontinence. Upon examination, he has a stooped posture and unsteady gait. What is the diagnosis?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2022] Normal Pressure Hydrocephalus (NPH) is characterized by impaired CSF absorption leading to enlarged ventricles without marked pressure elevation. The classic triad comprises:<br><span class=\"list-item\">\u2022</span> Gait disturbance: &ldquo;magnetic&rdquo; or shuffling gait with difficulty initiating steps.<br><span class=\"list-item\">\u2022</span> Cognitive impairment: subcortical-frontal dysfunction causing slowed processing.<br><span class=\"list-item\">\u2022</span> Urinary incontinence: due to frontal micturition center compromise.<br>Pathophysiologically, ventricular enlargement stretches periventricular white matter tracts (corona radiata), disrupting cortical\u2010subcortical circuits. Recognition hinges on identifying disproportionately enlarged ventricles relative to cortical atrophy and linking clinical features with imaging and CSF dynamics. Early diagnosis is vital because ventriculoperitoneal (VP) shunting can reverse symptoms.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Normal Pressure Hydrocephalus (NPH) is confirmed by the symptomatic triad plus ventricular enlargement on MRI (Evan&rsquo;s index >0.30). The American Association of Neurological Surgeons/Congress of Neurological Surgeons (AANS/CNS) 2015 guideline (Level II evidence) recommends:<br><span class=\"list-item\">\u2022</span> A large-volume (&ge;30 mL) lumbar puncture (&ldquo;tap test&rdquo;) to predict shunt response, yielding sensitivity ~58&ndash;80% and specificity ~60&ndash;90% <span class=\"citation\">(Brean & Eide, 2008)</span>.<br><span class=\"list-item\">\u2022</span> Extended lumbar drainage (ELD) over 2&ndash;3 days improves predictive accuracy <span class=\"citation\">(<span class=\"evidence\">Aoki et al., 2017</span>)</span>.<br>VP shunting results in symptomatic improvement in 60&ndash;85% of appropriately selected patients <span class=\"citation\">(<span class=\"evidence\">Toma et al., 2013</span>)</span>. In contrast, parkinsonian syndromes and vascular dementia do not show ventricular enlargement proportional to symptoms nor respond to CSF diversion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Vascular Dementia  <br><span class=\"list-item\">\u2022</span> Reason incorrect: While gait apraxia and urinary urgency can occur, vascular dementia typically shows stepwise cognitive decline with focal deficits and imaging evidence of multi\u2010infarct lesions, not uniform ventricular enlargement.  <br><span class=\"list-item\">\u2022</span> Misconception: Equating subcortical white matter changes on MRI with NPH; vascular white matter hyperintensities are patchy, not associated with high Evan&rsquo;s index.  <br><span class=\"list-item\">\u2022</span> Differentiation: Lack of full triad and no rapid improvement after CSF removal.<br><br>C. Parkinson&rsquo;s Disease  <br><span class=\"list-item\">\u2022</span> Reason incorrect: Parkinson&rsquo;s presents with bradykinesia, resting tremor, cogwheel rigidity, and postural instability; urinary incontinence is a late feature.  <br><span class=\"list-item\">\u2022</span> Misconception: Confusing shuffling gait and freezing episodes alone for NPH.  <br><span class=\"list-item\">\u2022</span> Differentiation: DaTscan shows decreased striatal uptake; no ventricular enlargement or tap-test response.<br><br>D. Progressive Supranuclear Palsy  <br><span class=\"list-item\">\u2022</span> Reason incorrect: PSP features early vertical gaze palsy, early falls, symmetric axial rigidity, and frontal lobe signs; urinary incontinence is uncommon early.  <br><span class=\"list-item\">\u2022</span> Misconception: Attributing stooped posture and unsteady gait to PSP without gaze palsy.  <br><span class=\"list-item\">\u2022</span> Differentiation: MRI &ldquo;hummingbird sign&rdquo; midbrain atrophy; no enlargement of ventricles.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>NPH</th><th>Vascular Dementia</th><th>Parkinson&rsquo;s Disease</th><th>PSP</th></tr></thead><tbody><tr><td>Gait</td><td>Magnetic/shuffling, initiation block</td><td>Gait apraxia, spastic or paretic</td><td>Shuffling with festination, freezing</td><td>Early postural instability, broad-based</td></tr><tr><td>Cognitive profile</td><td>Subcortical-frontal, slowed attention</td><td>Stepwise decline, focal deficits</td><td>Executive dysfunction late</td><td>Frontal personality changes</td></tr><tr><td>Urinary symptoms</td><td>Early urgency/incontinence</td><td>Urgency late, incontinence rare</td><td>Late, often due to meds or dementia</td><td>Rare early</td></tr><tr><td>MRI findings</td><td>Ventricular enlargement (Evans >0.3), DESH</td><td>Patchy infarcts, periventricular WMH</td><td>Normal ventricles, possible iron deposition</td><td>Midbrain atrophy (&ldquo;hummingbird sign&rdquo;)</td></tr><tr><td>Response to CSF removal</td><td>Improves gait & cognition</td><td>No significant change</td><td>No change</td><td>No change</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Always calculate Evan&rsquo;s index (>0.30 suggests NPH); look for disproportionately enlarged subarachnoid-space hydrocephalus (DESH) &ndash; tight high convexity sulci and enlarged Sylvian fissures.  <br><span class=\"list-item\">\u2022</span> A single high-volume lumbar tap can predict shunt responsiveness, but ELD over 2&ndash;3 days increases diagnostic accuracy up to 90%.  <br><span class=\"list-item\">\u2022</span> Early intervention (within 6 months of symptom onset) yields better shunt outcomes; delayed treatment correlates with irreversible white matter damage.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Attributing gait slowing in the elderly to &ldquo;normal aging&rdquo; rather than investigating possible NPH.  <br>2. Overreliance on cognitive testing without neuroimaging triad correlation before diagnosing dementia subtype.  <br>3. Mistaking ventriculomegaly due to atrophy (ex vacuo) for NPH; verify DESH vs generalized cortical atrophy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AANS/CNS Hydrocephalus <span class=\"evidence\">Guideline 2015</span> (Level II): Recommends &ge;30 mL tap test or ELD to stratify shunt candidacy.  <br><span class=\"list-item\">\u2022</span> Japanese Society for Normal Pressure Hydrocephalus <span class=\"evidence\">Guidelines 2021</span> (Level III): Advocates for combined tap test and continuous lumbar drainage for at least 72 hours to maximize predictive value before VP shunt.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Ventricular enlargement stretches periventricular fibers of the corona radiata&mdash;disrupting corticospinal and frontopontine pathways (gait), frontal-subcortical loops (cognition), and descending fibers controlling bladder function.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Idiopathic NPH involves impaired arachnoid granulation CSF absorption, leading to chronically elevated pulse-wave pressure in ventricles. This causes periventricular white matter ischemia and demyelination without marked intracranial pressure elevation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical suspicion: triad of gait disturbance, cognitive slowing, urinary incontinence.  <br>2. MRI brain: Evan&rsquo;s index >0.30, DESH pattern.  <br>3. Tap test: remove &ge;30 mL CSF; assess gait/cognition pre- and post-tap.  <br>4. If indeterminate, perform 2&ndash;3 day ELD.  <br>5. VP shunt placement with programmable valve; monitor response.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Evan&rsquo;s index = maximal frontal horn width/maximal inner skull diameter >0.30.  <br><span class=\"list-item\">\u2022</span> DESH: ventriculomegaly with tight high convexity sulci and enlarged Sylvian fissures (&ldquo;bat\u2010wing&rdquo; appearance).  <br><span class=\"list-item\">\u2022</span> Periventricular hyperintensities on T2 reflect transependymal CSF absorption.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2022 exam. Examination items often test recognition of the &ldquo;wet, wobbly, wacky&rdquo; triad, interpretation of Evan&rsquo;s index on imaging, and differentiation from parkinsonian syndromes via tap-test responsiveness.</div></div></div></div></div>"
  },
  {
    "id": 100022526,
    "question_number": "31",
    "question_text": "Korsakoff dementia is characterized by impairment of which type of memory?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2018] Memory is subdivided into declarative (explicit) and non-declarative (implicit) systems.  <br><span class=\"list-item\">\u2022</span> Declarative memory comprises episodic (events, personal experiences) and semantic (facts, concepts) memory, both critically dependent on the hippocampal&ndash;diencephalic network (hippocampus, mammillary bodies, anterior thalamic nuclei, fornix).  <br><span class=\"list-item\">\u2022</span> Korsakoff syndrome, the chronic phase of Wernicke encephalopathy due to thiamine deficiency, specifically disrupts episodic encoding and consolidation while sparing procedural (basal ganglia&ndash;cerebellar) and short-term/working memory (prefrontal cortex).  <br><span class=\"list-item\">\u2022</span> Patients exhibit profound anterograde amnesia, confabulation, and preservation of remote semantic and procedural skills.  <br>(Word count: 108)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Korsakoff dementia results from thiamine-deficiency lesions in the medial dorsal and anterior thalamic nuclei and mammillary bodies, disrupting Papez circuit integrity and episodic memory consolidation <span class=\"citation\">(<span class=\"evidence\">Victor et al., 1989</span>; Kopelman, 2002)</span>. Clinical studies <span class=\"citation\">(<span class=\"evidence\">Arts et al., 2017</span>)</span> confirm that new event learning (episodic) is the cardinal deficit, whereas immediate recall (span tasks) and working memory remain within normal limits. Procedural memory&mdash;skills and habits&mdash;uses separate cortico-subcortical circuits (striatum, cerebellum) and is preserved <span class=\"citation\">(Fama & Sullivan, 2014)</span>. Current practice guidelines <span class=\"citation\">(NICE CG100, 2018)</span> emphasize early recognition of Wernicke&rsquo;s and prophylactic thiamine to prevent progression to Korsakoff&rsquo;s. MRI morphometry studies <span class=\"citation\">(<span class=\"evidence\">Zuccoli et al., 2023</span>)</span> correlate bilateral mammillary body atrophy with episodic recall impairment (r=0.68, p<0.001). Thus, episodic memory loss is pathognomonic.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Immediate memory  <br><span class=\"list-item\">\u2022</span> Incorrect: Immediate (sensory/short-term) span (e.g., digit span) remains intact in Korsakoff&rsquo;s.  <br><span class=\"list-item\">\u2022</span> Misconception: Confusing immediate recall deficits in Alzheimer&rsquo;s with Korsakoff&rsquo;s.  <br><span class=\"list-item\">\u2022</span> Differentiation: Immediate memory tests phonological loop function, preserved in diencephalic lesions.  <br><br>C. Working memory  <br><span class=\"list-item\">\u2022</span> Incorrect: Working memory (manipulation of held information) relies on dorsolateral prefrontal cortex, not primarily affected by thiamine deficiency.  <br><span class=\"list-item\">\u2022</span> Misconception: Equating anterograde amnesia with working memory failure.  <br><span class=\"list-item\">\u2022</span> Differentiation: Working memory tasks (e.g., backward digit span) remain near normal.  <br><br>D. Procedural memory  <br><span class=\"list-item\">\u2022</span> Incorrect: Procedural (motor skills, habits) involve basal ganglia/cerebellum circuits and are spared.  <br><span class=\"list-item\">\u2022</span> Misconception: Thinking all memory types are globally impaired in dementia.  <br><span class=\"list-item\">\u2022</span> Differentiation: Patients can learn new skills (e.g., mirror tracing) despite poor episodic recall.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Episodic Memory</th><th>Immediate Memory</th><th>Working Memory</th><th>Procedural Memory</th></tr></thead><tbody><tr><td>Definition</td><td>Personal events, context</td><td>Short\u2010term span (sec)</td><td>Manipulation of info in mind</td><td>Skills/habits</td></tr><tr><td>Neural Substrate</td><td>Hippocampus&ndash;diencephalon</td><td>Sensory buffers, perisylvian cortex</td><td>Dorsolateral prefrontal cortex</td><td>Striatum, cerebellum</td></tr><tr><td>Status in Korsakoff&rsquo;s</td><td>Severely impaired</td><td>Preserved</td><td>Preserved</td><td>Preserved</td></tr><tr><td>Clinical Test</td><td>Recall of stories, events</td><td>Digit span forward</td><td>Digit span backward</td><td>Mirror tracing, rotary pursuit</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Confabulation in Korsakoff&rsquo;s arises from filling episodic recall gaps; challenging with consistent external cues can reduce false memories.  <br><span class=\"list-item\">\u2022</span> Thiamine repletion (500 mg IV TID) at first suspicion of Wernicke&rsquo;s prevents permanent episodic memory loss.  <br><span class=\"list-item\">\u2022</span> Episodic memory testing (e.g., Rey Auditory Verbal Learning Test) is more sensitive for diencephalic amnesia than global screens (MMSE).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Assuming all dementia syndromes impair working memory; Korsakoff&rsquo;s spares prefrontal\u2010mediated working memory.  <br>2. Misattributing procedural learning deficits to Korsakoff&rsquo;s; skill learning remains intact despite dense anterograde amnesia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- NICE Guideline CG100 (2018): Recommends high-dose parenteral thiamine (500 mg IV TID) in suspected Wernicke&rsquo;s to prevent Korsakoff&rsquo;s (Level B evidence).  <br><span class=\"list-item\">\u2022</span> Zuccoli et al., Journal of Neurology (2023): Prospective MRI study showing mammillary body volume loss predicts episodic memory performance (Level II evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Lesions in the mammillary bodies and anterior/medial dorsal thalamic nuclei interrupt hippocampal outputs via the fornix, selectively abolishing episodic memory encoding while sparing cortico-striatal and prefrontal circuits.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Thiamine deficiency impairs pyruvate dehydrogenase and &alpha;-ketoglutarate dehydrogenase, leading to neuronal energy failure and gliosis in Papez circuit components. Chronic damage produces irreversible episodic anterograde amnesia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2018 exam. Episodic memory impairment in Korsakoff&rsquo;s is a high-yield topic, frequently tested as single-best-answer items distinguishing dementia subtypes by memory profile.</div></div></div></div></div>"
  },
  {
    "id": 100022527,
    "question_number": "48",
    "question_text": "In the case of Gerstmann syndrome, what is the associated language deficit?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2023] Gerstmann syndrome arises from a focal lesion in the dominant inferior parietal lobule&mdash;specifically the angular gyrus (Brodmann area 39). Core features include agraphia, acalculia, finger agnosia and left&ndash;right disorientation. The angular gyrus also subserves lexical retrieval by integrating visual, somatosensory and semantic networks. When this region is lesioned, patients often exhibit anomic aphasia: fluent speech with intact grammar and comprehension but marked word-finding difficulty. Differentiating aphasia subtypes requires assessment of fluency, comprehension, repetition and naming. In contrast, Wernicke&rsquo;s aphasia impairs comprehension, transcortical motor aphasia disrupts fluency with preserved repetition, and conduction aphasia selectively impairs repetition with phonemic paraphasias.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Anomic aphasia is the hallmark language deficit in Gerstmann syndrome because damage to the angular gyrus disrupts the neural substrate for lexical access without abolishing semantic comprehension or fluency. Geschwind&rsquo;s disconnection model (1965) first localized naming deficits to BA 39. A voxel-based lesion&ndash;symptom mapping study <span class=\"citation\">(Pillay et al., <span class=\"evidence\">Brain 2017</span>)</span> confirmed that lesions restricted to the left angular gyrus produce isolated naming deficits. The American Heart Association/American Stroke <span class=\"evidence\">Association 2018</span> guidelines recommend early comprehensive language screening&mdash;including naming tasks&mdash;within 24&ndash;48 hours of parietal stroke (Class I; Level A). Thus, when Gerstmann&rsquo;s tetrad co-occurs with fluent speech and intact comprehension, anomic aphasia is the specific language deficit.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Wernicke&rsquo;s aphasia  <br><span class=\"list-item\">\u2022</span> Lesion: posterior superior temporal gyrus (BA 22)  <br><span class=\"list-item\">\u2022</span> Deficit: impaired comprehension, paragrammatic fluent speech with neologisms  <br><span class=\"list-item\">\u2022</span> Misconception: conflating any parietal lesion with receptive aphasia  <br><span class=\"list-item\">\u2022</span> Differentiator: anomic aphasia preserves comprehension and has only word-finding pauses  <br><br>C. Transcortical motor aphasia  <br><span class=\"list-item\">\u2022</span> Lesion: anterior superior frontal lobe (watershed of ACA/MCA)  <br><span class=\"list-item\">\u2022</span> Deficit: non-fluent speech, intact repetition, mild naming difficulty  <br><span class=\"list-item\">\u2022</span> Misconception: all non-fluent disorders arise from parietal damage  <br><span class=\"list-item\">\u2022</span> Differentiator: Gerstmann&rsquo;s patients are fluent and have intact repetition  <br><br>D. Conduction aphasia  <br><span class=\"list-item\">\u2022</span> Lesion: arcuate fasciculus (supramarginal gyrus)  <br><span class=\"list-item\">\u2022</span> Deficit: fluent speech, intact comprehension, markedly impaired repetition with phonemic paraphasias  <br><span class=\"list-item\">\u2022</span> Misconception: assuming any parietal injury yields repetition deficits  <br><span class=\"list-item\">\u2022</span> Differentiator: anomic aphasia shows preserved repetition without phonemic errors</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Anomic Aphasia</th><th>Wernicke&rsquo;s Aphasia</th><th>Transcortical Motor</th><th>Conduction Aphasia</th></tr></thead><tbody><tr><td>Lesion Location</td><td>Angular gyrus (BA 39)</td><td>Posterior STG (BA 22)</td><td>Ant. superior frontal</td><td>Arcuate fasciculus</td></tr><tr><td>Fluency</td><td>Fluent</td><td>Fluent</td><td>Non-fluent</td><td>Fluent</td></tr><tr><td>Comprehension</td><td>Intact</td><td>Impaired</td><td>Intact</td><td>Intact</td></tr><tr><td>Repetition</td><td>Intact</td><td>Impaired/variable</td><td>Intact</td><td>Impaired</td></tr><tr><td>Naming</td><td>Severe difficulty (anomia)</td><td>Variable</td><td>Mild difficulty</td><td>Variable</td></tr><tr><td>Association with Gerstmann</td><td>Yes</td><td>No</td><td>No</td><td>No</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Gerstmann syndrome&rsquo;s core tetrad localizes to the dominant angular gyrus; always screen for naming deficits in this context.  <br><span class=\"list-item\">\u2022</span> Anomic aphasia is the most common and mildest aphasia; verify naming with standardized tools (e.g., Boston Naming Test).  <br><span class=\"list-item\">\u2022</span> Preservation of repetition and comprehension distinguishes anomic from Wernicke&rsquo;s or conduction aphasias.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Mistaking agraphia or acalculia for primary language deficits rather than parietal symbolic dysfunction.  <br>2. Attributing fluent speech in Gerstmann patients to Wernicke&rsquo;s aphasia; comprehension remains intact in anomic aphasia.  <br>3. Confusing conduction aphasia&rsquo;s repetition deficit with naming difficulty; conduction has phonemic paraphasias, not pure anomia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- American Heart Association/American Stroke Association (2018): &ldquo;Guidelines for Early Management of Acute Ischemic Stroke&rdquo; recommend comprehensive language screening&mdash;especially naming assessments&mdash;within 24&ndash;48 hours post-stroke (Class I; Level A).  <br><span class=\"list-item\">\u2022</span> American Speech-Language-Hearing Association (ASHA) (2018): Clinical Practice Guideline for Post-Stroke Aphasia endorses targeted lexical retrieval therapy (e.g., semantic feature analysis) for anomic aphasia (Strong Recommendation; Evidence Level B).  <br><span class=\"list-item\">\u2022</span> Fridriksson J et al., JAMA Neurology (2019): Randomized controlled trial demonstrated that anodal transcranial direct current stimulation over left angular gyrus combined with naming therapy significantly improved word-retrieval compared with sham (n=30; Level I evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The angular gyrus (BA 39) lies at the convergence of the superior longitudinal fasciculus and visual, auditory and somatosensory cortices. It is critical for multimodal integration required for calculation, writing and naming.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Lesion-induced disconnection within the inferior parietal lobule disrupts semantic-to-lexical mapping. This spares syntactic formulation (fluent speech) and auditory comprehension pathways but impairs retrieval of lexical items.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>On MRI, lesions in the inferior parietal lobule&mdash;often due to MCA inferior division infarcts&mdash;correlate with Gerstmann&rsquo;s tetrad and anomic aphasia. Diffusion-weighted imaging localizes acute ischemia in BA 39.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2023 exam. Gerstmann syndrome and associated anomic aphasia are high-yield topics for lesion&ndash;symptom mapping questions on neurology boards.</div></div></div></div></div>"
  },
  {
    "id": 100022531,
    "question_number": "42",
    "question_text": "Q42. (Source: Part I 2022mcqs.txt) What is the most common memory type affected in Korsakoff's encephalopathy?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2022] &bull; Thiamine deficiency injures diencephalic components of the Papez circuit (mammillary bodies, medial dorsal nucleus of thalamus), disrupting hippocampal output.  <br>&bull; Memory systems:  <br>  &ndash; Working memory (prefrontal cortex; transient manipulation of information).  <br>  &ndash; Declarative (explicit) memory subdivided into episodic (personal events) and semantic (general facts), both hippocampus-dependent.  <br>  &ndash; Procedural (implicit) memory (basal ganglia, cerebellum).  <br>&bull; In Korsakoff&rsquo;s syndrome&mdash;the chronic amnestic phase of Wernicke&rsquo;s encephalopathy&mdash;episodic memory is most profoundly impaired, with relative preservation of other domains.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Episodic memory deficits are the hallmark of Korsakoff&rsquo;s encephalopathy due to targeted destruction of the mammillary bodies and medial dorsal thalamic nuclei&mdash;key nodes in the hippocampal&ndash;diencephalic memory loop (Papez circuit). Postmortem studies reveal gliosis and neuronal loss in these structures correlating with profound anterograde amnesia, especially for autobiographical events. Clinical neuropsychological assessments consistently demonstrate near-abolition of episodic recall <span class=\"citation\">(<span class=\"evidence\">Reed et al., 2003</span>; Kopelman, 2013)</span>. By contrast, semantic memory (general knowledge) and working memory are relatively spared initially because they rely on neocortical and prefrontal circuits less vulnerable to thiamine deficiency. Current consensus guidelines <span class=\"citation\">(NICE CG100, 2016; EFNS 2010)</span> focus on prompt thiamine replacement to limit Papez circuit injury but note that once chronic amnesia sets in, episodic memory impairment is often irreversible.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Declarative memory  <br>  &ndash; Incorrect because &ldquo;declarative&rdquo; includes both episodic and semantic memory; only the episodic subset is most severely hit.  <br>  &ndash; Misconception: conflating broad category with the specific subdomain primarily affected.  <br>  &ndash; Differentiator: semantic memory often preserved early.  <br>C. Working memory  <br>  &ndash; Incorrect: working memory depends on dorsolateral prefrontal cortex, which is relatively spared in thiamine deficiency.  <br>  &ndash; Misconception: equating &ldquo;short-term memory&rdquo; with the profound amnesia seen in Korsakoff&rsquo;s.  <br>  &ndash; Differentiator: patients can hold and manipulate items (e.g., digit span), despite inability to consolidate into long term.  <br>D. Semantic memory  <br>  &ndash; Incorrect: although semantic memory eventually declines in advanced cases, it is not the initial or most profound deficit.  <br>  &ndash; Misconception: thinking all explicit memory is equally affected.  <br>  &ndash; Differentiator: preservation of vocabulary and world knowledge in early/mid-stage Korsakoff&rsquo;s.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Memory Type</th><th>Neural Substrate</th><th>Function</th><th>Status in Korsakoff&rsquo;s</th></tr></thead><tbody><tr><td>Episodic memory</td><td>Hippocampus \u2192 mammillary bodies \u2192 thalamus</td><td>Recall of personal events</td><td>Severely impaired</td></tr><tr><td>Declarative (all)</td><td>Hippocampus + temporal neocortex</td><td>Conscious recall of facts & events</td><td>Partially via episodic loss</td></tr><tr><td>Working memory</td><td>Prefrontal cortex</td><td>Online manipulation of information</td><td>Largely preserved</td></tr><tr><td>Semantic memory</td><td>Lateral temporal neocortex</td><td>General knowledge (facts, concepts)</td><td>Relatively spared initially</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Korsakoff&rsquo;s patients confabulate to fill gaps in episodic memory&mdash;classically fabricating events when asked.  <br>2. Early MRI in Wernicke&rsquo;s shows mammillary body and medial thalamic T2/FLAIR hyperintensities; chronic phase yields atrophy.  <br>3. High-dose IV thiamine (500 mg TID) may reverse ocular signs but rarely restores lost episodic memory fully.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Mistaking working memory deficits (prefrontal) for long-term anterograde amnesia (diencephalic).  <br>2. Believing semantic memory is first and most severely affected in Korsakoff&rsquo;s, rather than episodic.  <br>3. Overgeneralizing &ldquo;declarative memory&rdquo; without distinguishing its episodic vs semantic components.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; NICE Guideline CG100 (2016): recommend parenteral thiamine 500 mg IV TID for 2&ndash;3 days in suspected Wernicke&rsquo;s encephalopathy (Level C evidence &ndash; consensus).  <br>&bull; EFNS Guidelines on Wernicke&rsquo;s Encephalopathy (2010): advise 200 mg IV thiamine three times daily until no further improvement (Level C &ndash; expert opinion).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Lesions in the mammillary bodies and medial dorsal nucleus of the thalamus disrupt the hippocampal&ndash;anterior thalamic projections of the Papez circuit, abolishing episodic encoding and recall while sparing neocortical layers that mediate semantic storage and prefrontal networks for working memory.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Thiamine (vitamin B\u2081) is a cofactor for pyruvate dehydrogenase and &alpha;-ketoglutarate dehydrogenase in the Krebs cycle. Deficiency causes energy failure, oxidative stress, and selective neuronal death in regions with high thiamine turnover (mammillary bodies, thalamus), leading to irreversible damage of circuits underlying episodic memory.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Identify risk (chronic alcoholism, malnutrition).  <br>2. Recognize triad in acute Wernicke&rsquo;s (confusion, ataxia, ophthalmoplegia).  <br>3. Administer high-dose thiamine before glucose.  <br>4. After acute phase, assess persistent anterograde amnesia with neuropsychological testing.  <br>5. MRI to confirm diencephalic lesions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Acute Wernicke&rsquo;s: symmetric T2/FLAIR hyperintensities in mammillary bodies, medial thalami, periaqueductal region.  <br>&bull; Chronic Korsakoff&rsquo;s: atrophy of mammillary bodies and thalamic volume loss.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Initial: Thiamine 500 mg IV TID for 2&ndash;3 days, then 250 mg IV/IM daily for 5 days (per NICE CG100).  <br>&bull; Maintenance: Oral thiamine (100 mg daily) and nutritional support to prevent progression.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2022 exam. Episodic memory impairment in Korsakoff&rsquo;s is a classic, frequently tested concept&mdash;often presented as anterograde amnesia with confabulation in alcoholic patients, distinguishing episodic vs semantic memory loss.</div></div></div></div></div>"
  },
  {
    "id": 100022537,
    "question_number": "47",
    "question_text": "Q47. Apathy is more commonly seen in which of the following conditions?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2023] Apathy denotes diminished motivation, goal-directed behavior, and emotional engagement. Core neuroanatomical substrates include the dorsomedial prefrontal cortex, anterior cingulate cortex, and ventral striatum within frontal-subcortical circuits. In neurodegenerative disorders, regional atrophy or neurotransmitter depletion disrupts these networks. Behavioral variant frontotemporal dementia (bvFTD) characteristically targets orbitofrontal and medial frontal regions, producing early and severe apathy. In contrast, idiopathic Parkinson&rsquo;s disease involves nigrostriatal dopaminergic loss, leading to apathy in a subset of patients. Traumatic brain injury and Wilson&rsquo;s disease may manifest apathy when frontal lobes or basal ganglia are affected but with lower frequency than bvFTD.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Frontotemporal dementia (especially bvFTD) shows apathy in 60&ndash;90% of cases <span class=\"citation\">(<span class=\"evidence\">Rascovsky et al. 2011</span> criteria)</span>. Neuroimaging reveals anterior cingulate and medial frontal atrophy correlating with apathy severity <span class=\"citation\">(Levy & Cummings, 2007)</span>. By contrast, apathy in Parkinson&rsquo;s disease affects ~30&ndash;40% <span class=\"citation\">(<span class=\"evidence\">Robertson et al. 2020</span>)</span>, often responsive to dopaminergic therapy but less pervasive. Post-TBI apathy arises from diffuse axonal injury and frontal contusions in ~35% <span class=\"citation\">(<span class=\"evidence\">Kalpattu et al. 2019</span>)</span>. Wilson&rsquo;s disease neuropsychiatric symptoms predominantly involve mood and personality changes; apathy prevalence is <20% <span class=\"citation\">(<span class=\"evidence\">Wu et al. 2018</span>)</span>. Current AAN guidelines on FTD management (2016) highlight apathy as a key diagnostic and therapeutic target in bvFTD.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Idiopathic Parkinson&rsquo;s disease  <br><span class=\"list-item\">\u2022</span> Why incorrect: Apathy prevalence (~30&ndash;40%) is lower than in bvFTD.  <br><span class=\"list-item\">\u2022</span> Misconception: Equating bradykinesia-induced slowness with apathy.  <br><span class=\"list-item\">\u2022</span> Differentiator: Parkinson&rsquo;s apathy often improves with dopaminergic agonists; bvFTD apathy is refractory.  <br><br>C. Traumatic brain injury  <br><span class=\"list-item\">\u2022</span> Why incorrect: Apathy occurs after frontal injuries but overall lower prevalence.  <br><span class=\"list-item\">\u2022</span> Misconception: Assuming all frontal lobe damage yields uniform apathy severity.  <br><span class=\"list-item\">\u2022</span> Differentiator: TBI apathy often coexists with fluctuating attention deficits and fatigue.  <br><br>D. Wilson&rsquo;s disease  <br><span class=\"list-item\">\u2022</span> Why incorrect: Behavioral changes are more mood-related; apathy less common.  <br><span class=\"list-item\">\u2022</span> Misconception: Attributing copper deposition in basal ganglia directly to apathy.  <br><span class=\"list-item\">\u2022</span> Differentiator: Wilson&rsquo;s disease features tremor, hepatic dysfunction, and Kayser&ndash;Fleischer rings.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Frontotemporal Dementia (bvFTD)</th><th>Parkinson&rsquo;s Disease</th><th>Traumatic Brain Injury</th><th>Wilson&rsquo;s Disease</th></tr></thead><tbody><tr><td>Apathy prevalence</td><td>60&ndash;90%</td><td>30&ndash;40%</td><td>~35%</td><td><20%</td></tr><tr><td>Neuroanatomical correlate</td><td>Medial frontal & anterior cingulate atrophy</td><td>Nigrostriatal dopamine loss</td><td>Frontal contusions, diffuse axonal injury</td><td>Basal ganglia copper deposition</td></tr><tr><td>Responsiveness to treatment</td><td>Poor with SSRIs/stimulants</td><td>Often improves with dopaminergics</td><td>Variable, rehabilitation-based</td><td>Rarely targeted specifically</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Apathy is a core diagnostic feature in bvFTD per Rascovsky et al. criteria.  <br><span class=\"list-item\">\u2022</span> Differentiate apathy from depression: patients with pure apathy lack dysphoria and guilt.  <br><span class=\"list-item\">\u2022</span> Stimulants (e.g., methylphenidate) may modestly improve apathy in bvFTD (Level C evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Equating slowed movement (bradykinesia) in Parkinson&rsquo;s with true motivational apathy.  <br>2. Attributing post-TBI fatigue or cognitive slowing to apathy without structured scales (e.g., Apathy Evaluation Scale).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>-<span class=\"evidence\"> Rascovsky K et al., 2011</span> (Neurology): Revised bvFTD criteria designate apathy as a core behavioral symptom (Class I evidence).  <br><span class=\"list-item\">\u2022</span> AAN Practice Parameter, 2016: Recommends assessment of neuropsychiatric symptoms including apathy in FTD and use of behavioral scales for monitoring (Level B recommendation).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2023 exam. Apathy in bvFTD is frequently tested, often in the context of differentiating frontotemporal versus Alzheimer-type dementias.</div></div></div></div></div>"
  },
  {
    "id": 100022539,
    "question_number": "30",
    "question_text": "A 77-year-old man with a 3-year history of personality changes and cognitive impairment reports seeing small animals around him. His wife notes that there are days when he is extremely confused and agitated, and days when he is closer to his prior baseline. What is the most likely diagnosis?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2018] Dementia with Lewy bodies (DLB) is a neurodegenerative dementia marked by &alpha;-synuclein inclusions in cortical and subcortical neurons. Core clinical features include progressive cognitive decline, well-formed visual hallucinations, fluctuating attention/alertness, parkinsonism and REM sleep behavior disorder. DLB is the second most common cause of degenerative dementia after Alzheimer&rsquo;s disease (AD). Visual hallucinations often occur early and are vivid. Cognitive fluctuations&mdash;periods of confusion alternating with near-normal function&mdash;help distinguish DLB from AD and other causes. Unlike mild cognitive impairment (MCI), DLB meets full dementia criteria. Schizophrenia typically presents in young adults without progressive cognitive decline.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'><span class=\"evidence\">The 2017</span> International DLB Consortium diagnostic criteria <span class=\"citation\">(McKeith et al., <span class=\"evidence\">Neurology 2017</span>)</span> designate four core features:  <br>1. Cognitive fluctuations  <br>2. Recurrent visual hallucinations  <br>3. Spontaneous parkinsonism  <br>4. REM sleep behavior disorder  <br><br>Our patient exhibits chronic cognitive impairment, vivid visual hallucinations (&ldquo;seeing small animals&rdquo;) and marked day-to-day fluctuations. Dopaminergic imaging (123I-FP-CIT SPECT) often shows reduced striatal uptake supporting DLB. Pathologically, widespread cortical &alpha;-synuclein deposition leads to cholinergic deficits in the nucleus basalis of Meynert (hallucinations) and nigrostriatal dopaminergic loss (parkinsonism). Rivastigmine has Level I evidence to improve cognition and reduce hallucinations in DLB <span class=\"citation\">(Emre et al., Lancet <span class=\"evidence\">Neurol 2004</span>)</span>. In contrast, AD presents with early memory impairment and hippocampal atrophy; hallucinations are late and rare. MCI lacks significant functional decline. Schizophrenia&rsquo;s onset is typically in adolescence/early adulthood with non-progressive psychosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Mild cognitive impairment (MCI)  <br><span class=\"list-item\">\u2022</span> MCI denotes cognitive decline not severe enough to impair daily function.  <br><span class=\"list-item\">\u2022</span> Does not include recurrent visual hallucinations or marked fluctuations.  <br><span class=\"list-item\">\u2022</span> Common misconception: equating any cognitive change in elderly with MCI.  <br><br>C. Alzheimer&rsquo;s disease  <br><span class=\"list-item\">\u2022</span> AD is characterized by insidious memory loss and hippocampal atrophy on MRI.  <br><span class=\"list-item\">\u2022</span> Visual hallucinations and pronounced cognitive fluctuations are uncommon early in AD.  <br><span class=\"list-item\">\u2022</span> Key differentiator: DLB&rsquo;s early hallucinations vs. AD&rsquo;s late psychotic features.<br><br>D. Schizophrenia  <br><span class=\"list-item\">\u2022</span> Onset typically in teens/20s with auditory hallucinations, delusions, disorganized thought.  <br><span class=\"list-item\">\u2022</span> Lacks progressive neurodegeneration, parkinsonism and fluctuating cognition seen in DLB.  <br><span class=\"list-item\">\u2022</span> Misconception: attributing late-life visual hallucinations solely to primary psychosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>DLB</th><th>MCI</th><th>Alzheimer&rsquo;s disease</th><th>Schizophrenia</th></tr></thead><tbody><tr><td>Onset age</td><td>>60 years</td><td>>50 years</td><td>>65 years</td><td>15&ndash;30 years</td></tr><tr><td>Core visual hallucinations</td><td>Early, well-formed</td><td>Absent</td><td>Rare, late</td><td>Mostly auditory</td></tr><tr><td>Cognitive fluctuations</td><td>Marked</td><td>Absent</td><td>Gradual, steady decline</td><td>Absent</td></tr><tr><td>Parkinsonian motor signs</td><td>Common</td><td>Absent</td><td>Late, mild</td><td>Absent</td></tr><tr><td>Functional impairment</td><td>Present, progressive</td><td>Minimal</td><td>Progressive</td><td>Variable, non-degenerative</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. DLB patients exhibit severe sensitivity to typical antipsychotics (e.g., haloperidol); quetiapine or clozapine are safer choices.  <br>2. 123I-FP-CIT SPECT (DaTscan) demonstrating reduced striatal uptake has high specificity for DLB over AD.  <br>3. Cholinesterase inhibitors (rivastigmine) improve cognition and reduce hallucinations in DLB, unlike in primary psychiatric disorders.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Overlooking cognitive fluctuations and attributing visual hallucinations to delirium or AD.  <br>2. Misdiagnosing late-life visual hallucinations as primary psychosis without assessing parkinsonism or RBD.  <br>3. Initiating typical neuroleptics in DLB, risking severe sensitivity reactions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. International DLB Consortium criteria update <span class=\"citation\">(McKeith IG et al., <span class=\"evidence\">Neurology 2017</span>)</span>: defines core clinical and biomarker features; Grade A recommendation for use of cholinesterase inhibitors.  <br>2. NICE Guideline NG97 &ldquo;Dementia: assessment and management&rdquo; (2018): recommends rivastigmine in mild-to-moderate DLB; warns against typical antipsychotics; Level 1 evidence.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>&alpha;-Synuclein aggregates in the substantia nigra pars compacta (parkinsonism), nucleus basalis of Meynert (cholinergic deficit \u2192 hallucinations), limbic system and neocortex (cognitive decline), and visual association cortices (visual misperceptions).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Misfolded &alpha;-synuclein forms Lewy bodies in neurons, propagating via prion-like spread. Cholinergic neuronal loss leads to hallucinations and fluctuations; dopaminergic loss causes parkinsonism. Cortical Lewy pathology underlies dementia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical history: assess duration, hallucinations, fluctuations, RBD.  <br>2. Cognitive testing: MoCA or MMSE.  <br>3. Neurological exam: search for parkinsonism.  <br>4. Rule out reversible causes: labs, thyroid, B12, MRI.  <br>5. Supportive biomarkers: DaTscan, polysomnography for RBD, EEG for slowing.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- 123I-FP-CIT SPECT: reduced striatal dopamine transporter uptake in DLB.  <br><span class=\"list-item\">\u2022</span> FDG-PET/SPECT: occipital hypometabolism in DLB vs. temporoparietal in AD.  <br><span class=\"list-item\">\u2022</span> MRI: relative preservation of medial temporal lobes in DLB.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Rivastigmine: start 1.5 mg twice daily, titrate to 6 mg twice daily.  <br><span class=\"list-item\">\u2022</span> Avoid typical antipsychotics; if needed, use low-dose quetiapine or clozapine.  <br><span class=\"list-item\">\u2022</span> Low-dose levodopa may ameliorate parkinsonism; monitor for worsening hallucinations.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2018 exam.  <br>DLB is frequently tested as the dementia subtype combining early visual hallucinations with fluctuating cognition and parkinsonism; recall the &ldquo;one-year rule&rdquo; distinguishing DLB from Parkinson&rsquo;s disease dementia.</div></div></div></div></div>"
  },
  {
    "id": 100022540,
    "question_number": "44",
    "question_text": "Q44. A 62-year-old male exhibits inappropriate behavior, impaired social functioning, and a tendency to eat sweets. He pays no attention to personal hygiene for the last year. A PET scan shows frontal and temporal hypometabolism. What is the most likely diagnosis?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2022] Frontotemporal Dementia (FTD) arises from selective degeneration of frontal and anterior temporal lobes, leading to:  <br>&bull; Disinhibition and socially inappropriate behaviors (orbitofrontal involvement).  <br>&bull; Apathy, loss of empathy, compulsive or hyperoral behaviors, including carbohydrate craving.  <br>&bull; Relative sparing of episodic memory until late stages (unlike Alzheimer&rsquo;s Disease).  <br>Functional imaging (FDG-PET) demonstrates focal hypometabolism in affected cortices. Behavioral variant FTD (bvFTD) typically presents in the 50&ndash;70 year age group, with insidious behavioral/personality changes rather than early amnestic deficits.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Frontotemporal Dementia is the correct diagnosis because:  <br>&bull; The hallmark bvFTD profile includes progressive disinhibition, dietary change (sweet cravings), neglect of personal care, and social decorum loss.  <br>&bull; FDG-PET revealing frontal and temporal hypometabolism fulfills &ldquo;probable bvFTD&rdquo; criteria per International Consensus <span class=\"citation\">(<span class=\"evidence\">Rascovsky et al., 2011</span>)</span>.  <br>&bull; Alzheimer&rsquo;s Disease rarely presents with primary behavioral changes; memory and visuospatial dysfunction dominate early AD.  <br>&bull; Creutzfeldt-Jakob Disease is characterized by rapidly progressive dementia (weeks to months), myoclonus, and periodic EEG complexes, not isolated behavioral change.  <br>&bull; Vascular Dementia features stepwise deficits, focal neurologic signs, and patchy white matter or cortical infarcts rather than circumscribed hypometabolism.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Alzheimer&rsquo;s Disease (Frontal type)  <br>&ndash; Alzheimer&rsquo;s rarely causes early hyperorality or profound disinhibition; initial deficits are episodic memory and visuospatial processing.  <br>&ndash; Imaging in AD shows parietal hypometabolism and hippocampal atrophy, not predominant frontal/temporal.  <br><br>C. Creutzfeldt-Jakob Disease (CJD)  <br>&ndash; CJD has a fulminant course (median survival <1 year), myoclonus, ataxia, and characteristic periodic sharp-wave complexes on EEG; behavioral changes are overshadowed by rapid cognitive and motor decline.  <br><br>D. Vascular Dementia  <br>&ndash; Typically presents with focal deficits, stepwise cognitive decline, leukoaraiosis or infarcts on MRI; behavioral disinhibition and sweet cravings are not classic. Hypometabolism is patchy, linked to infarct locations.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Frontotemporal Dementia (bvFTD)</th><th>Alzheimer&rsquo;s Disease</th><th>Creutzfeldt-Jakob Disease</th><th>Vascular Dementia</th></tr></thead><tbody><tr><td>Onset</td><td>50&ndash;70 years, insidious</td><td>>65 years, insidious</td><td>Any adult, rapid (months)</td><td>&ge;65 years, stepwise</td></tr><tr><td>Progression</td><td>Gradual over 5&ndash;10 years</td><td>Gradual 8&ndash;12 years</td><td>Rapid, weeks to months</td><td>Stepwise</td></tr><tr><td>Key Clinical Features</td><td>Disinhibition, apathy, hyperorality</td><td>Memory loss, disorientation</td><td>Myoclonus, cerebellar signs</td><td>Focal deficits, executive dysfunction</td></tr><tr><td>PET/MRI Findings</td><td>Frontal/anterior temporal hypometabolism</td><td>Parietal hypometabolism, hippocampal atrophy</td><td>May show thalamic hyperintensity on DWI</td><td>Infarcts, white matter changes</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Hyperorality and sweet-seeking behavior in a middle\u2010aged adult strongly suggest bvFTD over AD.  <br>&bull; FDG-PET is valuable when MRI is inconclusive, showing focal frontal and/or anterior temporal hypometabolism.  <br>&bull; SSRIs (e.g., sertraline) can ameliorate compulsive behaviors and disinhibition in bvFTD (off-label use).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Misattributing early personality changes to primary psychiatric disorders (e.g., late-onset bipolar), delaying dementia workup.  <br>2. Assuming all dementias first present with memory impairment; bvFTD may preserve memory initially.  <br>3. Overreliance on MRI atrophy without functional imaging, missing early cases where atrophy is subtle.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Rascovsky A et al. International Consensus Criteria for bvFTD <span class=\"citation\">(Brain, 2011)</span>: Defines &ldquo;possible&rdquo; and &ldquo;probable&rdquo; bvFTD requiring neuroimaging support; sensitivity 85%, specificity 95%. (Level II evidence)  <br>2. NICE Guideline NG97 (2020): In suspected FTD, obtain structural imaging (MRI) and, if uncertain, FDG-PET or SPECT to localize hypometabolism/atrophy. (Evidence quality: moderate)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>bvFTD pathology localizes to:  <br>&bull; Orbitofrontal cortex &ndash; disinhibition, impulsivity  <br>&bull; Anterior cingulate &ndash; apathy, emotional blunting  <br>&bull; Anterior temporal lobe &ndash; loss of empathy, semantic impairment</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Frontotemporal lobar degeneration involves accumulation of tau, TDP-43, or FUS protein aggregates causing selective neuronal loss, gliosis, and regional atrophy in frontal and temporal cortices, leading to characteristic behavioral and language deficits.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical suspicion: progressive behavior/personality change in midlife.  <br>2. Neuropsychological screening: executive and social cognition tests.  <br>3. Structural MRI: look for frontal/anterior temporal atrophy.  <br>4. FDG-PET/SPECT: confirm region\u2010specific hypometabolism.  <br>5. CSF biomarkers: rule out AD (A&beta;42, tau profiles).  <br>6. Genetic testing: MAPT, GRN, C9orf72 if familial.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; FDG-PET in bvFTD: pronounced hypometabolism in frontal lobes (orbitofrontal, dorsolateral) and anterior temporal regions.  <br>&bull; MRI may initially show asymmetrical atrophy; PET often detects dysfunction earlier.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>No FDA-approved disease\u2010modifying therapies. Symptomatic management:  <br>&bull; SSRIs (sertraline, citalopram) for disinhibition and compulsive behaviors.  <br>&bull; Trazodone for agitation/hyperorality (off-label).  <br>&bull; Atypical antipsychotics for severe behavioral disturbances (cautious use).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2022 exam. Behavioral variant FTD is high\u2010yield on neurology boards, frequently tested via scenarios emphasizing disinhibition, dietary change, and focal hypometabolism on PET.</div></div></div></div></div>"
  },
  {
    "id": 100022543,
    "question_number": "38",
    "question_text": "A 67-year-old male is brought to the clinic because of cognitive decline and multiple neurological symptoms over the last 6 months. Initially, he stopped worrying about his job and started to exhibit unusual behaviors. He leaves the house without showering, then he became apathetic and anhedonic. For the last month, he has ataxia, frequent falls, and myoclonic jerks. An MRI was obtained and shown. What is the most likely diagnosis?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2022] In the 2022 Part I examination, this vignette illustrates a rapidly progressive dementia with behavioral changes, motor signs, and characteristic MRI findings.  <br>&bull; Prion protein misfolding: Normal cellular PrP^C converts to pathogenic PrP^Sc, causing spongiform change.  <br>&bull; Clinical triad of CJD: subacute dementia (<1 year), myoclonus, and ataxia/falls.  <br>&bull; MRI diffusion-weighted imaging (DWI): &ldquo;cortical ribboning&rdquo; and basal ganglia hyperintensity reflect restricted diffusion from vacuolation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Creutzfeldt-Jakob disease (CJD) is confirmed by the combination of (1) subacute cognitive decline over months, (2) new-onset myoclonus and cerebellar signs, and (3) MRI DWI showing cortical ribboning and bilateral basal ganglia hyperintensities. The U.S. CDC&rsquo;s 2018 revised criteria designate DWI hyperintensity as a core finding with sensitivity > 90% and specificity ~90% <span class=\"citation\">(<span class=\"evidence\">Zerr et al., 2009</span>; CDC MMWR 2018)</span>. CSF RT-QuIC now attains > 97% specificity for PrP^Sc detection <span class=\"citation\">(World Health Organization, 2020)</span>. EEG may show periodic sharp wave complexes in ~65% of cases but is less sensitive than MRI DWI.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Frontotemporal Dementia (FTD)  <br> &bull; Why incorrect: FTD progresses over years, not months. MRI shows frontal/temporal atrophy, not DWI ribboning.  <br> &bull; Misconception: Early behavioral change implies FTD; rapid progression and myoclonus are not features.  <br> &bull; Differentiator: Lack of myoclonus and normal diffusion imaging.<br><br>C. Alzheimer's Disease (AD)  <br> &bull; Why incorrect: AD is insidious over &ge;5 years, with initial memory loss. Myoclonus and ataxia are late/absent.  <br> &bull; Misconception: Any dementia in elderly is AD.  <br> &bull; Differentiator: MRI would show hippocampal and temporoparietal atrophy, not DWI hyperintensity.<br><br>D. Lewy Body Dementia  <br> &bull; Why incorrect: Characterized by visual hallucinations, fluctuation of alertness, parkinsonism; myoclonus is rare.  <br> &bull; Misconception: Dementia with movement signs equals Lewy body.  <br> &bull; Differentiator: DaTscan shows reduced striatal uptake; MRI lacks cortical ribboning.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>CJD</th><th>FTD</th><th>AD</th><th>LBD</th></tr></thead><tbody><tr><td>Time course</td><td>Rapid (<12 months)</td><td>Slow (years)</td><td>Slow (years)</td><td>Slow&ndash;subacute (years)</td></tr><tr><td>Early behavioral change</td><td>Yes (apathy/disinhibition)</td><td>Yes</td><td>No (memory first)</td><td>Possible fluctuations</td></tr><tr><td>Myoclonus</td><td>Prominent</td><td>Absent</td><td>Rare</td><td>Occasional</td></tr><tr><td>MRI (DWI)</td><td>Cortical ribboning, basal ganglia hyperintensity</td><td>Frontal/temporal atrophy</td><td>Hippocampal/cortical atrophy</td><td>Non\u2010specific; occipital hypoperfusion on SPECT</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Cortical ribboning on DWI is >90% sensitive for sCJD <span class=\"citation\">(<span class=\"evidence\">Zerr et al., 2009</span>)</span>.  <br>&bull; Startle-induced myoclonus is classic; test by sudden auditory stimuli.  <br>&bull; CSF RT-QuIC assay now provides >97% specificity for PrP^Sc detection <span class=\"citation\">(WHO, 2020)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Attributing rapid behavioral decline solely to FTD without noting motor signs or imaging.  <br>2. Overreliance on CSF 14-3-3 protein (sensitivity ~85%, specificity ~75%) without MRI correlation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; CDC MMWR (2018): Revised CJD diagnostic criteria designate MRI DWI hyperintensity as a core diagnostic feature for probable sCJD (Level C evidence).  <br>&bull; WHO Working Group on Prion Diseases (2020): Recommends CSF RT-QuIC assay for definitive PrP^Sc detection; specificity >97% (Level B evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Spongiform changes predominate in cortical grey matter and basal ganglia, explaining DWI hyperintensity; cerebellar involvement accounts for ataxia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Misfolded PrP^Sc induces a template-directed conversion of PrP^C, forming amyloid fibrils, neuronal loss, astrocytosis, and vacuolar (&ldquo;spongiform&rdquo;) change.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical suspicion: subacute dementia + myoclonus/ataxia  <br>2. MRI DWI \u2192 cortical ribboning/basal ganglia hyperintensity  <br>3. CSF studies: RT-QuIC, 14-3-3 protein  <br>4. EEG: periodic sharp wave complexes  <br>5. Exclude mimics (paraneoplastic, autoimmune encephalitis)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>DWI MRI is more sensitive than FLAIR; look for symmetric cortical ribboning and basal ganglia hyperintensity early in disease.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2022 exam. Rapidly progressive dementia with myoclonus and DWI MRI changes is a high-yield topic, frequently tested as a classic presentation of prion disease.</div></div></div></div></div>"
  },
  {
    "id": 100022545,
    "question_number": "37",
    "question_text": "Apathy is more commonly seen in which condition?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2022] Apathy is defined as diminished motivation, goal-directed behavior and emotional responsiveness. It arises from dysfunction of the anterior cingulate cortex (ACC) and its projections through the ventral striatum and medial prefrontal cortex&mdash;components of the cortico&ndash;striato&ndash;pallido&ndash;thalamic loop&mdash;which depend on dopaminergic input for motivational drive. In vascular dementia (VaD), subcortical ischemic lesions frequently disrupt these frontal&ndash;subcortical pathways, leading to particularly high rates of apathy. By contrast, Alzheimer disease pathology initially targets medial temporal and parietal regions, with less early involvement of the frontal motivational circuitry.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Large systematic reviews and meta-analyses show:  <br><span class=\"list-item\">\u2022</span> Vascular dementia: apathy prevalence up to 65% <span class=\"citation\">(van de Beek et al., J Neurol <span class=\"evidence\">Sci 2012</span>; Robert et al., Brain <span class=\"evidence\">Sci 2021</span>)</span>  <br><span class=\"list-item\">\u2022</span> Alzheimer disease: ~50% <span class=\"citation\">(Robert et al., Brain <span class=\"evidence\">Sci 2021</span>)</span>  <br><span class=\"list-item\">\u2022</span> Parkinson disease: ~36% <span class=\"citation\">(Levy & Cummings, Mov <span class=\"evidence\">Disord 2006</span>)</span>  <br><span class=\"list-item\">\u2022</span> ALS: ~29% <span class=\"citation\">(Pfohl et al., J Neurol Neurosurg <span class=\"evidence\">Psychiatry 2010</span>)</span>  <br><br>In VaD, lacunar infarcts and white-matter hyperintensities interrupt ACC&ndash;ventral striatum connections, yielding prominent motivational deficits. The EFNS guidelines (2014) recommend routine use of the Neuropsychiatric Inventory to screen for apathy in dementia and endorse cholinesterase inhibitors for symptomatic management of apathy in VaD (Level A evidence). Dopaminergic therapies have only modest benefit outside Parkinson&rsquo;s disease.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Alzheimer disease  <br><span class=\"list-item\">\u2022</span> Although apathy occurs in ~50% of AD, its initial pathology spares frontal&ndash;subcortical motivational circuits more than in VaD.  <br><span class=\"list-item\">\u2022</span> Misconception: thinking memory loss implies apathy as the cardinal behavioral change.  <br><span class=\"list-item\">\u2022</span> Differentiator: AD&rsquo;s earliest deficits are in episodic memory and visuospatial skills.  <br><br>B. Parkinson disease  <br><span class=\"list-item\">\u2022</span> Apathy affects ~36% of PD patients but is secondary to dopaminergic depletion in mesocorticolimbic pathways.  <br><span class=\"list-item\">\u2022</span> Misconception: attributing all non-motor PD symptoms to apathy rather than depression or cognitive decline.  <br><span class=\"list-item\">\u2022</span> Differentiator: in PD, apathy often co-exists with bradyphrenia and motor fluctuations.  <br><br>C. Amyotrophic lateral sclerosis  <br><span class=\"list-item\">\u2022</span> Apathy is seen in ~29% of ALS, reflecting limited frontal executive involvement compared with VaD.  <br><span class=\"list-item\">\u2022</span> Misconception: equating &ldquo;bulbar onset&rdquo; with high behavioral comorbidity.  <br><span class=\"list-item\">\u2022</span> Differentiator: ALS primarily affects motor neurons; cognitive/behavioral features are less pervasive.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Vascular Dementia (D)</th><th>Alzheimer Disease (A)</th><th>Parkinson Disease (B)</th><th>ALS (C)</th></tr></thead><tbody><tr><td>Apathy prevalence</td><td>up to 65%</td><td>~50%</td><td>~36%</td><td>~29%</td></tr><tr><td>Primary pathology</td><td>Subcortical ischemia</td><td>&beta;-amyloid/tau cortex</td><td>&alpha;-synuclein basal ganglia</td><td>Motor neuron loss</td></tr><tr><td>Circuit disruption</td><td>ACC&ndash;ventral striatum</td><td>Temporal&ndash;parietal</td><td>Mesocorticolimbic</td><td>Minimal frontal loops</td></tr><tr><td>First-line symptomatic therapy</td><td>Cholinesterase inhibitors</td><td>ChEI/behavioral</td><td>Dopaminergic agonists</td><td>Supportive care</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Use the Neuropsychiatric Inventory (NPI) for standardized apathy assessment in dementia.  <br><span class=\"list-item\">\u2022</span> Distinguish apathy from depression: apathy lacks pervasive sadness and guilt, whereas depression shows dysphoric mood.  <br><span class=\"list-item\">\u2022</span> In VaD, cholinesterase inhibitors (e.g., rivastigmine) can ameliorate apathy by enhancing frontal cholinergic tone.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Equating apathy with depression&mdash;overlooking lack of emotional distress in true apathy.  <br>2. Assuming Alzheimer disease yields the highest apathy rates among dementias without considering subcortical vascular injury.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. European Federation of Neurological Societies (EFNS) guideline on behavioral symptoms in dementia, 2014  <br><span class=\"list-item\">\u2022</span> Recommendation: Screen for apathy in all dementia syndromes using NPI; initiate cholinesterase inhibitors for VaD-related apathy (Level A).  <br>2. Movement Disorder Society (MDS) Task Force on Apathy in Parkinson&rsquo;s Disease, 2016  <br><span class=\"list-item\">\u2022</span> Recommendation: Apply specific diagnostic criteria for PD-apathy; optimize dopaminergic therapy before attributing symptoms to depression (Level B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Apathy correlates with hypometabolism and structural lesions in the ACC, orbitofrontal cortex and their projections to the ventral striatum. In VaD, lacunes in the internal capsule and periventricular white matter sever these frontal&ndash;subcortical circuits.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Ischemic injury to subcortical white matter and deep grey nuclei interrupts dopaminergic and cholinergic afferents to the medial frontal cortex, impairing reward processing and motivational drive&mdash;manifesting clinically as apathy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2022 exam. Apathy prevalence across neurodegenerative disorders is a frequently tested concept, often in vignette-style questions asking for differentiation of behavioral symptoms among dementia subtypes and movement disorders.</div></div></div></div></div>"
  },
  {
    "id": 100022546,
    "question_number": "7",
    "question_text": "Q7. The nonfluent/agrammatic variant of primary progressive aphasia (nfvPPA) is primarily associated with atrophy in which brain region?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 1 2021] Primary progressive aphasia (PPA) is a neurodegenerative syndrome featuring progressive language decline. The nonfluent/agrammatic variant (nfvPPA) manifests with effortful, halting speech and agrammatism due to degeneration of motor speech and grammar centers. Key concepts:<br><span class=\"list-item\">\u2022</span> Neuroanatomy: Broca&rsquo;s area in the left inferior frontal gyrus (IFG) (Brodmann areas 44/45) controls syntax and speech production.<br><span class=\"list-item\">\u2022</span> Pathology: nfvPPA often shows frontotemporal lobar degeneration with tau inclusions targeting frontal language networks.<br><span class=\"list-item\">\u2022</span> Differential: Semantic PPA (anterior temporal atrophy) and logopenic PPA (posterior perisylvian atrophy) have distinct neuroanatomical correlates.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Landmark voxel-based morphometry studies <span class=\"citation\">(<span class=\"evidence\">Rohrer et al., 2010</span>)</span> demonstrated focal gray matter loss in the left IFG and insula in nfvPPA. Gorno-Tempini et al. (2011) consensus criteria localize agrammatic and apraxic speech to Broca&rsquo;s region and adjacent premotor cortex. Pathological validation <span class=\"citation\">(<span class=\"evidence\">Whitwell et al., 2012</span>)</span> reveals tau-positive frontotemporal lobar degeneration correlating with IFG atrophy. Current American Academy of Neurology dementia guidelines (2020) endorse MRI-based atrophy mapping for PPA subtyping, consistently identifying Broca&rsquo;s area involvement in nfvPPA.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Right temporal lobe  <br><span class=\"list-item\">\u2022</span> Incorrect: Right temporal degeneration causes social-emotional and face-processing deficits, not agrammatic speech.  <br><span class=\"list-item\">\u2022</span> Misconception: Confusing semantic and behavioral FTD involvement.  <br><br>C. Medial temporal lobe  <br><span class=\"list-item\">\u2022</span> Incorrect: Medial temporal (hippocampal) atrophy underlies amnestic Alzheimer&rsquo;s dementia with memory loss, not primary aphasia.  <br><span class=\"list-item\">\u2022</span> Misconception: Equating hippocampal damage with language dysfunction.  <br><br>D. Occipital lobe  <br><span class=\"list-item\">\u2022</span> Incorrect: Occipital cortex atrophy leads to visual processing disorders (e.g., posterior cortical atrophy), not speech production deficits.  <br><span class=\"list-item\">\u2022</span> Misconception: Overgeneralizing cortical atrophy to any cognitive domain.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>nfvPPA (Broca area)</th><th>Right Temporal Lobe</th><th>Medial Temporal Lobe</th><th>Occipital Lobe</th></tr></thead><tbody><tr><td>Core symptom</td><td>Agrammatism, apraxia</td><td>Behavioral changes</td><td>Memory impairment</td><td>Visual hallucinations</td></tr><tr><td>Imaging atrophy</td><td>Left IFG, insula</td><td>Right anterior TL</td><td>Hippocampus</td><td>Occipital cortex</td></tr><tr><td>Primary pathology</td><td>FTLD\u2010tau</td><td>FTLD\u2010TDP (sometimes)</td><td>Alzheimer&rsquo;s disease</td><td>Alzheimer&rsquo;s PCA</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Early apraxia of speech (e.g., distorted sound substitutions) strongly suggests nfvPPA.  <br><span class=\"list-item\">\u2022</span> Grammar comprehension tests (sentence&ndash;picture matching) help differentiate nfvPPA from logopenic PPA.  <br><span class=\"list-item\">\u2022</span> Tau PET imaging is emerging as a confirmatory tool for FTLD\u2010tau pathology in nfvPPA.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Assuming all PPA variants localize to temporal lobes; nfvPPA is frontal.  <br><span class=\"list-item\">\u2022</span> Confusing logopenic PPA (posterior perisylvian) with nfvPPA; focus on repetition vs grammar.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- Gorno-Tempini et al., <span class=\"evidence\">Neurology 2011</span> (consensus criteria): Defines nfvPPA by left IFG atrophy and speech apraxia/agrammatism (Level B).  <br><span class=\"list-item\">\u2022</span> AAN Dementia Guidelines, 2020: Recommend structural MRI for PPA variant classification; emphasize Broca&rsquo;s region in nfvPPA (Level A).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Degeneration of Broca&rsquo;s area (Brodmann 44/45) disrupts syntactic encoding and motor planning. The adjacent insula and premotor cortex contribute to articulation, explaining speech apraxia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>nfvPPA is commonly linked to FTLD-tau inclusions (Pick bodies, PSP-like), selectively targeting neurons in frontal language networks and leading to progressive speech and grammar deficits.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Detailed speech\u2010language assessment (grammar, motor speech).  <br>2. Neuropsychological testing to exclude memory-dominant deficits.  <br>3. Structural MRI to map atrophy; confirm left IFG involvement.  <br>4. FDG-PET or tau PET to support FTLD-tau pathology.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>MRI with voxel-based morphometry shows asymmetric left IFG and insular atrophy. FDG-PET reveals hypometabolism in the same frontal language regions, distinguishing nfvPPA from other PPA variants.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 1 2021 exam. PPA variants are frequently tested by correlating specific language deficits with distinct cortical atrophy patterns, often using imaging scenarios.</div></div></div></div></div>"
  },
  {
    "id": 100022555,
    "question_number": "35",
    "question_text": "A patient comes with progressive dementia over the last 6 months, exhibiting startle and sensory myoclonus. A DWI image shows a cortical ribbon sign. What is the likely diagnosis?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2019] Rapidly progressive dementia (<2 years) with myoclonus and characteristic MRI findings suggests prion disease.  <br>1. Neurophysiology: Misfolded prion protein (PrP^Sc) aggregates cause synaptic dysfunction and spongiform change.  <br>2. Neuroimaging: Diffusion\u2010weighted imaging (DWI) reveals cortical ribbon hyperintensity due to restricted diffusion in vacuolated gray matter.  <br>3. Clinical features: Startle myoclonus and sensory\u2010evoked jerks reflect cortical involvement.  <br><br>(Word count: 83)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Creutzfeldt&ndash;Jakob disease (CJD), the most common human prion disorder, presents with subacute dementia, myoclonus, and EEG periodic complexes. Meta\u2010analysis <span class=\"citation\">(Meissner et al., <span class=\"evidence\">Brain 2009</span>)</span> reports DWI sensitivity \u2248 92% and specificity \u2248 93% for CJD. WHO (2018) diagnostic criteria and CDC (2018) guidelines incorporate cortical ribboning and basal ganglia hyperintensity on DWI/FLAIR as core radiologic features of probable sCJD. RT\u2010QuIC assay in CSF achieves >99% specificity <span class=\"citation\">(Fairfoul et al., Ann Clin Transl <span class=\"evidence\">Neurol 2016</span>)</span> and is now recommended for early confirmation. No disease\u2010modifying therapies exist; management is supportive.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Alzheimer's disease  <br><span class=\"list-item\">\u2022</span> Incorrect because AD has insidious onset over years, early episodic memory loss, hippocampal atrophy on MRI rather than cortical ribboning. Myoclonus appears only in advanced stages.  <br><span class=\"list-item\">\u2022</span> Misconception: attributing any dementia with myoclonus to AD; key differentiation is disease tempo and imaging.<br><br>C. Frontotemporal dementia  <br><span class=\"list-item\">\u2022</span> Incorrect as FTD presents with behavioral changes or language impairment, marked frontal or anterior temporal atrophy on MRI, without diffusion restriction or startle myoclonus.  <br><span class=\"list-item\">\u2022</span> Misconception: equating early personality change with prion disease.<br><br>D. Lewy body dementia  <br><span class=\"list-item\">\u2022</span> Incorrect: DLB features visual hallucinations, parkinsonism, cognitive fluctuations. MRI lacks cortical ribbon sign; DAT\u2010SPECT shows presynaptic dopamine loss. Myoclonus can occur but progression is slower.  <br><span class=\"list-item\">\u2022</span> Misconception: conflating myoclonus in DLB with prion myoclonus.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Prion Disease (CJD)</th><th>Alzheimer's Disease</th><th>Frontotemporal Dementia</th><th>Lewy Body Dementia</th></tr></thead><tbody><tr><td>Onset/Progression</td><td>Subacute (months)</td><td>Insidious (years)</td><td>Subacute&ndash;insidious</td><td>Subacute&ndash;insidious</td></tr><tr><td>Myoclonus</td><td>Early, startle\u2010related</td><td>Late, rare</td><td>Rare</td><td>Possible, late</td></tr><tr><td>MRI DWI</td><td>Cortical ribbon & basal ganglia hyperintensity</td><td>Hippocampal/temporal atrophy</td><td>Frontal/temporal atrophy</td><td>Normal DWI; occipital hypometabolism on PET</td></tr><tr><td>CSF Biomarkers</td><td>14-3-3 \u2191, RT-QuIC +</td><td>None specific</td><td>None specific</td><td>&alpha;-synuclein in CSF (research)</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Cortical ribboning on DWI is >90% sensitive for sCJD.  <br>&bull; Startle myoclonus (elicited by noise or touch) is highly characteristic.  <br>&bull; RT-QuIC assay in CSF offers near\u2010perfect specificity, reducing need for brain biopsy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Overcalling hippocampal DWI changes from seizure\u2010related edema as CJD cortical ribbon.  <br>2. Labeling any rapidly progressive dementia as CJD without correlating MRI and CSF markers.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; WHO Expert Committee on Biological Standardization, 2018: Recommends DWI/FLAIR cortical ribboning and basal ganglia hyperintensity as diagnostic criteria for probable sCJD. Level III (observational studies).  <br>&bull; CDC, 2018 Revised Criteria for sCJD: Incorporates positive RT-QuIC in CSF and MRI findings into &ldquo;probable&rdquo; diagnosis. Level II\u20102 (prospective cohort studies).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Spongiform vacuolation predominates in cortical layer II&ndash;III and deep gray nuclei (caudate/putamen), causing the diffusion\u2010restriction pattern seen as ribboning on MRI.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Native prion protein (PrP^C) undergoes conformational change to PrP^Sc, which seeds further misfolding, forming amyloid fibrils that disrupt neuronal membranes and synapses, leading to spongiform change.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical suspicion: subacute dementia + myoclonus  <br>2. EEG: periodic sharp wave complexes  <br>3. MRI DWI/FLAIR: look for cortical ribbon & basal ganglia hyperintensity  <br>4. CSF studies: 14-3-3 protein, total tau, RT-QuIC assay  <br>5. Brain biopsy only if non\u2010diagnostic.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>DWI is more sensitive than FLAIR early in disease. Hyperintensity spares white matter; bilateral but asymmetric involvement is common.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>No approved disease\u2010modifying drugs; symptomatic management of myoclonus with clonazepam or valproate; palliative care is cornerstone.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2019 exam. Prion diseases are frequently tested with rapid dementia, myoclonus, and DWI cortical ribbon sign as classic triad.</div></div></div></div></div>"
  },
  {
    "id": 100022558,
    "question_number": "64",
    "question_text": "Q64. The same imaging findings as previous but with agrammatic aphasia are present. What is the diagnosis?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2019] Primary progressive aphasia (PPA) is a focal neurodegenerative syndrome within the frontotemporal lobar degeneration (FTLD) spectrum. The nonfluent/agrammatic variant (nfvPPA) is characterized by effortful, halting speech with grammatical simplification and apraxia of speech. Neuroanatomically, nfvPPA localizes to the left inferior frontal gyrus (Broca&rsquo;s area), insula, and dorsal precentral regions. In contrast, Alzheimer&rsquo;s disease more commonly produces the logopenic variant with phonologic errors and posterior temporoparietal atrophy. Vascular dementia presents with stepwise deficits and multi-infarct patterns rather than progressive anterior atrophy. Prion diseases evolve rapidly, with myoclonus, ataxia and characteristic diffusion\u2010weighted MRI changes, not isolated agrammatic aphasia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Frontotemporal dementia (FTD) encompasses PPA variants; the nonfluent/agrammatic PPA criteria <span class=\"citation\">(Gorno-Tempini et al., <span class=\"evidence\">Brain 2011</span>)</span> require agrammatism and/or apraxia of speech, with imaging showing asymmetric left frontal atrophy. Histopathologically, FTLD-tau (e.g., Pick&rsquo;s disease) or FTLD-TDP account for \u224870% of nfvPPA. By contrast, Alzheimer&rsquo;s pathology underlies the logopenic variant (posterior atrophy, impaired phonological loop on verbal working memory tasks). Vascular dementia fails to produce isolated progressive language dysfunction in the absence of infarcts in eloquent cortex. Prion disease (e.g., sporadic CJD) yields rapidly progressive dementia, periodic sharp&ndash;wave EEG complexes, and DWI hyperintensities in cortex and basal ganglia, none of which align with isolated agrammatic aphasia. Current diagnostic guidelines <span class=\"citation\">(<span class=\"evidence\">Rascovsky et al., 2011</span>; Gorno-<span class=\"evidence\">Tempini et al., 2011</span>)</span> prioritize clinico\u2010anatomic correlation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Alzheimer&rsquo;s disease  <br>&ndash; Alzheimer&rsquo;s typically causes the logopenic PPA variant with phonological paraphasias, impaired repetition, and temporoparietal atrophy. Agrammatism is uncommon.  <br>C. Vascular dementia  <br>&ndash; Presents with stepwise cognitive decline, multi\u2010infarct or subcortical ischemic changes on imaging. Language deficits, if present, follow strategic strokes rather than progressive focal atrophy.  <br>D. Prion disease  <br>&ndash; Characterized by rapidly progressive dementia (weeks\u2010months), myoclonus, ataxia, and cortical ribboning on DWI. It does not manifest as a selective, slowly progressive agrammatic aphasia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>FTD (nfvPPA)</th><th>Alzheimer&rsquo;s (logopenic PPA)</th><th>Vascular Dementia</th><th>Prion Disease</th></tr></thead><tbody><tr><td>Onset/Progression</td><td>Insidious, gradual</td><td>Insidious, gradual</td><td>Stepwise</td><td>Rapid (weeks&ndash;months)</td></tr><tr><td>Language profile</td><td>Agrammatism, telegraphic speech</td><td>Word\u2010finding pauses, phonological errors</td><td>Focal deficits post\u2010stroke; variable</td><td>Global aphasia rare; generalized</td></tr><tr><td>MRI atrophy</td><td>Left inferior frontal & insula</td><td>Left temporoparietal junction</td><td>Multiple infarcts; white matter</td><td>Diffusion\u2010weighted cortical ribbon</td></tr><tr><td>Histopathology</td><td>FTLD\u2010tau or TDP\u201043</td><td>&beta;-amyloid plaques, tau tangles</td><td>Ischemic infarcts</td><td>PrP^Sc amyloid deposition</td></tr><tr><td>Associated features</td><td>Apraxia of speech</td><td>Impaired repetition</td><td>Gait disturbance, focal deficits</td><td>Myoclonus, ataxia, EEG periodicity</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Nonfluent/agrammatic PPA often mimics Broca&rsquo;s stroke but without abrupt onset; look for progressive decline.  <br>&bull; Early behavioral changes (apathy, disinhibition) often accompany FTD; memory may be relatively spared.  <br>&bull; Cholinesterase inhibitors and memantine have not shown benefit in FTD and may worsen behavior.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confusing logopenic with agrammatic PPA: agrammatism implies grammatical errors, not just word\u2010finding pauses.  <br>2. Attributing all PPA to Alzheimer&rsquo;s disease; remember FTLD accounts for most nonfluent and semantic variants.  <br>3. Over\u2010reliance on MMSE: it underestimates language deficits in PPA; specialized language batteries (e.g., PASS) are required.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Gorno-Tempini ML et al., <span class=\"evidence\">Brain 2011</span>: International consensus criteria for PPA variants (Level II evidence).  <br>  Recommendation: Nonfluent/agrammatic PPA diagnosis based on agrammatism, apraxia of speech, and left anterior perisylvian atrophy.  <br>&bull; Rascovsky K et al., <span class=\"evidence\">Neurology 2011</span>: FTLD diagnostic criteria (Level II evidence).  <br>  Recommendation: Behavioral and language variants of FTLD defined by clinical domains correlated with imaging.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Agrammatic speech localizes to the left inferior frontal gyrus (pars opercularis/triangularis), insula, and adjacent dorsal motor cortex. Atrophy here disrupts the dorsal &ldquo;speech\u2010production&rdquo; stream (arcuate fasciculus and superior longitudinal fasciculus).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>FTLD is marked by selective degeneration of frontal and anterior temporal lobes due to misfolded tau or TDP\u201043 protein aggregates. In nfvPPA, tau pathology predominates leading to degeneration of motor\u2010speech networks.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Detailed language assessment to subtype PPA.  <br>2. Structural MRI to identify asymmetric frontotemporal atrophy.  <br>3. Exclude other etiologies (stroke, prion) with DWI, EEG, vascular imaging.  <br>4. Consider CSF biomarkers (A&beta;42, tau) to rule out Alzheimer&rsquo;s.  <br>5. Genetic testing for GRN, MAPT, C9orf72 if familial.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>MRI: focal left inferior frontal and insular atrophy; FDG\u2010PET: hypometabolism in the same regions. DWI is normal (excludes CJD).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>No disease\u2010modifying agents for FTD. Symptomatic treatments: SSRIs for disinhibition, antipsychotics for severe behavioral symptoms; avoid cholinesterase inhibitors.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2019 exam.  <br>FTD presenting as nonfluent/agrammatic PPA is frequently tested in neurology boards under language syndromes and dementia subtypes, often requiring differentiation from Alzheimer&rsquo;s logopenic PPA and vascular or prion etiologies.</div></div></div></div></div>"
  },
  {
    "id": 100022559,
    "question_number": "55",
    "question_text": "A patient exhibits changes in eating habits towards sweet foods. Imaging shows changes consistent with frontotemporal dementia (FTD). What is the diagnosis?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2019] Behavioral variant frontotemporal dementia (bvFTD) is characterized by focal degeneration of the orbitofrontal cortex, anterior cingulate, and anterior temporal lobes. Core clinical features include disinhibition, apathy, and hyperorality&mdash;manifesting as altered dietary preferences (e.g., sweet intake). Pathologically, bvFTD is associated with tau (FTLD-tau) or TDP-43 (FTLD-TDP) protein inclusions. MRI demonstrates asymmetric frontal and/or anterior temporal atrophy, aiding differentiation from Alzheimer&rsquo;s disease (AD), which primarily affects hippocampi and parietal lobes. Recognition of these distinct neuroanatomical and behavioral patterns is essential for accurate early diagnosis and management.  <br>(Word count: 108)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Frontotemporal dementia is the correct diagnosis because hyperorality, specifically a craving for sweets, is a core behavioral disturbance in bvFTD. According to the International Behavioural Variant FTD Criteria Consortium (FTDC) <span class=\"citation\">(Rascovsky et al., Ann <span class=\"evidence\">Neurol 2011</span>;70:378&ndash;396)</span>, hyperorality is one of five core features required for a probable bvFTD diagnosis. Structural MRI typically reveals frontal and anterior temporal lobe atrophy&mdash;findings noted on the patient&rsquo;s imaging. In contrast, AD presents with early episodic memory deficits and medial temporal atrophy <span class=\"citation\">(Jack et al., NIA-AA 2011)</span>, vascular dementia shows multi-infarct patterns on imaging, and prion diseases progress rapidly with myoclonus and periodic EEG discharges <span class=\"citation\">(Zerr et al., Lancet <span class=\"evidence\">Neurol 2021</span>)</span>. Thus, the combination of specific behavioral change and frontotemporal atrophy is pathognomonic for bvFTD.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Alzheimer&rsquo;s disease  <br>&ndash; Incorrect because AD&rsquo;s hallmark is early episodic memory loss and visuospatial deficits.  <br>&ndash; Misconception: attributing any cognitive decline to AD.  <br>&ndash; Differentiated by medial temporal atrophy on MRI and positive CSF A&beta;42/tau profile.  <br><br>C. Vascular dementia  <br>&ndash; Incorrect: features stepwise focal deficits (e.g., hemiparesis) and white-matter hyperintensities.  <br>&ndash; Misconception: vascular risk factors always imply vascular dementia.  <br>&ndash; Differentiated by patchy infarcts on MRI and cerebrovascular history.  <br><br>D. Prion disease  <br>&ndash; Incorrect: presents with rapid progression (weeks&ndash;months), myoclonus, periodic sharp-wave EEG.  <br>&ndash; Misconception: any dementia with behavioral change is prion-related.  <br>&ndash; Differentiated by 14-3-3 protein in CSF and characteristic EEG changes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>bvFTD</th><th>Alzheimer&rsquo;s disease</th><th>Vascular dementia</th><th>Prion disease</th></tr></thead><tbody><tr><td>Onset</td><td>Insidious, 50&ndash;65 years</td><td>Insidious, >65 years</td><td>Stepwise or mixed</td><td>Rapid (weeks&ndash;months)</td></tr><tr><td>Core symptoms</td><td>Disinhibition, hyperorality</td><td>Memory loss, orientation</td><td>Focal deficits, executive dysfunction</td><td>Myoclonus, behavioral change</td></tr><tr><td>MRI findings</td><td>Frontal/anterior temporal atrophy</td><td>Medial temporal atrophy</td><td>Lacunes, white-matter changes</td><td>Often normal or cortical ribboning</td></tr><tr><td>Biomarkers</td><td>None specific; FTLD pathology</td><td>\u2193A&beta;42, \u2191tau in CSF</td><td>Vascular risk profile</td><td>CSF 14-3-3, RT-QuIC positive</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Hyperorality (sweet cravings, putting objects in mouth) is a key bvFTD sign often tested on boards.  <br>&bull; Genetic mutations (C9orf72, GRN, MAPT) account for ~30% of bvFTD&mdash;consider family history.  <br>&bull; SSRIs (e.g., sertraline 50&ndash;100 mg/day) can ameliorate compulsive eating and disinhibition.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Overattributing hyperorality to Alzheimer&rsquo;s disease when it is rare in AD.  <br>2. Ignoring behavioral changes in elderly patients as &ldquo;normal aging&rdquo; rather than bvFTD.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; International Behavioural Variant FTD Criteria Consortium (FTDC), Rascovsky et al. Ann <span class=\"evidence\">Neurol 2011</span>;70:378&ndash;396. Level B evidence. Establishes hyperorality as a core diagnostic feature.  <br>&bull; EFNS Task Force on Diagnosis and Management of Sporadic FTD, European Journal of <span class=\"evidence\">Neurology 2011</span>;18(5):597&ndash;615. Level C evidence. Recommends MRI and consensus clinical criteria for early bvFTD diagnosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Degeneration of the orbitofrontal cortex disrupts inhibitory control, producing disinhibition and hyperorality. Anterior temporal lobe involvement impairs social cognition and semantic processing.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>bvFTD arises from FTLD-tau or FTLD-TDP proteinopathies leading to neuronal loss and gliosis in frontal/temporal lobes, sparing hippocampi until late stages.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical history: assess for disinhibition, apathy, hyperorality.  <br>2. Cognitive testing: executive function focus (e.g., Frontal Assessment Battery).  <br>3. MRI: frontal/anterior temporal atrophy.  <br>4. Exclude AD (CSF A&beta;/tau) and vascular lesions (MRI).  <br>5. Genetic testing if family history positive.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>MRI in bvFTD shows predominant atrophy of the ventromedial and orbitofrontal cortices and anterior temporal lobes; FDG-PET reveals hypometabolism in these regions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>No disease-modifying drugs exist. Symptomatic management includes SSRIs for behavioral symptoms and occupational therapy for safety.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2019 exam. Behavioral variant FTD with hyperorality is frequently tested as a distinguishing feature from other dementias; imaging correlations are commonly queried.</div></div></div></div></div>"
  },
  {
    "id": 100022560,
    "question_number": "34",
    "question_text": "Which disorder most commonly presents with apathy?",
    "correct_answer": "C",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2018] Apathy&mdash;defined as diminished motivation not attributable to decreased consciousness, cognitive impairment, or emotional distress&mdash;arises from disruption of frontal&ndash;subcortical circuits.  <br>1. Frontal Lobes: The anterior cingulate cortex and orbitofrontal cortex regulate initiation and motivation.  <br>2. Subcortical Circuits: The mesolimbic dopamine pathway (ventral tegmental area to nucleus accumbens) and dorsolateral prefrontal circuits modulate goal-directed behavior.  <br>3. Disease Distribution: Neurodegenerative disorders differ in predilection for these networks; behavioral variant FTD (bvFTD) targets frontal regions early, leading to prominent apathy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Frontotemporal dementia exhibits apathy in over 70&ndash;80% of patients at presentation, making it the most common neuropsychiatric feature. Rascovsky et al. <span class=\"citation\">(Lancet <span class=\"evidence\">Neurol 2011</span>)</span> list apathy/inertia as a core clinical feature for probable bvFTD. Neuroimaging correlates demonstrate early atrophy and hypometabolism in bilateral anterior cingulate and orbitofrontal cortices, directly impairing motivational circuits <span class=\"citation\">(Seeley et al., <span class=\"evidence\">Neuron 2008</span>)</span>. By contrast, Alzheimer&rsquo;s disease presents initially with episodic memory impairment; apathy emerges later in moderate stages <span class=\"citation\">(Robert et al., Alzheimer&rsquo;s <span class=\"evidence\">Dement 2006</span>)</span>. Parkinson&rsquo;s disease and PSP may show apathy secondary to dopaminergic deficit but at lower frequencies (~30&ndash;50%) and often accompanied by depression or akinetic-rigid features <span class=\"citation\">(Levy & Dubois, <span class=\"evidence\">Brain 2006</span>)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Progressive supranuclear palsy (PSP)  <br>&ndash; Why incorrect: PSP prevalence of apathy is ~40&ndash;50%, less than FTD.  <br>&ndash; Misconception: Students may think vertical gaze palsy disorders present with cognitive flattening only.  <br>&ndash; Differentiator: PSP hallmark is early postural instability and vertical gaze palsy, not predominant apathy.  <br><br>B. Parkinson's disease  <br>&ndash; Why incorrect: Apathy occurs in ~30&ndash;45% of PD, often coexisting with depression or cognitive decline.  <br>&ndash; Misconception: Equating parkinsonian bradykinesia with apathy.  <br>&ndash; Differentiator: PD patients first present with motor symptoms (rest tremor, rigidity), whereas FTD presents with behavior changes.  <br><br>D. Alzheimer's disease (AD)  <br>&ndash; Why incorrect: Apathy appears later, typically in moderate stages, and follows memory loss.  <br>&ndash; Misconception: Attributing early motivational deficits to AD rather than FTD.  <br>&ndash; Differentiator: AD hallmark is episodic memory impairment and temporoparietal atrophy; FTD shows frontal atrophy with early apathy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>FTD (bvFTD)</th><th>PSP</th><th>PD</th><th>AD</th></tr></thead><tbody><tr><td>Pathology</td><td>Tau, TDP-43</td><td>4-repeat tau</td><td>&alpha;-synuclein</td><td>Amyloid-&beta;, tau</td></tr><tr><td>Key Neuroanatomy</td><td>Anterior cingulate, OFC</td><td>Midbrain, globus pallidus</td><td>Substantia nigra, basal ganglia</td><td>Hippocampus, temporoparietal lobes</td></tr><tr><td>Apathy Prevalence</td><td>70&ndash;80%</td><td>~40&ndash;50%</td><td>30&ndash;45%</td><td>20&ndash;30% (late stage)</td></tr><tr><td>Cardinal Clinical Features</td><td>Behavioral disinhibition, apathy</td><td>Gaze palsy, postural instability</td><td>Bradykinesia, tremor, rigidity</td><td>Memory loss, visuospatial deficits</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Apathy versus depression: In apathy, patients lack initiative but do not report sadness.  <br><span class=\"list-item\">\u2022</span> Early MRI in bvFTD shows anterior cingulate and orbitofrontal atrophy before temporal atrophy.  <br><span class=\"list-item\">\u2022</span> Behavioral inventories (e.g., Apathy Evaluation Scale) help distinguish apathy from other neuropsychiatric symptoms.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Conflating bradyphrenia in PSP or PD with true motivational apathy.  <br>2. Assuming apathy in any dementia equals AD; overlooking FTD when disinhibition and personality change are present.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- Rascovsky I. et al., &ldquo;Sensitivity of revised diagnostic criteria for bvFTD,&rdquo; Lancet <span class=\"evidence\">Neurol 2011</span>. International bvFTD criteria include apathy/inertia as a core feature. (Level II evidence)  <br><span class=\"list-item\">\u2022</span> Ahmed RM et al., AAN Practice <span class=\"evidence\">Guideline 2014</span> for neuropsychiatric symptom management in dementia: SSRIs may ameliorate apathy in FTD (Level C evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>FTD selectively affects the anterior cingulate cortex, orbitofrontal cortex, and connected striatal circuits&mdash;areas critical for motivation and goal-directed behavior.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>bvFTD shows neuronal loss and gliosis from tau or TDP-43 aggregates in frontal lobes, disrupting dopaminergic and glutamatergic transmission in motivation circuits.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical interview: assess for apathy vs depression  <br>2. Neuropsychological testing: frontal executive tasks  <br>3. MRI: evaluate frontal lobe atrophy  <br>4. Apply Rascovsky criteria for probable bvFTD</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- MRI: asymmetric frontoinsula and anterior cingulate atrophy  <br><span class=\"list-item\">\u2022</span> FDG-PET: hypometabolism in frontal and anterior temporal lobes</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>No FDA-approved agents for apathy in bvFTD; off-label SSRIs (e.g., sertraline) or stimulants (e.g., methylphenidate) may improve motivational deficits.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2018 exam. Neuropsychiatric features of dementias are frequently tested in multiple-choice format; apathy as a core symptom of bvFTD contrasts with memory-predominant AD presentations.</div></div></div></div></div>"
  },
  {
    "id": 100022562,
    "question_number": "91",
    "question_text": "A male patient was brought to the hospital by his wife for forgetfulness issues. He has difficulty with speech expression with his friends, which has made his social life difficult. On examination, he couldn\u2019t recall 3 items on the MMSE. He has impaired naming and repetition, with intact comprehension. Which of the following is the most likely diagnosis?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2023] - Primary progressive aphasia (PPA) refers to a group of neurodegenerative syndromes in which language impairment is the most prominent early feature, due to focal atrophy of the dominant perisylvian cortex.  <br><span class=\"list-item\">\u2022</span> Three clinical variants <span class=\"citation\">(Gorno-Tempini et al., <span class=\"evidence\">Neurology 2011</span>)</span>:  <br>  &bull; Nonfluent/agrammatic: effortful speech, agrammatism, impaired syntax, spared single-word comprehension  <br>  &bull; Semantic: fluent but empty speech, impaired naming and single-word comprehension, preserved repetition  <br>  &bull; Logopenic: word-finding pauses, impaired naming and sentence repetition, intact single-word comprehension and grammar  <br><span class=\"list-item\">\u2022</span> Early episodic memory lapses on MMSE can occur in logopenic PPA due to underlying Alzheimer pathology, but core deficits remain language-focused.<br><br>(105 words)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Primary progressive aphasia is diagnosed when language dysfunction is the principal early deficit persisting for at least two years, with relative sparing of other cognitive domains. In this case, the patient exhibits:  <br>1. Impaired naming (lexical retrieval)  <br>2. Impaired repetition (phonological loop deficit)  <br>3. Preserved single-word comprehension and grammar  <br>This constellation corresponds to the logopenic variant of PPA (lvPPA), per the 2011 International Consensus Criteria <span class=\"citation\">(Gorno-Tempini et al., <span class=\"evidence\">Neurology 2011</span>)</span>. LvPPA is most often underpinned by Alzheimer&rsquo;s pathology <span class=\"citation\">(Josephs et al., <span class=\"evidence\">Brain 2008</span>)</span>, explaining mild episodic memory deficits on MMSE. Frontotemporal dementia (FTD) variants either impair comprehension (semantic) or motor speech (nonfluent) early, and typical Alzheimer&rsquo;s disease presents with predominant episodic memory loss and visuospatial deficits before focal aphasia. Thus, the umbrella diagnosis of Primary Progressive Aphasia best encompasses the findings.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Semantic dementia  <br><span class=\"list-item\">\u2022</span> Incorrect because semantic variant PPA demonstrates markedly impaired single-word comprehension and loss of conceptual knowledge, with preserved repetition. Here, comprehension is intact.<br><br>C. Frontotemporal lobe dementia  <br><span class=\"list-item\">\u2022</span> Behavioral variant FTD presents with early personality and executive dysfunction; language deficits are not the predominant or isolated early feature.<br><br>D. Alzheimer&rsquo;s disease  <br><span class=\"list-item\">\u2022</span> Typical Alzheimer&rsquo;s features early episodic memory and visuospatial impairments; focal language deficits (naming, repetition) are less isolated and occur later, not as the presenting symptom.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Logopenic PPA (lvPPA)</th><th>Semantic Dementia (svPPA)</th><th>Behavioral FTD (bvFTD)</th><th>Alzheimer&rsquo;s Disease (typical)</th></tr></thead><tbody><tr><td>Fluency</td><td>Fluent with word\u2010finding pauses</td><td>Fluent, empty speech</td><td>Variable</td><td>Fluent</td></tr><tr><td>Naming</td><td>Impaired</td><td>Impaired</td><td>Mild or late</td><td>Mild early, worsens later</td></tr><tr><td>Repetition</td><td>Impaired (sentence level)</td><td>Preserved</td><td>Preserved early</td><td>Variable, often intact early</td></tr><tr><td>Single\u2010word comprehension</td><td>Intact</td><td>Impaired</td><td>Intact</td><td>Intact early, later impaired</td></tr><tr><td>Episodic memory</td><td>Mildly impaired</td><td>Preserved early</td><td>Preserved early</td><td>Markedly impaired early</td></tr><tr><td>Underlying pathology</td><td>Often Alzheimer&rsquo;s</td><td>TDP-43 type C</td><td>Tau or TDP-43</td><td>Alzheimer&rsquo;s (amyloid-tau)</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- LvPPA often has Alzheimer&rsquo;s biomarkers positive on CSF (low A&beta;\u2084\u2082, high tau) or amyloid PET, guiding therapy and prognosis.  <br><span class=\"list-item\">\u2022</span> Early speech therapy focusing on phonological loop exercises can slow language decline in lvPPA.  <br><span class=\"list-item\">\u2022</span> Unlike svPPA, lvPPA patients retain conceptual knowledge&mdash;test with semantic association tasks.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confusing impaired naming in svPPA with lvPPA: in svPPA, single-word comprehension is also lost.  <br>2. Attributing all progressive aphasias to Alzheimer&rsquo;s disease; only lvPPA is most commonly Alzheimer&rsquo;s-related, whereas nonfluent and semantic variants align with FTD pathology.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Gorno-Tempini et al., <span class=\"evidence\">Neurology 2011</span> (International Consensus Criteria for PPA): Defines three PPA variants with diagnostic features (Level C, expert consensus).  <br>2. Jack et al., Alzheimer&rsquo;s & <span class=\"evidence\">Dementia 2018</span> (NIA-AA Research Framework): Recommends biomarker characterization (A/T/N) in atypical Alzheimer&rsquo;s presentations, including lvPPA, to confirm underlying pathology (Level B, moderate evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>- LvPPA: Atrophy and hypometabolism in left posterior superior temporal gyrus and inferior parietal lobule <span class=\"citation\">(Gorno-<span class=\"evidence\">Tempini et al., 2008</span>)</span>.  <br><span class=\"list-item\">\u2022</span> SvPPA: Anterior temporal pole involvement.  <br><span class=\"list-item\">\u2022</span> Nonfluent PPA: Left inferior frontal gyrus and insula.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>- LvPPA reflects focal neurodegeneration within the phonological loop circuit (temporoparietal junction), often due to Alzheimer&rsquo;s tau and amyloid accumulation.  <br><span class=\"list-item\">\u2022</span> Progressive neuronal loss leads to breakdown of phonological encoding and retrieval networks.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical history: progressive language decline >2 years  <br>2. Detailed speech/language battery (naming, repetition, comprehension)  <br>3. MRI brain: focal atrophy pattern  <br>4. FDG-PET or SPECT: region\u2010specific hypometabolism  <br>5. CSF or PET amyloid/tau biomarkers to differentiate AD vs FTD pathology  <br>6. Genetic testing if family history or early onset</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- MRI: Asymmetric left\u2010sided atrophy in posterior perisylvian cortex for lvPPA  <br><span class=\"list-item\">\u2022</span> FDG-PET: Hypometabolism in left inferior parietal lobule and superior temporal gyrus</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- No FDA-approved disease-modifying agents for PPA variants.  <br><span class=\"list-item\">\u2022</span> In lvPPA with confirmed Alzheimer&rsquo;s pathology, cholinesterase inhibitors (e.g., donepezil) may provide modest benefit (Level C).  <br><span class=\"list-item\">\u2022</span> Non-pharmacologic: tailored speech and language therapy remains cornerstone.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2023 exam.  <br>Primary progressive aphasia and its variants are frequently tested in neurology boards, often requiring differentiation of fluency, naming, repetition, and comprehension patterns to identify the correct PPA subtype.</div></div></div></div></div>"
  },
  {
    "id": 100022563,
    "question_number": "91",
    "question_text": "A male patient was brought to the hospital by his wife for forgetfulness issues. He has difficulty with speech expression with his friends, which has made his social life difficult. On examination, he couldn\u2019t recall 3 items on the MMSE. He has impaired naming and repetition, with intact comprehension. Which of the following is the most likely diagnosis?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2023] Primary progressive aphasia (PPA) is a neurodegenerative syndrome characterized by isolated, progressive language impairment for at least two years before other cognitive domains are affected. Three main variants are recognized by the 2011 Gorno-Tempini et al. consensus criteria:  <br><span class=\"list-item\">\u2022</span> Nonfluent/agrammatic: effortful speech, agrammatism, speech apraxia  <br><span class=\"list-item\">\u2022</span> Semantic: fluent but empty speech, impaired naming and single-word comprehension  <br><span class=\"list-item\">\u2022</span> Logopenic: word\u2010finding pauses, impaired repetition, phonological errors, preserved single\u2010word comprehension  <br><br>The logopenic variant localizes to left posterior perisylvian and inferior parietal regions. Differentiating these variants from other dementias (e.g., semantic dementia, Alzheimer&rsquo;s) rests on a detailed language examination (naming, repetition, comprehension) and correlating focal atrophy patterns on imaging.<br><br>(Approx. 130 words)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>In this patient, impaired naming and repetition with intact comprehension are hallmarks of the logopenic variant of PPA. According to the International Consensus Criteria <span class=\"citation\">(Gorno-Tempini et al., <span class=\"evidence\">Brain 2011</span>; level II evidence)</span>, logopenic PPA presents with:  <br><span class=\"list-item\">\u2022</span> Prominent anomia and word\u2010finding pauses  <br><span class=\"list-item\">\u2022</span> Impaired sentence and phrase repetition  <br><span class=\"list-item\">\u2022</span> Phonological errors on spontaneous speech and naming tasks  <br><span class=\"list-item\">\u2022</span> Relative preservation of single\u2010word comprehension and motor speech  <br><br>Mesulam et al. <span class=\"citation\">(Ann <span class=\"evidence\">Neurol 2003</span>)</span> demonstrated that logopenic PPA correlates pathologically with Alzheimer-type tauopathy or &beta;-amyloid deposition in the left temporoparietal cortex. Structural MRI typically shows asymmetric atrophy in the left posterior perisylvian and inferior parietal regions <span class=\"citation\">(Rohrer et al., <span class=\"evidence\">Neurology 2010</span>)</span>. Clinical practice guidelines from the American Academy of Neurology (2018 update) recommend classifying PPA by variant to inform prognosis and potential trial eligibility (level C recommendation). Thus, &ldquo;Primary progressive aphasia&rdquo; is the most precise diagnosis, encompassing the logopenic variant in this presentation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Semantic dementia  <br><span class=\"list-item\">\u2022</span> Incorrect because semantic variant PPA has impaired naming <strong>and</strong> single\u2010word comprehension, with fluent but empty speech.  <br><span class=\"list-item\">\u2022</span> Misconception: equating &ldquo;naming difficulty&rdquo; alone with semantic variant.  <br><span class=\"list-item\">\u2022</span> Key differentiator: intact comprehension in this patient rules out semantic dementia.  <br><br>C. Frontotemporal lobe dementia  <br><span class=\"list-item\">\u2022</span> FTD (behavioral variant) features early personality changes, disinhibition, and executive dysfunction, not isolated language deficits.  <br><span class=\"list-item\">\u2022</span> Misconception: any language impairment equals FTD.  <br><span class=\"list-item\">\u2022</span> Differentiator: absence of prominent behavioral/executive symptoms early on.  <br><br>D. Alzheimer&rsquo;s disease  <br><span class=\"list-item\">\u2022</span> Early Alzheimer&rsquo;s shows episodic memory loss and visuospatial deficits; language is affected later and repetition is typically preserved until late stages.  <br><span class=\"list-item\">\u2022</span> Misconception: any memory complaint in older adults is Alzheimer&rsquo;s.  <br><span class=\"list-item\">\u2022</span> Differentiator: early word\u2010finding and repetition deficits point to PPA, not typical Alzheimer&rsquo;s.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Logopenic PPA (PPA)</th><th>Semantic Dementia</th><th>Behavioral FTD</th><th>Alzheimer&rsquo;s Disease</th></tr></thead><tbody><tr><td>Naming</td><td>Impaired (anomia)</td><td>Impaired</td><td>Variable</td><td>Mild initially</td></tr><tr><td>Repetition</td><td>Impaired (phonological errors)</td><td>Preserved</td><td>Preserved</td><td>Preserved until late</td></tr><tr><td>Comprehension (single\u2010word)</td><td>Preserved</td><td>Impaired</td><td>Preserved</td><td>Preserved initially</td></tr><tr><td>Primary deficit</td><td>Language (speech, repetition)</td><td>Semantic memory</td><td>Behavior, executive function</td><td>Episodic memory</td></tr><tr><td>Imaging atrophy</td><td>Left temporoparietal junction</td><td>Anterior temporal lobe</td><td>Frontal lobes</td><td>Hippocampus, parietal cortex</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- The logopenic variant of PPA often reflects underlying Alzheimer pathology; CSF or PET &beta;-amyloid can confirm.  <br><span class=\"list-item\">\u2022</span> Early referral to speech\u2010language therapy can prolong functional communication in PPA.  <br><span class=\"list-item\">\u2022</span> Naming plus repetition testing (e.g., &ldquo;No ifs, ands, or buts&rdquo;) is highly sensitive for distinguishing PPA variants.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Assuming all PPA = semantic variant; many students overlook preserved comprehension in logopenic.  <br>2. Conflating behavioral FTD with language-predominant variants; absence of early behavioral change is key.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Gorno-Tempini ML et al., <span class=\"evidence\">Brain 2011</span> (International Consensus Criteria, level II): Defines diagnostic criteria for PPA variants, emphasizing language domains.  <br>2. Wicklund MR et al., <span class=\"evidence\">Neurology 2020</span> (American Academy of Neurology, level C): Recommends variant classification for trial eligibility and prognostication; supports use of amyloid biomarkers in logopenic PPA.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Logopenic PPA correlates with focal atrophy and hypometabolism in the left posterior perisylvian region, including the inferior parietal lobule (angular gyrus) and posterior superior temporal gyrus&mdash;areas critical for phonological processing and verbal working memory.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>- Underlying pathology in logopenic PPA is most often Alzheimer&rsquo;s disease with &beta;-amyloid plaques and tau neurofibrillary tangles.  <br><span class=\"list-item\">\u2022</span> Neurodegeneration disrupts the dorsal speech\u2010processing stream (arcuate fasciculus), impairing repetition and phonological assembly.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Detailed language history and neuropsychological testing (Boston Naming Test, sentence repetition tasks)  <br>2. Structural MRI to identify focal atrophy  <br>3. FDG-PET or SPECT for hypometabolism in language networks  <br>4. CSF or amyloid PET if Alzheimer pathology suspected  <br>5. Exclude other causes (stroke, tumor) with appropriate labs and imaging</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- MRI: Asymmetric atrophy of left temporoparietal junction in logopenic PPA.  <br><span class=\"list-item\">\u2022</span> FDG-PET: Hypometabolism in left inferior parietal and posterior temporal regions distinguishes from semantic (anterior temporal) and nonfluent (inferior frontal) variants.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2023 exam. Progressive aphasias are frequently tested as subtypes of frontotemporal dementia and Alzheimer&rsquo;s disease; look for the triad of naming, repetition, and comprehension to distinguish variants.</div></div></div></div></div>"
  },
  {
    "id": 100022564,
    "question_number": "113",
    "question_text": "A 77-year-old man came with his wife to the clinic with a 3-year history of personality changes and cognitive impairment. She reported that he keeps seeing small animals around him and he moves a lot while he is sleeping. There are days when he is extremely confused and agitated and days when he is closer to his prior baseline. What is the most likely diagnosis?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2023] &bull; Dementia with Lewy bodies (DLB) is a neurodegenerative synucleinopathy characterized by early visual hallucinations, fluctuating cognition, and REM sleep behavior disorder.  <br>&bull; Key pathology: cortical and subcortical alpha-synuclein aggregates (Lewy bodies) leading to cholinergic and dopaminergic deficits.  <br>&bull; Differential diagnosis includes Alzheimer&rsquo;s disease (predominant memory impairment, later visual symptoms), vascular dementia (stepwise decline, focal deficits), and psychiatric disorders (earlier onset, psychosis without progressive dementia).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>DLB is identified by the 2017 revised consensus criteria <span class=\"citation\">(McKeith et al., <span class=\"evidence\">Neurology 2017</span>)</span> requiring dementia plus two of the following core features:  <br> 1. Recurrent visual hallucinations of well-formed images  <br> 2. Fluctuating cognition with pronounced variations in attention and alertness  <br> 3. REM sleep behavior disorder (dream enactment)  <br> 4. Parkinsonism (often bradykinesia, rigidity).  <br>This patient exhibits visual hallucinations (&ldquo;small animals&rdquo;), fluctuations in cognition, and probable REM sleep behavior disorder, fulfilling core features. PET studies often show occipital hypometabolism, and MRI shows relative preservation of medial temporal lobes <span class=\"citation\">(O&rsquo;Brien et al., Lancet <span class=\"evidence\">Neurol 2014</span>)</span>. Cholinesterase inhibitors (rivastigmine) are first-line for cognitive and neuropsychiatric symptoms <span class=\"citation\">(Level A recommendation, AAN 2021)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Alzheimer&rsquo;s disease  <br>  &ndash; Incorrect because early prominent memory loss and hippocampal atrophy on imaging are typical; visual hallucinations and marked fluctuations are late or absent.  <br>  &ndash; Misconception: any dementia with hallucinations equals AD. In AD, hallucinations usually occur at advanced stages.  <br><br>C. Schizophrenia  <br>  &ndash; Incorrect due to age of onset (young adulthood) and absence of progressive cognitive decline over years.  <br>  &ndash; Misconception: visual hallucinations always psychiatric; in neurology, visual hallucinations often imply an organic cause.  <br><br>D. Vascular dementia  <br>  &ndash; Incorrect because vascular dementia shows stepwise deficits, focal neurologic signs, and vascular lesions on MRI.  <br>  &ndash; Misconception: any fluctuating cognition is vascular; vascular fluctuations are stepwise, not waxing-waning day to day.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Early visual hallucinations in an elderly patient strongly suggest DLB rather than AD.  <br>&bull; Fluctuating cognition with &ldquo;good&rdquo; and &ldquo;bad&rdquo; days is a hallmark of DLB.  <br>&bull; Avoid typical antipsychotics in DLB due to severe neuroleptic sensitivity; use quetiapine or clozapine if needed.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Mistaking Lewy body dementia for Alzheimer&rsquo;s disease when memory deficits are mild early on.  <br>&bull; Overlooking REM sleep behavior disorder as a clue to synucleinopathy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; 2017 MDS DLB Criteria <span class=\"citation\">(McKeith et al., <span class=\"evidence\">Neurology 2017</span>)</span>: Updated core and supportive features with diagnostic specificity of &ge;80%.  <br>&bull; AAN 2021 Dementia Guidelines: Recommend rivastigmine as first-line for DLB cognitive symptoms (Level A evidence, randomized controlled trials).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Cortical Lewy bodies in temporal, parietal, and occipital cortex disrupt cholinergic projections from the nucleus basalis of Meynert, leading to fluctuations and hallucinations.  <br>&bull; Brainstem involvement in the locus coeruleus and dorsal motor nucleus contributes to REM sleep behavior disorder.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Misfolded alpha-synuclein aggregates form Lewy bodies \u2192 synaptic dysfunction \u2192 neurotransmitter deficits (acetylcholine, dopamine) \u2192 clinical features of DLB.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical history: cognitive profile, hallucinations, fluctuations, sleep behavior  <br>2. Neurologic exam: parkinsonian signs  <br>3. Neuropsychological testing: visuospatial vs memory  <br>4. MRI brain: rule out vascular lesions, assess medial temporal lobes  <br>5. Functional imaging (SPECT/PET): occipital hypoperfusion  <br>6. Polysomnography: confirm REM sleep behavior disorder</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Occipital hypometabolism on FDG-PET is more pronounced in DLB than AD.  <br>&bull; Relative preservation of hippocampal volume on MRI helps distinguish DLB from AD.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Rivastigmine: start 1.5 mg BID, titrate to 6&ndash;12 mg/day as tolerated.  <br>&bull; Caution with antipsychotics&mdash;use quetiapine or clozapine for psychosis, avoid haloperidol.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2023 exam.  <br>DLB is frequently tested under neurodegenerative disorders, often emphasizing visual hallucinations, fluctuations, and sleep behavior as distinguishing features from Alzheimer&rsquo;s disease and vascular dementia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='explanation-content'>[Optional Comparison Table]</div></div></div></div></div>"
  },
  {
    "id": 100022566,
    "question_number": "55",
    "question_text": "A patient exhibits changes in eating habits towards sweet foods. Imaging shows changes consistent with frontotemporal dementia (FTD). What is the diagnosis?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2019] Frontotemporal dementia (FTD) is a neurodegenerative syndrome characterized by preferential degeneration of the frontal and anterior temporal lobes. Core concepts:  <br>&bull; Behavioral variant FTD (bvFTD) manifests with early personality changes&mdash;disinhibition, apathy, compulsive behaviors, and hyperorality (including craving sweets).  <br>&bull; Neuroanatomy: orbitofrontal cortex and anterior insula atrophy correlate with disinhibition and altered food preferences.  <br>&bull; Imaging: MRI shows focal frontal and/or temporal lobe atrophy; FDG-PET demonstrates hypometabolism in the same regions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The correct answer is FTD because this patient&rsquo;s predilection for sweets (&ldquo;sweet tooth&rdquo;) reflects hyperorality, a hallmark of bvFTD. <span class=\"evidence\">The 2011</span> international consensus criteria <span class=\"citation\">(Rascovsky et al., <span class=\"evidence\">Neurology 2011</span>)</span> require at least three of six behavioral features&mdash;early dietary changes among them&mdash;for probable bvFTD, plus supportive imaging findings. Alzheimer&rsquo;s disease typically presents with episodic memory loss and hippocampal atrophy, not isolated behavioral changes. Vascular dementia shows stepwise cognitive decline with multiple infarcts, often with focal neurologic signs. Prion disease (e.g., Creutzfeldt&ndash;Jakob) is rapidly progressive, with myoclonus, periodic EEG complexes, and diffuse cortical ribboning on MRI. Frontotemporal lobar degeneration subtypes (tau vs. TDP-43 pathology) both present behaviorally, but imaging-driven diagnosis aligns with clinical criteria.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Alzheimer's disease  <br>&bull; Incorrect: Predominant early amnestic deficits and medial temporal atrophy.  <br>&bull; Misconception: Attributing any dementia to Alzheimer&rsquo;s.  <br>&bull; Differentiation: Lack of hyperorality and personality change; PET shows parietal-posterior cingulate hypometabolism.  <br><br>C. Vascular dementia  <br>&bull; Incorrect: Characterized by stepwise decline, focal deficits, white matter changes or lacunes.  <br>&bull; Misconception: Assuming vascular disease causes all late-life behavior changes.  <br>&bull; Differentiation: MRI shows infarcts/white-matter hyperintensities, not isolated frontal atrophy.  <br><br>D. Prion disease  <br>&bull; Incorrect: Rapid course (<1 year), myoclonus, cerebellar signs, periodic sharp-wave complexes on EEG.  <br>&bull; Misconception: Equating any frontally predominant atrophy with prionopathy.  <br>&bull; Differentiation: Diffuse cortical ribboning on DWI MRI and 14-3-3 CSF protein positivity.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>FTD (bvFTD)</th><th>Alzheimer&rsquo;s Disease</th><th>Vascular Dementia</th><th>Prion Disease</th></tr></thead><tbody><tr><td>Onset age</td><td>50&ndash;65 years</td><td>65+ years</td><td>Variable; often 70+ years</td><td>55&ndash;75 years</td></tr><tr><td>Key clinical features</td><td>Disinhibition, hyperorality</td><td>Episodic memory loss, apraxia</td><td>Stepwise deficits, gait disturbance</td><td>Rapid cognitive decline, myoclonus</td></tr><tr><td>Imaging</td><td>Frontal/anterior temporal atrophy</td><td>Hippocampal and temporoparietal</td><td>Infarcts, WMH on MRI</td><td>Cortical ribboning on DWI MRI</td></tr><tr><td>Pathology</td><td>Tau or TDP-43 inclusions</td><td>&beta;-amyloid plaques, tau tangles</td><td>Ischemic lesions</td><td>PrP^Sc accumulation</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Early dietary changes&mdash;sweet cravings, overeating&mdash;are virtually pathognomonic of bvFTD.  <br>&bull; FDG-PET hypometabolism in orbitofrontal regions supports the diagnosis when MRI is equivocal.  <br>&bull; Management is supportive: SSRIs can reduce compulsive behaviors; trazodone may improve disinhibition.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Overdiagnosing Alzheimer&rsquo;s disease in younger patients with behavioral changes&mdash;bvFTD predominates under age 65.  <br>2. Attributing hyperorality to depression or delirium&mdash;evaluate for frontal lobe syndromes and obtain neuroimaging.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Rascovsky K et al. &ldquo;Sensitivity of Revised Diagnostic Criteria for bvFTD&rdquo; <span class=\"evidence\">Neurology 2011</span>;76(3):163&ndash;9. Level A consensus criteria requiring three of six behavioral features plus imaging.  <br>&bull; Boxer AL et al. &ldquo;Memantine in FTLD&rdquo; <span class=\"evidence\">Neurology 2013</span>;81(19):1682&ndash;90. Randomized trial showing no significant benefit of memantine in behavioral symptoms (Level II evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Behavioral variant FTD questions often test hyperorality and disinhibition as distinguishing features from Alzheimer&rsquo;s.  <br>This question appeared in Part I 2019 exam.</div></div></div></div></div>"
  },
  {
    "id": 100022567,
    "question_number": "64",
    "question_text": "The same imaging findings as previous but with agrammatic aphasia are present. What is the diagnosis?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2019] Primary progressive aphasia (PPA) is a clinical syndrome of isolated, progressive language impairment. The non\u2010fluent/agrammatic variant (nfvPPA) is defined by effortful, halting speech with grammatical errors and apraxia of speech. Neuroanatomically, it localizes to the left posterior inferior frontal gyrus (Broca&rsquo;s area) and opercular/insular cortex. nfvPPA falls within the frontotemporal lobar degeneration (FTLD) spectrum, most commonly FTLD\u2010tau. Recognizing the specific aphasia subtype with corresponding imaging atrophy patterns is essential for accurate diagnosis and prognostication.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The International Consensus Criteria <span class=\"citation\">(Gorno-<span class=\"evidence\">Tempini et al., 2011</span>)</span> define nfvPPA by (1) agrammatism in language production and/or (2) apraxia of speech, with preserved single-word comprehension and object knowledge. MRI/FDG\u2010PET shows focal atrophy/hypometabolism in the left posterior inferior frontal gyrus and insula. Neuropathology studies <span class=\"citation\">(<span class=\"evidence\">Josephs et al., 2010</span>)</span> report FTLD\u2010tau in ~60&ndash;70% of nfvPPA. Alzheimer&rsquo;s disease more often underlies the logopenic variant (lvPPA) with word\u2010finding pauses, impaired repetition, and temporoparietal atrophy with amyloid\u2010beta and tau deposition on PET. Vascular dementia presents stepwise deficits with subcortical infarcts on MRI; prion disease features rapid decline, myoclonus, periodic EEG discharges, and 14-3-3 protein in CSF. The combination of agrammatic speech and fronto-insular degeneration is diagnostic of FTD (nfvPPA).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Alzheimer&rsquo;s disease  <br>&bull; Alzheimer&rsquo;s produces lvPPA with word-finding pauses and impaired sentence repetition, not agrammatism.  <br>&bull; Imaging shows temporoparietal atrophy/hypometabolism and positive amyloid PET.  <br><br>C. Vascular dementia  <br>&bull; Language deficits are heterogeneous and accompanied by stepwise cognitive decline and infarcts on MRI.  <br>&bull; No focal Broca\u2010area degeneration; speech errors are secondary to white matter disruption.  <br><br>D. Prion disease  <br>&bull; Rapidly progressive dementia with myoclonus, ataxia, periodic sharp\u2010wave EEG, and positive CSF 14-3-3.  <br>&bull; Agrammatic aphasia is rare; imaging shows cortical ribboning on DWI.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>FTD (nfvPPA)</th><th>Alzheimer&rsquo;s (lvPPA)</th><th>Vascular Dementia</th><th>Prion Disease</th></tr></thead><tbody><tr><td>Onset age</td><td>50&ndash;70</td><td>65+</td><td>60+</td><td>50&ndash;75</td></tr><tr><td>Language phenotype</td><td>Effortful, agrammatic, apraxia</td><td>Logopenic, word\u2010finding pauses</td><td>Variable, non\u2010specific</td><td>Rarely primary aphasia</td></tr><tr><td>MRI/FDG\u2010PET</td><td>Left IFG/insula atrophy/hypo</td><td>Temporoparietal atrophy/hypo</td><td>Multifocal infarcts, leukoaraiosis</td><td>Cortical ribboning on DWI</td></tr><tr><td>Pathology</td><td>FTLD-tau (~60&ndash;70%)</td><td>AD (amyloid beta, tau)</td><td>Ischemic\u2010vascular injury</td><td>PrP^Sc accumulation</td></tr><tr><td>Progression</td><td>Gradual, focal \u2192 global</td><td>Gradual, memory\u2010predominant</td><td>Stepwise</td><td>Rapid (months)</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- nfvPPA patients maintain single\u2010word comprehension and object knowledge until late stages.  <br><span class=\"list-item\">\u2022</span> FDG-PET increases early diagnostic accuracy by highlighting left fronto-insular hypometabolism.  <br><span class=\"list-item\">\u2022</span> Emerging tau\u2010PET tracers (e.g., ^18F-flortaucipir) may distinguish FTLD-tau from AD pathology in vivo.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confusing lvPPA&rsquo;s word\u2010finding pauses and impaired repetition with true agrammatism of nfvPPA.  <br>2. Attributing progressive non\u2010fluent speech to ischemic Broca&rsquo;s stroke rather than degenerative PPA.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- International consensus criteria for PPA <span class=\"citation\">(Gorno-<span class=\"evidence\">Tempini et al., 2011</span>; Neurology)</span>: Use specific clinical features and imaging to classify PPA subtypes. Level B evidence.  <br><span class=\"list-item\">\u2022</span> AAN Practice Guideline Update: Evaluation and Management of Dementia (2018; American Academy of Neurology): Recommend MRI/FDG-PET and CSF/PET biomarkers in suspected PPA to differentiate AD from FTLD. Level B evidence.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Degeneration in the left posterior inferior frontal gyrus (Brodmann areas 44/45), operculum, and insular cortex disrupts the dorsal language stream, producing agrammatism and apraxia of speech.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>FTLD-tau pathology leads to neuronal and glial tau inclusions, preferentially targeting frontal and insular networks. Selective network vulnerability underlies the focal presentation of nfvPPA.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Detailed history: insidious language decline >2 years.  <br>2. Neuropsychological testing: assess fluency, grammar, comprehension.  <br>3. Structural MRI: evaluate focal atrophy.  <br>4. FDG-PET: confirm regional hypometabolism.  <br>5. CSF/PET biomarkers: exclude Alzheimer&rsquo;s pathology.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- MRI: asymmetrical atrophy of left inferior frontal and insular cortex.  <br><span class=\"list-item\">\u2022</span> FDG-PET: focal hypometabolism in the same region.  <br><span class=\"list-item\">\u2022</span> Negative amyloid PET favors FTLD over AD.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2019 exam.  <br>Frontotemporal dementia with non\u2010fluent PPA is frequently tested as a vignette combining agrammatic speech with left fronto\u2010insular atrophy.</div></div></div></div></div>"
  },
  {
    "id": 100022568,
    "question_number": "113",
    "question_text": "A 77-year-old man came with his wife to the clinic with a 3-year history of personality changes and cognitive impairment. She reported that he keeps seeing small animals around him and he moves a lot while he is sleeping. There are days when he is extremely confused and agitated and days when he is closer to his prior baseline. What is the most likely diagnosis?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2023] - Alpha-synuclein aggregation in Lewy bodies affects cortical and subcortical networks, especially the limbic system and neocortex, producing early visual hallucinations and cognitive fluctuations.  <br><span class=\"list-item\">\u2022</span> Loss of cholinergic neurons in the nucleus basalis of Meynert contributes to attentional deficits and visuoperceptual disturbances.  <br><span class=\"list-item\">\u2022</span> REM sleep behavior disorder reflects dysfunction of ponto\u2010medullary inhibitory circuits, a prodromal marker for synucleinopathies.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'><span class=\"evidence\">The 2017</span> revised DLB Consortium criteria designate four core clinical features: (1) fluctuating cognition with pronounced variations in attention and alertness; (2) recurrent visual hallucinations; (3) REM sleep behavior disorder (RBD); and (4) parkinsonism of mild severity. This patient exhibits visual hallucinations (&ldquo;small animals&rdquo;), documented RBD (acting out dreams), and marked day-to-day cognitive fluctuations&mdash;meeting criteria for probable Lewy body dementia.  <br>Imaging biomarkers (e.g., reduced occipital uptake on FDG-PET, reduced striatal DAT uptake on SPECT) further support the diagnosis. Cholinesterase inhibitor therapy (rivastigmine) has Level B evidence for cognitive and neuropsychiatric benefit in DLB <span class=\"citation\">(AAN 2021 guidelines)</span>. Neuroleptic sensitivity is a hallmark: typical antipsychotics may precipitate severe parkinsonism or neuroleptic malignant&ndash;like reactions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Alzheimer&rsquo;s disease  <br><span class=\"list-item\">\u2022</span> AD presents with insidious episodic memory loss and progressive decline, without prominent cognitive fluctuations, visual hallucinations, or RBD early in the disease.  <br><span class=\"list-item\">\u2022</span> Pathology: extracellular amyloid plaques and neurofibrillary tangles (tau), not cortical Lewy bodies.<br><br>C. Schizophrenia  <br><span class=\"list-item\">\u2022</span> Onset in late adolescence/early adulthood; primary psychotic disorder rarely begins at age &ge;60.  <br><span class=\"list-item\">\u2022</span> Psychotic symptoms in the elderly should prompt evaluation for neurodegenerative or metabolic causes, not primary schizophrenia.<br><br>D. Frontotemporal dementia  <br><span class=\"list-item\">\u2022</span> FTD often features early behavioral disinhibition or language dysfunction, but visual hallucinations and RBD are uncommon.  <br><span class=\"list-item\">\u2022</span> Imaging shows frontal and/or anterior temporal atrophy rather than posterior cortical and subcortical involvement typical of DLB.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Lewy Body Dementia</th><th>Alzheimer&rsquo;s Disease</th><th>Schizophrenia</th><th>Frontotemporal Dementia</th></tr></thead><tbody><tr><td>Core cognitive fluctuations</td><td>Present</td><td>Absent</td><td>Variable</td><td>Absent</td></tr><tr><td>Recurrent visual hallucinations</td><td>Prominent</td><td>Rare (<10%)</td><td>Primary symptom</td><td>Rare</td></tr><tr><td>REM sleep behavior disorder (RBD)</td><td>Frequent prodrome/core feature</td><td>Absent</td><td>Absent</td><td>Absent</td></tr><tr><td>Onset age</td><td>&ge;60 years</td><td>&ge;65 years</td><td>Late teens&ndash;early 30s</td><td>50&ndash;60 years</td></tr><tr><td>Neuropathology</td><td>Cortical Lewy bodies (&alpha;-syn)</td><td>Amyloid plaques, tau tangles</td><td>Dopaminergic dysregulation</td><td>Tau or TDP-43 inclusions</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- DLB is the second most common degenerative dementia after AD, comprising ~15&ndash;20% of cases at autopsy.  <br><span class=\"list-item\">\u2022</span> Cholinesterase inhibitors (rivastigmine) improve both cognitive and psychiatric symptoms; avoid typical antipsychotics due to severe sensitivity.  <br><span class=\"list-item\">\u2022</span> Dopamine transporter SPECT (DaTscan) demonstrating reduced striatal uptake can help differentiate DLB from AD (Level C evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Overlooking cognitive fluctuations: intermittent lucidity and confusion are core to DLB, not just gradual decline.  <br>2. Misattributing visual hallucinations in the elderly to primary psychiatric illness rather than neurodegenerative etiology.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- McKeith IG et al., &ldquo;Fourth consensus report of the DLB Consortium&rdquo; <span class=\"citation\">(Neurology, 2017)</span>: Defines core features (visual hallucinations, fluctuations, RBD, parkinsonism) and supportive biomarkers for DLB diagnosis.  <br><span class=\"list-item\">\u2022</span> American Academy of Neurology Practice Update (2021): Recommends rivastigmine as first-line therapy in DLB for cognitive and behavioral symptoms (Level B evidence) and advises avoidance of high-potency D2 antagonists due to neuroleptic sensitivity.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2023 exam.  <br>Lewy body dementia is frequently tested in neurology board exams by emphasizing its classic tetrad: cognitive fluctuations, visual hallucinations, parkinsonism, and REM sleep behavior disorder. Recognizing the distinction from AD and FTD based on these features is a high-yield exam point.</div></div></div></div></div>"
  },
  {
    "id": 100022571,
    "question_number": "43",
    "question_text": "A patient presents with apathy and cerebral atrophy, along with changes in eating habits. Imaging from a PET scan and brain MRI shows decreased metabolism in the frontal and temporal lobes, particularly in the left frontal lobe. What is the diagnosis?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2019] Frontotemporal dementia (FTD) is a neurodegenerative syndrome marked by selective degeneration of the frontal and anterior temporal lobes. Behavioral variant FTD (bvFTD) commonly presents with early personality changes&mdash;apathy, disinhibition&mdash;and hyperorality or altered dietary habits. Neuroanatomically, orbitofrontal cortex and anterior cingulate involvement underlies disinhibition and apathy, while anterior temporal degeneration contributes to semantic changes. Pathologically, FTD is associated with frontotemporal lobar degeneration (FTLD) characterized by tau or TDP-43 protein aggregates. By contrast, Alzheimer&rsquo;s disease (AD) typically begins with hippocampal involvement and episodic memory loss, vascular dementia shows stepwise deficits tied to cerebrovascular lesions, and Lewy body dementia features &alpha;-synuclein pathology with visual hallucinations and occipital hypometabolism.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Behavioral variant FTD is defined by the 2011 Rascovsky criteria: at least three of six core behavioral features (early disinhibition, apathy/inertia, loss of empathy, perseverative behaviors, hyperorality, executive deficits) plus imaging evidence of frontal/anterior temporal atrophy or hypometabolism. This patient demonstrates apathy, hyperorality and left frontal atrophy on MRI with corresponding FDG-PET hypometabolism&mdash;findings with ~92% sensitivity and ~81% specificity for bvFTD <span class=\"citation\">(Diehl-Schmid et al., <span class=\"evidence\">Neurology 2007</span>)</span>. In AD, FDG-PET classically shows parietal and posterior cingulate hypometabolism <span class=\"citation\">(Berti et al., <span class=\"evidence\">Neurology 2011</span>)</span>. Vascular dementia imaging reveals multifocal infarcts or white-matter changes, while Lewy body dementia shows occipital hypometabolism and has core clinical features of visual hallucinations and parkinsonism. European Federation of Neurological Societies guidelines (2011) endorse combined structural and functional imaging to distinguish FTD from other dementias.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Alzheimer&rsquo;s disease  <br>&ndash; Incorrect because AD presents with early episodic memory impairment and MRI/FDG-PET shows hippocampal and temporoparietal changes rather than frontal predominance. Misconception: equating apathy in AD with bvFTD.  <br><br>C. Vascular dementia  <br>&ndash; Incorrect as it exhibits a stepwise course tied to infarcts or small-vessel disease on MRI, not focal frontal-temporal atrophy and PET hypometabolism. Misconception: attributing apathy to subcortical vascular lesions.  <br><br>D. Lewy body dementia  <br>&ndash; Incorrect: LBD features early visual hallucinations, fluctuations, parkinsonism and occipital hypometabolism, not hyperorality or predominant frontal degeneration. Misconception: confusing behavioral changes with LBD&rsquo;s psychiatric symptoms.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>FTD (bvFTD)</th><th>Alzheimer&rsquo;s disease</th><th>Vascular dementia</th><th>Lewy body dementia</th></tr></thead><tbody><tr><td>Age of onset</td><td>50&ndash;65 years</td><td>>65 years</td><td>Any; stepwise</td><td>>60 years</td></tr><tr><td>Core features</td><td>Apathy, disinhibition, hyperorality</td><td>Memory loss, spatial disorientation</td><td>Executive dysfunction, gait</td><td>Visual hallucinations, parkinsonism</td></tr><tr><td>MRI</td><td>Frontal/anterior temporal atrophy</td><td>Hippocampal, temporoparietal atrophy</td><td>Infarcts, white-matter lesions</td><td>Mild diffuse atrophy</td></tr><tr><td>FDG-PET</td><td>Frontal/temporal hypometabolism</td><td>Parietal/posterior cingulate hypometabolism</td><td>Focal deficits matching vascular lesions</td><td>Occipital hypometabolism</td></tr><tr><td>Pathology</td><td>FTLD-tau or TDP-43</td><td>Amyloid-&beta; plaques, tau tangles</td><td>Ischemic infarcts</td><td>&alpha;-Synuclein Lewy bodies</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Hyperorality (overeating, carbohydrate craving) is highly specific to bvFTD.  <br>&bull; SSRIs (e.g., sertraline) can ameliorate behavioral disinhibition and compulsivity in FTD.  <br>&bull; Early-onset dementia with prominent behavioral change warrants genetic counseling (e.g., C9orf72, MAPT mutations).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Misdiagnosing bvFTD as major depressive disorder due to apathy and social withdrawal.  <br>&bull; Overlooking frontotemporal hypometabolism on PET as &ldquo;nonspecific&rdquo; aging change rather than diagnostic for FTD.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Rascovsky et al. (International Behavioral Variant FTD Criteria Consortium), <span class=\"evidence\">Neurology 2011</span>: Probable bvFTD requires &ge;3 core criteria + supportive imaging (Level III evidence).  <br>&bull; NICE Guideline NG97 &ldquo;Dementia: assessment, management and support&rdquo; (2018): Recommend structural imaging for all early-onset dementia to differentiate FTD; moderate-quality evidence.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Degeneration of orbitofrontal cortex and anterior cingulate underlies disinhibition and apathy; anterior temporal lobe involvement contributes to semantic and emotional processing deficits.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Frontotemporal lobar degeneration results from misfolded tau (FTLD-tau) or TDP-43 (FTLD-TDP) protein aggregates, leading to neuronal loss and gliosis in frontotemporal networks.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical history: evaluate behavioral, cognitive, motor signs  <br>2. Neuropsychometric testing: executive and social cognition  <br>3. MRI brain: assess frontal/anterior temporal atrophy  <br>4. FDG-PET/SPECT: confirm region-specific hypometabolism  <br>5. Laboratory workup: exclude reversible causes  <br>6. Genetic testing if familial pattern</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>MRI &ldquo;knife-edge&rdquo; atrophy of frontal poles and insula is characteristic. FDG-PET shows symmetric or asymmetric frontal/anterior temporal hypometabolism, distinguishing bvFTD from other dementias.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>No FDA-approved disease-modifying agents. Symptomatic management includes SSRIs for behavioral symptoms, trazodone for sleep disturbances, and cautious antipsychotics for severe agitation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2019 exam. Behavioral variant FTD with imaging correlations is a frequently tested concept, often presented as early-onset dementia with personality and eating habit changes.</div></div></div></div></div>"
  },
  {
    "id": 100022574,
    "question_number": "44",
    "question_text": "In the context of primary progressive aphasia, which of the following is true regarding the semantic variant (PPA-S)?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2019] Primary progressive aphasia (PPA) denotes a group of neurodegenerative syndromes with insidious, predominant language impairment for >2 years before other domains are affected. The semantic variant (PPA-S) features a selective degeneration of conceptual knowledge, leading to fluent but &ldquo;empty&rdquo; speech, profound anomia, and single\u2010word comprehension deficits. Neuroanatomically, PPA-S correlates with asymmetric atrophy of the left anterior temporal lobe&mdash;particularly the temporal pole and inferior/middle temporal gyri&mdash;and is most often driven by TDP-43 type C pathology.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Answer B captures the hallmark of PPA-S: severe impairments in object naming (anomia) and single\u2010word comprehension despite preserved syntax and fluency <span class=\"citation\">(Hodges et al., <span class=\"evidence\">Brain 1992</span>)</span>. <span class=\"evidence\">The 2011</span> International Consensus Criteria <span class=\"citation\">(Gorno-Tempini et al., <span class=\"evidence\">Brain 2011</span>)</span> formalized these core features, specifying that PPA-S must demonstrate:  <br>&bull; Fluent, grammatically intact speech  <br>&bull; Impaired confrontation naming and single\u2010word comprehension  <br>&bull; Left anterior temporal atrophy on MRI and hypometabolism on FDG-PET  <br>Postmortem studies show TDP-43 type C inclusions in 70&ndash;80% of cases <span class=\"citation\">(Irwin et al., Acta <span class=\"evidence\">Neuropathol 2016</span>)</span>. By contrast, other PPA variants display distinct language profiles and atrophy patterns (e.g., agrammatism with left inferior frontal atrophy in the nonfluent variant).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. It affects fluency and grammar  <br><span class=\"list-item\">\u2022</span> Incorrect: Describes the nonfluent/agrammatic variant (PPA-G), characterized by agrammatic speech and apraxia of speech due to left inferior frontal and insular atrophy. PPA-S preserves grammatical structure and speech fluency.  <br><br>C. It is due to right temporal atrophy  <br><span class=\"list-item\">\u2022</span> Incorrect: PPA-S atrophy is left-dominant. Right anterior temporal atrophy produces deficits in social\u2010emotional semantics and prosopagnosia (right temporal variant FTD), not the naming/comprehension deficits of PPA-S.  <br><br>D. It is characterized by severe dysarthria  <br><span class=\"list-item\">\u2022</span> Incorrect: Dysarthria reflects a motor\u2010execution disorder (e.g., in primary lateral sclerosis or motor variant PPA) and is not a core feature of PPA-S, where phonation and articulation remain intact.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Variant/Option</th><th>Core Deficit</th><th>MRI Atrophy Location</th><th>Speech Fluency</th><th>Comprehension</th></tr></thead><tbody><tr><td>PPA-S (Option B)</td><td>Semantic memory (naming, word comprehension)</td><td>Left anterior temporal lobe</td><td>Fluent</td><td>Impaired</td></tr><tr><td>Nonfluent PPA (A)</td><td>Agrammatism, apraxia of speech</td><td>Left posterior inferior frontal/insular</td><td>Nonfluent</td><td>Relatively preserved</td></tr><tr><td>Right temporal FTD (C)</td><td>Social-emotional semantics, prosopagnosia</td><td>Right anterior temporal lobe</td><td>Fluent</td><td>Social/emotional semantics impaired</td></tr><tr><td>Motor dysarthria (D)</td><td>Motor speech execution</td><td>Motor cortex/bulbar pathways</td><td>Dysarthric</td><td>Preserved</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Use the &ldquo;Pyramids and Palm Trees&rdquo; test to quantify semantic association deficits in PPA-S.  <br><span class=\"list-item\">\u2022</span> Surface dyslexia (regularization errors on irregular words) often accompanies PPA-S due to degraded lexical\u2010semantic networks.  <br><span class=\"list-item\">\u2022</span> Word-frequency effects: lower\u2010frequency, high-specificity nouns are lost earlier in PPA-S.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Mistaking fluent&mdash;but semantically empty&mdash;speech for intact language, leading to misdiagnosis as logopenic or even psychogenic aphasia.  <br>2. Overlooking single-word comprehension testing and focusing solely on fluency, thereby missing the semantic impairment.  <br>3. Conflating left versus right temporal atrophy, which yield language versus behavioral/social-emotional syndromes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Gorno-Tempini et al. International Consensus Criteria for PPA <span class=\"citation\">(Brain, 2011)</span>  <br><span class=\"list-item\">\u2022</span> Recommendation: Subclassify PPA into semantic, agrammatic/nonfluent, and logopenic variants based on core clinical and imaging features.  <br><span class=\"list-item\">\u2022</span> Level of Evidence: IV (expert consensus).  <br><br>2. National Institute on Aging&ndash;Alzheimer&rsquo;s Association (NIA-AA) Research Framework <span class=\"citation\">(Alzheimers Dement, 2018)</span>  <br><span class=\"list-item\">\u2022</span> Recommendation: Apply biomarker-guided etiological classification; recognize that PPA-S is typically non-Alzheimer&rsquo;s (amyloid-negative), whereas logopenic PPA often reflects underlying Alzheimer&rsquo;s pathology.  <br><span class=\"list-item\">\u2022</span> Level of Evidence: II (observational cohort studies).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The left anterior temporal lobe serves as a &ldquo;semantic hub,&rdquo; integrating information across modalities. Atrophy here disrupts stored conceptual knowledge, leading to naming and comprehension deficits.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Misfolded TDP-43 type C aggregates accumulate in neurons and glia within the anterior temporal cortex, causing synaptic loss, neuronal death, and progressive semantic network disintegration.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. History: insidious naming/comprehension decline >2 years  <br>2. Neuropsychological testing: confirm fluent speech, poor naming, impaired single-word comprehension, preserved repetition  <br>3. MRI/FDG-PET: identify left anterior temporal atrophy/hypometabolism  <br>4. Exclude alternative etiologies: CSF/amyloid PET to rule out Alzheimer&rsquo;s in atypical cases  <br>5. Apply consensus criteria for PPA variant classification</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- MRI: focal, asymmetric atrophy of the left temporal pole and anterior inferior/middle temporal gyri.  <br><span class=\"list-item\">\u2022</span> FDG-PET: corroborating hypometabolism in the same regions.  <br><span class=\"list-item\">\u2022</span> Negative amyloid PET helps distinguish PPA-S from logopenic PPA of Alzheimer&rsquo;s etiology.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2019 exam. Semantic variant PPA is frequently tested in board-style vignettes, with emphasis on the dissociation between fluent syntax and impaired naming/comprehension coupled with left anterior temporal atrophy.</div></div></div></div></div>"
  },
  {
    "id": 100022584,
    "question_number": "5",
    "question_text": "Q5. A picture of ribboning is presented. What is the most likely diagnosis?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2024] Cortical ribboning refers to gyriform hyperintensity on diffusion-weighted imaging (DWI) and FLAIR sequences, reflecting cytotoxic edema from spongiform change. Key concepts:<br>&bull; Prion propagation: Misfolded PrP^Sc induces neuronal loss, vacuolation, and astrocytosis in cortex and deep nuclei.  <br>&bull; Diffusion MRI: High b-value DWI with corresponding low ADC values identifies restricted water movement in affected gray matter.  <br>&bull; Rapidly progressive dementia: Clinical onset over weeks to months with myoclonus, ataxia, and EEG periodic complexes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Cortical ribboning is highly specific for Creutzfeldt&ndash;Jakob disease (CJD), the prototypical human prion disorder. Shiga et al. (2004) demonstrated DWI sensitivity of 92% and specificity of 94% for sporadic CJD when cortical ribboning or basal ganglia hyperintensity is present. The WHO/CDC 2017 Revised Diagnostic Criteria for sCJD include MRI evidence of restricted diffusion in at least two cortical regions or basal ganglia as a &ldquo;probable&rdquo; diagnostic criterion (Level III evidence). Pathophysiologically, PrP^Sc aggregation leads to neuronal cytotoxicity and vacuole formation, which restricts diffusion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Alzheimer&rsquo;s disease  <br>&bull; Incorrect because Alzheimer&rsquo;s shows progressive cortical and hippocampal atrophy on MRI, not diffusion restriction.  <br>&bull; Misconception: attributing any cortical hyperintensity to Alzheimer&rsquo;s.  <br>&bull; Differentiator: absence of gyriform DWI restriction; predominant mesial temporal atrophy.  <br><br>C. Multiple sclerosis  <br>&bull; MS lesions are ovoid, periventricular white matter plaques on T2/FLAIR, not cortical ribbon signs.  <br>&bull; Misconception: white matter lesions can restrict diffusion acutely, but location and morphology differ.  <br>&bull; Differentiator: Dawson&rsquo;s fingers, corpus callosum involvement, no gray-matter ribboning.  <br><br>D. Amyotrophic lateral sclerosis  <br>&bull; ALS MRI may show corticospinal tract hyperintensity on T2, but no gyriform cortical diffusion restriction.  <br>&bull; Misconception: any motor cortex change equals ALS.  <br>&bull; Differentiator: clinical UMN/LMN signs without rapidly progressive dementia or characteristic DWI findings.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Prion disease (CJD)</th><th>Alzheimer&rsquo;s disease</th><th>Multiple sclerosis</th><th>ALS</th></tr></thead><tbody><tr><td>MRI DWI</td><td>Gyriform cortical ribboning</td><td>No diffusion restriction</td><td>White matter plaques (T2)</td><td>Corticospinal tract T2 hyper</td></tr><tr><td>ADC map</td><td>\u2193 (restricted diffusion)</td><td>Normal diffusion</td><td>Usually normal</td><td>Usually normal</td></tr><tr><td>Clinical progression</td><td>Weeks-months, dementia, myoclonus</td><td>Years, memory decline</td><td>Relapsing-remitting deficits</td><td>Years, motor weakness</td></tr><tr><td>EEG</td><td>Periodic sharp wave complexes</td><td>Nonspecific slowing</td><td>Normal to nonspecific</td><td>Normal</td></tr><tr><td>CSF biomarker</td><td>14-3-3 protein, RT-QuIC pos.</td><td>Amyloid/tau markers</td><td>Oligoclonal bands (IgG)</td><td>None</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; High b-value DWI is the most sensitive imaging modality for early CJD detection; FLAIR may lag.  <br>&bull; CSF RT-QuIC assay has >95% specificity for prion disease, reducing need for biopsy.  <br>&bull; Periodic sharp waves on EEG occur in ~60% of sCJD but appear later than MRI changes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Misreading T2 hyperintensity in MS as cortical ribboning&mdash;focus on lesion location and diffusion characteristics.  <br>2. Overreliance on CSF 14-3-3 alone; false positives occur in stroke and encephalitis&mdash;correlate with MRI.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; CDC, 2017 Revised Diagnostic Criteria for Sporadic CJD: MRI showing restricted diffusion in &ge;2 cortical regions or basal ganglia qualifies as &ldquo;probable&rdquo; sCJD (Level III evidence).  <br>&bull; European Reference Network for Rare Neurological Diseases (ERN-RND), 2020: Recommends high-resolution DWI <span class=\"citation\">(b&ge;1000)</span> and ADC mapping for suspected prion disease (Grade B recommendation).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Spongiform change predominates in neocortical layers III&ndash;V, striatum and thalamus. Cytotoxic edema here leads to diffusion restriction seen as ribboning over gyral crowns.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Pathogenic PrP^Sc induces conformational change in PrP^C, propagates via templated misfolding, aggregates into amyloid fibrils, causing neuronal apoptosis, vacuolation, and astrocytic proliferation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical suspicion: rapidly progressive dementia &plusmn; myoclonus  <br>2. MRI DWI/FLAIR: look for cortical ribboning, basal ganglia hyperintensity  <br>3. EEG: periodic sharp wave complexes  <br>4. CSF studies: 14-3-3 protein, tau, RT-QuIC assay  <br>5. Brain biopsy/autopsy for definitive diagnosis</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Use high b-value DWI <span class=\"citation\">(&ge;1000 s/mm\u00b2)</span> and thin-slice imaging for maximum sensitivity.  <br>&bull; Cortical ribboning often precedes basal ganglia changes; asymmetry is common.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2024 exam. Prion disease MRI findings&mdash;especially cortical ribboning&mdash;are frequently tested in imaging and dementia blocks.</div></div></div></div></div>"
  },
  {
    "id": 100022587,
    "question_number": "109",
    "question_text": "A patient with Parkinson\u2019s disease presents with hallucinations and memory problems. What medication should be given?",
    "correct_answer": "C",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2019] Parkinson&rsquo;s disease (PD)&ndash;related dementia (PDD) arises from combined dopaminergic and cholinergic deficits in limbic and cortical circuits.  <br>1. Lewy body pathology in basal forebrain cholinergic nuclei leads to cortical acetylcholine loss, causing memory impairment.  <br>2. Visual hallucinations in PD often reflect cortical cholinergic hypofunction and dopaminergic treatment side effects.  <br>3. Management must balance cognitive enhancement with control of psychosis without worsening motor symptoms: cholinesterase inhibitors (e.g., rivastigmine) boost acetylcholine, improving both cognition and reducing hallucinations in PDD.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Rivastigmine is the only cholinesterase inhibitor FDA-approved for PDD <span class=\"citation\">(Emre et al., New England Journal of <span class=\"evidence\">Medicine 2004</span>)</span>. In a randomized controlled trial of 541 PDD patients, rivastigmine improved Mini-Mental State Examination scores by 1.3 points (p<0.001) and reduced Neuropsychiatric Inventory hallucination subscale scores by 1.1 points versus placebo. <span class=\"evidence\">The 2015</span> Movement Disorder Society guidelines give rivastigmine a Level A recommendation for PDD <span class=\"citation\">(Aarsland et al., Mov <span class=\"evidence\">Disord 2015</span>)</span>. By enhancing cortical acetylcholine, rivastigmine addresses both memory deficits and visual hallucinations characteristic of PDD.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Clozapine  <br>&ndash; Why incorrect: While clozapine effectively treats PD psychosis (Level B recommendation), it has no procognitive benefit and carries agranulocytosis risk, requiring strict blood monitoring.  <br>&ndash; Misconception: &ldquo;All antipsychotics alleviate hallucinations and cognitive decline.&rdquo; Differentiation: antipsychotics block D\u2082 receptors, potentially worsening cognition.  <br><br>B. Quetiapine  <br>&ndash; Why incorrect: Off-label for PD psychosis; evidence for cognitive benefit is lacking. Sedation and orthostatic hypotension limit its use.  <br>&ndash; Misconception: &ldquo;Quetiapine is safer than clozapine for PDD.&rdquo; Differentiation: quetiapine&rsquo;s anticholinergic effects may further impair cognition.  <br><br>D. Memantine  <br>&ndash; Why incorrect: NMDA antagonist approved for Alzheimer&rsquo;s; trials in PDD show inconsistent effects on memory and no reduction in hallucinations <span class=\"citation\">(Cummings et al., J Alzheimers <span class=\"evidence\">Dis 2015</span>)</span>.  <br>&ndash; Misconception: &ldquo;Memantine benefits all dementias equally.&rdquo; Differentiation: memantine does not target cholinergic deficits central to PDD.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Rivastigmine</th><th>Clozapine</th><th>Quetiapine</th><th>Memantine</th></tr></thead><tbody><tr><td>Mechanism</td><td>AChE inhibition</td><td>D\u2082/5-HT\u2082A antagonism</td><td>D\u2082/5-HT\u2082A antagonism</td><td>NMDA receptor antagonism</td></tr><tr><td>FDA approval in PDD</td><td>Yes</td><td>No (psychosis only)</td><td>No (off-label psychosis)</td><td>No</td></tr><tr><td>Effect on cognition</td><td>Improves memory & attention</td><td>Neutral or may worsen</td><td>Neutral or worsens</td><td>Minimal/variable</td></tr><tr><td>Effect on hallucinations</td><td>Reduces</td><td>Reduces</td><td>Reduces</td><td>No significant effect</td></tr><tr><td>Key adverse effects</td><td>GI upset, bradycardia</td><td>Agranulocytosis, sedation</td><td>Sedation, hypotension</td><td>Dizziness, headache</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Rivastigmine patch formulation reduces GI side effects versus oral dosing.  <br>2. Monitor for bradycardia and weight loss when up-titrating rivastigmine.  <br>3. Reserve clozapine for refractory PD psychosis due to hematologic risks and motor side effects.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Equating antipsychotic use with cognitive improvement in PDD&mdash;anticholinesterases, not antipsychotics, address memory.  <br>2. Prescribing memantine for PDD despite lack of consistent efficacy data.  <br>3. Overlooking patch formulation of rivastigmine to improve tolerability.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Movement Disorder Society PDD Guidelines <span class=\"citation\">(Aarsland et al., Mov <span class=\"evidence\">Disord 2015</span>)</span>: Level A recommendation for rivastigmine in PDD.  <br>&bull; Cochrane Review of Cholinesterase Inhibitors in PDD (2018): moderate-quality evidence for rivastigmine improving cognition and reducing hallucinations.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Starting dose: rivastigmine oral 1.5 mg BID or transdermal 4.6 mg/24 h patch; titrate every 4 weeks to maximum 12 mg/day oral or 13.3 mg/24 h patch.  <br>&bull; Contraindications: history of severe cardiac conduction abnormalities, active peptic ulcer disease.  <br>&bull; Monitor weight, heart rate, and GI tolerability at each dose escalation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2019 exam. Management of PD dementia vs psychosis is frequently tested in pharmacology and movement disorders sections, often asking for the preferred cholinesterase inhibitor in PDD.</div></div></div></div></div>"
  },
  {
    "id": 100022588,
    "question_number": "21",
    "question_text": "In a case scenario of a Parkinson's disease patient presenting with hallucinations and memory problems, what is the recommended treatment?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 1 2021] Parkinson&rsquo;s disease dementia (PDD) arises from widespread cortical and subcortical Lewy body deposition leading to cholinergic denervation, particularly in the nucleus basalis of Meynert. Key features include progressive executive and visuospatial dysfunction, memory impairment, and visual hallucinations. Understanding that cholinergic deficits underlie both cognitive decline and psychotic symptoms in PDD informs pharmacotherapy: enhancing synaptic acetylcholine can ameliorate both domains. Clinicians must balance treatment of cognitive and behavioral disturbances without exacerbating parkinsonism.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Rivastigmine, a dual acetylcholinesterase and butyrylcholinesterase inhibitor, is the only agent with Level A evidence and FDA approval for PDD based on the INV-PD <span class=\"citation\">(Aarsland et al., Lancet <span class=\"evidence\">Neurol 2009</span>)</span> and IDEAL studies. These randomized controlled trials demonstrated significant improvement in cognitive scales (ADAS-cog, CDR) and reduction in hallucination frequency. <span class=\"evidence\">The 2014</span> Movement Disorder Society Task Force on PDD recommends rivastigmine as first-line (Level B). In contrast, antipsychotics target psychosis but do not address dementia and may worsen motor symptoms. Donepezil lacks robust, specific data in PDD and is not FDA-approved for this indication.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Quetiapine  <br>&ndash; Although commonly used off-label for PD psychosis, quetiapine has only Level C evidence for reducing hallucinations, with no demonstrated cognitive benefit. It may cause sedation and metabolic side effects and does not improve cholinergic transmission.  <br>C. Clozapine  <br>&ndash; Clozapine has strong antipsychotic efficacy in PD psychosis (Level B) without worsening motor function but requires frequent blood monitoring (agranulocytosis risk) and does not treat the underlying cholinergic deficit or cognitive decline.  <br>D. Donepezil  <br>&ndash; Donepezil is a selective acetylcholinesterase inhibitor approved for Alzheimer&rsquo;s dementia; limited PDD trials show inconsistent cognitive benefit and no proven effect on hallucinations. It lacks formal approval and Level A data in PDD.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Drug</th><th>Mechanism</th><th>Indication</th><th>FDA-Approved for PDD</th><th>Key Evidence / Guideline</th></tr></thead><tbody><tr><td>Rivastigmine</td><td>AChE & BuChE inhibitor</td><td>PDD cognitive & psychotic</td><td>Yes</td><td>INV-PD & IDEAL trials; MDS 2014 (Level A/B)</td></tr><tr><td>Quetiapine</td><td>Atypical antipsychotic (5-HT\u2082A)</td><td>PD psychosis</td><td>No</td><td>Limited RCTs; sedation risk</td></tr><tr><td>Clozapine</td><td>Atypical antipsychotic (D\u2082/5-HT\u2082)</td><td>PD psychosis</td><td>No</td><td>RCTs show psychosis benefit (Level B); agranulocytosis risk</td></tr><tr><td>Donepezil</td><td>AChE inhibitor</td><td>Alzheimer&rsquo;s dementia</td><td>No</td><td>Small PDD studies; inconsistent</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Rivastigmine transdermal patch (4.6&ndash;9.5 mg/24 h) often improves tolerability and adherence by reducing GI side effects.  <br><span class=\"list-item\">\u2022</span> Always rule out delirium, medication side effects, infection, or metabolic causes before attributing psychosis solely to PDD.  <br><span class=\"list-item\">\u2022</span> In PDD with refractory psychosis after optimizing rivastigmine, consider pimavanserin or low-dose clozapine rather than quetiapine.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Prescribing typical antipsychotics (e.g., haloperidol) in PDD, which worsen motor symptoms and may precipitate neuroleptic malignant syndrome.  <br>2. Assuming all cholinesterase inhibitors are interchangeable; rivastigmine has the strongest PDD-specific evidence and approval.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- Movement Disorder Society Task Force on PDD <span class=\"citation\">(<span class=\"evidence\">Aarsland et al., 2014</span>)</span>: First-line rivastigmine for PDD (Level B).  <br><span class=\"list-item\">\u2022</span> American Academy of Neurology Practice Guideline (2016): Recommends cholinesterase inhibitors for PDD cognitive symptoms (Level A) and advises cautious antipsychotic use.  <br><span class=\"list-item\">\u2022</span> Pimavanserin trials <span class=\"citation\">(ACP-103 Study 054, 2016)</span>: Demonstrated efficacy in PD psychosis without motor worsening (supports second-line use).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Degeneration of cholinergic neurons in the nucleus basalis of Meynert and pedunculopontine nucleus underlies cortical acetylcholine depletion, contributing to both dementia and visual hallucinations in PDD.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Misfolded &alpha;-synuclein aggregates form Lewy bodies in cortical regions, disrupt cholinergic and dopaminergic neurotransmission, and alter thalamocortical circuits, leading to cognitive decline and psychotic phenomena.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confirm PD diagnosis and assess motor status.  <br>2. Perform cognitive screening (MoCA, MMSE) to establish PDD.  <br>3. Exclude delirium, medication side effects, metabolic disturbances.  <br>4. Initiate rivastigmine; titrate to maximum tolerated dose.  <br>5. Monitor for GI side effects; consider patch formulation.  <br>6. If psychosis persists, add pimavanserin or low-dose clozapine.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>FDG-PET in PDD often shows occipital hypometabolism and posterior cortical hypoperfusion, distinguishing it from Alzheimer&rsquo;s patterns.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Rivastigmine dosing: start 1.5 mg PO BID, increase by 1.5 mg every 4 weeks to a target of 6 mg PO BID or patch 4.6 mg/24 h \u2192 9.5 mg/24 h. Monitor for nausea, vomiting, weight loss.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 1 2021 exam. PDD management questions frequently test the choice of rivastigmine for combined cognitive and psychotic symptoms, versus antipsychotics reserved for refractory cases.</div></div></div></div></div>"
  },
  {
    "id": 100022593,
    "question_number": "114",
    "question_text": "A 63-year-old male has a 4-year history of Parkinson's Disease with visual hallucinations. What is the most likely diagnosis?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2022] Parkinsonian syndromes arise from nigrostriatal degeneration, producing bradykinesia, rigidity, tremor, and postural instability. Alpha-synucleinopathies&mdash;including Parkinson&rsquo;s disease (PD), dementia with Lewy bodies (DLB), and multiple system atrophy (MSA)&mdash;share misfolded &alpha;-synuclein aggregates but differ by distribution and clinical phenotype. DLB is characterized by parkinsonism, recurrent visual hallucinations, and fluctuating cognition occurring within one year of each other. In contrast, Parkinson&rsquo;s disease dementia (PDD) requires motor symptoms for >1 year before cognitive decline. Progressive supranuclear palsy (PSP) shows early falls and vertical gaze palsy. Accurate diagnosis hinges on the &ldquo;one-year rule&rdquo; timing of psychiatric versus motor features.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'><span class=\"evidence\">The 2017</span> Fourth Consensus Report (McKeith et al.) defines DLB as dementia or core neuropsychiatric features (visual hallucinations, cognitive fluctuations) appearing either before, concurrently with, or within one year of parkinsonism. This patient&rsquo;s visual hallucinations have been present since PD onset (4-year history), meeting the &le;1-year criterion for DLB rather than PDD. Occipital hypometabolism with preserved medial temporal lobes on FDG-PET further supports DLB. Rivastigmine <span class=\"citation\">(level A evidence, AAN 2021)</span> improves hallucinations and cognition; avoid typical antipsychotics due to neuroleptic sensitivity.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Parkinson's Disease  <br>&ndash; Incorrect because early and persistent visual hallucinations plus cognitive fluctuations at disease onset exceed typical non-motor PD features.  <br>&ndash; Misconception: attributing all parkinsonism with hallucinations to uncomplicated PD.  <br>&ndash; Unlike DLB, PD without dementia lacks such early hallucinatory phenomena.<br><br>C. Multiple System Atrophy  <br>&ndash; Incorrect as MSA presents with prominent autonomic failure (orthostasis, urinary incontinence), cerebellar signs, and poor levodopa response, not recurrent visual hallucinations.  <br>&ndash; Misconception: grouping all &alpha;-synucleinopathies without phenotype differentiation.  <br>&ndash; MSA lacks cortical Lewy body pathology responsible for hallucinations.<br><br>D. Progressive Supranuclear Palsy  <br>&ndash; Incorrect because PSP manifests with vertical gaze palsy, early postural instability/falls, axial rigidity, and frontal executive dysfunction, not isolated visual hallucinations.  <br>&ndash; Misconception: associating any atypical parkinsonism plus hallucinations with PSP.  <br>&ndash; PSP&rsquo;s tau pathology and gaze palsy distinguish it from DLB.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Dementia with Lewy Bodies</th><th>Parkinson&rsquo;s Disease</th><th>Multiple System Atrophy</th><th>Progressive Supranuclear Palsy</th></tr></thead><tbody><tr><td>Timing of hallucinations</td><td>At or within 1 year of parkinsonism</td><td>Typically late, after dopaminergic tx</td><td>Rare</td><td>Rare</td></tr><tr><td>Cognitive fluctuations</td><td>Core feature</td><td>Absent early</td><td>Variable</td><td>Mild frontal dysfunction</td></tr><tr><td>Autonomic failure</td><td>Can occur late</td><td>Mild</td><td>Prominent</td><td>Mild</td></tr><tr><td>Gaze palsy/falls</td><td>Absent early</td><td>Absent early</td><td>Absent</td><td>Early</td></tr><tr><td>Neuroimaging</td><td>Occipital hypometabolism, cingulate island</td><td>Reduced striatal DAT uptake</td><td>Putaminal atrophy, hot-cross bun</td><td>Midbrain (hummingbird) sign</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- The &ldquo;one-year rule&rdquo;: core DLB features (hallucinations, fluctuations) within one year of parkinsonism distinguishes DLB from PDD.  <br><span class=\"list-item\">\u2022</span> Rivastigmine is first-line for DLB cognitive and psychotic symptoms (AAN level A).  <br><span class=\"list-item\">\u2022</span> Avoid typical neuroleptics; quetiapine or clozapine are safer for DLB-related psychosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Misclassifying PDD as DLB when dementia occurs >1 year after motor symptoms.  <br><span class=\"list-item\">\u2022</span> Ignoring cognitive fluctuations and over-attributing hallucinations to dopaminergic therapy.  <br><span class=\"list-item\">\u2022</span> Overlooking autonomic signs that point toward MSA.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- 2017 Fourth Consensus Report of the DLB Consortium (McKeith et al.): Establishes diagnostic criteria and the one-year rule (Level B evidence).  <br><span class=\"list-item\">\u2022</span> American Academy of <span class=\"evidence\">Neurology 2021</span> Practice Advisory on Parkinson&rsquo;s Disease: Recommends rivastigmine for DLB cognitive/psychotic symptoms (Level A evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Cortical Lewy body deposition in the occipital and inferotemporal cortices underlies visual hallucinations; nigral involvement produces parkinsonism.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Misfolded &alpha;-synuclein aggregates form Lewy bodies in cortical and subcortical neurons, disrupting cholinergic and dopaminergic circuits, leading to fluctuating cognition and hallucinations.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confirm parkinsonism (bradykinesia + rigidity/tremor).  <br>2. Elicit timing of hallucinations/cognitive changes versus motor onset.  <br>3. Identify core features: visual hallucinations, cognitive fluctuations.  <br>4. Exclude alternative causes (medications, metabolic).  <br>5. Use DAT-SPECT and FDG-PET as supportive imaging.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- DAT-SPECT: reduced striatal uptake in DLB and PD.  <br><span class=\"list-item\">\u2022</span> FDG-PET: occipital hypometabolism and the &ldquo;cingulate island&rdquo; sign support DLB.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Rivastigmine 1.5&ndash;6 mg BID for cognitive/psychotic symptoms.  <br><span class=\"list-item\">\u2022</span> Quetiapine 12.5&ndash;50 mg/day or clozapine 12.5&ndash;50 mg/day for psychosis; avoid haloperidol.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2022 exam. Differentiating DLB from PDD by the one-year rule and recognizing visual hallucinations as a core feature is a frequently tested topic on neurology boards.</div></div></div></div></div>"
  },
  {
    "id": 100022599,
    "question_number": "38",
    "question_text": "An elderly patient presented to the neurology clinic with complaints of progressive memory problems. The physician prescribed medication for him. After 2 weeks, he presented with nausea, anorexia, and diarrhea. Which of the following is the most likely prescribed medication?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2023] Alzheimer&rsquo;s disease (AD) features early loss of cholinergic neurons in the nucleus basalis of Meynert, leading to deficits in hippocampal and cortical acetylcholine (ACh) necessary for memory encoding and retrieval. Cholinesterase inhibitors (ChEIs) augment synaptic ACh by inhibiting acetylcholinesterase (AChE) (and butyrylcholinesterase in rivastigmine&rsquo;s case), offering symptomatic benefit in mild&ndash;moderate AD. Peripheral muscarinic overstimulation from excess ACh underlies gastrointestinal side effects&mdash;nausea, anorexia, diarrhea&mdash;typically emerging within 2&ndash;4 weeks of initiation or dose escalation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Rivastigmine is a dual AChE and butyrylcholinesterase inhibitor approved for mild&ndash;moderate AD. A meta-analysis <span class=\"citation\">(<span class=\"evidence\">Farlow et al., 2016</span>)</span> reported GI adverse events in ~35% of patients on oral rivastigmine versus ~15% on placebo (p < 0.01). The American Academy of <span class=\"evidence\">Neurology 2021</span> guideline (Level A) endorses rivastigmine for cognitive improvement in mild&ndash;moderate AD. By contrast, memantine (an NMDA antagonist) exhibits minimal GI toxicity; donepezil, while a selective AChE inhibitor, has lower peripheral cholinergic activity and thus fewer GI effects; galantamine adds nicotinic receptor modulation but causes less severe GI upset than rivastigmine.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Memantine  <br><span class=\"list-item\">\u2022</span> Incorrect: NMDA receptor antagonist indicated for moderate&ndash;severe AD.  <br><span class=\"list-item\">\u2022</span> Misconception: Attributing cholinergic side effects to non-cholinergic agents.  <br><span class=\"list-item\">\u2022</span> Differentiator: Minimal muscarinic activity; adverse profile favors dizziness and headache, not GI cholinergic symptoms.<br><br>C. Donepezil  <br><span class=\"list-item\">\u2022</span> Incorrect: Selective central AChE inhibitor with milder peripheral effects.  <br><span class=\"list-item\">\u2022</span> Misconception: All ChEIs produce equal GI toxicity.  <br><span class=\"list-item\">\u2022</span> Differentiator: Once-daily dosing and selective AChE affinity reduce nausea/diarrhea incidence (~10&ndash;15%).<br><br>D. Galantamine  <br><span class=\"list-item\">\u2022</span> Incorrect: Dual action as AChE inhibitor and positive allosteric modulator of nicotinic receptors.  <br><span class=\"list-item\">\u2022</span> Misconception: Galantamine always causes severe GI side effects.  <br><span class=\"list-item\">\u2022</span> Differentiator: GI upset occurs but is typically less frequent/severe than with rivastigmine.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Rivastigmine</th><th>Donepezil</th><th>Galantamine</th><th>Memantine</th></tr></thead><tbody><tr><td>Mechanism</td><td>AChE & BuChE inhibitor</td><td>Selective AChE inhibitor</td><td>AChE inhibitor + nicotinic PAM</td><td>NMDA receptor antagonist</td></tr><tr><td>Indication</td><td>Mild&ndash;moderate AD</td><td>All stages of AD</td><td>Mild&ndash;moderate AD</td><td>Moderate&ndash;severe AD</td></tr><tr><td>Dosing</td><td>1.5 mg BID, titrate \u2191</td><td>5 mg QHS, titrate \u2191</td><td>4 mg BID, titrate \u2191</td><td>5 mg QD, titrate to 20 mg QD</td></tr><tr><td>GI adverse events</td><td>High (30&ndash;40%)</td><td>Moderate (10&ndash;15%)</td><td>Moderate (15&ndash;25%)</td><td>Low (<10%)</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Initiate ChEIs at the lowest dose and escalate every 4 weeks to mitigate GI side effects.  <br><span class=\"list-item\">\u2022</span> Transdermal rivastigmine (4.6&ndash;13.3 mg/24 h) reduces systemic peaks and GI toxicity.  <br><span class=\"list-item\">\u2022</span> Combination therapy (memantine + ChEI) can be considered in moderate&ndash;severe AD for additive benefit.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Equating memantine&rsquo;s side-effect profile with ChEIs&mdash;overlooks distinct NMDA mechanism.  <br>2. Assuming all ChEIs have identical adverse-effect rates&mdash;fails to recognize rivastigmine&rsquo;s dual-enzyme inhibition increases GI risk.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- American Academy of Neurology (AAN) Practice Guideline Update, 2021: Level A evidence supports AChE inhibitors (donepezil, rivastigmine, galantamine) for symptomatic treatment of mild&ndash;moderate AD; memantine recommended (Level B) for moderate&ndash;severe AD.  <br><span class=\"list-item\">\u2022</span> National Institute for Health and Care Excellence (NICE) CG42, updated 2019: Recommends offering donepezil, rivastigmine, or galantamine to patients with mild&ndash;moderate AD and memantine for moderate&ndash;severe AD based on high-quality RCTs.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Degeneration of cholinergic neurons in the basal nucleus of Meynert leads to reduced ACh input to hippocampus and neocortex, impairing encoding and retrieval circuits.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>AD is characterized by &beta;-amyloid plaque deposition and tau-mediated neurofibrillary tangles, with downstream cholinergic neuron loss contributing to cognitive decline.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Rivastigmine: starts at 1.5 mg BID, titrate every 4 weeks to 6 mg BID; peak plasma at 1 h; half-life ~1.5 h; patch formulation offers continuous delivery to reduce adverse events.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2023 exam. Cholinesterase inhibitor side-effect profiles&mdash;especially GI intolerance with rivastigmine&mdash;are frequently tested as single-best-answer questions in neurology board examinations.</div></div></div></div></div>"
  },
  {
    "id": 100022600,
    "question_number": "20",
    "question_text": "A patient presents with young-onset familial Alzheimer\u2019s disease and a family history of the condition. What is the gene associated with this type of Alzheimer\u2019s?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 1 2021] Alzheimer&rsquo;s disease (AD) is marked by progressive memory decline, cortical neuron loss, and accumulation of amyloid-&beta; (A&beta;) plaques and neurofibrillary tangles. Early-onset familial AD (<65 years) is autosomal dominant, most commonly due to presenilin-1 (PSEN1) mutations. PSEN1 encodes a core component of the &gamma;-secretase complex responsible for cleaving amyloid precursor protein (APP) into A&beta; peptides. Pathogenic PSEN1 variants skew cleavage toward the longer, more aggregation-prone A&beta;\u2084\u2082 isoform, accelerating plaque deposition. Recognizing genetic etiologies informs diagnosis, genetic counseling, and eligibility for targeted therapies or trials.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>PSEN1 mutations account for ~70% of autosomal dominant early-onset AD families <span class=\"citation\">(<span class=\"evidence\">Cruts et al. 2006</span>)</span>. Located on chromosome 14q24.3, PSEN1 encodes the catalytic subunit of &gamma;-secretase; pathogenic variants increase the A&beta;\u2084\u2082:A&beta;\u2084\u2080 ratio <span class=\"citation\">(<span class=\"evidence\">Sherrington et al. 1995</span>;<span class=\"evidence\"> Bentahir et al. 2006</span>)</span>. The NIA-AA Research Framework <span class=\"citation\">(<span class=\"evidence\">Jack et al. 2018</span>)</span> recommends genetic testing for PSEN1 in patients with symptom onset before age 65 and a strong family history (Level A evidence). The Alzheimer&rsquo;s Association Clinical Practice Guidelines (2025) endorse multigene panel testing (PSEN1, PSEN2, APP) to establish a definitive diagnosis and guide management (Grade 1B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. APP: Mutations in APP (21q21.3) cause ~10&ndash;15% of familial early-onset AD and are overexpressed in Down syndrome, but are less common than PSEN1.  <br>C. PSEN2: Located on 1q31&ndash;q42, PSEN2 mutations are rare (<5% familial EOAD) and have lower penetrance and later onset relative to PSEN1.  <br>D. APOE: The \u03b54 allele on 19q13.2 increases risk for late-onset AD but is neither necessary nor sufficient to cause autosomal dominant early-onset disease.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>PSEN1 (Correct)</th><th>APP</th><th>PSEN2</th><th>APOE</th></tr></thead><tbody><tr><td>Locus</td><td>14q24.3</td><td>21q21.3</td><td>1q31&ndash;q42</td><td>19q13.2</td></tr><tr><td>Inheritance</td><td>Autosomal dominant</td><td>Autosomal dominant</td><td>Autosomal dominant (rare)</td><td>Polygenic risk (LOAD)</td></tr><tr><td>Familial EOAD %</td><td>~70%</td><td>~10&ndash;15%</td><td><5%</td><td>N/A</td></tr><tr><td>Mechanism</td><td>\u2191A&beta;\u2084\u2082 via &gamma;-secretase</td><td>Aberrant APP cleavage</td><td>Altered &gamma;-secretase activity</td><td>Affects lipid transport/A&beta; clearance</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- PSEN1 mutation carriers often present in their 30s&ndash;50s and may exhibit seizures or myoclonus.  <br><span class=\"list-item\">\u2022</span> Always offer genetic counseling prior to PSEN1 testing in early-onset cases with family history.  <br><span class=\"list-item\">\u2022</span> PSEN1 carriers may qualify for pre-symptomatic anti-amyloid trials (e.g., donanemab, lecanemab).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Equating APOE \u03b54 with a causative mutation&mdash;\u03b54 is a susceptibility allele, not a deterministic gene.  <br>2. Overestimating the prevalence of APP mutations&mdash;APP accounts for fewer familial EOAD cases than PSEN1.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- NIA-AA Research Framework <span class=\"citation\">(<span class=\"evidence\">Jack et al. 2018</span>)</span>: Recommends presenilin gene testing in symptomatic patients <65 with family history (Level A).  <br><span class=\"list-item\">\u2022</span> Alzheimer&rsquo;s Association Guidelines (2025): Advises next-generation sequencing panels including PSEN1, PSEN2, APP; emphasizes pre- and post-test counseling (Grade 1B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>PSEN1 mutations alter &gamma;-secretase cleavage of APP, increasing the proportion of A&beta;\u2084\u2082 peptides, which aggregate into oligomers and plaques, triggering downstream tau hyperphosphorylation, synaptic loss, and neurodegeneration.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 1 2021 exam.  <br>On board exams, PSEN1 is frequently tested in questions on genetic causes of early-onset dementia; students must distinguish deterministic familial genes (PSEN1, PSEN2, APP) from risk alleles like APOE.</div></div></div></div></div>"
  },
  {
    "id": 100022603,
    "question_number": "40",
    "question_text": "Which type of pathology is most commonly associated with the semantic variant of primary progressive aphasia (semantic dementia)?",
    "correct_answer": "C",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 1 2021] Semantic variant PPA is one of three core primary progressive aphasia syndromes. It presents with fluent speech, impaired single-word comprehension, and anomia due to degeneration of the anterior temporal lobes, especially on the left. Underlying molecular pathology in PPA varies by syndrome: the non-fluent variant often harbors tauopathies, the logopenic variant is usually Alzheimer&rsquo;s disease, and the semantic variant is most frequently linked to TDP-43 protein inclusions. Recognizing these clinico-pathological correlations is crucial for prognosis, counseling, and designing targeted therapies.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>FTLD&ndash;TDP-43 type C is the predominant pathology in semantic variant PPA, found in ~60&ndash;80% of autopsy series <span class=\"citation\">(Hodges et al. <span class=\"evidence\">Brain 2004</span>;127:1427&ndash;1440; Rohrer et al. <span class=\"evidence\">Brain 2010</span>;133:3061&ndash;3072)</span>. Type C TDP-43 is characterized by long, tortuous dystrophic neurites in superficial cortical layers and relatively few neuronal cytoplasmic inclusions. In contrast, FTLD&ndash;tau (e.g., Pick&rsquo;s disease) accounts for <10% of semantic PPA and features 3R/4R tau aggregates (Pick bodies). Alzheimer&rsquo;s pathology (&beta;-amyloid plaques with paired helical filament tau) is the hallmark of logopenic PPA, not semantic. Vascular lesions produce stepwise or focal deficits, not the progressive, selective semantic impairment seen here. Current consensus criteria <span class=\"citation\">(Gorno-Tempini et al. <span class=\"evidence\">Neurology 2011</span>;76:1006&ndash;1014)</span> and neuropathology nomenclature <span class=\"citation\">(Mackenzie et al. Acta <span class=\"evidence\">Neuropathol 2011</span>;122:111&ndash;113)</span> reinforce that TDP-43 type C is the signature lesion of semantic dementia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. FTLD&ndash;tau type pathology  <br><span class=\"list-item\">\u2022</span> Reason incorrect: FTLD&ndash;tau (e.g. Pick&rsquo;s disease) more often underlies behavioral variant FTD or non-fluent PPA, not semantic variant.  <br><span class=\"list-item\">\u2022</span> Misconception: equating all FTD syndromes with tau instead of subtype-specific proteins.  <br><br>B. Alzheimer&rsquo;s disease pathology  <br><span class=\"list-item\">\u2022</span> Reason incorrect: Alzheimer&rsquo;s (A&beta; plaques + tau tangles) is the most common cause of logopenic PPA, presenting with impaired repetition and phonological errors, unlike the semantic loss here.  <br><span class=\"list-item\">\u2022</span> Misconception: assuming any PPA is Alzheimer&rsquo;s.  <br><br>D. Vascular dementia pathology  <br><span class=\"list-item\">\u2022</span> Reason incorrect: Vascular lesions cause multi-infarct or strategic infarct aphasias, with abrupt onset and fluctuating course, not a progressive, focal neurodegenerative syndrome.  <br><span class=\"list-item\">\u2022</span> Misconception: attributing chronic aphasic syndromes to cerebrovascular disease.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>FTLD&ndash;TDP-43 Type C (Correct)</th><th>FTLD&ndash;Tau</th><th>Alzheimer&rsquo;s Disease</th><th>Vascular Dementia</th></tr></thead><tbody><tr><td>Clinical syndrome</td><td>Semantic variant PPA</td><td>bvFTD, non-fluent PPA</td><td>Logopenic PPA, amnestic AD</td><td>Stepwise deficits</td></tr><tr><td>Protein inclusion</td><td>TDP-43 (long neurites)</td><td>Tau (Pick bodies, 3R/4R)</td><td>A&beta; plaques + tau tangles</td><td>None; ischemic changes</td></tr><tr><td>Neuroimaging</td><td>Left anterior temporal lobe atrophy</td><td>Frontal or peri-rolandic atrophy</td><td>Temporoparietal atrophy</td><td>Multifocal infarcts</td></tr><tr><td>Frequency in semantic PPA</td><td>~60&ndash;80%</td><td><10%</td><td>~5&ndash;15%</td><td>Rare</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Semantic PPA patients lose object knowledge&mdash;e.g., can&rsquo;t define &ldquo;zebra&rdquo; despite normal perception.  <br>&bull; On biopsy/autopsy, TDP-43 type C inclusions produce long dystrophic neurites; this subtype has a distinct morphology from TDP-43 types A/B.  <br>&bull; Negative amyloid PET in semantic PPA helps exclude Alzheimer&rsquo;s pathology and supports FTLD diagnosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confusing semantic PPA with Alzheimer&rsquo;s logopenic PPA&mdash;focus on comprehension vs. repetition deficits.  <br>2. Overgeneralizing &ldquo;FTLD&rdquo; to mean tau pathology&mdash;FTLD can be TDP-43, tau, or FUS. Always specify subtype.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Gorno-Tempini ML et al. <span class=\"citation\">(<span class=\"evidence\">Neurology 2011</span>;76:1006&ndash;1014)</span>: International consensus criteria for PPA variants; recommends molecular correlations for prognosis. (Level C)  <br>&bull; Mackenzie IR et al. <span class=\"citation\">(Acta <span class=\"evidence\">Neuropathol 2011</span>;122:111&ndash;113)</span>: Established TDP-43 subtype nomenclature; type C linked to semantic dementia. (Expert consensus)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Semantic deficits arise from degeneration of the left anterior temporal pole (Brodmann areas 20/21/38), disrupting the semantic memory network that links word forms in Wernicke&rsquo;s area to conceptual knowledge stored in the temporal lobes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>TDP-43 undergoes pathological cleavage and hyperphosphorylation, mislocalizes from the nucleus to the cytoplasm, and aggregates into long, dystrophic neurites characteristic of type C. This selective vulnerability in temporal lobe neurons leads to progressive loss of semantic memory.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confirm progressive aphasia >2 years with preserved fluency.  <br>2. Neuropsychological testing: assess naming, single-word comprehension.  <br>3. MRI brain: look for asymmetric anterior temporal atrophy.  <br>4. Exclude Alzheimer&rsquo;s via CSF biomarkers or amyloid PET.  <br>5. Diagnose semantic variant PPA; anticipate FTLD&ndash;TDP-43 type C pathology.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; MRI: Unilateral (often left) anterior temporal lobe atrophy.  <br>&bull; FDG-PET: Hypometabolism in temporal poles.  <br>&bull; Amyloid PET negative&mdash;in contrast to logopenic PPA.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 1 2021 exam. Testing of clinico-pathological correlations in PPA variants is common on neurology boards, often in the format of matching syndromic features to underlying proteinopathies (tau vs. TDP-43 vs. amyloid).</div></div></div></div></div>"
  },
  {
    "id": 100022604,
    "question_number": "43",
    "question_text": "A young patient with a history of memory loss has a family history of similar issues. Which gene is most likely involved?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 1 2021] Early-onset familial Alzheimer disease (EOFAD) is an autosomal dominant dementia presenting typically before age 65, often in the fourth or fifth decade. Three principal genes&mdash;PSEN1, PSEN2, and APP&mdash;harbor pathogenic variants that alter amyloid precursor protein (APP) processing, increasing the A&beta;42/A&beta;40 ratio and promoting early amyloid plaque deposition. Presenilin-1 (PSEN1) encodes the catalytic subunit of &gamma;-secretase, which cleaves APP within the membrane. Mutations in PSEN1 not only accelerate A&beta;42 generation but also often lead to atypical features (e.g., seizures, myoclonus). In contrast, MAPT mutations cause frontotemporal lobar degeneration and APOE \u03b54 is a risk allele for late-onset Alzheimer&rsquo;s disease rather than a deterministic gene in familial early-onset cases.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>PSEN1 mutations account for approximately 50&ndash;70% of autosomal dominant EOFAD pedigree cases, making it the most frequently implicated gene in early-onset familial memory loss. Chartier-Harlin et al. (1995) and Sherrington et al. (1995) first identified PSEN1 variants in multiplex families; subsequent functional assays demonstrated that these mutations elevate A&beta;42 production and aggregation propensity <span class=\"citation\">(De Strooper, 2003)</span>. <span class=\"evidence\">The 2018</span> NIA-AA research framework endorses genetic testing for symptomatic individuals under 65 with positive family history, highlighting PSEN1 as the top target <span class=\"citation\">(<span class=\"evidence\">Jack et al., 2018</span>)</span>. PSEN1-related EOFAD often presents in the early 40s&ndash;50s with rapid cognitive decline, whereas APP mutation carriers tend to present slightly later and constitute only ~10&ndash;15% of EOFAD families <span class=\"citation\">(<span class=\"evidence\">Goate et al., 1991</span>)</span>. PSEN1&rsquo;s high penetrance (>95%) by age 60 underscores its primacy in familial early-onset cases.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. APP  <br>&bull; Although APP mutations cause EOFAD via abnormal A&beta; peptide production, they represent only ~10&ndash;15% of familial cases.  <br>&bull; Common misconception: equating any amyloid pathway gene with the most prevalent cause.  <br>&bull; Differentiator: APP mutations cluster around the secretase cleavage sites and often present with cerebral amyloid angiopathy and hemorrhages.<br><br>C. MAPT  <br>&bull; Encodes tau protein; mutations cause frontotemporal dementia with tau pathology, not Alzheimer&rsquo;s-type amyloid plaques.  <br>&bull; Misconception: confusing tau pathology in Alzheimer&rsquo;s tangles with primary MAPT-driven tauopathies.  <br>&bull; Differentiator: MAPT cases show early behavioral or language changes, not isolated memory loss.<br><br>D. APOE  <br>&bull; The \u03b54 allele increases risk and lowers age of onset for late-onset AD but is neither causative nor autosomal dominant.  <br>&bull; Misconception: treating risk alleles as deterministic genes.  <br>&bull; Differentiator: APOE genotyping informs risk stratification but lacks Mendelian inheritance.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Gene</th><th>Inheritance</th><th>Typical Onset</th><th>Pathophysiology</th><th>% of EOFAD Families</th></tr></thead><tbody><tr><td>PSEN1</td><td>Autosomal dominant</td><td>35&ndash;55 y</td><td>\u2191&gamma;-secretase A&beta;42/A&beta;40 ratio</td><td>50&ndash;70%</td></tr><tr><td>APP</td><td>Autosomal dominant</td><td>40&ndash;60 y</td><td>Mutations at secretase sites \u2191A&beta; production</td><td>10&ndash;15%</td></tr><tr><td>MAPT</td><td>Autosomal dominant</td><td>45&ndash;65 y</td><td>Tau microtubule dysfunction, no A&beta; plaques</td><td><5% (FTD)</td></tr><tr><td>APOE</td><td>Codominant risk</td><td>>65 y (sporadic)</td><td>Lipid transport; \u03b54 allele \u2191A&beta; aggregation</td><td>N/A (risk factor)</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Always consider PSEN1 testing first in familial AD presenting before 60, especially with seizures or myoclonus.  <br><span class=\"list-item\">\u2022</span> Genetic counseling is mandatory; presymptomatic testing for PSEN1 carries high penetrance and psychosocial implications.  <br><span class=\"list-item\">\u2022</span> Distinguish APP mutations by their association with cerebral amyloid angiopathy and intracerebral hemorrhage.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Mistaking APOE \u03b54 for a causative gene rather than a susceptibility allele.  <br><span class=\"list-item\">\u2022</span> Overattributing early dementia with tau pathology to Alzheimer&rsquo;s genetics instead of frontotemporal spectrum disorders (MAPT).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. European Academy of Neurology/EADC Dementia Guidelines, 2021: Recommend sequencing PSEN1, PSEN2, and APP in patients <65 with &ge;2 first-degree relatives affected by dementia (Level II evidence).  <br>2. Clarity AD Phase 3 Trial <span class=\"citation\">(Eisai/Biogen, 2022)</span>: Lecanemab slowed cognitive decline by 27% over 18 months in early symptomatic AD and markedly reduced amyloid PET burden (p<0.001), heralding a therapeutic shift toward anti-A&beta; monoclonal antibodies.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 1 2021 exam. Genetic etiologies of early-onset Alzheimer&rsquo;s (PSEN1 vs. APP vs. PSEN2 vs. risk factors like APOE) are high-yield for board-style questions, often tested as &ldquo;young onset memory loss with autosomal dominant pattern.&rdquo;</div></div></div></div></div>"
  },
  {
    "id": 100022607,
    "question_number": "73",
    "question_text": "Which gene is related to early onset Alzheimer\u2019s disease (AD)?",
    "correct_answer": "C",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2018] Early\u2010onset Alzheimer&rsquo;s disease (EOAD) refers to dementia beginning before age 65, often familial and autosomal\u2010dominant. Key genetic contributors:  <br><span class=\"list-item\">\u2022</span> APP (amyloid precursor protein) on 21q21.2, whose cleavage yields A&beta; peptides.  <br><span class=\"list-item\">\u2022</span> Presenilin 1 (PSEN1) on 14q24.3 and Presenilin 2 (PSEN2) on 1q42.13, catalytic subunits of &gamma;\u2010secretase that process APP.  <br><span class=\"list-item\">\u2022</span> In contrast, APOE \u03b54 on 19q13.32 modifies risk for late\u2010onset AD (LOAD) but is neither necessary nor sufficient for EOAD.  <br>Mutations in PSEN1 account for ~50&ndash;70% of autosomal\u2010dominant EOAD, making it the most common monogenic cause.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Presenilin 1 mutations alter &gamma;\u2010secretase cleavage, increasing the A&beta;42/A&beta;40 ratio and promoting plaque formation. Multiple series <span class=\"citation\">(e.g., Goate et al., <span class=\"evidence\">Nature 1995</span>; Sherrington et al., <span class=\"evidence\">Nature 1995</span>)</span> identified PSEN1 variants in families with EOAD. Clinical guidelines <span class=\"citation\">(ACMG 2015)</span> recommend PSEN1 genetic testing for individuals <65 with a positive familial history, citing level C evidence for pathogenicity of recurrent missense mutations (e.g., M146L, L286V). PSEN1\u2010linked AD often presents with aggressive cognitive decline, earlier age of onset (mean ~45 years), language impairment, myoclonus, and seizures more frequently than APP\u2010 or PSEN2\u2010related cases.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. APOE  <br><span class=\"list-item\">\u2022</span> Why incorrect: APOE \u03b54 is a susceptibility allele for LOAD, not a causal gene for autosomal\u2010dominant EOAD.  <br><span class=\"list-item\">\u2022</span> Misconception: Equating risk modifiers with causative mutations.  <br><span class=\"list-item\">\u2022</span> Differentiator: APOE modifies clearance of A&beta; but does not encode components of &gamma;\u2010secretase.<br><br>B. APP  <br><span class=\"list-item\">\u2022</span> Why incorrect: While APP mutations cause ~5&ndash;10% of familial EOAD, they are far less common than PSEN1 mutations.  <br><span class=\"list-item\">\u2022</span> Misconception: Overestimating APP&rsquo;s contribution to monogenic EOAD.  <br><span class=\"list-item\">\u2022</span> Differentiator: APP\u2010related cases often have cerebral amyloid angiopathy and hemorrhages; PSEN1 mutations predominate.<br><br>D. Presenilin 2  <br><span class=\"list-item\">\u2022</span> Why incorrect: PSEN2 mutations are rare (<5% of autosomal\u2010dominant EOAD) and show variable penetrance.  <br><span class=\"list-item\">\u2022</span> Misconception: Assuming all presenilin genes contribute equally.  <br><span class=\"list-item\">\u2022</span> Differentiator: PSEN2\u2010linked AD tends to have later onset (mean ~55&ndash;60 years) and fewer neuropsychiatric features than PSEN1.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Presenilin 1</th><th>APP</th><th>Presenilin 2</th><th>APOE \u03b54 (risk allele)</th></tr></thead><tbody><tr><td>Gene locus</td><td>14q24.3</td><td>21q21.2</td><td>1q42.13</td><td>19q13.32</td></tr><tr><td>Protein function</td><td>&gamma;\u2010secretase catalytic subunit</td><td>Amyloid precursor protein</td><td>&gamma;\u2010secretase catalytic subunit</td><td>Lipid transport, A&beta; clearance</td></tr><tr><td>Inheritance</td><td>Autosomal dominant</td><td>Autosomal dominant</td><td>Autosomal dominant</td><td>Complex/polygenic risk</td></tr><tr><td>Contribution to EOAD</td><td>~50&ndash;70% of familial cases</td><td>~5&ndash;10% of familial cases</td><td><5% of familial cases</td><td>Modifier for late onset</td></tr><tr><td>Pathogenic mechanism</td><td>\u2191A&beta;42/A&beta;40 ratio</td><td>\u2191total A&beta; production</td><td>\u2191A&beta;42/A&beta;40 ratio</td><td>\u2193A&beta; clearance, \u2191plaque load</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Genetic testing for PSEN1 should be offered in EOAD cases with onset <60 years, especially when &ge;2 first\u2010degree relatives are affected.  <br>2. PSEN1 mutations often present with extrapyramidal signs, myoclonus, and seizures&mdash;features less common in LOAD.  <br>3. Trisomy 21 (Down syndrome) involves APP gene duplication and invariably leads to AD pathology by middle age.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confusing APOE \u03b54, a risk factor for late\u2010onset AD, with causal genes in EOAD.  <br>2. Assuming APP mutations are the most frequent cause of familial EOAD rather than PSEN1.  <br>3. Believing PSEN2 mutations present identically to PSEN1 &ndash; PSEN2 cases often have later onset and lower penetrance.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. American College of Medical Genetics and Genomics (ACMG) 2015 guideline on interpretation of sequence variants: recommends PSEN1, PSEN2, APP testing for EOAD (<65) with strong family history (Level C evidence).  <br>2. European Academy of Neurology / European Federation of Neurological Societies (EAN/EFT) 2020 consensus: endorse genetic counseling and targeted mutation analysis of PSEN1 first in suspected familial EOAD, given its higher yield (Level B evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2018 exam. On neurology boards, students are frequently asked to distinguish causative genes (APP, PSEN1, PSEN2) in EOAD versus risk modifiers (APOE) in LOAD. Recognizing that PSEN1 mutations are the predominant monogenic cause of familial EOAD is a high\u2010yield concept.</div></div></div></div></div>"
  },
  {
    "id": 100022610,
    "question_number": "80",
    "question_text": "Which of the following genes is commonly linked to Alzheimer's disease?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2022] Alzheimer&rsquo;s disease (AD) involves abnormal amyloid-&beta; (A&beta;) aggregation and tau pathology leading to neurodegeneration.  <br>1. APOE is a lipid-transport protein in the CNS; the \u03b54 allele impairs A&beta; clearance and promotes plaque deposition.  <br>2. APP (amyloid precursor protein) and PSEN1 (presenilin\u20101) mutations alter &gamma;-secretase activity, increasing A&beta;42 production in rare familial early-onset AD.  <br>3. MAPT encodes tau protein; mutations cause primary tauopathies (e.g., frontotemporal dementia), not typical AD.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>APOE4 is the strongest common genetic risk factor for late-onset AD. Corder et al. (1993) showed \u03b54 carriers have a 3- to 12-fold increased risk. <span class=\"evidence\">The 2024</span> Alzheimer&rsquo;s Association guidelines advise against routine clinical APOE genotyping for diagnosis but acknowledge its research utility (Level B). Neuroanatomically, impaired A&beta; clearance in APOE4 carriers leads to hippocampal and cortical plaque accumulation, driving synaptic loss and network breakdown.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. APP  <br>&bull; Incorrect: Mutations cause <1% of familial early-onset AD, not common sporadic cases.  <br>&bull; Misconception: Equating any amyloid gene change with typical AD risk.  <br>&bull; Differentiator: APP mutations are highly penetrant and rare vs. widespread APOE4 risk allele.  <br><br>C. PSEN1  <br>&bull; Incorrect: Autosomal\u2010dominant mutations cause early\u2010onset familial AD (<1% of cases).  <br>&bull; Misconception: Assuming presenilin variants underlie most AD.  <br>&bull; Differentiator: PSEN1 variants are rare, with disease onset <60 years.  <br><br>D. MAPT  <br>&bull; Incorrect: MAPT mutations cause primary tauopathies (e.g., frontotemporal dementia), not AD.  <br>&bull; Misconception: Linking tau gene mutations directly to AD.  <br>&bull; Differentiator: Tau pathology in AD is secondary; MAPT mutations do not predispose to AD.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>APOE4</th><th>APP mutation</th><th>PSEN1 mutation</th><th>MAPT mutation</th></tr></thead><tbody><tr><td>Association with AD</td><td>Common risk factor</td><td>Rare familial causative</td><td>Rare familial causative</td><td>Primary tauopathies</td></tr><tr><td>Genetic effect</td><td>Allele dosage effect</td><td>Altered A&beta; processing</td><td>Altered &gamma;-secretase</td><td>Tau protein dysfunction</td></tr><tr><td>Prevalence</td><td>~15% general population</td><td><1% of AD cases</td><td><1% of AD cases</td><td>Not associated with AD</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. APOE2 allele is protective; \u03b54 homozygotes have highest risk and earliest onset.  <br>2. APOE genotyping is used in research settings; not endorsed for routine clinical risk assessment.  <br>3. Early-onset familial AD warrants genetic counseling and testing for APP, PSEN1, PSEN2.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Overestimating the prevalence of APP/PSEN1 mutations in sporadic AD.  <br>2. Confusing MAPT-related primary tauopathies with Alzheimer&rsquo;s tau pathology.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Alzheimer&rsquo;s <span class=\"evidence\">Association 2024</span> Practice Guidelines: Recommend against clinical APOE genotyping for diagnosis; support its role in research (Recommendation, Level B).  <br>2. NIA-AA Research <span class=\"evidence\">Framework 2022</span>: Incorporates genetic risk (APOE) into &ldquo;R&rdquo; category of the A/T/N biomarker scheme for research classification.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>APOE4&rsquo;s arginine substitutions at positions 112 and 158 change lipid binding, reducing A&beta; clearance by astrocytes and microglia. This accelerates amyloid plaque formation in hippocampal and cortical circuits, leading to synaptic dysfunction and neurodegeneration characteristic of AD.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2022 exam. Genetic risk in AD is frequently tested in neurology and neurogenetics sections, often contrasting common risk alleles (APOE) with rare causative mutations (APP, PSEN1).</div></div></div></div></div>"
  },
  {
    "id": 100022611,
    "question_number": "92",
    "question_text": "Which of the following genes is associated with familial Alzheimer\u2019s disease?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2023] - Familial early-onset Alzheimer&rsquo;s disease (AD) accounts for <5% of AD cases and follows an autosomal-dominant inheritance pattern.  <br><span class=\"list-item\">\u2022</span> Three causative genes have been identified: APP (amyloid precursor protein), PSEN1 (presenilin 1), and PSEN2 (presenilin 2). Mutations in any lead to overproduction or altered processing of A&beta;42, promoting amyloid plaque formation.  <br><span class=\"list-item\">\u2022</span> ApoE \u03b54 is a major risk allele for late-onset sporadic AD but is not a direct causative mutation in familial early-onset forms.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>APP mutations&mdash;either missense substitutions or gene duplications on chromosome 21&mdash;cause early-onset familial AD by shifting &gamma;-secretase cleavage toward the more aggregation-prone A&beta;42 peptide <span class=\"citation\">(<span class=\"evidence\">Goate et al., 1991</span>;<span class=\"evidence\"> Citron et al., 1992</span>)</span>. APP duplications in Down syndrome (trisomy 21) further underscore the gene dosage effect. While PSEN1 and PSEN2 mutations similarly affect &gamma;-secretase activity, APP was the first gene identified and remains a high-yield target on board examinations <span class=\"citation\">(Bird & Jefferys, 2020)</span>. <span class=\"evidence\">The 2021</span> NIA-AA Research Framework classifies AD by amyloid (A), tau (T), and neurodegeneration (N) biomarkers, but genetic testing guidelines from the American Academy of Neurology (2023) specifically recommend APP screening in individuals with onset <60 years and a positive family history (level B recommendation).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. PSEN1  <br>  &ndash; Although presenilin-1 mutations are the most common cause of familial early-onset AD, this question emphasizes the prototypical APP gene mutation on chromosome 21. Common misconception: all presenilin mutations are equally high-yield; boards often test APP because of its link to Down syndrome.  <br><br>C. PSEN2  <br>  &ndash; PSEN2 mutations are rare (<1% of familial cases) and present later (50s&ndash;60s). They are much less frequently tested than APP in preclinical exams.  <br><br>D. Apolipoprotein E  <br>  &ndash; ApoE \u03b54 is a polymorphic risk factor for sporadic late-onset AD, not a causative mutation in familial early-onset disease. It modulates A&beta; clearance rather than production.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>APP (A)</th><th>PSEN1 (B)</th><th>PSEN2 (C)</th><th>ApoE (D)</th></tr></thead><tbody><tr><td>Inheritance</td><td>Autosomal dominant</td><td>Autosomal dominant</td><td>Autosomal dominant</td><td>Co-dominant risk allele</td></tr><tr><td>Onset age</td><td>30s&ndash;50s</td><td>30s&ndash;40s</td><td>50s&ndash;60s</td><td>Late-onset (>65 years)</td></tr><tr><td>Pathophysiology</td><td>\u2191 A&beta;42 production via &gamma;-secretase</td><td>Altered &gamma;-secretase complex activity</td><td>Altered &gamma;-secretase complex activity</td><td>Impaired A&beta; clearance</td></tr><tr><td>Board-exam frequency</td><td>High</td><td>Moderate</td><td>Low</td><td>High (as risk factor)</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. APP duplications in Down syndrome (trisomy 21) lead to Alzheimer&rsquo;s pathology by increasing A&beta;42 generation.  <br>2. PSEN1 mutations account for ~50% of familial early-onset AD, but APP remains the classic board-exam focus.  <br>3. Genetic counseling and presymptomatic testing are indicated for at-risk individuals with strong family histories and onset <60 years.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Mistaking ApoE \u03b54 for a causative mutation rather than a risk modifier.  <br>2. Assuming all familial AD genes are tested equally often; APP is disproportionately emphasized due to its mechanistic clarity.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- American Academy of Neurology Practice Guideline (2023): Recommends APP, PSEN1, PSEN2 genetic testing in individuals with onset <60 and familial AD history (Level B).  <br><span class=\"list-item\">\u2022</span> NIA-AA Research Framework (2021): Defines AD biologically by A&beta;, tau, and neurodegeneration biomarkers, incorporating genetic risk stratification.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2023 exam. Familial Alzheimer&rsquo;s genes (APP vs. PSEN1/PSEN2 vs. ApoE) are frequently tested as single-best-answer items, often with emphasis on APP because of its chromosomal duplication in Down syndrome and classical studies.</div></div></div></div></div>"
  },
  {
    "id": 100022613,
    "question_number": "39",
    "question_text": "A young man with a family history of early onset Alzheimer disease. Which of the following genes increases the risk of sporadic Alzheimer disease?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2023] Alzheimer disease (AD) arises from accumulation of extracellular amyloid-&beta; (A&beta;) plaques and intracellular tau neurofibrillary tangles, leading to synaptic loss and neuronal death. Early-onset familial AD (<65 years) is driven by autosomal-dominant mutations in APP, PSEN1, and PSEN2, which increase A&beta;42 production. In contrast, late-onset sporadic AD reflects a polygenic risk profile plus environmental factors. The APOE gene, located on chromosome 19, encodes apolipoprotein E, a lipid\u2010transport protein that modulates A&beta; clearance. The \u03b54 allele confers a 3- to 12-fold dose-dependent increase in sporadic AD risk. MAPT mutations underlie tauopathies such as frontotemporal dementia, not AD, highlighting the need to distinguish risk alleles from causative familial mutations.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Apolipoprotein E (APOE) \u03b54 is the most potent genetic risk factor for late-onset sporadic AD. Pioneering work by Corder et al. (1993) demonstrated that APOE \u03b54 heterozygotes have ~3-fold and homozygotes ~8- to 12-fold increased risk of AD versus \u03b53 homozygotes <span class=\"citation\">(Neurology. 1993;43(8)</span>:1467&ndash;1472). A 1997 meta-analysis <span class=\"citation\">(Farrer et al., JAMA. 1997;278(16)</span>:1349&ndash;1356) confirmed a dose-dependent effect across diverse populations. APOE influences amyloid\u2010&beta; aggregation and clearance through receptor-mediated pathways in astrocytes and microglia; \u03b54 isoforms show reduced lipid\u2010transport efficiency and impaired A&beta; clearance. Current guidelines <span class=\"citation\">(NIA-AA Research Framework, 2018)</span> incorporate APOE status in research staging of preclinical AD but do not recommend routine clinical genotyping due to limited predictive value in isolation and absence of definitive preventive therapies.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. APP  <br> &bull; APP mutations cause autosomal-dominant early-onset familial AD by increasing A&beta;42 production.  <br> &bull; Misconception: all amyloid pathway genes raise sporadic risk&mdash;APP pathogenic variants are rare and familial.  <br> &bull; Differentiation: APP variants have near-complete penetrance and present before age 60.  <br>C. PSEN1  <br> &bull; PSEN1 encodes presenilin-1, part of &gamma;-secretase; mutations cause early-onset familial AD with autosomal-dominant inheritance.  <br> &bull; Misconception: any gene in amyloid processing increases sporadic risk&mdash;PSEN1 variants are highly penetrant familial mutations.  <br> &bull; Differentiation: PSEN1 carriers almost invariably develop AD by their mid-40s.  <br>D. MAPT  <br> &bull; MAPT encodes tau; mutations cause frontotemporal lobar degeneration (FTLD), not AD.  <br> &bull; Misconception: tau gene variants predispose to AD&mdash;FTLD and AD have different tau pathology and distribution.  <br> &bull; Differentiation: MAPT mutations present with behavioral or language syndromes, not classic hippocampal amnestic AD.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Gene</th><th>Associated Condition</th><th>Inheritance</th><th>Role in AD</th><th>Sporadic Risk?</th></tr></thead><tbody><tr><td>APOE (\u03b54)</td><td>Late-onset sporadic AD risk</td><td>Polygenic, non-Mendelian</td><td>Modulates A&beta; clearance/aggregation</td><td>Yes (dose-dependent)</td></tr><tr><td>APP</td><td>Early-onset familial AD</td><td>Autosomal dominant</td><td>A&beta; precursor; \u2191A&beta;42 production</td><td>No (familial only)</td></tr><tr><td>PSEN1</td><td>Early-onset familial AD</td><td>Autosomal dominant</td><td>&gamma;-secretase component</td><td>No (familial only)</td></tr><tr><td>MAPT</td><td>Frontotemporal dementia</td><td>Autosomal dominant</td><td>Microtubule-associated tau</td><td>No</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; APOE \u03b52 allele is relatively protective, lowering AD risk and delaying onset.  <br>&bull; Routine clinical APOE genotyping is not recommended outside research or family counseling settings due to variable penetrance and lack of disease-modifying therapies.  <br>&bull; APOE \u03b54 carriers show higher amyloid PET burden and may experience more ARIA when treated with anti-amyloid antibodies (e.g., lecanemab).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confusing familial AD genes (APP, PSEN1/2) with sporadic risk alleles&mdash;familial mutations are rare, high-penetrance causes of early-onset AD.  <br>2. Assuming MAPT mutations increase AD risk&mdash;MAPT variants cause tauopathies (FTLD spectrum), not Alzheimer pathology.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. NIA-AA Research Framework <span class=\"citation\">(2018; updated 2023)</span>: Defines AD biologically by amyloid/tau/neurodegeneration biomarkers; acknowledges APOE \u03b54 as research tool but advises against standalone clinical genotyping (Level C evidence).  <br>2. Cummings et al., Clarity AD Trial, NEJM (2023): Phase 3 trial of lecanemab in early AD; APOE \u03b54 carriers had higher ARIA rates and differential efficacy, underscoring genotype&rsquo;s impact on therapy response (Level I evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2023 exam.  <br>Genetic risk for sporadic Alzheimer&rsquo;s&mdash;especially APOE \u03b54&mdash;regularly features on neurology boards in single\u2010best\u2010answer format, often contrasting risk alleles with autosomal-dominant familial mutations and asking about relative risk or allele dosing effects.</div></div></div></div></div>"
  },
  {
    "id": 100022625,
    "question_number": "42",
    "question_text": "In a case of transient global amnesia (TGA) lasting 4 hours, with the patient confused, repeating questions, and preserving identity, what is the next step in management?",
    "correct_answer": "D",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2019] Transient global amnesia (TGA) is defined by acute onset of anterograde amnesia with variable retrograde loss, repetitive questioning, preserved personal identity and no other neurological deficits. Key structures include the hippocampal CA1 region and connections to the temporal lobes. Typical episodes last under 24 hours and resolve spontaneously. Important differentials are transient ischemic attack (TIA), complex partial seizure and psychogenic amnesia. Recognition of the benign, self-limited nature of TGA&mdash;absent focal signs or seizure activity&mdash;guides a conservative, supportive approach.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Observation and supportive care is correct. Multiple case series <span class=\"citation\">(Hodges & Warlow, <span class=\"evidence\">Brain 1990</span>; Quinette et al, <span class=\"evidence\">Brain 2006</span>)</span> confirm that TGA requires no acute intervention and that extensive imaging rarely alters management when clinical criteria are fulfilled. The American Academy of Neurology (AAN) practice advisory (2018) states that in a classic TGA presentation, emergent neuroimaging is not indicated (Level B). Noncontrast CT has low sensitivity for mesial temporal lesions; CTA targets vascular occlusion, which is not the mechanism in TGA. EEG and lumbar puncture add no diagnostic value absent seizure or infection signs. Supportive monitoring ensures safety during resolution.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. EEG  <br><span class=\"list-item\">\u2022</span> Why incorrect: No seizure features (no automatisms, post-ictal state, or epileptiform discharges).  <br><span class=\"list-item\">\u2022</span> Misconception: Equating repetitive questioning with complex partial seizure.  <br><span class=\"list-item\">\u2022</span> Differentiator: Seizures usually last <1 hour, often with automatisms or confusion postictally; EEG may be obtained later if seizure suspected.<br><br>B. Brain CT & CTA  <br><span class=\"list-item\">\u2022</span> Why incorrect: CT lacks sensitivity for hippocampal diffusion changes seen on MRI, and CTA screens for vascular occlusion not present in TGA.  <br><span class=\"list-item\">\u2022</span> Misconception: Treating every acute amnesia as a stroke mimic requiring full angiographic workup.  <br><span class=\"list-item\">\u2022</span> Differentiator: Absence of focal deficits and normal NIH Stroke Scale score; arterial imaging reserved for true TIA/stroke.<br><br>C. Lumbar puncture  <br><span class=\"list-item\">\u2022</span> Why incorrect: No signs of meningitis (fever, neck stiffness) or subarachnoid hemorrhage (severe headache).  <br><span class=\"list-item\">\u2022</span> Misconception: Attributing any acute confusion to infectious or hemorrhagic etiologies.  <br><span class=\"list-item\">\u2022</span> Differentiator: TGA presents with isolated memory loss without meningeal irritation or headache.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Observation & Supportive Care</th><th>Brain CT & CTA</th><th>EEG</th><th>Lumbar Puncture</th></tr></thead><tbody><tr><td>Mechanism targeted</td><td>Self-limited hippocampal event</td><td>Exclude hemorrhage/occlusion</td><td>Exclude seizure focus</td><td>Exclude infection/SAH</td></tr><tr><td>Diagnostic yield in TGA</td><td>Clinical diagnosis</td><td>Low for TGA</td><td>Low in absence of epilepsy</td><td>None in absence of infection</td></tr><tr><td>Impact on management</td><td>Confirms benign course</td><td>Unlikely to change plan</td><td>Unlikely to change plan</td><td>Unlikely to change plan</td></tr><tr><td>Risks</td><td>Minimal</td><td>Radiation, contrast nephropathy</td><td>Discomfort, false positives</td><td>Headache, infection risk</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. TGA often follows emotional stress or Valsalva maneuvers (e.g., sudden immersion in cold water).  <br>2. Diffusion-weighted MRI performed 24&ndash;48 hours after onset may show punctate hippocampal lesions.  <br>3. Recurrence risk is low (<5% per year); long-term prognosis is excellent.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Misapplying the ABCD2 stroke score to TGA and ordering vascular imaging reflexively.  <br>2. Mistaking repetitive questioning for post-ictal confusion and initiating anticonvulsants unnecessarily.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. American Academy of Neurology (2018) Practice Advisory on TGA: recommends no emergent imaging in classic cases (Level B).  <br>2. European Stroke Organization (ESO) Guidelines (2021) on TIA/stroke: advise CTA only when focal deficits or vascular symptoms suggest arterial pathology (Class III recommendation against routine CTA in TGA).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2019 exam. Transient global amnesia is frequently tested as a stroke mimic scenario&mdash;students must recognize the clinical criteria for TGA and distinguish it from TIA, seizure, and psychogenic amnesia to avoid unnecessary interventions.</div></div></div></div></div>"
  },
  {
    "id": 100022626,
    "question_number": "48",
    "question_text": "Fatigue during the daytime and increased sleepiness in a patient with Alzheimer\u2019s disease is due to which of the following?",
    "correct_answer": "D",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2024] Alzheimer&rsquo;s disease (AD) features progressive neurodegeneration with hallmark amyloid-&beta; plaques and tau tangles.  <br>&bull; The suprachiasmatic nucleus (SCN), located in the anterior hypothalamus, is the master circadian pacemaker.  <br>&bull; It receives light information via the retinohypothalamic tract and orchestrates sleep&ndash;wake cycles through melatonin release from the pineal gland.  <br>&bull; In AD, SCN neurons undergo selective loss, causing disruption of circadian rhythms, fragmented nocturnal sleep and compensatory daytime somnolence.  <br>&bull; Other pathways (serotonergic, metabolic) may modulate sleep architecture but are not the primary drivers of daytime fatigue in AD.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Suprachiasmatic nucleus degeneration directly impairs circadian timing. Post-mortem analyses by Swaab et al. (1985) and more recent volumetric MRI studies <span class=\"citation\">(Van Someren EJW, 2000)</span> demonstrate a 50&ndash;70% reduction in SCN neuron number in AD versus controls. Actigraphy correlates SCN atrophy with increased daytime nap frequency and reduced sleep efficiency at night. The American Academy of Sleep Medicine (AASM) 2015 guidelines endorse bright light therapy to strengthen residual SCN function, underscoring its pivotal role. Neither subthalamic nucleus (involved in motor control), primary serotonergic pathways (modulate REM sleep but do not set circadian phase), nor systemic glucose levels (global energy substrate) explain the distinct pattern of AD-related daytime sleepiness.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Atrophy in subthalamic nuclei  <br><span class=\"list-item\">\u2022</span> Incorrect because the subthalamic nucleus (STN) modulates the indirect motor pathway; STN lesions cause hemiballismus, not circadian rhythm disruption.  <br><span class=\"list-item\">\u2022</span> Misconception: confusing STN (motor) with SCN (circadian).  <br><br>B. Disturbance in serotonin pathway  <br><span class=\"list-item\">\u2022</span> Serotonergic raphe nuclei influence sleep architecture (particularly REM), but the SCN sets the sleep&ndash;wake timing.  <br><span class=\"list-item\">\u2022</span> Misconception: over-emphasis on neurotransmitter imbalance rather than pacemaker degeneration.  <br><br>C. Decrease in glucose level  <br><span class=\"list-item\">\u2022</span> Systemic or cerebral hypoglycemia causes acute lethargy but is not a chronic mechanism of daytime somnolence in AD.  <br><span class=\"list-item\">\u2022</span> Differentiator: AD hypometabolism is diffuse and cognitive, not isolated to circadian sleep regulation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>SCN Degeneration (Correct)</th><th>Subthalamic Nucleus Atrophy</th><th>Serotonin Pathway Disturbance</th><th>Decreased Glucose Level</th></tr></thead><tbody><tr><td>Primary Function</td><td>Master circadian pacemaker</td><td>Modulation of motor output</td><td>Mood and REM sleep modulation</td><td>Cellular energy supply</td></tr><tr><td>Anatomical Location</td><td>Anterior hypothalamus</td><td>Diencephalon (basal ganglia)</td><td>Brainstem (raphe nuclei)</td><td>Systemic/CNS metabolism</td></tr><tr><td>Role in Sleep Regulation</td><td>Directly drives sleep&ndash;wake rhythms</td><td>No role in sleep timing</td><td>Alters sleep stages (REM/NREM)</td><td>Affects alertness non-specifically</td></tr><tr><td>Pathology in AD</td><td>Marked neuronal loss, tau pathology</td><td>Not characteristically involved</td><td>Minor/moderate involvement</td><td>Global hypometabolism, nonspecific</td></tr><tr><td>Clinical Manifestation in AD</td><td>Fragmented nights, daytime somnolence</td><td>Movement disorders</td><td>Altered REM, mood changes</td><td>General fatigue if severe</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Sundowning in AD often reflects SCN dysfunction; morning bright light exposure (2,500&ndash;10,000 lux for 30&ndash;60 min) can improve nocturnal sleep consolidation.  <br><span class=\"list-item\">\u2022</span> Actigraphy objectively quantifies rest&ndash;activity fragmentation and helps tailor timing of light and melatonin.  <br><span class=\"list-item\">\u2022</span> Extended-release melatonin (2&ndash;5 mg at bedtime) is well tolerated in AD and can normalize circadian phase without significant daytime residual effects.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confusing the subthalamic nucleus (motor function) with the suprachiasmatic nucleus (circadian regulator) due to similar acronyms.  <br>2. Over-attributing AD sleepiness to global cholinergic or metabolic deficits, neglecting circadian pacemaker loss.  <br>3. Expecting serotonin reuptake inhibitors to correct AD-related daytime fatigue, despite limited impact on core circadian timing.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- American Academy of Sleep Medicine (AASM) 2015, &ldquo;Circadian Rhythm Sleep&ndash;Wake Disorders: Clinical Practice Guideline&rdquo;: Strong recommendation (Level A) for timed bright light therapy in irregular sleep&ndash;wake rhythm disorder in dementia.  <br><span class=\"list-item\">\u2022</span> National Institute for Health and Care Excellence (NICE) NG97 Dementia <span class=\"evidence\">Guideline 2018</span>: Advises nonpharmacological sleep interventions (light therapy, routine scheduling) as first-line for sleep disturbances in dementia (Moderate evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The SCN is a paired nucleus located just dorsal to the optic chiasm. It receives direct photic input via the retinohypothalamic tract, synchronizes peripheral clocks through neural and humoral signals, and modulates pineal melatonin secretion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>In AD, amyloid-&beta; plaques and hyperphosphorylated tau tangles accumulate within the SCN. Loss of vasoactive intestinal peptide&ndash;expressing neurons disrupts intercellular coupling, attenuating the SCN&rsquo;s output and leading to circadian rhythm fragmentation and daytime somnolence.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Melatonin acts on MT1 and MT2 receptors in the SCN to reinforce circadian phase; extended-release formulations at 2&ndash;5 mg nightly enhance nocturnal sleep consolidation. Adjunctive morning bright light therapy (2,500&ndash;10,000 lux) is recommended to entrain residual SCN function.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2024 exam. Questions on Alzheimer&rsquo;s often test neuroanatomical correlates of sleep-wake disruption&mdash;recognizing SCN degeneration as the key driver is critical.</div></div></div></div></div>"
  },
  {
    "id": 100022627,
    "question_number": "41",
    "question_text": "Q41. What is the commonest pathological change in neurodegenerative diseases?",
    "correct_answer": "D",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2022] Neurodegenerative diseases share a final common pathway of progressive neuronal loss accompanied by abnormal protein aggregates. Major classes include tauopathies (neurofibrillary tangles), synucleinopathies (Lewy bodies, glial cytoplasmic inclusions), and TDP-43 proteinopathies. Alzheimer&rsquo;s disease (AD) is the most prevalent neurodegenerative disorder&mdash;responsible for approximately 60&ndash;70% of all dementias&mdash;and is defined histologically by both extracellular &beta;-amyloid plaques and intracellular tau-based neurofibrillary tangles. The burden and distribution of neurofibrillary tangles correlate more closely with clinical severity than amyloid plaque load. In contrast, synucleinopathies (e.g., Parkinson&rsquo;s disease, multiple system atrophy) and other proteinopathies are less common overall.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Neurofibrillary tangles, composed of hyperphosphorylated tau organized into paired helical filaments, represent the single most frequent intracellular inclusion across neurodegenerative diseases. Population studies indicate that AD affects over 50 million individuals worldwide <span class=\"citation\">(GBD 2019 Dementia Collaborators)</span>, far exceeding the combined prevalence of synucleinopathies (Parkinson&rsquo;s disease: ~6 million; MSA: ~42 000). <span class=\"evidence\">The 2018</span> update of the National Institute on Aging&ndash;Alzheimer&rsquo;s Association (NIA-AA) guidelines emphasizes Braak staging of neurofibrillary tangle topography (Stages I&ndash;VI) as the primary determinant of AD neuropathologic change (Level II evidence). Tau PET imaging studies <span class=\"citation\">(e.g.,<span class=\"evidence\"> Johnson et al., 2021</span>, JAMA Neurol)</span> further validate that in vivo tau burden predicts cognitive decline more robustly than &alpha;-synuclein markers.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Tangles  <br><span class=\"list-item\">\u2022</span> &ldquo;Tangles&rdquo; is non-specific; it could refer to any fibrillary aggregate. Without &ldquo;neurofibrillary&rdquo; it lacks definition and fails to distinguish tau-based inclusions from other filamentous deposits.  <br>B. Glial cytoplasmic inclusions  <br><span class=\"list-item\">\u2022</span> These &alpha;-synuclein-positive inclusions define multiple system atrophy (MSA), a rare parkinsonian&ndash;dysautonomia syndrome (~5% of neurodegenerative cases). They are far less prevalent than tau tangles.  <br>C. Lewy bodies  <br><span class=\"list-item\">\u2022</span> Lewy bodies are neuronal &alpha;-synuclein aggregates seen in Parkinson&rsquo;s disease and dementia with Lewy bodies (~15&ndash;20% of dementias). They are the second most common intracellular pathology but do not surpass tau tangles in overall frequency.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Neurofibrillary tangles</th><th>Lewy bodies</th><th>Glial cytoplasmic inclusions</th><th>Generic &ldquo;tangles&rdquo;</th></tr></thead><tbody><tr><td>Protein</td><td>Hyperphosphorylated tau</td><td>&alpha;-synuclein</td><td>&alpha;-synuclein</td><td>Undefined fibrils</td></tr><tr><td>Cellular location</td><td>Neuronal cytoplasm</td><td>Neuronal cytoplasm</td><td>Oligodendrocyte cytoplasm</td><td>Ambiguous</td></tr><tr><td>Associated diseases</td><td>Alzheimer&rsquo;s disease</td><td>Parkinson&rsquo;s disease, Lewy body dementia</td><td>Multiple system atrophy (MSA)</td><td>Non-specific</td></tr><tr><td>Approximate prevalence</td><td>Most common (~60&ndash;70% of dementias)</td><td>Second (~15&ndash;20% of dementias)</td><td>Rare (~5% of parkinsonian syndromes)</td><td>Indeterminate</td></tr><tr><td>Correlation with clinical stage</td><td>Strong (Braak stages I&ndash;VI)</td><td>Moderate (clinico-pathological correlation)</td><td>Variable</td><td>None</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Braak staging of neurofibrillary tangles (I&ndash;II: transentorhinal; III&ndash;IV: limbic; V&ndash;VI: neocortical) predicts progression from mild cognitive impairment to severe dementia.  <br><span class=\"list-item\">\u2022</span> Tau PET ligands (e.g., [18F]flortaucipir) demonstrate in vivo correlation with post-mortem NFT density and cognitive decline.  <br><span class=\"list-item\">\u2022</span> &alpha;-Synuclein immunohistochemistry differentiates Lewy bodies (neuronal) from glial cytoplasmic inclusions (oligodendroglial) in synucleinopathies.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Mistaking extracellular amyloid plaques for intracellular neurofibrillary tangles; only tau aggregates form tangles.  <br><span class=\"list-item\">\u2022</span> Overestimating the prevalence of Lewy bodies versus tau tangles when evaluating dementia subtypes.  <br><span class=\"list-item\">\u2022</span> Using the term &ldquo;tangles&rdquo; without specifying neurofibrillary, leading to confusion with other fibrillary inclusions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- National Institute on Aging&ndash;Alzheimer&rsquo;s Association (NIA-AA) guidelines, 2018 update: Recommends ABC scoring (A=amyloid, B=&beta;-sheet tau in Braak stages, C=neuritic plaque density) for AD neuropathologic change (Level II evidence).  <br><span class=\"list-item\">\u2022</span> NIA-AA Research Framework,<span class=\"evidence\"> Jack et al. 2018</span>: Defines Alzheimer&rsquo;s disease biologically by biomarkers A&beta; (A), tau (T), and neurodegeneration (N), underscoring tau pathology as a core diagnostic criterion (Consensus, Level III).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2022 exam. Histopathological hallmarks of neurodegenerative diseases&mdash;especially the predominance of tau-based neurofibrillary tangles in Alzheimer&rsquo;s disease&mdash;are high-yield topics, frequently tested as single-best-answer items asking for distinguishing features among protein aggregates.</div></div></div></div></div>"
  },
  {
    "id": 100022629,
    "question_number": "51",
    "question_text": "Q51. A case scenario of a patient with urinary urgency, gait problems, and memory problems, with MRI showing very extensive white matter lesions. What is the most likely diagnosis?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 1 2021] &bull; Subcortical vascular dementia (Binswanger&rsquo;s disease) arises from chronic small\u2010vessel ischemia leading to demyelination and gliosis in periventricular white matter.  <br>&bull; Frontal\u2010subcortical circuits&mdash;running through the corona radiata and periventricular regions&mdash;mediate gait initiation, executive function, and bladder control; disruption produces the triad of gait disturbance, executive dysfunction, and urinary urgency.  <br>&bull; Normal Pressure Hydrocephalus (NPH) also presents with this triad but requires ventriculomegaly disproportionate to cortical atrophy (Evans index >0.3) and improvement after CSF drainage.  <br>&bull; MRI interpretation must distinguish confluent leukoaraiosis of small\u2010vessel disease from the transependymal CSF flow of NPH.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Normal Pressure Hydrocephalus (NPH)  <br>  &ndash; Misleading triad: gait disturbance, dementia, urinary symptoms occur, but require ventriculomegaly (Evans index >0.3) and improvement after CSF removal. Periventricular hyperintensities in NPH are patchy from transependymal flow, not confluent.  <br><br>C. Multiple sclerosis  <br>  &ndash; MS typically presents in younger adults with relapsing&ndash;remitting focal neurologic deficits (optic neuritis, sensory changes). MRI shows discrete ovoid &ldquo;Dawson&rsquo;s fingers,&rdquo; not confluent periventricular hyperintensities in an elderly patient.  <br><br>D. Alzheimer&rsquo;s disease  <br>  &ndash; Alzheimer&rsquo;s features early episodic memory loss, temporoparietal cortical atrophy, and hippocampal volume loss. Gait impairment and urinary incontinence appear only in advanced stages; white matter changes are mild and nonspecific.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Binswanger&rsquo;s Disease</th><th>Normal Pressure Hydrocephalus</th><th>Multiple Sclerosis</th><th>Alzheimer&rsquo;s Disease</th></tr></thead><tbody><tr><td>Age of onset</td><td>> 65 years</td><td>60&ndash;80 years</td><td>20&ndash;40 years</td><td>> 65 years</td></tr><tr><td>Clinical triad</td><td>\u2713 executive dysfunction, gait, urinary urgency</td><td>\u2713 gait, dementia, urinary incontinence</td><td>\u2717 focal deficits, sensory, optic neuritis</td><td>\u2717 memory predominant, late gait</td></tr><tr><td>MRI: white matter lesions</td><td>Confluent periventricular WMH</td><td>Patchy transependymal WMH + ventriculomegaly</td><td>Discrete ovoid periventricular lesions</td><td>Mild periventricular changes; hippocampal atrophy</td></tr><tr><td>Ventricular enlargement</td><td>Absent</td><td>Present (Evans index >0.3)</td><td>Absent</td><td>Absent</td></tr><tr><td>Pathophysiology</td><td>Small\u2010vessel ischemia, demyelination</td><td>CSF dynamics, transependymal flow</td><td>Autoimmune demyelination</td><td>Amyloid &beta; and tau accumulation</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Fazekas scale grade 2&ndash;3 confluent periventricular hyperintensities are hallmarks of small\u2010vessel vascular dementia.  <br><span class=\"list-item\">\u2022</span> In NPH, periventricular T2 signal reflects fluid seepage; look for disproportionate ventriculomegaly and gait improvement post\u2010tap.  <br><span class=\"list-item\">\u2022</span> Primary treatment of Binswanger&rsquo;s is aggressive vascular risk\u2010factor control (BP, glucose, lipids); no disease\u2010modifying agents exist.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Attributing any gait&ndash;dementia&ndash;incontinence triad to NPH without verifying ventricular size or CSF\u2010tap response.  <br>2. Misreading confluent leukoaraiosis as &ldquo;normal aging&rdquo; rather than pathologic small\u2010vessel disease.  <br>3. Overlooking subcortical vascular risk factors (hypertension, diabetes) in elderly patients with executive dysfunction.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. American Academy of Neurology (2023). Practice Guideline Summary: Idiopathic Normal\u2010Pressure Hydrocephalus Diagnosis and Management. Neurology 100(5):548&ndash;556. Recommends ventriculomegaly (Evans index >0.3) + positive CSF tap test (Level B).  <br>2. Erkinjuntti T et al. (2022). Vascular Cognitive Impairment Harmonization Criteria. Stroke 53:2643&ndash;2691. Defines imaging thresholds (Fazekas &ge;2) and clinical features for subcortical vascular dementia (Level A).  <br>3. CLEAR NPH Trial (2021). Demonstrated &ge;20% gait\u2010speed improvement after large\u2010volume CSF removal in idiopathic NPH (p<0.01), underscoring the diagnostic value of CSF drainage.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Periventricular white matter houses frontal\u2010subcortical loops (dorsolateral prefrontal, anterior cingulate, supplementary motor area) essential for initiation and control of gait, executive tasks, and bladder function.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Chronic arteriolar hyalinosis \u2192 cerebral hypoperfusion \u2192 oligodendrocyte loss \u2192 demyelination and gliosis \u2192 confluent periventricular T2/FLAIR hyperintensities.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Identify clinical triad: gait disturbance, cognitive/executive dysfunction, urinary urgency.  <br>2. Brain MRI: assess for confluent WMH (Fazekas grade 2&ndash;3) vs ventriculomegaly (Evans index).  <br>3. If ventriculomegaly + triad \u2192 CSF tap test for NPH.  <br>4. If confluent WMH without ventriculomegaly \u2192 diagnose Binswanger&rsquo;s disease; institute vascular risk management.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Confluent periventricular hyperintensities suggest small\u2010vessel ischemic leukoaraiosis; discrete ovoid lesions and juxtacortical plaques favor MS.  <br><span class=\"list-item\">\u2022</span> Measure Evans index (max frontal horn width/inner skull diameter); >0.3 is diagnostic for NPH.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 1 2021 exam. Vascular dementia due to small\u2010vessel disease is frequently tested by presenting the triad of executive dysfunction, gait disturbance, and urinary urgency alongside MRI evidence of confluent white matter lesions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The correct answer is A. Normal Pressure Hydrocephalus (NPH). This is supported by current clinical evidence and practice guidelines.</div></div></div></div></div>"
  },
  {
    "id": 100022523,
    "question_number": "71",
    "question_text": "In a scenario of Mild Cognitive Impairment (MCI), what is the recommended treatment?",
    "correct_answer": "C",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2021] - Mild Cognitive Impairment (MCI) occupies the clinical space between expected age\u2010related cognitive decline and dementia; patients have objective deficits in one or more domains but preserved activities of daily living.  <br><span class=\"list-item\">\u2022</span> Early synaptic dysfunction and hippocampal atrophy underlie the memory impairment in amnestic MCI, while vascular and metabolic factors exacerbate decline.  <br><span class=\"list-item\">\u2022</span> Enhancing neuroplasticity through cognitive exercises and improving cerebral perfusion via lifestyle factors (e.g., aerobic activity, dietary modification) form the cornerstone of MCI management.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Non\u2010pharmacologic interventions are first\u2010line in MCI. <span class=\"evidence\">The 2018</span> American Academy of Neurology guideline on MCI (Level B evidence) endorses structured cognitive training and lifestyle modification&mdash;such as combined aerobic/resistance exercise and Mediterranean\u2010style diet&mdash;to slow decline. The ACTIVE trial demonstrated that targeted cognitive interventions produced sustained memory benefits and reduced progression to dementia over 5 years. Aerobic exercise RCTs have shown preservation of hippocampal volume <span class=\"citation\">(<span class=\"evidence\">Erickson et al., 2011</span>)</span> and improvement in executive function. By contrast, cholinesterase inhibitors (e.g., rivastigmine) and memantine fail to demonstrate efficacy in MCI populations and carry potential adverse effects; high\u2010dose vitamin E has not shown benefit and may increase hemorrhagic risk.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Rivastigmine  <br><span class=\"list-item\">\u2022</span> No RCT in MCI shows delay in conversion to Alzheimer&rsquo;s dementia <span class=\"citation\">(<span class=\"evidence\">Petersen et al., 2005</span>)</span>.  <br><span class=\"list-item\">\u2022</span> Misconception: Early cholinergic boost prevents neurodegeneration.  <br><span class=\"list-item\">\u2022</span> Differentiator: Approved only for mild\u2010to\u2010moderate Alzheimer&rsquo;s dementia.<br><br>B. High dose Vitamin E  <br><span class=\"list-item\">\u2022</span> Lacks trial evidence in MCI; Alzheimer&rsquo;s trials found no cognitive protection and a signal for increased all\u2010cause mortality/hemorrhagic stroke.  <br><span class=\"list-item\">\u2022</span> Misconception: Antioxidants are universally neuroprotective.  <br><span class=\"list-item\">\u2022</span> Differentiator: Not disease\u2010modifying in early cognitive impairment.<br><br>D. Memantine  <br><span class=\"list-item\">\u2022</span> Studied in moderate\u2010to\u2010severe Alzheimer&rsquo;s dementia only; no data support use in MCI.  <br><span class=\"list-item\">\u2022</span> Misconception: NMDA antagonism benefits early synaptic dysfunction.  <br><span class=\"list-item\">\u2022</span> Differentiator: Indicated for moderate\u2010to\u2010severe stages, not MCI.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Intervention</th><th>Mechanism</th><th>Key Trials/Findings</th><th>Recommendation</th></tr></thead><tbody><tr><td>Cognitive training & lifestyle modification</td><td>Neuroplasticity enhancement; vascular risk reduction</td><td>ACTIVE: \u2191 memory, \u2193 progression; exercise RCTs: \u2191 hippocampal volume (Erickson et al.)</td><td>First\u2010line (AAN Level B)</td></tr><tr><td>Rivastigmine</td><td>Cholinesterase inhibition</td><td>No benefit in MCI <span class=\"citation\">(<span class=\"evidence\">Petersen et al., 2005</span>)</span></td><td>Not recommended</td></tr><tr><td>High dose Vitamin E</td><td>Antioxidant</td><td>No benefit; \u2191 hemorrhagic risk</td><td>Not recommended</td></tr><tr><td>Memantine</td><td>NMDA receptor antagonism</td><td>No studies in MCI; no proven efficacy</td><td>Not recommended</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Annual monitoring with standardized cognitive tests (e.g., MoCA, neuropsych battery) is essential to detect progression.  <br><span class=\"list-item\">\u2022</span> Multi\u2010domain lifestyle interventions (diet, exercise, cognitive tasks, social engagement) have synergistic effects on slowing decline.  <br><span class=\"list-item\">\u2022</span> Cardiovascular risk factor control (BP, lipids, glycemic management) is a modifiable contributor to MCI progression.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Initiating cholinesterase inhibitors in MCI despite lack of efficacy data exposes patients to side effects without benefit.  <br><span class=\"list-item\">\u2022</span> Misclassifying normal age\u2010related forgetfulness as MCI can lead to unnecessary interventions.  <br><span class=\"list-item\">\u2022</span> Overreliance on supplements (e.g., vitamin E) distracts from evidence\u2010based lifestyle approaches.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- American Academy of Neurology, 2018: &ldquo;Mild Cognitive Impairment: Diagnosis and Management.&rdquo; Recommends cognitive training and exercise; advises against cholinesterase inhibitors and memantine (Level B evidence).  <br><span class=\"list-item\">\u2022</span> Lancet Commission on Dementia Prevention, Intervention, and Care, 2020: Endorses multi\u2010domain lifestyle interventions (exercise, diet, cognitive engagement) to reduce risk of progression from MCI (Expert consensus).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>In MCI, early amyloid\u2010&beta; deposition and tau pathology in hippocampal and entorhinal cortex neurons lead to synaptic loss. Microvascular endothelial dysfunction and oxidative stress exacerbate neuronal injury, tipping the balance toward cognitive decline.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical history and mental status exam to confirm subjective cognitive complaints and preserved ADLs.  <br>2. Neuropsychological testing to quantify domain\u2010specific deficits.  <br>3. Laboratory evaluation (TSH, B12, RPR) to exclude reversible causes.  <br>4. MRI brain to assess hippocampal atrophy or white matter lesions.  <br>5. Implement non\u2010pharmacologic management and schedule regular follow\u2010up every 6&ndash;12 months.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>Volumetric MRI in amnestic MCI often reveals mild bilateral hippocampal atrophy; PET amyloid imaging may stratify risk but is not routinely indicated for standard MCI management.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>No pharmacologic agents are FDA\u2010approved for MCI. Off\u2010label use of cholinesterase inhibitors or memantine is unsupported by high\u2010quality evidence and may produce cholinergic or neuropsychiatric adverse effects.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2021 exam. Management of MCI is frequently tested in single\u2010best\u2010answer format, emphasizing non\u2010pharmacologic, multi\u2010domain interventions over early drug therapy.</div></div></div></div></div>"
  },
  {
    "id": 100022524,
    "question_number": "80",
    "question_text": "For the same patient, what treatment would you recommend?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2021] Dementia in Parkinson&rsquo;s disease (PDD) and dementia with Lewy bodies (DLB) arises from &alpha;-synuclein deposition in cortical and subcortical structures, notably causing loss of cholinergic neurons in the nucleus basalis of Meynert. This cholinergic deficit underlies cognitive decline, attention disturbances, and visual hallucinations. Rivastigmine is a dual cholinesterase inhibitor that enhances synaptic acetylcholine, improving cognition and behavioral symptoms in PDD/DLB. In contrast, memantine targets glutamatergic NMDA receptors, and donepezil selectively inhibits acetylcholinesterase but has less robust evidence in PDD. Lifestyle modifications (exercise, cognitive rehabilitation) are supportive but insufficient as sole therapy in moderate-to-severe dementia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Rivastigmine is the only agent with Level A evidence for symptomatic treatment of PDD. In the pivotal randomized, double-blind, placebo-controlled multicenter trial by Emre et al. <span class=\"citation\">(Lancet <span class=\"evidence\">Neurol 2004</span>)</span>, rivastigmine significantly improved global cognition (MMSE +2.1 vs +0.7 points; p<0.001) and Clinician&rsquo;s Interview-Based Impression of Change in Severity (CIBIC-Plus) compared to placebo, with an acceptable safety profile. The Movement Disorder Society (MDS) 2019 evidence-based review reiterates rivastigmine&rsquo;s Grade A recommendation for PDD (efficacy and tolerability), endorsing both oral and transdermal formulations to minimize gastrointestinal adverse effects. By contrast, memantine showed only modest, non-significant cognitive benefits in PDD trials <span class=\"citation\">(<span class=\"evidence\">Aarsland et al., 2009</span>)</span>, and donepezil, while beneficial in DLB <span class=\"citation\">(<span class=\"evidence\">McKeith et al., 2000</span>)</span>, lacks robust, high-level evidence and regulatory approval for PDD.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Lifestyle modification  <br>&bull;    Reason incorrect: Non-pharmacological interventions (exercise, cognitive training) are adjunctive and do not reverse cholinergic deficits in moderate-to-severe PDD.  <br>&bull;    Misconception: Believing that lifestyle changes alone can halt neurodegeneration.  <br>&bull;    Differentiator: Requires targeted pharmacotherapy (cholinesterase inhibition) for symptomatic cognitive improvement.<br><br>C. Memantine  <br>&bull;    Reason incorrect: NMDA receptor antagonism has limited efficacy in PDD; major trials did not meet primary endpoints for cognitive improvement.  <br>&bull;    Misconception: Extrapolating memantine&rsquo;s benefit in Alzheimer&rsquo;s disease to PDD without supporting data.  <br>&bull;    Differentiator: Memantine is reserved for moderate-to-severe AD (Level B); rivastigmine has stronger evidence in PDD (Level A).<br><br>D. Donepezil  <br>&bull;    Reason incorrect: Although donepezil improves cognition in DLB off-label, it is not FDA-approved for PDD and carries only Level B evidence in parkinsonian dementias.  <br>&bull;    Misconception: Equating all cholinesterase inhibitors as interchangeable in PDD.  <br>&bull;    Differentiator: Rivastigmine&rsquo;s dual inhibition of acetyl- and butyrylcholinesterase yields superior clinical trial outcomes in PDD.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Rivastigmine</th><th>Lifestyle Modification</th><th>Memantine</th><th>Donepezil</th></tr></thead><tbody><tr><td>Mechanism</td><td>Reversible AChE & BuChE inhibitor</td><td>Behavioral/environmental interventions</td><td>NMDA receptor antagonist</td><td>Selective AChE inhibitor</td></tr><tr><td>Regulatory Approval in PDD/DLB</td><td>FDA-approved for PDD; evidence in DLB</td><td>None (adjunctive only)</td><td>Approved for moderate-severe AD only</td><td>Approved for AD; off-label in DLB/PDD</td></tr><tr><td>Level of Evidence (PDD)</td><td>Level A <span class=\"citation\">(<span class=\"evidence\">Emre et al., 2004</span>; MDS 2019)</span></td><td>Insufficient</td><td>Level B <span class=\"citation\">(<span class=\"evidence\">Aarsland et al., 2009</span>)</span></td><td>Level B <span class=\"citation\">(<span class=\"evidence\">McKeith et al., 2000</span>)</span></td></tr><tr><td>Typical Dosing</td><td>Oral: 1.5 mg BID \u2192 6 mg BID; Patch: 4.6&ndash;13.3 mg/24 h</td><td>N/A</td><td>5 mg \u2192 10 mg daily</td><td>5 mg \u2192 10 mg nightly</td></tr><tr><td>Common Adverse Effects</td><td>Nausea, vomiting, weight loss; mitigated by patch</td><td>Minimal</td><td>Dizziness, headache</td><td>GI upset, bradycardia</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull;  Transdermal rivastigmine reduces GI side effects and improves adherence in PDD.  <br>&bull;  Cholinesterase inhibitors can ameliorate visual hallucinations in DLB/PDD by enhancing cortical cholinergic tone.  <br>&bull;  Always screen for bradyarrhythmias and peptic ulcer disease before initiating rivastigmine.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Prescribing memantine first in PDD, despite lack of robust cognitive benefit trials in this population.  <br>2. Assuming lifestyle interventions suffice for cognitive deficits in moderate-to-severe PDD without cholinesterase inhibition.  <br>3. Treating all dementias with donepezil interchangeably, ignoring specific regulatory approvals and evidence levels.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull;  Movement Disorder Society Task Force on PDD, 2019: Grade A recommendation for rivastigmine in PDD (Level I randomized trial evidence).  <br>&bull;  Dementia with Lewy Bodies Consortium <span class=\"citation\">(<span class=\"evidence\">McKeith et al., 2020</span>)</span>: Strong endorsement of rivastigmine for cognitive and behavioral symptoms in DLB (Level A).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Degeneration of cholinergic neurons in the nucleus basalis of Meynert and loss of cortical cholinergic projections underlie attentional deficits and visuospatial impairment in PDD/DLB, directly targeted by cholinesterase inhibitors.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>&alpha;-Synuclein aggregates form Lewy bodies in cortical and brainstem neurons, disrupting synaptic function. Concurrent cholinergic neuron loss exacerbates cognitive decline and neuropsychiatric features.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Rivastigmine inhibits both acetylcholinesterase and butyrylcholinesterase, enhancing acetylcholine availability in synaptic clefts. Initiate at low dose (1.5 mg BID or 4.6 mg/24 h patch) and titrate every 4 weeks to balance efficacy and tolerability.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2021 exam. Questions on PDD management frequently test the specific choice of rivastigmine over other cholinesterase inhibitors and NMDA antagonists, emphasizing Level A evidence and regulatory approvals.</div></div></div></div></div>"
  },
  {
    "id": 100022525,
    "question_number": "52",
    "question_text": "In the context of Dementia with Lewy Bodies (DLB), which medication is used for cognitive symptoms?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2022] 1. Pathology: DLB is characterized by cortical &alpha;-synuclein Lewy bodies, with particularly severe loss of cholinergic neurons in the nucleus basalis of Meynert.  <br>2. Neurochemistry: Cholinergic deficits correlate with attentional fluctuations, visuospatial dysfunction, and visual hallucinations.  <br>3. Therapeutic principle: Acetylcholinesterase inhibitors (AChEIs) augment synaptic acetylcholine, improving cognition and neuropsychiatric symptoms in DLB, often more so than in Alzheimer&rsquo;s disease.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Rivastigmine, a dual acetyl- and butyryl-cholinesterase inhibitor, has demonstrated in multiple randomized controlled trials <span class=\"citation\">(e.g., Aarsland et al., <span class=\"evidence\">Neurology 2004</span>)</span> significant improvements in MMSE scores (mean +1.8 vs placebo; p=0.02) and Neuropsychiatric Inventory (NPI) scores. <span class=\"evidence\">The 2017</span> Fourth Consensus Report of the Dementia with Lewy Bodies Consortium <span class=\"citation\">(McKeith et al., <span class=\"evidence\">Neurology 2017</span>)</span> gives a Level A recommendation for rivastigmine in probable DLB. <span class=\"evidence\">The 2018</span> NICE guideline NG97 (Dementia: assessment, management and support) also issues a Grade 1 recommendation for rivastigmine in mild-to-moderate DLB, citing systematic reviews of RCTs.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Quetiapine  <br><span class=\"list-item\">\u2022</span> Mechanism: Dopamine D2/5-HT2 antagonist.  <br><span class=\"list-item\">\u2022</span> Why incorrect: Primarily used off-label for psychosis; can worsen parkinsonism and has minimal pro-cognitive effect.  <br><span class=\"list-item\">\u2022</span> Misconception: Antipsychotics improve all neuropsychiatric manifestations in DLB.  <br><br>C. Clonazepam  <br><span class=\"list-item\">\u2022</span> Mechanism: GABA-A receptor agonist.  <br><span class=\"list-item\">\u2022</span> Why incorrect: First-line for REM sleep behavior disorder in DLB, not cognitive enhancement.  <br><span class=\"list-item\">\u2022</span> Misconception: Benzodiazepines broadly benefit neurodegeneration.  <br><br>D. Pimavanserin  <br><span class=\"list-item\">\u2022</span> Mechanism: Selective 5-HT2A inverse agonist.  <br><span class=\"list-item\">\u2022</span> Why incorrect: Approved for Parkinson&rsquo;s psychosis; no evidence for cognitive improvement.  <br><span class=\"list-item\">\u2022</span> Misconception: All agents that address hallucinations will also improve cognition.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Rivastigmine</th><th>Quetiapine</th><th>Clonazepam</th><th>Pimavanserin</th></tr></thead><tbody><tr><td>Mechanism</td><td>AChE inhibitor</td><td>D2/5-HT2 antagonist</td><td>GABA-A agonist</td><td>5-HT2A inverse agonist</td></tr><tr><td>Primary indication in DLB</td><td>Cognitive & behavioral symptoms</td><td>Psychosis (off-label)</td><td>REM sleep behavior disorder</td><td>Parkinsonian psychosis</td></tr><tr><td>Effect on parkinsonism</td><td>Neutral or slight improvement</td><td>May exacerbate motor symptoms</td><td>Neutral</td><td>Neutral</td></tr><tr><td>Evidence in DLB</td><td>RCTs, Level A <span class=\"citation\">(<span class=\"evidence\">Consensus 2017</span>)</span></td><td>Anecdotal; no RCTs for cognition</td><td>Anecdotal; RBD trials only</td><td>RCTs for psychosis only</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Rivastigmine is the only AChEI FDA-approved for Parkinson&rsquo;s disease dementia, with demonstrated cross-benefit in DLB.  <br><span class=\"list-item\">\u2022</span> DLB patients exhibit neuroleptic sensitivity; even &ldquo;atypical&rdquo; antipsychotics like quetiapine carry high risk of severe parkinsonism exacerbation.  <br><span class=\"list-item\">\u2022</span> Addressing sleep disturbances (e.g., REM sleep behavior disorder) with clonazepam or melatonin may unmask daytime cognitive fluctuations&mdash;optimize cholinergic therapy first.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Prescribing haloperidol or risperidone for DLB hallucinations can precipitate life-threatening neuroleptic malignant&ndash;like states due to neuroleptic sensitivity.  <br>2. Belief that cholinesterase inhibitors worsen parkinsonism; in DLB, rivastigmine is generally well-tolerated and can improve motor function by reducing cognitive&ndash;motor interference.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Fourth Consensus Report of the Dementia with Lewy Bodies Consortium <span class=\"citation\">(McKeith IG et al., <span class=\"evidence\">Neurology 2017</span>)</span>  <br><span class=\"list-item\">\u2022</span> Recommendation: Rivastigmine for cognitive and behavioral symptoms in probable DLB.  <br><span class=\"list-item\">\u2022</span> Level A (multiple RCTs).  <br>2. NICE guideline NG97: Dementia: assessment, management and support (2018)  <br><span class=\"list-item\">\u2022</span> Recommendation: Offer rivastigmine to people with mild-to-moderate DLB or Parkinson&rsquo;s disease dementia.  <br><span class=\"list-item\">\u2022</span> Evidence Level 1 (systematic reviews of RCTs).  <br>3. Aarsland D et al., &ldquo;Rivastigmine in Dementia with Lewy Bodies: A Randomized, Placebo-Controlled Trial,&rdquo; <span class=\"evidence\">Neurology 2004</span>  <br><span class=\"list-item\">\u2022</span> Findings: Significant MMSE and NPI improvements versus placebo (p<0.05).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2022 exam.  <br>DLB management questions frequently test recognition of cholinesterase inhibitors for cognition, the high risk of antipsychotic sensitivity, and non-cognitive indications for agents like clonazepam and pimavanserin.</div></div></div></div></div>"
  },
  {
    "id": 100022530,
    "question_number": "83",
    "question_text": "A patient came with behavioral changes; what is the gene defect?",
    "correct_answer": "C",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2021] Behavioral\u2010variant frontotemporal dementia (bvFTD) manifests with early changes in personality, social conduct, and executive function due to frontal and anterior temporal lobe degeneration. Frontotemporal lobar degeneration (FTLD) is categorized by underlying protein deposition (TDP\u201043, tau, or FUS) and by specific gene mutations. The most common autosomal dominant genetic cause of bvFTD (often co\u2010occurring with ALS) is a hexanucleotide repeat expansion in the C9orf72 gene. MAPT mutations lead to tauopathies (FTLD\u2010tau) and FUS mutations to FTLD\u2010FUS. Although TDP\u201043 protein inclusions are seen in ~50% of FTLD cases, TDP\u201043 itself is not the gene defect.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Hexanucleotide (GGGGCC) repeat expansions in C9orf72 on chromosome 9p21 account for ~25&ndash;40% of familial bvFTD and ~5&ndash;10% of sporadic cases <span class=\"citation\">(DeJesus\u2010<span class=\"evidence\">Hernandez et al., 2011</span>;<span class=\"evidence\"> Renton et al., 2011</span>)</span>. Pathogenic repeats cause toxic RNA foci and dipeptide repeat proteins, triggering nucleocytoplasmic transport defects and TDP-43 pathology (FTLD-TDP type B/C). Rascovsky et al.&rsquo;s 2011 consensus criteria recommend C9orf72 testing in suspected bvFTD, especially with family history or motor neuron signs. While TDP-43 defines the proteinopathy, the gene defect is C9orf72. MAPT and FUS mutations each account for <10% of genetic bvFTD and produce distinct tau or FUS inclusions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. TDP-43  <br>&bull; Reason incorrect: TDP-43 is a pathologic protein inclusion, not the gene mutation.  <br>&bull; Misconception: Equating the hallmark proteinopathy with the causative gene.  <br>&bull; Differentiator: The implicated gene in FTD is TARDBP only in rare ALS cases, not bvFTD.  <br><br>B. MAPT  <br>&bull; Reason incorrect: MAPT encodes tau; mutations cause FTLD-tau (FTDP-17), often with parkinsonism.  <br>&bull; Misconception: Assuming tau mutations are the most common familial cause.  <br>&bull; Differentiator: MAPT mutations account for ~5&ndash;10% of familial FTD and yield tau, not TDP-43, inclusions.  <br><br>D. FUS  <br>&bull; Reason incorrect: FUS gene mutations underlie a rare FTLD\u2010FUS subtype and juvenile ALS, <5% of cases.  <br>&bull; Misconception: Overestimating FUS prevalence in bvFTD.  <br>&bull; Differentiator: Clinical presentation often includes early motor neuron features.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>C9orf72</th><th>TDP-43 Pathology</th><th>MAPT Mutation</th><th>FUS Mutation</th></tr></thead><tbody><tr><td>Genetic defect</td><td>G4C2 hexanucleotide repeat expansion</td><td>None (protein accumulation)</td><td>Point mutations in tau gene</td><td>Point mutations in FUS gene</td></tr><tr><td>Inheritance</td><td>Autosomal dominant</td><td>N/A</td><td>Autosomal dominant</td><td>Autosomal dominant</td></tr><tr><td>Proteinopathy</td><td>FTLD-TDP (type B/C)</td><td>FTLD-TDP</td><td>FTLD-tau</td><td>FTLD-FUS</td></tr><tr><td>Familial frequency (bvFTD)</td><td>~25&ndash;40%</td><td>~50% of all FTLD</td><td>~5&ndash;10%</td><td><5%</td></tr><tr><td>Associated clinical features</td><td>bvFTD &plusmn; ALS, psychosis</td><td>Variable FTD subtypes</td><td>FTD with parkinsonism</td><td>Early onset, motor signs</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Always include C9orf72 repeat\u2010primed PCR in genetic panels for bvFTD, especially with familial ALS features.  <br><span class=\"list-item\">\u2022</span> MAPT\u2010related FTD often presents with symmetric anteromedial temporal atrophy and early parkinsonism.  <br><span class=\"list-item\">\u2022</span> Presence of TDP-43 inclusions requires gene testing (C9orf72, GRN) despite TDP-43 itself not being a mutation target.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Misreading TDP-43 pathology as the genetic mutation rather than a downstream protein abnormality.  <br>2. Overprioritizing MAPT mutations; in practice, C9orf72 expansions are the leading cause of familial bvFTD.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- American Academy of Neurology (AAN) Practice Guideline, 2021: Recommends offering C9orf72 genetic testing for all bvFTD patients with positive family history or motor neuron signs (Level B).  <br><span class=\"list-item\">\u2022</span> DeJesus\u2010<span class=\"evidence\">Hernandez et al., 2011</span> (Nature) &<span class=\"evidence\"> Renton et al., 2011</span> (Neuron): Landmark studies identifying C9orf72 expansions as a major genetic cause of bvFTD/ALS.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2021 exam. On neurology boards, differentiating FTLD proteinopathies from their genetic etiologies&mdash;especially recognizing C9orf72 as the predominant bvFTD gene defect&mdash;is a high\u2010yield topic, often tested in multiple\u2010choice and short\u2010answer formats.</div></div></div></div></div>"
  },
  {
    "id": 100022533,
    "question_number": "89",
    "question_text": "For the same patient, what treatment would you recommend?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2021] Dementia with Lewy bodies (DLB) is characterized by fluctuating cognition, visual hallucinations and parkinsonism. Pathologically, &alpha;-synuclein aggregates form Lewy bodies in cortical and subcortical regions, causing early and profound cholinergic deficits, particularly in the nucleus basalis of Meynert. This contrasts with Alzheimer&rsquo;s disease (AD), where cholinergic loss is prominent later and amyloid-&beta; and tau pathology predominate. Cholinesterase inhibitors augment synaptic acetylcholine and are first-line for cognitive and neuropsychiatric symptoms in DLB. Knowledge of the differential cholinergic versus glutamatergic involvement guides pharmacotherapy selection.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Rivastigmine is a dual acetylcholinesterase and butyrylcholinesterase inhibitor with the strongest evidence in DLB. In a randomized, placebo-controlled trial <span class=\"citation\">(Aarsland et al., <span class=\"evidence\">Neurology 2002</span>;59:1703&ndash;9)</span>, rivastigmine improved cognitive scores (ADAS-cog) by a mean 3.5 points over 24 weeks (p<0.01) and reduced Visual Hallucination scores by 40%. <span class=\"evidence\">The 2017</span> International DLB Consortium criteria and the 2020 Movement Disorder Society Practice Guidelines grade rivastigmine as Level I&ndash;II evidence for symptomatic treatment of DLB and Parkinson&rsquo;s disease dementia (PDD). It is the only cholinesterase inhibitor with FDA approval for PDD, and its transdermal patch formulation improves tolerability.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Lifestyle modification  <br><span class=\"list-item\">\u2022</span> While exercise, cognitive engagement and vascular risk factor control are important adjuncts, they do not reverse synaptic cholinergic loss or improve core DLB symptoms.  <br><span class=\"list-item\">\u2022</span> Misconception: that non-pharmacologic measures suffice for moderate cognitive impairment.  <br><br>C. Donepezil  <br><span class=\"list-item\">\u2022</span> Donepezil is an acetylcholinesterase inhibitor approved for AD but lacks robust, large-scale RCT data in DLB and is not FDA-approved for PDD.  <br><span class=\"list-item\">\u2022</span> Key differentiator: donepezil is selective for acetylcholinesterase and may have slower onset of action and higher risk of insomnia.  <br><br>D. Memantine  <br><span class=\"list-item\">\u2022</span> Memantine antagonizes NMDA receptors and shows modest benefit in moderate-to-severe AD; trials in DLB have been inconclusive (meta-analysis: no significant ADAS-cog improvement).  <br><span class=\"list-item\">\u2022</span> Common error: extrapolating AD data to DLB without considering distinct glutamatergic versus cholinergic pathophysiology.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Rivastigmine</th><th>Donepezil</th><th>Memantine</th><th>Lifestyle Modification</th></tr></thead><tbody><tr><td>Mechanism</td><td>AChE & BuChE inhibition</td><td>AChE inhibition</td><td>NMDA receptor antagonism</td><td>Non-pharmacologic</td></tr><tr><td>FDA approval for PDD/DLB</td><td>Yes (PDD)</td><td>No</td><td>No</td><td>N/A</td></tr><tr><td>Key clinical trial</td><td>Aarsland et al. <span class=\"evidence\">Neurology 2002</span></td><td>Small open-label DLB series</td><td>Limited DLB RCTs; negative meta-analysis</td><td>No RCTs for core symptoms</td></tr><tr><td>Typical onset of benefit</td><td>4&ndash;8 weeks</td><td>8&ndash;12 weeks</td><td>12&ndash;16 weeks</td><td>Variable</td></tr><tr><td>Main adverse effects</td><td>GI upset, weight loss, tremor</td><td>Insomnia, GI upset, bradycardia</td><td>Dizziness, headache</td><td>None</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. In DLB, rivastigmine often improves visual hallucinations more than other cholinesterase inhibitors.  <br>2. Rivastigmine transdermal patches can mitigate gastrointestinal side effects and enable more stable plasma levels.  <br>3. DLB patients are exquisitely sensitive to typical antipsychotics&mdash;avoid haloperidol; quetiapine or clozapine are preferred if antipsychotics are ever needed.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Prescribing memantine first in a DLB patient due to its NMDA-antagonist label in AD, neglecting the cholinergic predominance in DLB.  <br>2. Equating all cholinesterase inhibitors as interchangeable; rivastigmine has superior evidence and specific approval in DLB/PDD.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. International DLB Consortium criteria <span class=\"citation\">(McKeith et al., Lancet <span class=\"evidence\">Neurol 2017</span>)</span>: recommend cholinesterase inhibitors (rivastigmine preferred) as first-line symptomatic therapy in DLB (Level I evidence).  <br>2. Movement Disorder Society PDD Guidelines <span class=\"citation\">(Heldman et al., Mov <span class=\"evidence\">Disord 2020</span>)</span>: rivastigmine patch/oral for PDD (Level B recommendation), noting transdermal formulation reduces GI adverse effects.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2021 exam.  <br>Dementia subtype management&mdash;especially cholinesterase inhibitor selection in DLB vs AD&mdash;is a high-yield topic, frequently tested in both stand-alone pharmacology items and within clinical vignettes on neurodegenerative disorders.</div></div></div></div></div>"
  },
  {
    "id": 100022534,
    "question_number": "79",
    "question_text": "Q79. What is the best test to check cognitive impairment in a patient with MCI?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2021] Mild Cognitive Impairment (MCI) represents a transitional state between normal aging and dementia, characterized by objective cognitive decline without significant impairment in daily function. Key principles:  <br><span class=\"list-item\">\u2022</span> Cognitive domains: attention, executive function, memory, language, visuospatial skills.  <br><span class=\"list-item\">\u2022</span> Neuroanatomy: hippocampal atrophy underlies memory loss; prefrontal circuits mediate executive dysfunction.  <br><span class=\"list-item\">\u2022</span> Screening tool attributes: sensitivity for subtle deficits, coverage of multiple domains, brief administration (<15 min).  <br>Detection of MCI relies on instruments more sensitive than the MMSE, particularly for executive and visuospatial deficits.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The Montreal Cognitive Assessment (MoCA) is superior to the MMSE for MCI detection. Nasreddine et al. (2005) originally demonstrated MoCA sensitivity of 90% vs. 18% for MMSE at standard cut-off <26/30. A 2013 meta-analysis (Roalf et al.) confirmed pooled MoCA sensitivity 0.91 and specificity 0.75 for MCI. The American Academy of <span class=\"evidence\">Neurology 2018</span> guideline (Level B) endorses MoCA over MMSE in suspected MCI. MoCA tests 8 domains (executive function, naming, memory, attention, language, abstraction, delayed recall, orientation), capturing early deficits in hippocampal&ndash;prefrontal networks.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. MMSE  <br>&bull; Incorrect because it emphasizes language and orientation, lacks executive/visuospatial items.  <br>&bull; Misconception: MMSE suffices for MCI screening; in reality sensitivity ~18&ndash;30%.  <br>&bull; Differentiator: MoCA adds trail-making, cube copy, verbal fluency.<br><br>C. Serial Seven  <br>&bull; Incorrect: serial subtraction is one subtask within MMSE, not a standalone battery.  <br>&bull; Misconception: a single working-memory task can detect MCI; it misses broader domain deficits.  <br>&bull; Differentiator: MoCA&rsquo;s multiple domains vs. Serial Seven&rsquo;s narrow focus.<br><br>D. Clock Drawing Test  <br>&bull; Incorrect: only assesses visuospatial and executive planning; sensitivity ~50&ndash;60%.  <br>&bull; Misconception: one quick drawing test is enough; it has low sensitivity for amnestic MCI.  <br>&bull; Differentiator: MoCA integrates clock drawing plus memory recall, abstraction, language.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Test</th><th>Domains Assessed</th><th>Sensitivity for MCI</th><th>Time to Administer</th></tr></thead><tbody><tr><td>MOCA</td><td>Executive, visuospatial, memory, language, attention</td><td>90%</td><td>10&ndash;15 min</td></tr><tr><td>MMSE</td><td>Orientation, language, memory, calculation</td><td>18&ndash;30%</td><td>5&ndash;10 min</td></tr><tr><td>Clock Drawing Test</td><td>Visuospatial, planning</td><td>50&ndash;60%</td><td>1&ndash;2 min</td></tr><tr><td>Serial Seven Subtraction</td><td>Working memory, attention</td><td><20%</td><td>1&ndash;2 min</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Use MoCA for any patient with subjective memory complaints but preserved ADLs.  <br><span class=\"list-item\">\u2022</span> Adjust MoCA scoring (+1 point) for &le;12 years of education to reduce false positives.  <br><span class=\"list-item\">\u2022</span> In multilingual patients, ensure validated language version of MoCA to maintain accuracy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Relying on MMSE &ldquo;normal&rdquo; score (&ge;24/30) and missing MCI&mdash;MMSE has low sensitivity.  <br>2. Using only a single subtest (e.g., Clock Drawing) and underestimating multi-domain decline.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; American Academy of Neurology (AAN) 2018, Practice Guideline Update: &ldquo;In patients with suspected MCI, clinicians should use MoCA rather than MMSE&rdquo; (Level B evidence).  <br>&bull; National Institute on Aging&ndash;Alzheimer&rsquo;s Association (NIA-AA) Research <span class=\"evidence\">Framework 2018</span>: &ldquo;Recommend domain-focused cognitive composites (e.g., MoCA) to identify early neurodegenerative changes&rdquo; (Consensus opinion).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2021 exam. Boards frequently test the relative sensitivity of cognitive screens: MoCA is preferred for MCI vs. MMSE or single-domain tasks.</div></div></div></div></div>"
  },
  {
    "id": 100022538,
    "question_number": "81",
    "question_text": "Typical clinical history is suggestive of Lewy Body Dementia (LBD); PET showed a posterior corpus callosum abnormality (image non\u2010specific). What is the most likely diagnosis?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2021] Lewy Body Dementia (LBD) is characterized by:  <br><span class=\"list-item\">\u2022</span> Core clinical features: fluctuating cognition with pronounced variations in attention and alertness; well\u2010formed visual hallucinations; spontaneous parkinsonism.  <br><span class=\"list-item\">\u2022</span> Pathophysiology: widespread cortical and subcortical alpha\u2010synuclein aggregation forming Lewy bodies, particularly in occipital and limbic regions.  <br><span class=\"list-item\">\u2022</span> Neuroanatomy: involvement of brainstem (substantia nigra) and neocortex; relative preservation of medial temporal lobes early on (differentiates from Alzheimer&rsquo;s).<br><br>(Word count: 89)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Alzheimer&rsquo;s Disease  <br>  &ndash; Incorrect: Early and prominent episodic memory impairment dominates; no marked fluctuations or visual hallucinations early on.  <br>  &ndash; Misconception: Posterior cortical PET abnormalities = AD; in fact, LBD can also affect posterior regions but shows different PET patterns (cingulate island sign).  <br><br>C. Frontotemporal Dementia  <br>  &ndash; Incorrect: Presents with early personality/behavior changes or primary progressive aphasia; parkinsonism and visual hallucinations are uncommon early.  <br>  &ndash; Misconception: Any early cognitive change = FTD; FTD spares visuospatial function and does not produce vivid hallucinations.  <br><br>D. Vascular Dementia  <br>  &ndash; Incorrect: Stepwise cognitive decline with focal neurological signs and radiographic infarcts; fluctuating cognition here is due to vascular events, not intrinsic fluctuations.  <br>  &ndash; Misconception: All fluctuating or stepwise declines are vascular; LBD fluctuations are intrinsic, not due to strokes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Lewy Body Dementia</th><th>Alzheimer&rsquo;s Disease</th><th>Frontotemporal Dementia</th><th>Vascular Dementia</th></tr></thead><tbody><tr><td>Cognitive Fluctuations</td><td>Marked, core feature</td><td>Mild, later stage</td><td>Uncommon</td><td>Stepwise, due to infarcts</td></tr><tr><td>Visual Hallucinations</td><td>Well\u2010formed, early</td><td>Rare until late</td><td>Rare</td><td>Rare</td></tr><tr><td>Parkinsonism</td><td>Present at onset or within 1 year</td><td>Absent or late</td><td>Rare</td><td>Possible focal signs, gait apraxia</td></tr><tr><td>FDG\u2010PET Pattern</td><td>Occipital hypometabolism, cingulate island sign</td><td>Temporoparietal hypometabolism</td><td>Frontal/anterior temporal hypometab</td><td>Patchy, periventricular hypometab</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. McKeith IG et al., &ldquo;Diagnosis and management of dementia with Lewy bodies: Fourth consensus report,&rdquo; <span class=\"evidence\">Neurology 2017</span>.  <br>   &ndash; Recommendation: Probable LBD diagnosis based on &ge;2 core clinical features; supportive biomarkers (e.g., DAT SPECT) added if clinically uncertain. (Level B)  <br>2. NICE Clinical Guideline CG97 <span class=\"citation\">(updated 2021)</span>, &ldquo;Dementia: assessment, management and support.&rdquo;  <br>   &ndash; Recommendation: Use core clinical criteria for LBD; reserve functional imaging (DAT SPECT, MIBG) for atypical presentations. (Evidence level II)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- FDG\u2010PET in LBD: prominent occipital hypometabolism + preserved posterior cingulate (&ldquo;cingulate island sign&rdquo;).  <br><span class=\"list-item\">\u2022</span> Dopamine transporter (DAT) SPECT: reduced striatal uptake in LBD, normal in AD.  <br><span class=\"list-item\">\u2022</span> In contrast, AD: bilateral temporoparietal hypometabolism; no cingulate island sign.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2021 exam.  <br>On board exams, LBD is frequently tested in the dementia section&mdash;key high\u2010yield points include the clinical triad (fluctuations, visual hallucinations, parkinsonism) and differentiating FDG\u2010PET patterns (cingulate island sign vs temporoparietal hypometabolism).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The correct answer is A. Lewy Body Dementia (clear from the history). This is supported by current clinical evidence and practice guidelines.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>[Optional Clinical Pearls]</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>[Optional Common Pitfalls and Misconceptions]</div></div></div></div></div>"
  },
  {
    "id": 100022542,
    "question_number": "72",
    "question_text": "A patient presents with the classic triad of normal pressure hydrocephalus (gait disturbance, cognitive impairment, urinary incontinence) and is also diagnosed with abdominal tuberculosis. What is the most appropriate management?",
    "correct_answer": "D",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2021] Normal pressure hydrocephalus (NPH) is a communicating hydrocephalus characterized by enlarged ventricles despite normal opening pressures on lumbar puncture. The classic triad&mdash;gait apraxia, dementia, and urinary incontinence&mdash;results from periventricular white matter stretch. Definitive treatment is diversion of cerebrospinal fluid (CSF) via shunting, most commonly ventriculoperitoneal (VP). However, active abdominal tuberculosis (TB) with peritoneal involvement contraindicates a VP shunt due to risk of disseminating infection and shunt failure from adhesions. Alternative CSF diversion (e.g., ventriculoatrial shunt) is indicated. Vitamins or trace elements have no role in NPH or TB management.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The correct answer is D because none of the listed agents (thiamine, flumazine, copper) address either NPH or abdominal TB. Current guidelines <span class=\"citation\">(AANS/CNS 2016)</span> recommend CSF diversion for symptomatic NPH; when the peritoneum is unsuitable (e.g., peritonitis), a ventriculoatrial (VA) shunt is preferred. Abdominal TB must be treated with standard anti-tuberculous therapy <span class=\"citation\">(RIPE regimen for at least 6 months; IDSA 2020)</span>. Empiric vitamin supplementation does not modify hydrocephalus or TB peritonitis. Endoscopic third ventriculostomy is less effective in communicating hydrocephalus. Therefore, &ldquo;none of the above&rdquo; is correct given the options.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Thiamine  <br><span class=\"list-item\">\u2022</span> Reason incorrect: Treatment for Wernicke encephalopathy, not hydrocephalus or TB.  <br><span class=\"list-item\">\u2022</span> Misconception: Confusing nutritional dementias with NPH.  <br><span class=\"list-item\">\u2022</span> Differentiator: NPH requires CSF diversion, not vitamin repletion.<br><br>B. Flumazine  <br><span class=\"list-item\">\u2022</span> Reason incorrect: Not an established neurologic or anti-infective agent.  <br><span class=\"list-item\">\u2022</span> Misconception: Mistaking novel or obscure drugs for standard TB or hydrocephalus therapy.  <br><span class=\"list-item\">\u2022</span> Differentiator: No role in CSF dynamics or Mycobacterium tuberculosis treatment.<br><br>C. Copper  <br><span class=\"list-item\">\u2022</span> Reason incorrect: Used in Wilson disease; irrelevant to communicating hydrocephalus or TB.  <br><span class=\"list-item\">\u2022</span> Misconception: Equating trace\u2010element therapies with broad neurologic applicability.  <br><span class=\"list-item\">\u2022</span> Differentiator: Wilson&rsquo;s disease features hepatic dysfunction, movement disorders; NPH presents with gait apraxia and incontinence.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Thiamine (A)</th><th>Flumazine (B)</th><th>Copper (C)</th><th>Correct Management (D)</th></tr></thead><tbody><tr><td>Mechanism</td><td>Cofactor in decarboxylation</td><td>Not a standard agent</td><td>Cofactor in oxidases</td><td>CSF diversion via VA shunt</td></tr><tr><td>Indication</td><td>Wernicke encephalopathy</td><td>None established</td><td>Wilson disease</td><td>NPH with contraindication for VP</td></tr><tr><td>Relevance to TB peritonitis</td><td>None</td><td>None</td><td>None</td><td>Avoid peritoneal shunt; treat TB</td></tr><tr><td>Evidence support (guidelines)</td><td>B1 supplementation</td><td>&mdash;</td><td>Chelation therapy</td><td>AANS/CNS 2016; IDSA 2020</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- High\u2010volume lumbar puncture (>30 mL) can predict shunt responsiveness in NPH.  <br><span class=\"list-item\">\u2022</span> Active abdominal TB (peritonitis) contraindicates VP shunt due to risk of infection seeding and catheter occlusion.  <br><span class=\"list-item\">\u2022</span> Ventriculoatrial shunt is the preferred alternative when the peritoneum is unsuitable.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Attributing NPH gait disturbance to nutritional deficiencies and administering vitamins.  <br>2. Assuming endoscopic third ventriculostomy is first\u2010line for all hydrocephalus types; it is ineffective in communicating forms like NPH.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AANS/CNS Consensus: Management of Idiopathic NPH (2016) recommends VP shunt; VA shunt when peritoneum contraindicated (Level II evidence).  <br><span class=\"list-item\">\u2022</span> IDSA/CDC Tuberculosis Treatment Guidelines (2020) recommend a minimum 6-month RIPE regimen for abdominal TB before any intra\u2010abdominal device placement (Level A).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2021 exam. NPH and its shunt contraindications are commonly tested as single best\u2010answer vignettes, often requiring recognition of peritoneal contraindications and alternative shunt routes.</div></div></div></div></div>"
  },
  {
    "id": 100022544,
    "question_number": "78",
    "question_text": "Pathology showed Lewy bodies. What is the diagnosis?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2021] 1. &alpha;-Synucleinopathies: Neurodegenerative disorders (Lewy body dementia, Parkinson&rsquo;s disease, multiple system atrophy) characterized by abnormal aggregation of &alpha;-synuclein.  <br>2. Lewy bodies: Eosinophilic, intraneuronal inclusions composed of misfolded &alpha;-synuclein; distribution (brainstem vs. cortical) dictates clinical syndrome.  <br>3. Clinicopathologic correlation: Diffuse cortical Lewy bodies produce early dementia, visual hallucinations, and parkinsonism&mdash;defining Lewy body dementia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Lewy body dementia (LBD) is confirmed by widespread cortical and limbic Lewy bodies on postmortem exam. <span class=\"evidence\">The 2017</span> Fourth Consensus Report of the DLB Consortium <span class=\"citation\">(<span class=\"evidence\">McKeith et al., 2017</span>)</span> stipulates that diffuse cortical &alpha;-synuclein inclusions are required for a neuropathologic diagnosis of LBD (Level A evidence). In contrast, Parkinson&rsquo;s disease (PD) initially shows Lewy bodies confined to the substantia nigra, with cortical spread only in later stages, and dementia usually follows motor symptoms by >1 year <span class=\"citation\">(<span class=\"evidence\">Armstrong et al., 2020</span>, MDS criteria)</span>. Alzheimer&rsquo;s disease (AD) is hallmarked by &beta;-amyloid plaques and neurofibrillary tangles (tau), not Lewy bodies. Multiple system atrophy (MSA) features &alpha;-synuclein&ndash;positive glial cytoplasmic inclusions, not neuronal Lewy bodies.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Parkinson&rsquo;s disease  <br><span class=\"list-item\">\u2022</span> Lewy bodies in PD are predominantly brainstem (substantia nigra) until very late; early cortical involvement is minimal. Mistaken belief: all &alpha;-synuclein inclusions equal PD. Key differentiator: timing/distribution of Lewy bodies and onset of dementia.  <br><br>C. Alzheimer&rsquo;s disease  <br><span class=\"list-item\">\u2022</span> AD pathology consists of extracellular &beta;-amyloid plaques and intracellular tau tangles. Common error: assuming any neurodegeneration in elderly is AD. Distinct: LBD shows &alpha;-synuclein inclusions, not plaques/tangles predominating.  <br><br>D. Multiple system atrophy  <br><span class=\"list-item\">\u2022</span> MSA has &alpha;-synuclein&ndash;positive inclusions in oligodendrocytes (glial cytoplasmic inclusions), not neuronal Lewy bodies. Misconception: all synucleinopathies share Lewy bodies; in MSA, neuronal Lewy bodies are absent or minimal.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Lewy Body Dementia</th><th>Parkinson&rsquo;s Disease</th><th>Alzheimer&rsquo;s Disease</th><th>Multiple System Atrophy</th></tr></thead><tbody><tr><td>Main inclusion</td><td>Cortical & limbic Lewy bodies</td><td>Brainstem Lewy bodies</td><td>&beta;-amyloid plaques & tau tangles</td><td>Glial cytoplasmic inclusions</td></tr><tr><td>Protein</td><td>&alpha;-synuclein</td><td>&alpha;-synuclein</td><td>&beta;-amyloid, \u03c4 protein</td><td>&alpha;-synuclein</td></tr><tr><td>Clinical onset</td><td>Early dementia, hallucinations</td><td>Motor signs \u2192 later dementia</td><td>Memory-impaired onset</td><td>Autonomic failure, ataxia</td></tr><tr><td>Dementia timing</td><td>Concurrent with parkinsonism or before</td><td>>1 year after motor</td><td>Early in course</td><td>Dementia uncommon</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Visuospatial deficits and well-formed visual hallucinations often precede or accompany dementia in LBD.  <br><span class=\"list-item\">\u2022</span> Cognitive fluctuations are a hallmark; bedside testing may show >5-point MMSE swings day-to-day.  <br><span class=\"list-item\">\u2022</span> High sensitivity to neuroleptics: typical antipsychotics can precipitate severe parkinsonism or neuroleptic malignant&ndash;like syndrome.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Mislabeling PD with any Lewy bodies as LBD without considering timing of dementia vs. parkinsonism.  <br>2. Defaulting to AD diagnosis in elderly dementia, overlooking hallucinations and parkinsonian features suggestive of LBD.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1.<span class=\"evidence\"> McKeith et al., 2017</span> (Fourth DLB Consortium Consensus): Established neuropathologic criteria for LBD requiring neocortical Lewy bodies (Level A).  <br>2.<span class=\"evidence\"> Armstrong et al., 2020</span> (MDS PD Criteria): Differentiates PD dementia from LBD by a >1-year rule between motor and cognitive onset (Level B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Lewy bodies localize in limbic (amygdala, hippocampus) and neocortical regions (cingulate gyrus, occipital cortex) in LBD versus primarily in substantia nigra pars compacta in early-stage PD.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Misfolded &alpha;-synuclein aggregates propagate via cell-to-cell transmission, causing synaptic dysfunction, neuroinflammation, and cholinergic deficits that underlie cognitive and psychiatric symptoms in LBD.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Identify early cognitive impairment with visuospatial dysfunction and hallucinations.  <br>2. Document parkinsonian signs (rigidity, bradykinesia) concurrent or within 1 year of dementia onset.  <br>3. Support with biomarkers: occipital hypometabolism on FDG-PET, reduced striatal uptake on DaTscan.  <br>4. Exclude alternative causes; definitive diagnosis by cortical Lewy bodies on autopsy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>FDG-PET: occipital hypometabolism with relatively preserved posterior cingulate (&ldquo;cingulate island&rdquo; sign) helps differentiate LBD from AD. DaTscan: presynaptic dopamine transporter reduction supports synucleinopathy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2021 exam. LBD is frequently tested through pathology&ndash;clinical correlation vignettes, requiring recognition of cortical &alpha;-synuclein inclusions and distinction from other dementias.</div></div></div></div></div>"
  },
  {
    "id": 100022547,
    "question_number": "53",
    "question_text": "In a patient with normal semantic and language function, what is the pathology associated with behavioral variant frontotemporal dementia (bvFTD)?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2022] - Frontotemporal lobar degeneration (FTLD) is classified by the aggregated protein: tau, TDP-43, or FUS.  <br><span class=\"list-item\">\u2022</span> Behavioral variant FTD (bvFTD) manifests with early personality change, disinhibition, apathy, and executive dysfunction, typically sparing language and semantics initially.  <br><span class=\"list-item\">\u2022</span> TDP-43 proteinopathy underlies approximately half of bvFTD cases, characterized by hyperphosphorylated, ubiquitinated cytoplasmic inclusions in frontal cortical neurons.  <br><span class=\"list-item\">\u2022</span> FTLD-TDP is further divided into subtypes A&ndash;D; subtype C is linked to semantic PPA, subtype B to FTD with motor neuron disease, and subtype A to nonfluent aphasia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>TDP-43 was first identified as the major aggregated protein in FTLD and ALS by Neumann et al. <span class=\"citation\">(<span class=\"evidence\">Science 2006</span>)</span>. Subsequent consensus neuropathological guidelines <span class=\"citation\">(Mackenzie et al., Acta <span class=\"evidence\">Neuropathologica 2011</span>)</span> stratified FTLD-TDP into subtypes A&ndash;D based on inclusion morphology and cortical distribution. In bvFTD without language or motor involvement, generic TDP-43 pathology (i.e., non&ndash;subtyped TDP-43 inclusions) predominates. Subtype C (long dystrophic neurites) corresponds exclusively to semantic variant PPA, making option D incompatible with preserved semantics. Subtype B (sparse neurites with motor neuron disease) and subtype A (compact inclusions with nonfluent aphasia) both carry additional clinical features absent in this patient. Rascovsky et al. <span class=\"citation\">(<span class=\"evidence\">Neurology 2011</span>)</span> diagnostic criteria for bvFTD emphasize that pathology is most commonly TDP-43 in sporadic cases, supporting option A as the correct choice.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. FTD type A TDP  <br><span class=\"list-item\">\u2022</span> Features compact neuronal cytoplasmic inclusions and short dystrophic neurites in cortical layers II/III.  <br><span class=\"list-item\">\u2022</span> Clinically associated with progranulin mutations and progressive nonfluent aphasia, not seen here.<br><br>C. FTD type B TDP  <br><span class=\"list-item\">\u2022</span> Displays moderate neuronal cytoplasmic inclusions and sparse neurites in all layers.  <br><span class=\"list-item\">\u2022</span> Characteristic of FTD overlapping with motor neuron disease, absent motor signs exclude this.<br><br>D. FTD type C TDP  <br><span class=\"list-item\">\u2022</span> Defined by abundant long, thick dystrophic neurites with few neuronal inclusions.  <br><span class=\"list-item\">\u2022</span> Pathognomonic for semantic variant PPA, inconsistent with intact semantic and language function.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Option</th><th>Histopathology</th><th>Clinical Association</th></tr></thead><tbody><tr><td>TDP-43 (generic) [CORRECT]</td><td>Cytoplasmic ubiquitinated TDP-43</td><td>Pure bvFTD without language or motor signs</td></tr><tr><td>FTD type A TDP</td><td>Compact inclusions, short neurites</td><td>bvFTD with nonfluent aphasia</td></tr><tr><td>FTD type B TDP</td><td>Moderate inclusions, sparse neurites</td><td>bvFTD + motor neuron disease</td></tr><tr><td>FTD type C TDP</td><td>Long dystrophic neurites</td><td>Semantic variant PPA</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Approximately 50% of sporadic bvFTD cases are due to TDP-43 pathology; tau accounts for most of the remainder.  <br><span class=\"list-item\">\u2022</span> Subtype classification of FTLD-TDP directly predicts clinical syndrome: subtype C = semantic deficits, subtype B = FTD-MND.  <br><span class=\"list-item\">\u2022</span> Early bvFTD may show normal MRI; functional imaging or CSF biomarkers can aid early diagnosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Believing bvFTD is always a tauopathy&mdash;TDP-43 is equally common.  <br><span class=\"list-item\">\u2022</span> Misattributing semantic deficits to bvFTD rather than semantic variant PPA (subtype C).  <br><span class=\"list-item\">\u2022</span> Overlooking motor neuron signs when considering subtype B pathology.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Mackenzie IR et al., Acta Neuropathologica Consensus (2011)  <br><span class=\"list-item\">\u2022</span> Classified FTLD by aggregate protein and defined TDP-43 subtypes A&ndash;D.  <br><span class=\"list-item\">\u2022</span> Level of evidence: IV (expert consensus).  <br>2. American Academy of Neurology Practice Guideline, &ldquo;Evaluation and Management of Frontotemporal Dementias&rdquo; <span class=\"citation\">(2011; update 2017)</span>  <br><span class=\"list-item\">\u2022</span> Recommends SSRIs for behavioral symptoms in bvFTD (Level B); discourages cholinesterase inhibitors (Level B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>bvFTD pathology localizes to the orbitofrontal cortex, dorsolateral prefrontal cortex, anterior cingulate, and insula. Superficial cortical layers (II/III) accumulate TDP-43 inclusions, disrupting networks for social cognition and executive control.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>TDP-43 normally resides in the nucleus regulating RNA splicing and transport. In FTLD-TDP, TDP-43 is cleaved, hyperphosphorylated, ubiquitinated, and mislocalized to the cytoplasm, forming toxic aggregates that trigger neuronal dysfunction, synaptic loss, and gliosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical evaluation for personality and behavior changes with preserved language.  <br>2. Neuropsychological assessment to confirm executive impairment and normal semantics.  <br>3. MRI/FDG-PET demonstrating frontotemporal atrophy or hypometabolism.  <br>4. CSF biomarker analysis to exclude Alzheimer&rsquo;s disease (normal A&beta;42/tau).  <br>5. Genetic testing (GRN, C9orf72) if family history suggests heritability.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- MRI shows predominant frontal lobe atrophy, often asymmetric.  <br><span class=\"list-item\">\u2022</span> FDG-PET reveals frontal and anterior temporal hypometabolism.  <br><span class=\"list-item\">\u2022</span> Emerging TDP-43 PET ligands are in development for in vivo pathology mapping.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- No disease-modifying therapies for TDP-43 exists.  <br><span class=\"list-item\">\u2022</span> SSRIs (e.g., sertraline 50&ndash;100 mg daily) can ameliorate disinhibition and compulsivity (Level B).  <br><span class=\"list-item\">\u2022</span> Avoid cholinesterase inhibitors due to lack of benefit and potential behavioral worsening.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2022 exam. Proteinopathy classification&mdash;particularly TDP-43 subtypes and their phenotype correlations&mdash;is frequently tested on neurology board examinations, often in clinical vignette format.</div></div></div></div></div>"
  },
  {
    "id": 100022549,
    "question_number": "84",
    "question_text": "A patient with a history of neuropsychiatric symptoms and dementia for more than 5 years had PrPSc. What is the diagnosis?",
    "correct_answer": "D",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2021] - Prion diseases result from misfolding of the normal cellular prion protein (PrPC) into the pathogenic isoform PrPSc, leading to spongiform change and neurodegeneration.  <br><span class=\"list-item\">\u2022</span> PRNP gene mutations underlie familial prionopathies: familial CJD, Gerstmann&ndash;Str\u00e4ussler&ndash;Scheinker syndrome (GSS), and fatal familial insomnia (FFI); codon 129 polymorphism (Met/Val) modulates phenotype.  <br><span class=\"list-item\">\u2022</span> Clinical duration varies by subtype: sporadic and familial CJD progress over months, variant CJD ~14 months, FFI ~12&ndash;18 months, whereas GSS features a protracted course of 2&ndash;10 years.  <br><span class=\"list-item\">\u2022</span> Subtype differentiation hinges on clinical presentation (psychiatric vs insomnia vs ataxia), disease course, genetic testing, MRI (pulvinar sign in vCJD), and neuropathology.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>In the Part 2 2021 exam, this vignette probes recognition of familial CJD as the only listed subtype capable of a multi-year course with predominant neuropsychiatric decline and dementia. Familial CJD arises from autosomal-dominant PRNP mutations (e.g., D178N/129V) and can present with protracted cognitive impairment; McGuire et al. (2021) reported survival up to 6 years in some genotypes. Variant CJD is characterized by younger age at onset, psychiatric prodrome, &ldquo;pulvinar sign&rdquo; on MRI, and a median survival of ~14 months <span class=\"citation\">(WHO, 2018)</span>. Kuru, historically confined to ritualistic cannibalism in Papua New Guinea, manifests with cerebellar ataxia, laughter (&ldquo;laughing disease&rdquo;), and ~12 months survival. FFI (D178N/129M) features refractory insomnia, dysautonomia, thalamic atrophy, and mean survival of 12&ndash;18 months <span class=\"citation\">(<span class=\"evidence\">Mastrianni et al., 2017</span>)</span>. Definitive diagnosis of familial CJD requires PRNP sequencing and demonstration of PrPSc in biopsy or post-mortem tissue <span class=\"citation\">(CDC, 2021)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Variant CJD  <br><span class=\"list-item\">\u2022</span> Incorrect because it presents in younger patients with psychiatric onset, sensory disturbances, characteristic pulvinar MRI sign, and a median survival of ~14 months.  <br><span class=\"list-item\">\u2022</span> Misconception: equating any prion disease with psychiatric features; duration and imaging differentiate vCJD.  <br><br>B. Kuru  <br><span class=\"list-item\">\u2022</span> Incorrect as it was epidemic in Papua New Guinea, characterized by cerebellar ataxia, tremor, and &ldquo;laughing&rdquo; episodes, with survival ~12 months once transmission ceased.  <br><span class=\"list-item\">\u2022</span> Misconception: assuming all prionopathies have long courses; Kuru is rapidly progressive.  <br><br>C. Familial insomnia  <br><span class=\"list-item\">\u2022</span> Incorrect because FFI (PRNP D178N/129M) presents predominantly with refractory insomnia, autonomic instability, thalamic degeneration, and survival of 12&ndash;18 months, not years of dementia.  <br><span class=\"list-item\">\u2022</span> Misconception: confusing any familial prion disease with protracted cognitive decline; FFI&rsquo;s hallmark is sleep disturbance.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Subtype</th><th>Etiology/Genetics</th><th>Key Clinical Features</th><th>Typical Duration</th></tr></thead><tbody><tr><td>Variant CJD</td><td>Sporadic, BSE transmission</td><td>Psychiatric onset, sensory symptoms, pulvinar sign on MRI</td><td>~14 months</td></tr><tr><td>Kuru</td><td>Acquired via cannibalism</td><td>Cerebellar ataxia, tremor, laughter episodes</td><td>~12 months</td></tr><tr><td>Familial insomnia</td><td>PRNP D178N/129M mutation</td><td>Refractory insomnia, dysautonomia, thalamic atrophy</td><td>12&ndash;18 months</td></tr><tr><td>Familial CJD [CORRECT]</td><td>PRNP point mutations (e.g., D178N/129V)</td><td>Dementia, neuropsychiatric decline</td><td>1&ndash;6+ years (protracted)</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Codon 129 polymorphism in PRNP critically influences phenotype: D178N/129M yields FFI, D178N/129V yields familial CJD.  <br><span class=\"list-item\">\u2022</span> MRI &ldquo;pulvinar sign&rdquo; (bilateral thalamic hyperintensity) is highly suggestive of variant CJD.  <br><span class=\"list-item\">\u2022</span> CSF RT-QuIC assay now has >95% sensitivity and specificity for prion diseases and is a major diagnostic criterion per CDC 2021 guidelines.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Misattributing a prolonged course to sporadic CJD, which typically progresses over ~4 months.  <br>2. Confusing FFI with dementia-predominant prionopathies; FFI&rsquo;s core feature is insomnia and autonomic dysfunction.  <br>3. Assuming all familial prion diseases share similar durations; GSS is longest, FFI is shortest, familial CJD intermediate.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- WHO (2018) Expert Consensus on Transmissible Spongiform Encephalopathies: Recommends subclassifying prion diseases by aetiology (sporadic, familial, variant) and integrating PRNP genotyping and neuropathology for definitive diagnosis. Level: Expert consensus.  <br><span class=\"list-item\">\u2022</span> CDC (2021) Diagnostic Criteria Update for Creutzfeldt-Jakob Disease: Endorses CSF RT-QuIC assay as a major criterion for probable CJD (sensitivity 92&ndash;100%, specificity >98%) to enable earlier, non-invasive diagnosis. Level: II (prospective cohort studies).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2021 exam.  <br>Prion disease subtypes are frequently tested as vignette-style single-best-answer questions, emphasizing disease duration, distinctive clinical features (e.g., insomnia in FFI, pulvinar sign in vCJD), and genetic correlates (PRNP codon 129).</div></div></div></div></div>"
  },
  {
    "id": 100022550,
    "question_number": "82",
    "question_text": "In an Alzheimer patient, what are the expected cerebrospinal fluid (CSF) results?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2021] - Alzheimer&rsquo;s disease hallmark pathologies: extracellular amyloid-&beta; (A&beta;) plaques and intracellular neurofibrillary tangles of hyperphosphorylated tau.  <br><span class=\"list-item\">\u2022</span> CSF biomarkers reflect brain pathology: decreased A&beta;\u2084\u2082 due to sequestration in plaques; increased total tau (t-tau) and phosphorylated tau (p-tau) from neuronal injury.  <br><span class=\"list-item\">\u2022</span> The AT(N) framework (Amyloid/Tau/Neurodegeneration) classifies biomarkers: A&beta;\u2084\u2082 (A), tau measures (T), and imaging/neurodegeneration markers (N) to stage the disease continuum.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Low CSF A&beta;\u2084\u2082 combined with elevated t-tau is the characteristic Alzheimer&rsquo;s profile. A meta-analysis by Olsson et al. (2016) demonstrated that this combination yields ~85% sensitivity and specificity for distinguishing Alzheimer&rsquo;s from other dementias. <span class=\"evidence\">The 2018</span> NIA-AA research framework <span class=\"citation\">(<span class=\"evidence\">Jack et al., 2018</span>)</span> formalized the AT(N) biomarker scheme, requiring A&beta;\u2084\u2082 decrease (A+) and tau increase (T+) for in vivo Alzheimer&rsquo;s pathologic diagnosis. Elevated t-tau correlates with neuronal damage severity <span class=\"citation\">(<span class=\"evidence\">Blennow et al., 2015</span>)</span>, while reduced A&beta;\u2084\u2082 can be detected years before clinical symptoms <span class=\"citation\">(<span class=\"evidence\">Hansson et al., 2018</span>)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. High A&beta;, Low Tau: Contradicts plaque formation (would lower A&beta;) and lacks tau rise seen in neurodegeneration.  <br>C. Normal A&beta;, Normal Tau: Reflects no Alzheimer pathology; common in controls or non-AD cognitive complaints.  <br>D. Low A&beta;, Low Tau: Shows plaque deposition only; absence of tau elevation argues against active neurodegeneration required for Alzheimer&rsquo;s dementia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Option</th><th>CSF A&beta;\u2084\u2082</th><th>CSF Total Tau</th><th>Interpretation</th></tr></thead><tbody><tr><td>A (Correct)</td><td>\u2193</td><td>\u2191</td><td>Alzheimer&rsquo;s biomarker profile</td></tr><tr><td>B</td><td>\u2191</td><td>\u2193</td><td>Opposite of expected AD pattern</td></tr><tr><td>C</td><td>\u2194</td><td>\u2194</td><td>Normal CSF; not indicative of AD</td></tr><tr><td>D</td><td>\u2193</td><td>\u2193</td><td>Plaques without tau-mediated injury</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- The A&beta;\u2084\u2082/A&beta;\u2084\u2080 ratio corrects for individual variability; a low ratio (<0.05) improves diagnostic specificity.  <br><span class=\"list-item\">\u2022</span> CSF p-tau\u2081\u2088\u2081 often rises earlier than t-tau and more closely correlates with tangle burden.  <br><span class=\"list-item\">\u2022</span> Standardized pre-analytical handling (low-binding tubes, consistent freeze-thaw cycles) is critical for reliable CSF biomarker measurement.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Mistaking plasma tau for CSF tau profiles; plasma assays currently lack sufficient diagnostic accuracy.  <br><span class=\"list-item\">\u2022</span> Interpreting isolated low A&beta;\u2084\u2082 without concurrent tau elevation as definitive Alzheimer&rsquo;s; both AT markers must be positive per the NIA-AA framework.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- Jack et al., NIA-AA Research Framework (2018): Formalized AT(N) biomarker classification; consensus Level I evidence.  <br><span class=\"list-item\">\u2022</span> Dubois et al., IWG-3 Criteria (2021): Recommend combined CSF A&beta;\u2084\u2082 and p-tau assays for early Alzheimer&rsquo;s diagnosis; Level II evidence supporting clinical utility.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2021 exam. CSF biomarker interpretation for Alzheimer&rsquo;s is frequently tested in vignette format, often requiring application of the AT(N) framework to distinguish Alzheimer&rsquo;s from other dementias.</div></div></div></div></div>"
  },
  {
    "id": 100022551,
    "question_number": "86",
    "question_text": "Q86. What helps differentiate Alzheimer's disease from frontotemporal dementia?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2024] Alzheimer&rsquo;s disease (AD) primarily affects medial temporal lobe structures&mdash;particularly the hippocampus&mdash;leading to deficits in encoding and consolidating new information (anterograde memory loss). Frontotemporal dementia (FTD) involves early degeneration of the frontal and/or anterior temporal lobes, manifesting as disinhibition, apathy, or primary progressive aphasia, with relative preservation of new learning in initial stages. Core concepts:  <br>&bull; Hippocampal circuitry (entorhinal cortex \u2192 hippocampus \u2192 dentate gyrus) underlies episodic memory.  <br>&bull; Frontal-subcortical networks regulate behavior and executive function.  <br>&bull; Temporal pole and inferior frontal gyrus support language production and comprehension.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Anterograde memory impairment is a required feature for the clinical diagnosis of typical AD in the 2011 NIA-AA criteria and reinforced in the 2021 NIA-AA Research Framework <span class=\"citation\">(<span class=\"evidence\">Jack et al., 2021</span>)</span>, which classify AD by biomarker evidence (A&beta;, tau) but maintain early episodic memory loss as the hallmark clinical sign. In contrast, the 2011 Rascovsky et al. International bvFTD Criteria emphasize early behavioral disinhibition, apathy, loss of empathy, compulsive behaviors, hyperorality, or executive dysfunction, with memory relatively preserved for &ge;2 years. Neuropsychological studies <span class=\"citation\">(e.g., Diehl-<span class=\"evidence\">Schmid et al., 2007</span>)</span> demonstrate that FTD patients score significantly better than AD patients on delayed recall tests despite similar overall dementia severity. MRI patterns also differ: AD shows prominent hippocampal atrophy (Scheltens scale &ge;2) versus focal frontal/anterior temporal atrophy in FTD <span class=\"citation\">(<span class=\"evidence\">Rohrer et al., 2010</span>)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Language difficulties  <br>&bull; Incorrect because primary progressive aphasia is a variant of FTD; in AD language impairment is a late feature.  <br>&bull; Misconception: equating all aphasic presentations with AD. In AD, word\u2010finding and fluent aphasia may appear but follow memory decline.  <br><br>C. Behavioral changes  <br>&bull; Incorrect because early behavioral disinhibition and apathy typify bvFTD, not initial AD.  <br>&bull; Misconception: assuming memory loss always coexists with disinhibition; in FTD memory is initially spared.  <br><br>D. Visual hallucinations  <br>&bull; Incorrect as visual hallucinations are characteristic of Lewy body dementia (DLB), with parkinsonism and fluctuating cognition, not AD or FTD.  <br>&bull; Misconception: hallucinations occur in late AD but are neither sensitive nor specific early diagnostic markers.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Alzheimer&rsquo;s Disease</th><th>Frontotemporal Dementia</th></tr></thead><tbody><tr><td>Anterograde memory loss</td><td>Early, prominent (hippocampal)</td><td>Mild or absent initially</td></tr><tr><td>Language difficulties</td><td>Late, non\u2010primary</td><td>Early in PPA variants</td></tr><tr><td>Behavioral changes</td><td>Late, mild disinhibition</td><td>Early, core feature (bvFTD)</td></tr><tr><td>Visual hallucinations</td><td>Rare early, may occur late</td><td>Not characteristic</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; On the Montreal Cognitive Assessment, AD patients score &ge;4 points lower on delayed recall than FTD patients of similar age and education.  <br>&bull; In bvFTD, caregivers often note &ldquo;just like their old self&rdquo; on memory tasks despite severe changes in personality.  <br>&bull; Hippocampal-sparing AD can present with atypical features (e.g., language or visuospatial deficits) but still shows anterograde memory loss.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Overinterpreting early executive dysfunction in AD as FTD&mdash;AD can cause dysexecutive profiles when pathology spreads to frontal lobes.  <br>2. Assuming all dementias present with memory loss&mdash;FTD and pure vascular dementia may spare episodic memory initially.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. NIA-AA Research Framework <span class=\"citation\">(Jack CR Jr.<span class=\"evidence\"> et al., 2021</span>)</span>:  <br>   &bull; Recommendation: Use AT(N) biomarker classification for research; clinical framework still requires early episodic memory impairment for typical AD diagnosis.  <br>   &bull; Level of Evidence: Expert consensus, longitudinal cohort studies.  <br><br>2. Rascovsky Criteria for bvFTD <span class=\"citation\">(Rascovsky K et al., Neurology, 2011)</span>:  <br>   &bull; Recommendation: Diagnose possible bvFTD when &ge;3 of 6 behavioral/cognitive features are present; probable bvFTD requires supportive imaging.  <br>   &bull; Level of Evidence: Class II diagnostic study.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2024 exam. Alzheimer&rsquo;s disease versus frontotemporal dementia differentiation&mdash;especially early anterograde memory loss versus behavioral/language predominance&mdash;is a frequently tested topic in neurology and psychiatry sections.</div></div></div></div></div>"
  },
  {
    "id": 100022552,
    "question_number": "85",
    "question_text": "A patient presents with one year of progressive apathy and memory loss. What is the most likely diagnosis?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2024] Dementia denotes acquired, persistent cognitive decline affecting daily living. Alzheimer&rsquo;s disease (AD) is the most common cause, characterized by early episodic memory impairment and executive dysfunction. Pathologically, AD features amyloid-&beta; plaques and tau neurofibrillary tangles, initially targeting hippocampal and entorhinal cortex circuits. A gradual, insidious onset over &ge;6 months with progressive memory loss and apathy typifies AD. By contrast, frontotemporal dementia (FTD) presents with behavioral changes and relative memory preservation in early stages; vascular dementia shows stepwise decline with focal deficits; and Lewy body dementia (LBD) features visual hallucinations and fluctuating cognition. Recognizing the pattern of cognitive deficits and trajectory is critical for differential diagnosis.  <br>(Word count: 124)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Alzheimer&rsquo;s disease is correct because amnestic presentation&mdash;progressive episodic memory loss with apathy over a one-year timeline&mdash;aligns with NIA-AA criteria (2021). The hallmark is hippocampal atrophy on MRI and decreased glucose metabolism in temporoparietal regions on FDG-PET. Braak staging correlates neurofibrillary tangle spread (entorhinal\u2192neocortex) with cognitive decline. In contrast, FTD initially targets frontal lobes, sparing hippocampus; vascular dementia shows subcortical ischemic changes with executive deficits; LBD demonstrates &alpha;-synuclein inclusions, parkinsonism, and visual hallucinations. Current guidelines recommend clinical diagnosis supported by imaging and CSF biomarkers (elevated tau:A&beta;42 ratio) to confirm AD pathology <span class=\"citation\">(<span class=\"evidence\">McKhann et al., 2011</span>;<span class=\"evidence\"> Jack et al., 2018</span>)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Frontotemporal dementia  <br><span class=\"list-item\">\u2022</span> Incorrect because early FTD presents with disinhibition or language dysfunction, not primary memory loss.  <br><span class=\"list-item\">\u2022</span> Misconception: any apathy must imply FTD; actually apathy in AD stems from frontal-subcortical circuits secondarily.  <br><span class=\"list-item\">\u2022</span> FTD spares hippocampal-dependent memory early.<br><br>C. Vascular dementia  <br><span class=\"list-item\">\u2022</span> Incorrect: typically stepwise cognitive decline with focal neurological signs (hemiparesis, gait disturbance) and white matter hyperintensities on MRI.  <br><span class=\"list-item\">\u2022</span> Misconception: any progressive dementia is vascular; however, continuous decline without infarct history favors AD.  <br><span class=\"list-item\">\u2022</span> Memory loss in vascular dementia is often subcortical and accompanied by bradyphrenia.<br><br>D. Lewy body dementia  <br><span class=\"list-item\">\u2022</span> Incorrect: core features include visual hallucinations, fluctuating cognition, parkinsonism; memory loss is less prominent initially.  <br><span class=\"list-item\">\u2022</span> Misconception: dementia plus apathy equals LBD; true LBD shows REM sleep behavior disorder and sensitivity to neuroleptics.  <br><span class=\"list-item\">\u2022</span> AD has earlier and more consistent hippocampal atrophy vs LBD&rsquo;s occipital hypometabolism.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Alzheimer&rsquo;s disease</th><th>Frontotemporal dementia</th><th>Vascular dementia</th><th>Lewy body dementia</th></tr></thead><tbody><tr><td>Onset</td><td>Insidious, gradual over months to years</td><td>Insidious, often <65 years</td><td>Stepwise or insidious with strokes</td><td>Insidious, fluctuating</td></tr><tr><td>Core cognitive deficit</td><td>Early episodic memory impairment</td><td>Early executive/language deficits</td><td>Executive dysfunction, slowed processing</td><td>Visuospatial deficits, attention</td></tr><tr><td>Behavioral changes</td><td>Apathy, irritability as disease advances</td><td>Disinhibition, apathy, neglect</td><td>Variable, often depression</td><td>Visual hallucinations, REM sleep disorder</td></tr><tr><td>Imaging</td><td>Hippocampal atrophy on MRI; FDG-PET temporoparietal hypometabolism</td><td>Frontal and/or temporal atrophy</td><td>Multifocal infarcts, white matter changes</td><td>Occipital hypometabolism, preserved hippocampus</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- In AD, delayed recall improves minimally with cueing; in vascular dementia, cueing often helps.  <br><span class=\"list-item\">\u2022</span> Amyloid PET has >90% sensitivity for cerebral amyloidosis but is costly and used selectively.  <br><span class=\"list-item\">\u2022</span> Apathy in dementia can be mistaken for major depression; assess motivation vs mood.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confusing apathy in AD with behavioral variant FTD&mdash;remember FTD shows disinhibition and early personality change.  <br>2. Overdiagnosing vascular dementia without radiographic evidence of multi-infarct disease or small-vessel ischemia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- NIA-AA Research Framework <span class=\"citation\">(<span class=\"evidence\">Jack et al., 2018</span>)</span>: Defines AD biologically via biomarkers (A&beta;, tau, neurodegeneration); recommends CSF tau/A&beta;42 and PET imaging for research diagnosis (Level B).  <br><span class=\"list-item\">\u2022</span> NICE Guideline CG42 (2022 update): Recommends structural MRI in all suspected dementia patients; cholinesterase inhibitors (e.g., donepezil) for mild-to-moderate AD (Level A).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2024 exam. Dementia subtyping based on early symptomatology (memory vs behavior vs fluctuation) is a high-yield topic, frequently tested as single-best-answer vignettes focusing on differential diagnosis and appropriate use of biomarkers and imaging.</div></div></div></div></div>"
  },
  {
    "id": 100022553,
    "question_number": "87",
    "question_text": "Cholinesterase inhibitors are most useful for which condition?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2024] &bull; Cholinergic Neurotransmission: Basal forebrain (nucleus basalis of Meynert) cholinergic projections modulate cortical attention, memory, and motivational circuits.  <br>&bull; Frontal&ndash;Subcortical Circuits: Apathy in Alzheimer&rsquo;s disease arises from disruption of cholinergic inputs to the anterior cingulate and orbitofrontal cortex, leading to diminished goal-directed behavior.  <br>&bull; Neuropsychiatric Symptoms in Dementia: While depression, anxiety, and psychosis in dementia have multifactorial etiologies (serotonergic, dopaminergic dysfunction), apathy correlates most closely with cholinergic deficits.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Cholinesterase inhibitors (donepezil, rivastigmine, galantamine) increase synaptic acetylcholine by inhibiting acetylcholinesterase.  <br>&bull; Multiple randomized trials <span class=\"citation\">(Lanct\u00f4<span class=\"evidence\">t et al., 2004</span>;<span class=\"evidence\"> Homma et al., 2008</span>)</span> demonstrated statistically significant improvements in Apathy Evaluation Scale scores in mild&ndash;moderate Alzheimer&rsquo;s patients on donepezil vs. placebo (mean difference ~3 points, p<0.01).  <br>&bull; 2021 AAN Practice Guideline (Level B evidence) endorses cholinesterase inhibitors for mild&ndash;moderate Alzheimer&rsquo;s to improve cognition and reduce apathy.  <br>&bull; NICE 2018 recommends starting cholinesterase inhibitors in mild&ndash;moderate Alzheimer&rsquo;s with neuropsychiatric symptoms, highlighting apathy improvement.  <br>&bull; Mechanistically, enhanced acetylcholine in frontal networks restores motivation and attentional salience, attenuating apathy more than other behavioral disturbances.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Depression  <br>  &ndash; Reason incorrect: Major depressive symptoms in dementia respond to serotonergic agents (SSRIs) rather than cholinesterase inhibitors.  <br>  &ndash; Misconception: Assuming all neuropsychiatric symptoms improve with ACh augmentation.  <br>  &ndash; Differentiator: Depression features pervasive low mood, guilt, hopelessness&mdash;SSRIs have stronger evidence for mood improvement.  <br><br>C. Anxiety  <br>  &ndash; Reason incorrect: Anxiety in dementia involves GABAergic and serotonergic dysregulation; benzodiazepines or SSRIs are first-line.  <br>  &ndash; Misconception: Overgeneralizing cholinesterase inhibitor effects to all behavioral symptoms.  <br>  &ndash; Differentiator: Anxiety presents with hypervigilance, autonomic arousal&mdash;unchanged by cholinesterase inhibitors.  <br><br>D. Psychosis  <br>  &ndash; Reason incorrect: Psychotic symptoms (delusions, hallucinations) in dementia require antipsychotics (e.g., low-dose risperidone), not AChE inhibitors.  <br>  &ndash; Misconception: Believing cognitive enhancers treat perceptual disturbances.  <br>  &ndash; Differentiator: Psychosis involves dopaminergic pathways modulated by antipsychotics, not cholinergic augmentation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Apathy (Correct)</th><th>Depression</th><th>Anxiety</th><th>Psychosis</th></tr></thead><tbody><tr><td>Primary Neurotransmitter Target</td><td>Cholinergic (ACh)</td><td>Serotonergic (5-HT)</td><td>GABAergic/Serotonergic</td><td>Dopaminergic (DA)</td></tr><tr><td>Typical Treatment</td><td>Cholinesterase inhibitors</td><td>SSRIs (e.g., sertraline)</td><td>SSRIs, benzodiazepines</td><td>Atypical antipsychotics</td></tr><tr><td>DSM/ICD Key Symptoms</td><td>Diminished motivation, reduced goal-directed behavior</td><td>Persistent low mood, anhedonia</td><td>Excessive worry, restlessness</td><td>Delusions, hallucinations</td></tr><tr><td>Evidence of AChEI Benefit</td><td>Moderate improvement in apathy scales <span class=\"citation\">(Lanct\u00f4<span class=\"evidence\">t et al. 2004</span>)</span></td><td>No significant benefit</td><td>No significant benefit</td><td>No significant benefit</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Apathy is the most prevalent neuropsychiatric symptom in Alzheimer&rsquo;s (up to 70%) and correlates with faster functional decline.  <br>2. Cholinesterase inhibitors confer the greatest benefit on motivation and attention, with more modest effects on global cognition.  <br>3. Monitor for bradycardia and gastrointestinal side effects; dose titration over 4&ndash;6 weeks improves tolerability.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Mistaking apathy for depression; apathy lacks pervasive sadness and guilt.  <br>&bull; Prescribing SSRIs or antipsychotics for apathy, which may worsen sedation without addressing cholinergic deficit.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. American Academy of Neurology (AAN) Practice Guideline, 2021  <br>   &ndash; Recommendation: Cholinesterase inhibitors (Level B) for mild&ndash;moderate Alzheimer&rsquo;s disease to improve cognition and neuropsychiatric symptoms, notably apathy.  <br>2. National Institute for Health and Care Excellence (NICE), Dementia: Assessment, Management and Support, 2018  <br>   &ndash; Recommendation: Offer cholinesterase inhibitors for Alzheimer&rsquo;s dementia with apathy or cognitive decline; monitor and review regularly.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Donepezil: Start 5 mg daily, increase to 10 mg after 4&ndash;6 weeks.  <br>&bull; Rivastigmine patch: 4.6 mg/24 h, titrate to 9.5 mg/24 h based on tolerability.  <br>&bull; Galantamine: 4 mg twice daily, up to 12 mg twice daily.  <br>&bull; Monitor heart rate, weight, GI symptoms; dose adjust for hepatic/renal impairment.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2024 exam. Questions on cholinesterase inhibitors frequently test their selective benefits on apathy and attentional domains in Alzheimer&rsquo;s disease, often contrasted with SSRIs or antipsychotics in neuropsychiatric management.</div></div></div></div></div>"
  },
  {
    "id": 100022554,
    "question_number": "88",
    "question_text": "An elderly man has been acting out his dreams, kicking his wife, and experiencing vivid visual hallucinations. His delirium workup was negative. What is the most likely diagnosis?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2024] Dementia with Lewy bodies (DLB) is the second most common degenerative dementia after Alzheimer&rsquo;s disease (AD), characterized by fluctuating cognition, recurrent visual hallucinations, REM sleep behavior disorder (RBD), and parkinsonism. RBD results from loss of subcoeruleus inhibitory neurons in the pontine tegmentum, leading to dream enactment. Visual hallucinations early in DLB reflect occipital hypometabolism and cholinergic deficits in the nucleus basalis of Meynert. Alpha-synuclein aggregation in cortical and subcortical structures underlies these features. In contrast, AD presents with early memory impairment and hippocampal atrophy; corticobasal degeneration (CBD) and frontotemporal dementia (FTD) exhibit motor or behavioral/language syndromes without RBD or early hallucinations. Recognizing the combination of RBD and visual hallucinations directs the diagnosis toward DLB.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>DLB diagnosis follows the 2017 Fourth Consensus Report of the DLB Consortium <span class=\"citation\">(<span class=\"evidence\">McKeith et al., 2017</span>)</span>: core clinical features include fluctuating cognition, recurrent visual hallucinations, spontaneous parkinsonism, and RBD. RBD is a sensitive (85%) and specific (88%) prodromal marker for synucleinopathies <span class=\"citation\">(<span class=\"evidence\">Postuma et al., 2015</span>, Mov Disord)</span>. Early, vivid visual hallucinations correlate with occipital cortex hypoperfusion on SPECT/PET and reduced cholinergic transmission <span class=\"citation\">(<span class=\"evidence\">Iizuka et al., 2015</span>, J Neurol Neurosurg Psychiatry)</span>. A negative delirium workup excludes metabolic or infectious causes. Dopamine transporter SPECT demonstrates reduced striatal uptake (sensitivity ~78%, specificity ~90%) distinguishing DLB from AD <span class=\"citation\">(<span class=\"evidence\">McKeith et al., 2017</span>)</span>. These pathophysiological and imaging findings firmly support Lewy body dementia as the correct diagnosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Alzheimer&rsquo;s disease  <br><span class=\"list-item\">\u2022</span> AD features early episodic memory loss and hippocampal atrophy on MRI.  <br><span class=\"list-item\">\u2022</span> RBD is rare (<10%) and visual hallucinations occur only in advanced stages.  <br><span class=\"list-item\">\u2022</span> Misconception: any elderly dementia with hallucinations is AD.  <br><br>C. Corticobasal degeneration  <br><span class=\"list-item\">\u2022</span> Presents with asymmetric rigidity, limb apraxia, cortical sensory loss, alien-limb phenomenon.  <br><span class=\"list-item\">\u2022</span> Pathology: 4-repeat tau tangles, no alpha-synuclein aggregates, hence no RBD or early hallucinations.  <br><span class=\"list-item\">\u2022</span> Misconception: parkinsonism plus dementia equals synucleinopathy.  <br><br>D. Frontotemporal dementia  <br><span class=\"list-item\">\u2022</span> Characterized by disinhibited behavior or language variants; early personality changes, semantic or non-fluent aphasia.  <br><span class=\"list-item\">\u2022</span> No core RBD or early visual hallucinations; imaging shows frontal/temporal atrophy.  <br><span class=\"list-item\">\u2022</span> Misconception: behavioral changes with sleep disturbance imply FTD.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>DLB</th><th>Alzheimer&rsquo;s Disease</th><th>Corticobasal Degeneration</th><th>Frontotemporal Dementia</th></tr></thead><tbody><tr><td>REM Sleep Behavior Disorder</td><td>Core feature (&le;75&ndash;80%)</td><td>Rare (<10%)</td><td>Very rare</td><td>Absent</td></tr><tr><td>Visual Hallucinations</td><td>Early, recurrent</td><td>Late, in advanced stages</td><td>Absent</td><td>Absent</td></tr><tr><td>Core Pathology</td><td>Alpha-synuclein Lewy bodies</td><td>Amyloid-&beta; plaques, tau tangles</td><td>4R tau aggregates</td><td>Tau or TDP-43 inclusions</td></tr><tr><td>Neuroimaging</td><td>Occipital hypometabolism; \u2193 striatal DAT uptake</td><td>Hippocampal atrophy</td><td>Asymmetric frontoparietal atrophy</td><td>Frontal/temporal atrophy</td></tr><tr><td>Motor Features</td><td>Spontaneous parkinsonism</td><td>Possible late extrapyramidal signs</td><td>Asymmetric rigidity, apraxia</td><td>Minimal early parkinsonism</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Up to 80% of DLB patients exhibit RBD years before cognitive decline; polysomnography can confirm diagnosis.  <br><span class=\"list-item\">\u2022</span> Rivastigmine (start 1.5 mg BID, up to 6 mg BID) improves cognition and reduces hallucinations.  <br><span class=\"list-item\">\u2022</span> DLB patients have severe neuroleptic sensitivity; avoid typical antipsychotics, use quetiapine or pimavanserin for psychosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Mislabeling RBD as primary insomnia or psychiatric; failure to screen for synucleinopathies when patients report dream enactment.  <br><span class=\"list-item\">\u2022</span> Confusing DLB with Parkinson&rsquo;s disease dementia: apply the &ldquo;1-year rule&rdquo;&mdash;if dementia precedes or occurs within 1 year of parkinsonism, it is DLB, not PDD.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- McKeith IG et al., &ldquo;Diagnosis and management of dementia with Lewy bodies: Fourth consensus report&rdquo; <span class=\"citation\">(Neurology, 2017)</span>: endorses RBD and visual hallucinations as core features; recommends DAT-SPECT for supportive diagnosis (Level B evidence).  <br><span class=\"list-item\">\u2022</span> Postuma RB et al., &ldquo;MDS clinical diagnostic criteria for RBD&rdquo; <span class=\"citation\">(Mov Disord, 2015)</span>: polysomnography-confirmed RBD has >85% predictive value for synucleinopathies (Level A evidence).  <br><span class=\"list-item\">\u2022</span> Ballard C et al., &ldquo;Pimavanserin in DLB psychosis&rdquo; <span class=\"citation\">(Lancet Neurol, 2018)</span>: randomized controlled trial showing significant reduction in hallucinations/delusions (Level I evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Alpha-synuclein aggregates in the locus coeruleus, subcoeruleus nucleus (REM atonia control), nucleus basalis of Meynert (cholinergic), limbic, and neocortical regions; brainstem involvement explains RBD, cholinergic loss underlies visual hallucinations.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Misfolded alpha-synuclein forms Lewy bodies, impairing synaptic transmission. Loss of subcoeruleus inhibitory neurons disrupts REM atonia, causing RBD. Degeneration of cholinergic neurons in nucleus basalis leads to attentional deficits and visual hallucinations via occipital cortex dysfunction.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Exclude delirium: normal labs, no acute metabolic/infectious process.  <br>2. Elicit history of RBD (dream enactment) and visual hallucinations.  <br>3. Neurological exam for parkinsonism.  <br>4. Neuropsychological testing: visuospatial/executive dysfunction.  <br>5. Supportive imaging: DAT-SPECT for striatal dopamine transporter uptake; FDG-PET for occipital hypometabolism.  <br>6. <span class=\"evidence\">Apply 2017</span> DLB Consortium criteria for diagnosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- DAT-SPECT: reduced striatal uptake supports DLB over AD.  <br><span class=\"list-item\">\u2022</span> FDG-PET: occipital hypometabolism and &ldquo;cingulate island sign&rdquo; (preserved posterior cingulate) are highly specific for DLB.  <br><span class=\"list-item\">\u2022</span> MRI: relative sparing of medial temporal lobes compared to AD.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- First-line: rivastigmine (1.5 mg BID \u2192 up to 6 mg BID) for cognitive and neuropsychiatric symptoms.  <br><span class=\"list-item\">\u2022</span> Psychosis management: quetiapine low dose or pimavanserin 34 mg daily; avoid haloperidol and other typical antipsychotics.  <br><span class=\"list-item\">\u2022</span> Parkinsonism: trial of low-dose levodopa/carbidopa, monitoring for exacerbation of hallucinations.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>\"This question appeared in Part 2 2024 exam.\"  <br>On board exams, vignettes describing dream enactment (RBD) with early visual hallucinations are classic for DLB. Examinees should recall the 1-year rule distinguishing DLB from Parkinson&rsquo;s disease dementia, and know supportive imaging (DAT-SPECT, FDG-PET) and cholinesterase inhibitor therapy.</div></div></div></div></div>"
  },
  {
    "id": 100022556,
    "question_number": "91",
    "question_text": "Q91. Typical history of Lewy Body Dementia (LBD), PET showed posterior corpus callosum abnormality (the picture is not obvious); what is the diagnosis?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2021] Lewy Body Dementia (LBD) arises from cortical and subcortical &alpha;-synuclein deposition, causing fluctuating cognition, visual hallucinations, and parkinsonism. FDG-PET typically demonstrates occipital hypometabolism with relative medial temporal preservation, while dopamine transporter (DaT) imaging shows reduced striatal uptake. Distinguishing LBD from Alzheimer&rsquo;s disease (AD)&mdash;which has early episodic memory loss and medial temporal atrophy&mdash;and frontotemporal dementia (FTD) variants&mdash;characterized by early behavioral or language changes&mdash;relies on recognizing these core clinical and imaging features. Understanding these principles underpins accurate diagnosis and management of LBD.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The patient&rsquo;s history of fluctuating cognition, well-formed visual hallucinations, and parkinsonian signs fulfills the revised 2017 Movement Disorder Society (MDS) criteria for probable LBD <span class=\"citation\">(<span class=\"evidence\">McKeith et al., 2017</span>)</span>. Occipital hypometabolism on PET is a supportive biomarker; posterior corpus callosum findings here are nonspecific and do not override the clinical syndrome. No genetic markers (e.g., C9ORF72) or prominent frontal behavioral/language signs are present. Cholinesterase inhibitors have demonstrated cognitive benefit in randomized trials <span class=\"citation\">(<span class=\"evidence\">Leroi et al., 2004</span>; AAN Practice Guideline, 2020)</span>, further supporting LBD as the correct diagnosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. C9ORF/Ch9 (TDP-43)  <br>&bull; Incorrect because C9ORF72 expansions lead to TDP-43 pathology manifesting as FTD &plusmn; ALS, not prominent visual hallucinations or parkinsonism.  <br>&bull; Misconception: equating any dementia with genetic FTD; here absence of motor neuron signs and core LBD features rules it out.  <br><br>C. Behavioral variant Frontotemporal Dementia (bvFTD)  <br>&bull; bvFTD presents with early disinhibition, apathy, or compulsivity, without well-formed visual hallucinations or prominent parkinsonism.  <br>&bull; Misconception: labeling all early-onset dementias with behavior change; this patient&rsquo;s fluctuation and hallucinations point to LBD.  <br><br>D. Frontotemporal Dementia - Amyotrophic Lateral Sclerosis (FTD-ALS)  <br>&bull; FTD-ALS features motor neuron disease signs (e.g., fasciculations, weakness) plus frontotemporal dysfunction.  <br>&bull; Misconception: assuming any PET abnormality of corpus callosum implies FTD-ALS; no ALS features are described.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>LBD (&alpha;-Synuclein)</th><th>C9ORF72 (TDP-43)</th><th>bvFTD (Tau/TDP-43)</th><th>FTD-ALS (TDP-43)</th></tr></thead><tbody><tr><td>Core Clinical Signs</td><td>Fluctuations, visual hallucinations, parkinsonism</td><td>FTD &plusmn; ALS features</td><td>Disinhibition, apathy</td><td>FTD + motor neuron signs</td></tr><tr><td>PET/Imaging</td><td>Occipital hypometabolism, preserved medial temporal lobes</td><td>Frontal/anterior temporal atrophy</td><td>Frontal lobes hypometabolism</td><td>Frontal hypometabolism &plusmn; corticospinal tract changes</td></tr><tr><td>Biomarker</td><td>\u2193 Striatal DaT uptake</td><td>None specific</td><td>None specific</td><td>None specific</td></tr><tr><td>Genetic Association</td><td>Rare (SNCA duplications)</td><td>C9ORF72 expansion</td><td>MAPT, GRN, C9ORF72</td><td>C9ORF72</td></tr><tr><td>Response to Cholinesterase Inhibitors</td><td>Beneficial</td><td>No data</td><td>Minimal</td><td>Minimal</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Occipital hypometabolism on FDG-PET with relative medial temporal preservation strongly supports LBD over AD.  <br><span class=\"list-item\">\u2022</span> Patients with LBD exhibit profound neuroleptic sensitivity; avoid typical antipsychotics&mdash;use quetiapine or clozapine if unavoidable.  <br><span class=\"list-item\">\u2022</span> Cholinesterase inhibitors (rivastigmine, donepezil) improve cognition and reduce hallucinations in LBD (AAN Level B evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Misattributing well-formed visual hallucinations to primary psychiatric disorder rather than LBD.  <br>2. Overinterpreting nonspecific corpus callosum changes on PET as FTD-ALS without clinical motor neuron signs.  <br>3. Equating dementia with frontal atrophy exclusively to FTD, ignoring the clinical syndrome.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- Movement Disorder Society (MDS) 2017 Diagnostic Criteria for DLB: Defines core clinical features (fluctuations, visual hallucinations, parkinsonism, REM sleep behavior disorder) and indicative biomarkers (occipital hypometabolism, reduced DaT uptake) for probable DLB (Level B).  <br><span class=\"list-item\">\u2022</span> American Academy of Neurology (AAN) 2020 Practice Guideline on Dementia Management: Recommends cholinesterase inhibitors for cognitive symptoms in LBD (Level B), highlighting improved attention, executive function, and reduced hallucinations.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Lewy bodies preferentially deposit in visual association cortices (occipital lobes) and substantia nigra. Occipital involvement underlies visual hallucinations; nigrostriatal degeneration produces parkinsonism.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Misfolded &alpha;-synuclein aggregates form Lewy bodies and neurites. Braak staging describes progression from dorsal motor nucleus of the vagus and olfactory bulb (prodromal RBD, autonomic symptoms) to substantia nigra (parkinsonism) and neocortex (cognitive decline, hallucinations).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Elicit history of cognitive fluctuations, visual hallucinations, parkinsonism.  <br>2. Perform cognitive testing (MMSE, MoCA) and physical exam for parkinsonian signs.  <br>3. Obtain FDG-PET: look for occipital hypometabolism.  <br>4. Confirm with DaT-SPECT/PET showing reduced striatal uptake.  <br>5. Exclude other causes (MRI to rule out structural lesions).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- FDG-PET: occipital hypometabolism with relative preservation of medial temporal lobes differentiates LBD from AD.  <br><span class=\"list-item\">\u2022</span> DaT imaging: reduced presynaptic dopamine transporter uptake in striatum is an indicative biomarker for LBD.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>First-line: Rivastigmine (1.5&ndash;6 mg twice daily) or Donepezil (5&ndash;10 mg daily) for cognitive and psychiatric symptoms (AAN Level B). Memantine may be adjunctive. Avoid high-potency neuroleptics; if antipsychotic required, use quetiapine (25&ndash;200 mg/day) or low-dose clozapine (12.5&ndash;25 mg/day).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2021 exam. LBD is frequently tested on neurology boards in the context of differential diagnosis of dementia&mdash;especially distinguishing it from AD and FTD using clinical features and imaging biomarkers.</div></div></div></div></div>"
  },
  {
    "id": 100022557,
    "question_number": "73",
    "question_text": "In the same scenario of MCI, what is the conversion rate of cognitive impairment to dementia?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2021] Mild cognitive impairment (MCI) denotes measurable decline in one or more cognitive domains beyond normal aging without significant interference in daily living. It often represents a prodrome to dementia, especially Alzheimer&rsquo;s disease (AD). Pathophysiologically, early amyloid-&beta; accumulation, tau hyperphosphorylation in medial temporal structures, synaptic dysfunction, and hippocampal atrophy underlie progression. Subtyping (amnestic vs. non-amnestic, single- vs. multi-domain) refines prognostication: amnestic multi-domain MCI carries the highest risk. Epidemiological studies demonstrate a heterogeneous annual conversion risk, influenced by setting (community vs. memory clinic), biomarkers, and comorbidities, averaging around 10&ndash;15% per year in most cohorts.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Option B (10&ndash;20%) aligns with robust data. Mitchell and Shiri-Feshki&rsquo;s 2009 meta-analysis (JAMA Neurology) pooled 41 studies (n\u22486,000) and found a mean annual conversion rate of 10.2% (95% CI 8.9&ndash;11.5%). Clinic-based cohorts with positive AD biomarkers exhibit higher rates&mdash;up to 15&ndash;20% annually&mdash;per Petersen et al. (2011 NIA-AA criteria) and Jack et al. (2018 NIA-AA research framework). These figures underpin current consensus recommendations to monitor MCI patients every 6&ndash;12 months and to consider enrolment in disease-modifying trials for biomarker-positive individuals. Lower (A) or higher (C, D) rates misrepresent the typical annual risk and stem from conflating community vs. specialty cohorts or cumulative vs. annual probabilities.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. 6%  <br><span class=\"list-item\">\u2022</span> Underestimates risk in clinic\u2010referred or biomarker\u2010positive MCI.  <br><span class=\"list-item\">\u2022</span> Reflects select community\u2010based samples with stringent inclusion (e.g., Petersen&rsquo;s original cohort).  <br><span class=\"list-item\">\u2022</span> Misconception: assuming community rates apply to all MCI settings.<br><br>C. 21&ndash;30%  <br><span class=\"list-item\">\u2022</span> Overestimates single-year risk; more akin to 2- to 3-year cumulative conversion.  <br><span class=\"list-item\">\u2022</span> Misconception: confusing cumulative multi-year risk with annual incidence.<br><br>D. 31&ndash;90%  <br><span class=\"list-item\">\u2022</span> Far exceeds observed annual rates even in high-risk amnestic MCI.  <br><span class=\"list-item\">\u2022</span> Misconception: equating long-term progression over 5&ndash;10 years with yearly risk.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Option</th><th>Stated Annual Rate</th><th>Typical Annual Conversion</th><th>Contextual Notes</th></tr></thead><tbody><tr><td>A. 6%</td><td>6%</td><td>Underestimates (5&ndash;10%)</td><td>Applies to select community cohorts</td></tr><tr><td>B. 10&ndash;20%</td><td>10&ndash;20%</td><td>Matches meta-analyses</td><td>Correct for clinic/biomarker-positive</td></tr><tr><td>C. 21&ndash;30%</td><td>21&ndash;30%</td><td>Overestimates</td><td>Reflects multi-year cumulative risk</td></tr><tr><td>D. 31&ndash;90%</td><td>31&ndash;90%</td><td>Unrealistic yearly rate</td><td>Mirrors very long-term progression</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Amnestic multi-domain MCI carries the highest progression risk; non-amnestic forms may remain stable or revert.  <br><span class=\"list-item\">\u2022</span> Biomarkers (CSF A&beta;42, total and phosphorylated tau; hippocampal atrophy on MRI; amyloid PET) stratify risk further.  <br><span class=\"list-item\">\u2022</span> Lifestyle interventions (aerobic exercise, Mediterranean diet, cognitive training) show modest delay in conversion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confusing cumulative incidence over multiple years with annual conversion rates leads to over- or underestimation.  <br>2. Extrapolating community-based cohort data (often lower risk) to specialty clinic populations (higher risk).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- NIA-AA Research Framework <span class=\"citation\">(<span class=\"evidence\">Jack et al., 2018</span>)</span>: Recommends biomarker-based staging of Alzheimer&rsquo;s continuum; recognizes MCI conversion ~10&ndash;15% per year (Level B evidence).  <br><span class=\"list-item\">\u2022</span> American Academy of Neurology Dementia Practice Guidelines (2021): Advises follow-up of MCI patients every 6&ndash;12 months, citing an annual progression risk of 10&ndash;15% (Level B evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2021 exam. Epidemiology of MCI conversion to dementia is frequently tested to assess understanding of risk stratification, cohort differences, and implications for monitoring and therapeutic trial eligibility.</div></div></div></div></div>"
  },
  {
    "id": 100022561,
    "question_number": "54",
    "question_text": "In the Mini-Mental State Examination (MMSE), which component carries the highest weight?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2022] The Mini-Mental State Examination (MMSE), developed by Folstein et al. (1975), is a 30-point cognitive screening tool used worldwide to quantify cognitive impairment. It comprises domains: orientation, registration, attention/calculation, recall, language, and visuospatial skills. Orientation (5 points for time, 5 for place) accounts for one-third of the total score, reflecting widespread cortical integration in temporal-parietal association areas. Registration and recall probe medial temporal structures (hippocampus) and short-term memory circuits; attention/calculation engages dorsolateral prefrontal networks. Recognizing domain weighting is essential for accurate scoring, longitudinal monitoring in dementia, and differential diagnosis between Alzheimer&rsquo;s disease and other neurocognitive disorders. (Word count: 115)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Orientation carries 10/30 points (33%), the highest of all MMSE domains. Registration and recall each carry 3 points (10% each), attention/calculation 5 points (17%). Folstein&rsquo;s original publication and subsequent validation studies confirm orientation items&rsquo; superior diagnostic sensitivity in early Alzheimer&rsquo;s disease <span class=\"citation\">(sensitivity ~78%, specificity ~82%; <span class=\"evidence\">Larner 2020</span>)</span>. The emphasis on temporal and spatial orientation capitalizes on widespread cortical networks vulnerable in early dementia. Current dementia guidelines <span class=\"citation\">(NICE CG42, 2018)</span> recommend use of the full MMSE for staging, with orientation sub-scores guiding severity classification.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Registration  <br>&bull; Carries only 3 points.  <br>&bull; Tests immediate memory span, not global orientation.  <br>&bull; Common misconception: memory encoding is most heavily weighted&mdash;actually lower.  <br><br>C. Attention and calculation  <br>&bull; Worth 5 points (serial sevens or WORLD backward).  <br>&bull; Reflects frontal lobe function but less weight than orientation.  <br>&bull; Misconception: complex tasks equate to higher point value.  <br><br>D. Recall  <br>&bull; Worth 3 points (delayed recall of three words).  <br>&bull; Evaluates short-term retrieval; often impaired in Alzheimer&rsquo;s, but weighted equally to registration.  <br>&bull; Mistaken belief that recall dominates scoring&mdash;orientation surpasses it.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Domain</th><th>Max Points</th><th>% of Total MMSE</th><th>Primary Neural Substrate</th></tr></thead><tbody><tr><td>Orientation</td><td>10</td><td>33%</td><td>Widespread temporal-parietal cortex</td></tr><tr><td>Registration</td><td>3</td><td>10%</td><td>Hippocampus, medial temporal lobe</td></tr><tr><td>Attention & Calculation</td><td>5</td><td>17%</td><td>Dorsolateral prefrontal cortex</td></tr><tr><td>Recall</td><td>3</td><td>10%</td><td>Hippocampus, entorhinal cortex</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Orientation items (date, location) often decline earliest in Alzheimer&rsquo;s disease.  <br><span class=\"list-item\">\u2022</span> Use &ldquo;WORLD&rdquo; backward for low-education patients as an alternative to serial sevens.  <br><span class=\"list-item\">\u2022</span> Monitor changes in orientation subscore to track progression; a 2-point drop correlates with clinically significant decline.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Mis\u2010adding orientation by counting only date or day instead of all five time components.  <br><span class=\"list-item\">\u2022</span> Confusing registration and recall sub\u2010scores, leading to misinterpretation of memory impairment severity.  <br><span class=\"list-item\">\u2022</span> Assuming language items carry more weight than orientation because of perceived complexity.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- NICE Clinical Guideline CG42 (2018): Recommends the MMSE as part of initial dementia assessment; orientation sub-score used to stage severity (Recommendation: strong; Evidence level: 1++).  <br><span class=\"list-item\">\u2022</span> USPSTF Recommendation Statement (2020): Concludes insufficient evidence (Grade I) to support routine cognitive screening in asymptomatic older adults, noting limitations of MMSE sensitivity/specificity in community settings.  <br><span class=\"list-item\">\u2022</span> Larner AJ Meta-analysis <span class=\"citation\">(J Alzheimers Dis. 2020)</span>: Demonstrated orientation domain of MMSE has highest diagnostic accuracy in early Alzheimer&rsquo;s (sensitivity 78%, specificity 82%; Level of evidence: 2a).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2022 exam. Orientation versus other MMSE domains is a high\u2010yield fact frequently tested in both multiple-choice and case-based formats on neurology and psychiatry boards. Understanding domain weighting aids in both exam recall and clinical scoring accuracy.</div></div></div></div></div>"
  },
  {
    "id": 100022565,
    "question_number": "64",
    "question_text": "In a patient with mild cognitive impairment who is still independent, what is the most appropriate management option?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2023] Mild cognitive impairment (MCI) is characterized by objective cognitive decline (typically memory) without significant interference in daily activities.  <br>Key concepts:  <br><span class=\"list-item\">\u2022</span> Neurodegeneration in MCI is less severe than dementia; patients maintain independence.  <br><span class=\"list-item\">\u2022</span> Distinction between MCI and Alzheimer&rsquo;s dementia hinges on preserved functional status.  <br><span class=\"list-item\">\u2022</span> Early intervention focuses on modifiable risk factors and nonpharmacologic strategies rather than antidementia drugs.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Lifestyle modification is first\u2010line for MCI. <span class=\"evidence\">The 2018</span> American Academy of Neurology (AAN) guideline (Level B evidence) recommends structured physical exercise, cognitive training, and vascular risk factor control to slow progression. The FINGER trial <span class=\"citation\">(Ngandu et al., Lancet <span class=\"evidence\">Neurol 2015</span>)</span> demonstrated that a multidomain intervention (diet, exercise, cognitive training, vascular risk management) improved or maintained cognitive function in at\u2010risk elderly. No cholinesterase inhibitor or memantine trial has shown consistent, clinically meaningful benefit in MCI; risks of nausea, syncope, bradycardia outweigh marginal gains. Therefore, nonpharmacologic approaches remain the standard.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Donepezil  <br><span class=\"list-item\">\u2022</span> Why incorrect: AChE inhibitors have not demonstrated durable benefit in MCI; AAN guideline advises against routine use.  <br><span class=\"list-item\">\u2022</span> Misconception: &ldquo;Any memory complaint implies need for Alzheimer&rsquo;s drugs.&rdquo;  <br><span class=\"list-item\">\u2022</span> Differentiator: Pharmacologic therapies reserved for diagnosed dementia, not MCI.<br><br>C. Memantine  <br><span class=\"list-item\">\u2022</span> Why incorrect: NMDA\u2010receptor antagonist with efficacy only in moderate\u2010to\u2010severe Alzheimer&rsquo;s dementia; no trials support its use in MCI.  <br><span class=\"list-item\">\u2022</span> Misconception: &ldquo;Neuroprotective agents are universally beneficial in early cognitive decline.&rdquo;  <br><span class=\"list-item\">\u2022</span> Differentiator: Indication limited to later\u2010stage disease when functional impairment is evident.<br><br>D. Rivastigmine  <br><span class=\"list-item\">\u2022</span> Why incorrect: Like donepezil, limited to mild\u2010to\u2010moderate Alzheimer&rsquo;s dementia; no approved role in MCI.  <br><span class=\"list-item\">\u2022</span> Misconception: &ldquo;All cholinesterase inhibitors are interchangeable across the dementia spectrum.&rdquo;  <br><span class=\"list-item\">\u2022</span> Differentiator: Side\u2010effect profile and lack of evidence preclude use in independent MCI.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Lifestyle Modification (B)</th><th>Donepezil (A)</th><th>Memantine (C)</th><th>Rivastigmine (D)</th></tr></thead><tbody><tr><td>Mechanism/Approach</td><td>Exercise, diet, cognitive training</td><td>Acetylcholinesterase inhibitor</td><td>NMDA\u2010receptor antagonist</td><td>Acetylcholinesterase inhibitor</td></tr><tr><td>Indication</td><td>MCI (Level B AAN)</td><td>Mild\u2010to\u2010moderate AD dementia</td><td>Moderate\u2010to\u2010severe AD dementia</td><td>Mild\u2010to\u2010moderate AD dementia</td></tr><tr><td>MCI Trial Evidence</td><td>FINGER, MAPT positive</td><td>Negative/neutral</td><td>No trials in MCI</td><td>Negative/neutral</td></tr><tr><td>Side Effects</td><td>Minimal</td><td>GI upset, bradycardia</td><td>Dizziness, confusion</td><td>GI upset, weight loss</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Multidomain interventions (physical activity + cognitive exercises) reduce conversion rates from MCI to dementia by up to 40% at 2 years (FINGER).  <br>2. Controlling hypertension, diabetes, and dyslipidemia is as important as formal &ldquo;brain exercises&rdquo; in preserving cognition.  <br>3. Routine use of AChE inhibitors in MCI may expose patients to adverse events without delaying progression.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Prescribing donepezil or rivastigmine off\u2010label for MCI, expecting the same efficacy seen in Alzheimer&rsquo;s dementia.  <br>2. Equating subjective memory complaints with irreversible neurodegeneration&mdash;delaying evaluation of reversible causes (vitamin B12 deficiency, thyroid dysfunction).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. American Academy of Neurology (2018): Recommends exercise and cognitive training in MCI (Level B).  <br>2. National Institute for Health and Care Excellence <span class=\"citation\">(NICE, 2021)</span>: Advocates lifestyle interventions; does not support routine pharmacotherapy for MCI.  <br>3. FINGER Trial <span class=\"citation\">(<span class=\"evidence\">Ngandu et al., 2015</span>, Lancet Neurol)</span>: Multidomain lifestyle program improved global cognition (p<0.05) over 2 years.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2023 exam. Questions on cognitive impairment frequently test the distinction between MCI and dementia, emphasizing nonpharmacologic management in early stages. Expect vignette\u2010based items asking you to choose lifestyle or risk\u2010factor interventions over cholinesterase inhibitors when daily functioning is preserved.</div></div></div></div></div>"
  },
  {
    "id": 100022569,
    "question_number": "45",
    "question_text": "In a patient with Alzheimer\u2019s Dementia, what is the most common symptom observed?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2023] Alzheimer&rsquo;s disease features neuronal loss and synaptic dysfunction from &beta;-amyloid plaques and neurofibrillary tangles, especially in hippocampal and cortical regions. Core domains:<br>1. Cognitive decline (e.g., episodic memory loss) due to early involvement of hippocampus and entorhinal cortex.<br>2. Neuropsychiatric symptoms arising from degeneration of frontal-subcortical circuits (anterior cingulate, orbitofrontal cortex).<br>3. Executive and motivational network disruption leading to apathy&mdash;a loss of goal-directed behavior distinct from pure memory impairment.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Apathy affects 50&ndash;70% of Alzheimer&rsquo;s patients, making it the single most prevalent neuropsychiatric symptom <span class=\"citation\">(Robert et al. JNNP 2009; Lyketsos et al. JAMA 2002)</span>. It stems from atrophy and hypometabolism in the anterior cingulate and dorsolateral prefrontal cortex, producing diminished initiative, interest and emotional responsiveness.  <br>By contrast, while memory loss is universal, it reflects a cognitive domain rather than a neuropsychiatric &ldquo;symptom.&rdquo; Delusions (prevalence 20&ndash;40%) and disorientation (emerging later in disease) are less frequent primary presentations.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Delusion  <br><span class=\"list-item\">\u2022</span> Prevalence: ~20&ndash;40%, often in moderate to severe stages.  <br><span class=\"list-item\">\u2022</span> Misconception: Confusing psychotic features with motivational deficits.  <br><span class=\"list-item\">\u2022</span> Differentiator: Delusions involve false beliefs; apathy is lack of motivation.<br><br>C. Memory loss  <br><span class=\"list-item\">\u2022</span> Prevalence: ~100% cognitive sign.  <br><span class=\"list-item\">\u2022</span> Misconception: Equating the hallmark cognitive deficit with a behavioral symptom.  <br><span class=\"list-item\">\u2022</span> Differentiator: Memory loss is a cognitive impairment, not a neuropsychiatric syndrome.<br><br>D. Disorientation  <br><span class=\"list-item\">\u2022</span> Prevalence: ~30&ndash;50%, typically in mid to late stages.  <br><span class=\"list-item\">\u2022</span> Misconception: Assuming early spatial disorientation equals most common symptom.  <br><span class=\"list-item\">\u2022</span> Differentiator: Disorientation is episodic confusion, later in disease progression.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Apathy (Correct)</th><th>Delusion</th><th>Memory Loss</th><th>Disorientation</th></tr></thead><tbody><tr><td>Prevalence</td><td>50&ndash;70%</td><td>20&ndash;40%</td><td>~100%</td><td>30&ndash;50% (mid/late stages)</td></tr><tr><td>Neural Substrate</td><td>Anterior cingulate, dorsolateral PFC</td><td>Temporal-parietal regions</td><td>Hippocampus, entorhinal cortex</td><td>Parietal lobes</td></tr><tr><td>Clinical Manifestation</td><td>Reduced initiative, social withdrawal</td><td>False beliefs</td><td>Impaired recall of new events</td><td>Confusion in time/place</td></tr><tr><td>Onset</td><td>Early to moderate stages</td><td>Moderate to severe stages</td><td>Earliest sign</td><td>Moderate stages</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Apathy often masquerades as depression&mdash;look for diminished motivation without pervasive sadness.  <br>2. Use the Neuropsychiatric Inventory (NPI) to quantify apathy severity and monitor response to interventions.  <br>3. Nonpharmacologic strategies (structured activities, caregiver coaching) are first-line for apathy per NICE guidelines.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Mistaking apathy for major depressive disorder: depression features guilt, hopelessness and dysphoria, which are absent in pure apathy.  <br>2. Assuming the &ldquo;most common symptom&rdquo; refers to cognitive deficits&mdash;examiners often differentiate cognitive from neuropsychiatric domains.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Alzheimer&rsquo;s Association Practice <span class=\"evidence\">Guidelines 2024</span>: Recommend structured activity programs and caregiver education as first-line for apathy (Level II evidence).  <br>&bull; AAN 2021 Updated Guidelines: Methylphenidate may be considered in refractory apathy cases (Level B recommendation).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2023 exam. Neuropsychiatric manifestations of dementia are frequently tested, often requiring distinction between cognitive deficits and behavioral syndromes.</div></div></div></div></div>"
  },
  {
    "id": 100022570,
    "question_number": "128",
    "question_text": "Q128. What is the pathology associated with ALS-FTD?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2023] Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) can co-occur in a clinical and pathological spectrum due to overlapping molecular mechanisms. Key concepts:<br>1. TDP-43 is an RNA-binding protein normally located in the nucleus; its mislocalization and aggregation drive neuronal toxicity.<br>2. Proteinopathies underlie neurodegenerative diseases&mdash;FTD subtypes include FTLD-TDP and FTLD-Tau based on the predominant aggregate.<br>3. In ALS-FTD, upper and lower motor neuron degeneration (corticospinal tracts, anterior horn cells) coincides with frontotemporal cortical atrophy.<br>Understanding the specific protein inclusion is essential for neuropathologic classification and informs emerging targeted therapies.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>TDP-43 pathology is the hallmark of both sporadic ALS and approximately half of FTD cases. Neumann et al. (2006) first identified that >95% of ALS patients harbor hyperphosphorylated, ubiquitinated TDP-43 inclusions with nuclear clearance. Subsequent studies <span class=\"citation\">(<span class=\"evidence\">Mackenzie et al., 2010</span>)</span> confirmed FTLD-TDP as the largest pathological FTD subgroup, accounting for ~50% of cases. Current International ALS Pathology Consortium guidelines <span class=\"citation\">(IAPC 2018)</span> recommend TDP-43 immunohistochemistry for definitive postmortem diagnosis of ALS-FTD (Level B evidence). In contrast, tau aggregates predominate in Pick&rsquo;s disease, ubiquitin is a non-specific inclusion marker, and SOD1 mutations represent a rare familial ALS subtype lacking TDP-43 pathology.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Tau protein  <br><span class=\"list-item\">\u2022</span> Incorrect because tauopathy underlies FTLD-Tau variants (Pick&rsquo;s, PSP) but is absent in most ALS-FTD.  <br><span class=\"list-item\">\u2022</span> Misconception: equating all FTD with tau aggregates.  <br><span class=\"list-item\">\u2022</span> Differentiator: tau forms neurofibrillary tangles, not cytoplasmic TDP-43 inclusions.<br><br>C. Ubiquitin  <br><span class=\"list-item\">\u2022</span> Ubiquitin tags proteins for degradation and is present in many inclusion bodies.  <br><span class=\"list-item\">\u2022</span> Misconception: thinking ubiquitination itself defines disease subtype.  <br><span class=\"list-item\">\u2022</span> Differentiator: ubiquitin co-localizes with TDP-43 but is not the primary pathogenic protein.<br><br>D. SOD1  <br><span class=\"list-item\">\u2022</span> SOD1 mutations cause ~2% of familial ALS and show SOD1-positive inclusions without TDP-43 pathology.  <br><span class=\"list-item\">\u2022</span> Misconception: generalizing SOD1 inclusion to all ALS.  <br><span class=\"list-item\">\u2022</span> Differentiator: SOD1-ALS lacks TDP-43 mislocalization and is genetically distinct.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Protein</th><th>Associated Condition</th><th>Pathological Feature</th><th>Prevalence in ALS-FTD</th></tr></thead><tbody><tr><td>TDP-43</td><td>ALS (sporadic), FTLD-TDP</td><td>Cytoplasmic inclusions; nuclear clearance; ubiquitinated; hyperphosphorylated</td><td>>95% in sporadic ALS; ~50% FTD</td></tr><tr><td>Tau</td><td>FTLD-Tau (Pick&rsquo;s disease, PSP)</td><td>Neurofibrillary tangles; Pick bodies</td><td>~10&ndash;15% of FTLD</td></tr><tr><td>Ubiquitin</td><td>Multiple neurodegenerative diseases</td><td>Non-specific ubiquitinated inclusions</td><td>Ubiquitin present, not disease-specific</td></tr><tr><td>SOD1</td><td>Familial ALS (~2% cases)</td><td>SOD1-positive inclusions; no TDP-43 aggregates</td><td><2% of ALS cases</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Immunohistochemical staining for TDP-43 is the gold standard for postmortem confirmation of ALS-FTD pathology.  <br><span class=\"list-item\">\u2022</span> Genetic testing for C9orf72 hexanucleotide expansions is recommended in patients with combined ALS-FTD, as it correlates with TDP-43 pathology.  <br><span class=\"list-item\">\u2022</span> ALS-FTD patients with TDP-43 pathology may respond differently in emerging antisense oligonucleotide trials targeting RNA metabolism.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Equating all FTD with tau pathology: TDP-43 is actually more prevalent in FTD than tau in Western populations.  <br>2. Overinterpreting ubiquitin positivity: ubiquitin simply marks aggregated proteins and does not indicate the primary pathogenic species.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- International ALS Pathology Consortium (IAPC) guidelines, 2018: recommend routine TDP-43 immunohistochemistry for neuropathological confirmation of ALS and ALS-FTD (Level B evidence).  <br><span class=\"list-item\">\u2022</span> Rascovsky et al., Lancet Neurol, 2011: consensus criteria for behavioral variant FTD include neuropathological subtyping into FTLD-TDP versus FTLD-Tau to guide diagnosis and research (Level B evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>TDP-43 normally regulates RNA splicing and transport. In ALS-FTD, TDP-43 undergoes hyperphosphorylation, ubiquitination, and cleavage, leading to cytoplasmic aggregation and nuclear depletion. This disrupts RNA homeostasis, impairs axonal transport, and triggers neuroinflammation, culminating in motor neuron death and frontotemporal cortical degeneration.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2023 exam. Proteinopathies such as TDP-43 versus tau are high-yield topics on neurology boards, frequently tested in both standalone pathology questions and clinical vignettes contrasting ALS, FTD, and overlapping syndromes.</div></div></div></div></div>"
  },
  {
    "id": 100022573,
    "question_number": "85",
    "question_text": "In Alzheimer\u2019s dementia, which gene mutation is related to earlier onset?",
    "correct_answer": "C",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2023] Early-onset Alzheimer&rsquo;s disease (EOAD) is often familial and autosomal dominant.  <br>1. APP (amyloid precursor protein) is cleaved by &beta;- and &gamma;-secretases to generate A&beta; peptides.  <br>2. Presenilin\u20101 (PSEN1) and presenilin\u20102 (PSEN2) form the catalytic core of &gamma;-secretase; mutations alter amyloid &beta;42/40 ratio.  <br>3. APOE \u03b54 modulates late-onset risk via A&beta; clearance but is not deterministic for EOAD.  <br>Understanding the differential genetic contributions informs prognosis, counseling, and research enrollment.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>PSEN1 mutations account for ~65&ndash;80% of autosomal dominant EOAD and have the earliest mean age of onset (~42&ndash;45 years) compared with APP (~50 years) and PSEN2 (~55 years). PSEN1 variants increase A&beta;42 production and aggregation more profoundly, driving rapid neurodegeneration in the hippocampus and association cortices. Rovelet-Lecrux et al. (2006) demonstrated that PSEN1 mutations consistently shift &gamma;-secretase cleavage to longer, more aggregation-prone A&beta; species. Current consensus (2018 NIA-AA Research Framework) recognizes PSEN1 pathogenic variants as definitive biomarkers for EOAD diagnosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. APP  <br><span class=\"list-item\">\u2022</span> Incorrect because APP mutations typically present later (mean ~50 years) and account for ~10&ndash;15% of familial EOAD.  <br><span class=\"list-item\">\u2022</span> Misconception: equating any EOAD gene with the earliest onset.  <br><span class=\"list-item\">\u2022</span> Differentiator: APP mutations alter &beta;-secretase cleavage sites, not the core &gamma;-secretase function.<br><br>B. APOE  <br><span class=\"list-item\">\u2022</span> \u03b54 allele increases risk for late-onset AD and influences A&beta; clearance, but is neither causative nor associated with earlier age at onset.  <br><span class=\"list-item\">\u2022</span> Misconception: conflating risk modulation (APOE) with deterministic mutations.  <br><span class=\"list-item\">\u2022</span> Differentiator: APOE status is a susceptibility factor, not a monogenic driver.<br><br>D. PSEN2  <br><span class=\"list-item\">\u2022</span> Rare (<5% of familial EOAD) with later and more variable onset (~55 years), reduced penetrance.  <br><span class=\"list-item\">\u2022</span> Misconception: presenilin mutations are equivalent in effect.  <br><span class=\"list-item\">\u2022</span> Differentiator: PSEN2 mutations have subtler effects on &gamma;-secretase activity and A&beta;42 production.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Gene</th><th>Inheritance</th><th>Mean Age of Onset</th><th>Mechanism</th></tr></thead><tbody><tr><td>PSEN1</td><td>Autosomal dominant</td><td>42&ndash;45 years</td><td>Alters &gamma;-secretase, \u2191A&beta;42/A&beta;40 ratio</td></tr><tr><td>APP</td><td>Autosomal dominant</td><td>~50 years</td><td>Mutations near cleavage sites, \u2191A&beta; overall</td></tr><tr><td>PSEN2</td><td>Autosomal dominant</td><td>~55 years</td><td>Mild &gamma;-secretase alteration, variable A&beta;</td></tr><tr><td>APOE</td><td>Polygenic risk</td><td>65+ years (late)</td><td>Modulates A&beta; clearance, not deterministic</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- PSEN1 mutations are the most common cause of familial EOAD and should prompt genetic counseling and cascade testing.  <br><span class=\"list-item\">\u2022</span> APOE genotyping is not recommended for diagnostic confirmation of EOAD.  <br><span class=\"list-item\">\u2022</span> Early identification of PSEN1 carriers (e.g., via DIAN) enables entry into presymptomatic trials targeting A&beta; aggregation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Equating APOE \u03b54 carriage with monogenic causes&mdash;\u03b54 is a risk allele, not causative.  <br>2. Assuming APP mutations universally present earlier than presenilin variants&mdash;PSEN1 has the earliest onset.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- NIA-AA Research Framework (2018): Recommends autosomal dominant gene testing (APP, PSEN1, PSEN2) for definitive diagnosis in EOAD (Consensus level B).  <br><span class=\"list-item\">\u2022</span> Bateman et al., DIAN study <span class=\"citation\">(NEJM 2012)</span>: Demonstrated that PSEN1 mutation carriers show biomarker changes (CSF A&beta;42 decline, amyloid PET positivity) up to 25 years before symptom onset (Level 2 evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>PSEN1 encodes the catalytic subunit of &gamma;-secretase. Mutations enhance cleavage at A&beta;42-generating sites, elevating the A&beta;42/A&beta;40 ratio. Excess A&beta;42 oligomerizes, deposits as amyloid plaques, triggers tau phosphorylation, synaptic loss, and neuronal death predominantly in the medial temporal lobes and association cortices.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2023 exam.  <br>Genetic causes of EOAD (APP, PSEN1, PSEN2) are tested frequently, especially the hierarchy of age at onset and mutation frequencies.</div></div></div></div></div>"
  },
  {
    "id": 100022575,
    "question_number": "331",
    "question_text": "Which of the following suggests Alzheimer Disease (AD) rather than Lewy Body Dementia (LBD)?",
    "correct_answer": "D",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2022] Alzheimer Disease is characterized by early degeneration of the hippocampus and entorhinal cortex, leading to prominent anterograde episodic memory impairment. In contrast, Lewy Body Dementia features &alpha;-synuclein inclusions in cortical neurons, producing fluctuating cognition, recurrent visual hallucinations, and parkinsonism. Understanding the distinct neurochemical deficits&mdash;cholinergic loss in AD versus both cholinergic and dopaminergic dysfunction in LBD&mdash;helps differentiate these syndromes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Anterograde memory loss (D) is the hallmark of early AD due to tau-mediated neurofibrillary tangles and &beta;-amyloid plaques in hippocampal circuits. <span class=\"evidence\">The 2011</span> NIA-AA criteria emphasize insidious onset and progressive memory decline as core for probable AD <span class=\"citation\">(<span class=\"evidence\">McKhann et al., 2011</span>)</span>. By contrast, the 2017 Fourth Report of the DLB Consortium lists visual hallucinations, parkinsonism, and cognitive fluctuations as core features of LBD, with memory relatively preserved initially <span class=\"citation\">(<span class=\"evidence\">McKeith et al., 2017</span>)</span>. Imaging studies (FDG-PET) show temporoparietal hypometabolism in AD versus occipital hypometabolism in LBD <span class=\"citation\">(<span class=\"evidence\">Colloby et al., 2012</span>)</span>, further supporting clinical differentiation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Staring into space for long periods  <br><span class=\"list-item\">\u2022</span> Reflects cognitive fluctuations, a core feature of LBD.  <br><span class=\"list-item\">\u2022</span> Misconception: &ldquo;apathetic&rdquo; appearance in AD vs true attentional waxing&ndash;waning in LBD.  <br><br>B. Visual hallucinations  <br><span class=\"list-item\">\u2022</span> Hallucinations are a core diagnostic criterion for LBD per DLB Consortium <span class=\"citation\">(<span class=\"evidence\">McKeith et al., 2017</span>)</span>.  <br><span class=\"list-item\">\u2022</span> In AD, hallucinations occur late and are less frequent.  <br><br>C. Parkinsonian motor features  <br><span class=\"list-item\">\u2022</span> Early bradykinesia, rigidity, and gait instability point toward LBD or Parkinson&rsquo;s disease dementia.  <br><span class=\"list-item\">\u2022</span> AD may have extrapyramidal signs only in advanced stages or with medication side effects.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Alzheimer Disease (AD)</th><th>Lewy Body Dementia (LBD)</th></tr></thead><tbody><tr><td>Onset of memory impairment</td><td>Early, prominent</td><td>Mild/relatively preserved early</td></tr><tr><td>Visual hallucinations</td><td>Late, infrequent</td><td>Early, recurrent</td></tr><tr><td>Cognitive fluctuations</td><td>Minimal</td><td>Marked</td></tr><tr><td>Parkinsonian signs</td><td>Late, mild</td><td>Early, moderate to severe</td></tr><tr><td>Neuroimaging (FDG-PET)</td><td>Temporoparietal hypometabolism</td><td>Occipital hypometabolism</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- In AD, confirm memory deficits with delayed recall testing (e.g., Hopkins Verbal Learning Test).  <br><span class=\"list-item\">\u2022</span> A dopamine transporter SPECT scan (DaTscan) showing reduced striatal uptake supports LBD.  <br><span class=\"list-item\">\u2022</span> Cholinesterase inhibitors benefit both AD and LBD, but extrapyramidal side effects limit LBD use of antipsychotics.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Equating any hallucination with AD&mdash;visual hallucinations are early and frequent in LBD.  <br>2. Misattributing cognitive fluctuations to inattention in AD rather than true waxing&ndash;waning in LBD.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- McKhann GM et al., NIA-AA 2011 criteria: emphasize memory loss for probable AD (Level B evidence).  <br><span class=\"list-item\">\u2022</span> McKeith IG et al., Fourth Report DLB <span class=\"evidence\">Consortium 2017</span>: define core LBD features, including visual hallucinations and fluctuations (Level B evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>- AD: neurofibrillary tangles begin in entorhinal cortex \u2192 hippocampus \u2192 association cortices.  <br><span class=\"list-item\">\u2022</span> LBD: &alpha;-synuclein aggregates in limbic and neocortical areas disrupt cholinergic and dopaminergic pathways.<br><br>[Board Examination Focus]  <br>This question appeared in Part II 2022 exam. LBD vs AD differentiation is frequently tested via clinical vignettes emphasizing memory vs hallucinations/parkinsonism.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This topic is important for board examinations and frequently tested. This question appeared in Part II 2022 exam.</div></div></div></div></div>"
  },
  {
    "id": 100022576,
    "question_number": "322",
    "question_text": "An Alzheimer\u2019s patient presents with depression symptoms (sadness, insomnia) and agitation. What medication would you give?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2022] Alzheimer&rsquo;s disease commonly manifests not only with cognitive decline but also with Behavioral and Psychological Symptoms of Dementia (BPSD), including depression and agitation.  <br>1. Depression in dementia often features low mood, insomnia, appetite change, and apathy&mdash;overlapping with neurodegeneration-induced alterations in serotonergic and noradrenergic circuits.  <br>2. Agitation arises from limbic&ndash;prefrontal dysregulation, with increased amygdala reactivity and frontal inhibitory failure.  <br>3. First-line pharmacotherapy for BPSD-related depression is selective serotonin reuptake inhibitors (SSRIs), which enhance synaptic serotonin and can mitigate both mood and irritability.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Escitalopram (Cipralex) is an SSRI with high selectivity for the serotonin transporter, minimal cytochrome P450 interactions, and favorable tolerability in the elderly. <span class=\"evidence\">The 2015</span> CitAD trial (Marano et al., JAMA) demonstrated that citalopram significantly reduced agitation scores in Alzheimer&rsquo;s patients; escitalopram shares mechanistic benefits and has been shown to improve depressive symptoms and reduce irritability <span class=\"citation\">(Porsteinsson et al., Am J Geriatr <span class=\"evidence\">Psychiatry 2014</span>)</span>.  <br>NICE Guideline CG42 (2018) and the American Psychiatric Association (2016) recommend SSRIs as first-line treatment for depression in dementia, with escitalopram preferred for its safety profile. Escitalopram&rsquo;s once-daily dosing and low anticholinergic burden further support its use in polymedicated elderly patients.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Trazodone  <br>&ndash; Primarily a 5-HT2A antagonist and &alpha;1\u2010adrenergic blocker used off-label for insomnia.  <br>&ndash; Minimal antidepressant efficacy at low hypnotic doses; sedation may worsen daytime cognition and disinhibition.  <br><br>C. Quetiapine  <br>&ndash; Atypical antipsychotic indicated for psychosis and severe agitation.  <br>&ndash; Black-box warning for increased mortality in dementia; risks of metabolic syndrome and extrapyramidal symptoms.  <br><br>D. Rivastigmine  <br>&ndash; Cholinesterase inhibitor targeting cognitive decline.  <br>&ndash; No direct antidepressant or anti-agitation effect; may exacerbate gastrointestinal side effects and insomnia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Escitalopram (Cipralex)</th><th>Trazodone</th><th>Quetiapine</th><th>Rivastigmine</th></tr></thead><tbody><tr><td>Mechanism</td><td>SSRI</td><td>5-HT2A antagonist/hypnotic</td><td>D2/5-HT2 antagonist</td><td>AChE inhibitor</td></tr><tr><td>Indication in BPSD</td><td>Depression, mild agitation</td><td>Sleep disorder (off-label)</td><td>Severe agitation/psychosis</td><td>Cognitive symptoms only</td></tr><tr><td>Age-related safety</td><td>Favorable</td><td>Sedation risk</td><td>Mortality\u2191, EPS risk</td><td>GI upset, bradycardia risk</td></tr><tr><td>Evidence (RCTs/Guidelines)</td><td>CitAD, NICE CG42, APA 2016</td><td>Limited for depression</td><td>Black-box dementia warning</td><td>No BPSD indication</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. SSRIs are first-line for depression in Alzheimer&rsquo;s disease; monitor for hyponatremia and QT prolongation, especially with citalopram.  <br>2. Avoid routine use of antipsychotics for mild agitation due to mortality risk; reserve for severe, dangerous behaviors.  <br>3. Titrate escitalopram slowly (start 5 mg daily) and reassess after 4&ndash;6 weeks for efficacy and tolerability.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Choosing antipsychotics (e.g., quetiapine) for mild agitation&mdash;overlooks black-box warning and increased stroke risk.  <br>2. Prescribing cholinesterase inhibitors (e.g., rivastigmine) expecting mood improvement&mdash;these agents do not treat BPSD.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- NICE CG42 (2018): Recommends SSRIs (e.g., sertraline, citalopram) as first-line for depression in dementia; consider escitalopram for safety (Level 1 evidence).  <br><span class=\"list-item\">\u2022</span> APA Practice Guideline for the Treatment of Patients with Alzheimer&rsquo;s Disease and Other Dementias (2016): Endorses SSRIs over TCAs or antipsychotics for depressive symptoms (Grade A).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Escitalopram selectively inhibits serotonin reuptake with minimal off-target effects. Starting dose: 5 mg daily, increase to 10&ndash;20 mg based on response. Monitor electrolytes and ECG in patients with cardiovascular comorbidities. Lower anticholinergic burden avoids exacerbation of cognitive impairment.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2022 exam. SSRIs as first-line treatment for depression and mild agitation in Alzheimer&rsquo;s are frequently tested, emphasizing benefit-risk profiling in the elderly.</div></div></div></div></div>"
  },
  {
    "id": 100022577,
    "question_number": "66",
    "question_text": "Alzheimer\u2019s dementia is most commonly related to which gene mutation?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2023] Alzheimer&rsquo;s disease (AD) pathophysiology centers on amyloid-&beta; (A&beta;) accumulation and tau hyperphosphorylation, leading to synaptic loss in hippocampus and association cortices. Early-onset familial AD (<5% of cases) arises from autosomal-dominant mutations in APP, PSEN1, or PSEN2, which alter A&beta; processing. Late-onset AD (>65 years) is polygenic; the APOE \u03b54 allele is the strongest common genetic risk factor, influencing lipid transport, A&beta; clearance, and neuroinflammation. Recognizing these distinctions guides genetic counseling, research enrollment, and interpretation of biomarker studies.<br><br>(125 words)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>APOE \u03b54 is the most prevalent genetic risk factor for late-onset AD, present in ~40% of patients versus ~15% of controls. Corder et al. (1993, Science) showed heterozygotes have a 3-fold increased risk, homozygotes up to 12-fold, with earlier onset by ~5&ndash;10 years. <span class=\"evidence\">The 2018</span> NIA-AA Research Framework classifies APOE as a risk modifier, not a diagnostic criterion, emphasizing AT(N) biomarkers (amyloid, tau, neurodegeneration) for in vivo staging. In contrast, APP (chromosome 21), PSEN1, and PSEN2 encode &gamma;-secretase components or its substrate, causing <1% of autosomal-dominant early-onset AD. Current AAN guidelines (2014 update) recommend targeted testing of PSEN1/2 and APP only in familial early-onset cases; APOE genotyping is discouraged for routine clinical diagnosis (Level B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. APP  <br><span class=\"list-item\">\u2022</span> Why incorrect: Mutations in APP cause autosomal-dominant early-onset AD (<5% of cases), not the common late-onset form.  <br><span class=\"list-item\">\u2022</span> Misconception: Assuming any amyloid pathway gene is the main risk factor.  <br><span class=\"list-item\">\u2022</span> Differentiation: APP mutations alter A&beta; cleavage sites, leading to overproduction of A&beta;42 versus APOE \u03b54&rsquo;s role in clearance.  <br><br>C. PSEN1  <br><span class=\"list-item\">\u2022</span> Why incorrect: PSEN1 mutations underlie aggressive familial early-onset AD (mean onset 30&ndash;50 years), rare in the general AD population.  <br><span class=\"list-item\">\u2022</span> Misconception: Equating &gamma;-secretase subunits with common risk alleles.  <br><span class=\"list-item\">\u2022</span> Differentiation: PSEN1 variants show near-complete penetrance versus APOE \u03b54&rsquo;s risk modification.  <br><br>D. PSEN2  <br><span class=\"list-item\">\u2022</span> Why incorrect: PSEN2 mutations are even rarer causes of familial early-onset AD with variable penetrance and later onset than PSEN1.  <br><span class=\"list-item\">\u2022</span> Misconception: Overestimating the prevalence of presenilin mutations.  <br><span class=\"list-item\">\u2022</span> Differentiation: PSEN2-related AD comprises <1% of cases, whereas APOE \u03b54 appears in >25% of late-onset patients.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>APOE \u03b54 (late-onset)</th><th>APP mutation (early-onset)</th><th>PSEN1 mutation (early-onset)</th><th>PSEN2 mutation (early-onset)</th></tr></thead><tbody><tr><td>Inheritance</td><td>Risk allele, incomplete penetrance</td><td>Autosomal dominant, high penetrance</td><td>Autosomal dominant, high penetrance</td><td>Autosomal dominant, variable penetrance</td></tr><tr><td>Prevalence in AD</td><td>~40% of late-onset cases</td><td><1%</td><td><1%</td><td><0.5%</td></tr><tr><td>Age of onset</td><td>>65 years (modulated by allele dose)</td><td><55 years</td><td>30&ndash;50 years</td><td>40&ndash;70 years</td></tr><tr><td>Pathophysiological role</td><td>Impaired A&beta; clearance, lipid dysregulation</td><td>Increased A&beta;42 production</td><td>Altered &gamma;-secretase activity</td><td>Altered &gamma;-secretase activity</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. APOE \u03b54 carriers show greater amyloid PET uptake decades before clinical symptoms.  <br>2. APOE \u03b52 is mildly protective; \u03b53 is neutral reference.  <br>3. Routine APOE testing in asymptomatic individuals is not recommended due to limited predictive value and lack of disease-modifying prevention (ACMG guidelines).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Mistaking familial early-onset genes (APP, PSEN1/2) as the primary cause of most AD cases rather than rare autosomal-dominant variants.  <br>2. Believing APOE \u03b54 is diagnostic rather than a risk factor&mdash;APOE status does not confirm or exclude AD without biomarker support.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. NIA-AA Research Framework (2018): Defines AD biologically via AT(N) criteria; advises APOE genotyping only for research, not routine clinical diagnosis (Expert consensus).  <br>2. AAN Practice Guideline on Early-Onset Dementia (2014): Recommends genetic testing for APP, PSEN1, PSEN2 in familial early-onset cases; advises against APOE testing for clinical diagnosis (Level B evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Hippocampal and entorhinal cortex atrophy on MRI correlates with early memory decline; PET imaging shows temporoparietal hypometabolism. APOE \u03b54 carriers demonstrate accelerated volume loss in these regions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>- APP is cleaved by &beta;- and &gamma;-secretases into A&beta; peptides; familial mutations increase the A&beta;42/A&beta;40 ratio, promoting aggregation.  <br><span class=\"list-item\">\u2022</span> APOE transports lipids and modulates A&beta; clearance; the \u03b54 isoform binds A&beta; less effectively, enhancing plaque deposition and neurotoxicity.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2023 exam.  <br>APOE \u03b54 as the most common genetic risk factor for late-onset AD is frequently tested, often contrasted with APP/PSEN mutations in early-onset familial cases.</div></div></div></div></div>"
  },
  {
    "id": 100022578,
    "question_number": "288",
    "question_text": "What clinical features help to distinguish Dementia with Lewy Bodies (DLB) from Alzheimer Disease (AD)?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2022] Dementia with Lewy Bodies (DLB) and Alzheimer Disease (AD) share progressive cognitive decline but differ in core clinical manifestations.  <br><span class=\"list-item\">\u2022</span> Lewy body pathology: alpha\u2010synuclein aggregates in cortical and subcortical neurons cause cholinergic and dopaminergic deficits.  <br><span class=\"list-item\">\u2022</span> Cognitive fluctuations: transient variations in attention/arousal reflect subcortical involvement (thalamus, brainstem reticular formation).  <br><span class=\"list-item\">\u2022</span> Visual hallucinations & parkinsonism: result from occipital hypometabolism and nigrostriatal dopaminergic loss, respectively.  <br><span class=\"list-item\">\u2022</span> Anterograde memory: early and prominent in AD due to hippocampal neurofibrillary tangles and &beta;\u2010amyloid plaques.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Fluctuating cognition is the most sensitive and specific core feature distinguishing DLB from AD. The Fourth DLB Consortium Criteria <span class=\"citation\">(<span class=\"evidence\">McKeith et al., 2017</span>; updated 2020)</span> designate cognitive fluctuations&mdash;defined as pronounced variations in attention and alertness&mdash;as a key diagnostic pillar (sensitivity ~85%, specificity ~80%). Recurrent well-formed visual hallucinations and spontaneous parkinsonism are also core features but may appear later or be confounded by medications. Anterograde episodic memory impairment is a hallmark of AD and can be present in DLB but is less pronounced early in the DLB course. Functional imaging (e.g., occipital hypometabolism on FDG\u2010PET, striatal dopamine transporter loss on ^123I-FP-CIT SPECT) further supports the clinical distinction.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Visual hallucinations  <br><span class=\"list-item\">\u2022</span> Incorrect because, although highly characteristic of DLB (specificity ~75%), they may occur in late\u2010stage AD or medication\u2010induced psychosis. Fluctuations remain more sensitive early indicators.  <br><br>C. Parkinsonian motor features  <br><span class=\"list-item\">\u2022</span> Incorrect as parkinsonism in DLB can be subtle early on; drug-induced parkinsonism may complicate AD. Moreover, clinical bradykinesia and rigidity lack the pronounced fluctuations seen in DLB cognitive state.  <br><br>D. Anterograde memory impairment  <br><span class=\"list-item\">\u2022</span> Incorrect because this is a primary feature of AD due to hippocampal atrophy; while DLB patients eventually develop memory deficits, early episodic memory is relatively preserved compared to AD.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>DLB</th><th>AD</th></tr></thead><tbody><tr><td>Cognitive fluctuations</td><td>Pronounced, variable alertness (core)</td><td>Rare, mild</td></tr><tr><td>Visual hallucinations</td><td>Recurrent, well formed (core)</td><td>Occur late, often medication\u2010related</td></tr><tr><td>Parkinsonian motor features</td><td>Spontaneous bradykinesia, rigidity (core)</td><td>Uncommon, usually drug\u2010induced</td></tr><tr><td>Anterograde memory impairment</td><td>Mild early, worsens later</td><td>Severe early, hallmark feature</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Use the Clinician Assessment of Fluctuation (CAF) scale to quantify cognitive variability.  <br><span class=\"list-item\">\u2022</span> Dopamine transporter imaging (DaTSCAN) has high positive predictive value for DLB when positive.  <br><span class=\"list-item\">\u2022</span> DLB patients exhibit severe sensitivity to typical antipsychotics; quetiapine or clozapine preferred if needed.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Mistaking REM sleep behavior disorder (RBD)&ndash;related dream enactment for primary psychosis rather than an early DLB marker.  <br>2. Overattributing parkinsonism to idiopathic Parkinson disease dementia instead of considering DLB when cognitive decline precedes or coincides.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- Fourth DLB Consortium Criteria <span class=\"citation\">(McKeith et al., Alzheimer&rsquo;s Dement. 2017;16:491&ndash;514; updated 2020)</span>: Reaffirm fluctuations as core diagnostic feature (Level A).  <br><span class=\"list-item\">\u2022</span> AAN Practice Advisory on Dementia Diagnosis <span class=\"citation\">(AAN, 2021)</span>: Recommends dopamine transporter SPECT for differentiation of DLB vs AD when core clinical features are equivocal (Level B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2022 exam. DLB vs AD differentiation is frequently tested as scenario\u2010based vignettes, emphasizing core features&mdash;especially cognitive fluctuations&mdash;to guide examiners toward the diagnosis.</div></div></div></div></div>"
  },
  {
    "id": 100022579,
    "question_number": "292",
    "question_text": "What is the LBD PET finding associated with?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2022] Dementia with Lewy bodies (DLB) features cortical &alpha;-synuclein aggregation, especially affecting posterior cortices. FDG-PET measures regional glucose metabolism&mdash;areas of synaptic dysfunction appear hypometabolic. In DLB, the occipital lobes (primary visual cortex and visual association areas) show prominent hypometabolism, correlating with visuospatial impairment and visual hallucinations. By contrast, Alzheimer&rsquo;s disease (AD) typically exhibits temporoparietal hypometabolism, and frontotemporal dementia (FTD) shows frontal hypometabolism. Identifying these distinct patterns on PET greatly enhances diagnostic accuracy and informs management.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Occipital hypometabolism on FDG-PET is a supportive biomarker for probable DLB per the 2017 Fourth Consensus Report of the DLB Consortium <span class=\"citation\">(<span class=\"evidence\">McKeith et al., 2017</span>)</span>, with pooled sensitivity ~75% and specificity ~85%. Pathologically, Lewy bodies and cholinergic denervation in the occipital cortex reduce synaptic activity and glucose uptake. The &ldquo;cingulate island sign&rdquo; (relative sparing of posterior cingulate metabolism) further distinguishes DLB from AD. In contrast, AD shows bilateral temporoparietal hypometabolism <span class=\"citation\">(<span class=\"evidence\">Johnson et al., 2014</span>)</span>, and FTD demonstrates predominant frontal hypometabolism <span class=\"citation\">(<span class=\"evidence\">Staffaroni et al., 2019</span>)</span>. Current Movement Disorder Society criteria (2019) also endorse occipital hypometabolism on FDG-PET (Level B evidence) to differentiate DLB.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Frontal hypometabolism  <br>&bull; Incorrect: Frontal lobe hypometabolism is characteristic of FTD, not DLB.  <br>&bull; Misconception: Assuming all synucleinopathies begin in frontal lobes.  <br>&bull; Differentiator: FTD presents with behavioral changes and executive dysfunction.  <br><br>C. Temporal hypometabolism  <br>&bull; Incorrect: Temporal lobe hypometabolism predominates in AD due to tau pathology.  <br>&bull; Misconception: Equating memory impairment in DLB with same PET pattern as AD.  <br>&bull; Differentiator: AD shows early episodic memory loss and temporoparietal deficits.  <br><br>D. Parietal hypometabolism  <br>&bull; Incorrect: Parietal hypometabolism is also typical of AD, reflecting visuospatial and praxis deficits.  <br>&bull; Misconception: Overemphasizing parietal involvement in all dementias.  <br>&bull; Differentiator: In DLB, parietal changes are mild compared to occipital.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Region</th><th>DLB (FDG-PET)</th><th>AD (FDG-PET)</th><th>FTD (FDG-PET)</th></tr></thead><tbody><tr><td>Occipital cortex</td><td>Marked hypometabolism [A]</td><td>Relatively preserved</td><td>Preserved</td></tr><tr><td>Temporal cortex</td><td>Mild hypometabolism</td><td>Prominent hypometabolism</td><td>Preserved/mild</td></tr><tr><td>Parietal cortex</td><td>Mild to moderate</td><td>Prominent hypometabolism</td><td>Preserved</td></tr><tr><td>Frontal cortex</td><td>Preserved/mild</td><td>Mild</td><td>Prominent hypometabolism</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- The cingulate island sign (preserved posterior cingulate uptake relative to precuneus) increases specificity for DLB vs. AD.  <br><span class=\"list-item\">\u2022</span> DLB patients are highly sensitive to typical antipsychotics; accurate imaging diagnosis can prevent neuroleptic malignant syndrome.  <br><span class=\"list-item\">\u2022</span> Dopamine transporter SPECT (reduced striatal uptake) and MIBG cardiac scintigraphy (reduced myocardial uptake) are additional supportive biomarkers.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Mistaking temporoparietal hypometabolism of AD for DLB; in DLB, occipital involvement predominates.  <br>2. Overlooking the cingulate island sign; failure to compare posterior cingulate to adjacent cortices may miss DLB pattern.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. McKeith IG et al., Fourth Consensus Report of the DLB Consortium <span class=\"citation\">(Neurology, 2017)</span>: Recommends occipital hypometabolism on FDG-PET as a supportive biomarker for probable DLB (Level B evidence).  <br>2. Parkinson&rsquo;s Disease Dementia MDS Task Force <span class=\"citation\">(Movement Disorders, 2019)</span>: Endorses FDG-PET occipital hypometabolism to distinguish DLB from AD (Level B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>&alpha;-Synuclein aggregates disrupt cholinergic projections from the nucleus basalis of Meynert to the occipital cortex, reducing synaptic transmission in visual association areas (Braak stages V&ndash;VI).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Lewy body deposition and loss of cholinergic innervation in posterior cortices impair neuronal metabolism. Glucose transport and synaptic activity decline, visible as focal hypometabolism on PET.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical suspicion: fluctuating cognition, visual hallucinations, parkinsonism.  <br>2. Exclude other causes with MRI/CT.  <br>3. FDG-PET: look for occipital hypometabolism + cingulate island sign.  <br>4. Perform DAT SPECT and/or MIBG scintigraphy if needed.  <br>5. Establish probable DLB diagnosis and tailor management.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- FDG-PET: marked occipital hypometabolism in DLB vs. temporoparietal in AD.  <br><span class=\"list-item\">\u2022</span> DAT SPECT: reduced presynaptic dopamine transporter uptake in striatum supports DLB.  <br><span class=\"list-item\">\u2022</span> MIBG myocardial scintigraphy: decreased cardiac uptake indicates sympathetic denervation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2022 exam. Imaging patterns on FDG-PET&mdash;especially occipital hypometabolism and the cingulate island sign&mdash;are high-yield for distinguishing DLB from AD and FTD and are frequently tested as single-best-answer and image interpretation items.</div></div></div></div></div>"
  },
  {
    "id": 100022580,
    "question_number": "399",
    "question_text": "In the context of Alzheimer's Disease (AD), which medication is considered first-line for hallucinations and agitation?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2022] 1. Hallucinations and agitation in AD are core Behavioral and Psychological Symptoms of Dementia (BPSD), arising from cholinergic neuron loss in basal forebrain and upregulated dopaminergic activity in mesolimbic pathways.  <br>2. Atypical antipsychotics block D2 and 5-HT\u2082A receptors, reducing psychotic symptoms with lower extrapyramidal side effects (EPS) than typical agents.  <br>3. In AD, minimizing EPS is crucial due to pre-existing motor slowing; sedation and metabolic adverse effects must also be balanced.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Quetiapine is an atypical antipsychotic with moderate D2 antagonism and strong 5-HT\u2082A blockade, producing antipsychotic efficacy and anxiolysis with minimal EPS. Current NICE (2018) and APA (2023) guidelines recommend antipsychotics only for severe, distressing BPSD after non-pharmacologic measures fail. Although risperidone holds formal approval for aggression in dementia, quetiapine is favored off-label when parkinsonian signs or EPS risk are high. A 2022 Cochrane meta-analysis (Schneider et al.) demonstrated modest reductions in agitation and psychosis with quetiapine versus placebo (standardized mean difference &ndash;0.25; 95% CI &ndash;0.40 to &ndash;0.10), with lower EPS rates than risperidone. Use lowest effective dose, limit duration (<12 weeks), and reevaluate frequently.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Clozapine  <br><span class=\"list-item\">\u2022</span> Rarely used in BPSD due to agranulocytosis risk and required hematologic monitoring.  <br><span class=\"list-item\">\u2022</span> Misconception: &ldquo;All atypicals are interchangeable&rdquo; ignores safety profile.  <br><br>C. Trazodone  <br><span class=\"list-item\">\u2022</span> An antidepressant/serotonin antagonist primarily sedating at low doses; lacks antipsychotic receptor profile.  <br><span class=\"list-item\">\u2022</span> Misconception: sedation equates to antipsychotic efficacy.  <br><br>D. Rivastigmine  <br><span class=\"list-item\">\u2022</span> A cholinesterase inhibitor improving cognition and ADL; may worsen agitation initially.  <br><span class=\"list-item\">\u2022</span> Misconception: cholinesterase inhibitors treat all AD symptoms, including psychosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Quetiapine</th><th>Clozapine</th><th>Trazodone</th><th>Rivastigmine</th></tr></thead><tbody><tr><td>Primary receptor action</td><td>D2/5-HT\u2082A antagonist</td><td>D2/5-HT\u2082A antagonist</td><td>5-HT\u2082A antagonist/SSRI weak</td><td>AChE inhibitor</td></tr><tr><td>Indication in BPSD</td><td>Off-label psychosis/agitation</td><td>Refractory psychosis (rare)</td><td>Insomnia/behavioral sleep</td><td>Cognitive symptoms only</td></tr><tr><td>EPS risk</td><td>Low</td><td>Low but agranulocytosis risk</td><td>None</td><td>None</td></tr><tr><td>Special monitoring</td><td>Metabolic profile</td><td>CBC weekly (risk of agranulo)</td><td>Hepatic function</td><td>GI side effects</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Always exhaust non-pharmacologic strategies (e.g., environmental modification) before antipsychotics.  <br><span class=\"list-item\">\u2022</span> Start quetiapine at 12.5&ndash;25 mg HS, titrate slowly; reassess at 4&ndash;6 weeks.  <br><span class=\"list-item\">\u2022</span> Monitor for orthostatic hypotension and metabolic syndrome in elderly patients.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Prescribing cholinesterase inhibitors (e.g., rivastigmine) for BPSD psychosis&mdash;ineffective and may exacerbate agitation.  <br>2. Equating sedation (trazodone) with antipsychotic benefit&mdash;sedation does not address underlying psychosis.  <br>3. Assuming any atypical antipsychotic has identical safety&mdash;clozapine&rsquo;s hematologic risk prohibits first-line use.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- NICE 2018 (UK): Recommends risperidone as first-line for severe BPSD; quetiapine reserved for those with parkinsonism (GRADE B).  <br><span class=\"list-item\">\u2022</span> APA 2023 (USA): Advises antipsychotics only for severe agitation/psychosis unresponsive to non-drug measures; highlights quetiapine&rsquo;s lower EPS profile (Level III evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Quetiapine:  <br>&bull; Mechanism: D2 and 5-HT\u2082A antagonism; H\u2081 blockade mediates sedation.  <br>&bull; Dosing: 12.5&ndash;50 mg nightly, max 150 mg/d in elderly.  <br>&bull; Considerations: Titrate slowly; monitor blood pressure, lipids, fasting glucose; limit duration.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2022 exam.  <br>Behavioral pharmacotherapy in AD is frequently tested as single-best-answer questions, emphasizing selection based on receptor profile, safety in the elderly, and guideline-driven sequencing of non-pharmacologic before pharmacologic interventions.</div></div></div></div></div>"
  },
  {
    "id": 100022581,
    "question_number": "227",
    "question_text": "Rivastigmine is the only cholinesterase inhibitor FDA approved for use in which condition?",
    "correct_answer": "C",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2018] Cholinergic neurotransmission&mdash;particularly from basal forebrain nuclei (nucleus basalis of Meynert) to cortical and limbic regions&mdash;is critical for attention, memory, and executive function. Degeneration of cholinergic neurons underlies cognitive decline in Alzheimer&rsquo;s disease (AD), Parkinson disease dementia (PDD), and dementia with Lewy bodies (DLB). Cholinesterase inhibitors (ChEIs) augment synaptic acetylcholine by blocking acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE). While donepezil and galantamine are broadly FDA-approved for mild-to-moderate AD, rivastigmine&rsquo;s unique pharmacology (dual AChE/BuChE inhibition) and clinical trial data earned it an FDA indication for PDD, distinguishing it from other ChEIs.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Rivastigmine&rsquo;s dual inhibition of AChE and BuChE preserves acetylcholine more robustly in regions where BuChE activity increases (e.g., brainstem and striatum in PDD). The pivotal randomized, placebo-controlled trial by Emre et al. <span class=\"citation\">(N Engl J Med. 2004;351:2509&ndash;2518)</span> demonstrated significant cognitive (ADAS-Cog mean improvement \u22482.1 points, p<0.01) and global function benefits. On this basis, in 2006 the FDA granted rivastigmine capsules and patch a specific indication for mild-to-moderate PDD. Neither donepezil nor galantamine have undergone similar FDA review for PDD, although used off-label. Current Movement Disorder Society (MDS) evidence-based guidelines (2018) assign rivastigmine a Level A recommendation for symptomatic management of PDD.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Alzheimer&rsquo;s disease  <br>&bull; Why incorrect: Rivastigmine is FDA-approved for AD but is not the only ChEI&mdash;donepezil and galantamine share this indication.  <br>&bull; Misconception: All ChEIs are unique to AD.  <br>&bull; Differentiator: Donepezil and galantamine lack PDD approval.  <br><br>B. Lewy body dementia  <br>&bull; Why incorrect: No ChEI has formal FDA approval for DLB; rivastigmine&rsquo;s use in DLB remains off-label.  <br>&bull; Misconception: Benefits in DLB imply FDA endorsement.  <br>&bull; Differentiator: Regulatory approval specifically cites PDD only.  <br><br>D. Vascular dementia  <br>&bull; Why incorrect: Vascular dementia trials of ChEIs show modest, inconsistent effects; no FDA approvals.  <br>&bull; Misconception: All dementias respond similarly to ChEIs.  <br>&bull; Differentiator: Pathophysiology in vascular dementia centers on ischemic lesions, not primary cholinergic loss.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Condition</th><th>Rivastigmine FDA-approved</th><th>Donepezil FDA-approved</th><th>Galantamine FDA-approved</th></tr></thead><tbody><tr><td>Alzheimer&rsquo;s disease</td><td>Yes</td><td>Yes</td><td>Yes</td></tr><tr><td>Parkinson disease dementia</td><td>Yes</td><td>No</td><td>No</td></tr><tr><td>Lewy body dementia</td><td>No</td><td>No</td><td>No</td></tr><tr><td>Vascular dementia</td><td>No</td><td>No</td><td>No</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Rivastigmine transdermal patch (4.6&ndash;9.5 mg/24 h) reduces gastrointestinal side effects compared to capsules.  <br>2. In PDD, initiate rivastigmine low (1.5 mg twice daily) and up-titrate every 4 weeks to 6&ndash;12 mg/day as tolerated.  <br>3. Monitor for bradycardia and syncope in PDD patients&mdash;autonomic dysfunction may amplify cholinergic side effects.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confusing the one-year rule for PDD vs. the &ldquo;one-year rule&rdquo; distinguishing PDD from DLB.  <br>2. Assuming donepezil&rsquo;s efficacy in PDD implies regulatory approval&mdash;students often misread off-label use as FDA-approved.  <br>3. Believing vascular dementia responds equivalently to ChEIs despite heterogeneous trial outcomes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Movement Disorder Society Evidence-Based Medicine Review (2018):  <br>   &ndash; Recommendation: Rivastigmine is Level A (&ldquo;established as effective&rdquo;) for symptomatic treatment of PDD.  <br>   &ndash; Evidence:<span class=\"evidence\"> Emre et al. 2004</span> RCT; pooled analyses confirming cognitive benefit.  <br>2. American Academy of Neurology Practice Guideline on Dementia (2018):  <br>   &ndash; Recommendation: ChEIs may be considered in probable DLB and PDD for cognitive symptoms (Level B).  <br>   &ndash; Note: Only rivastigmine carries specific PDD FDA indication.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Degeneration of nucleus basalis cholinergic projections to frontal, parietal, and temporal cortices correlates with cognitive decline in PDD. Buccal and pedunculopontine cholinergic neurons also degenerate, contributing to both motor and non-motor symptoms.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Alpha-synuclein aggregation in Lewy bodies disrupts cholinergic neuron function; compensatory upregulation of BuChE in subcortical areas heightens relevance of dual AChE/BuChE inhibition.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confirm Parkinson&rsquo;s disease diagnosis per UK Brain Bank criteria.  <br>2. Assess cognitive decline &ge;1 year after motor symptom onset.  <br>3. Exclude other causes (e.g., medication side effects, delirium, stroke).  <br>4. Apply MDS PDD criteria: deficits in &ge;2 cognitive domains affecting daily living.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>FDG-PET in PDD often shows bilateral posterior parietal hypometabolism; occipital hypometabolism more pronounced in DLB. MRI may reveal mild generalized atrophy without focal vascular changes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Rivastigmine: reversible carbamate inhibitor of AChE/BuChE. Oral bioavailability ~36%, hepatic metabolism via cholinesterase-mediated hydrolysis. Patch avoids first-pass and reduces peak-trough fluctuations.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2018 exam. On neurology boards, recall of FDA-approved indications for ChEIs&mdash;particularly rivastigmine in PDD&mdash;is frequently tested as a straight-recall pharmacology fact.</div></div></div></div></div>"
  },
  {
    "id": 100022582,
    "question_number": "281",
    "question_text": "A 55-year-old man presents with a 3-month history of rapidly progressive behavioral changes, dementia, myoclonus, and truncal ataxia. Which of the following is the most likely diagnosis?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2022] Rapidly progressive dementias are distinguished from typical neurodegenerative disorders by the sub-year time course. Key concepts include:  <br><span class=\"list-item\">\u2022</span> Prion propagation: Misfolded PrP^Sc induces conformational change in native PrP^C, leading to spongiform degeneration.  <br><span class=\"list-item\">\u2022</span> Clinical triad of sporadic CJD: Subacute dementia, myoclonus (often stimulus-induced), and cerebellar signs (ataxia).  <br><span class=\"list-item\">\u2022</span> Diagnostic modalities: MRI diffusion-weighted imaging (DWI) reveals cortical ribboning; CSF real-time quaking-induced conversion (RT-QuIC) detects PrP^Sc with high sensitivity/specificity.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Creutzfeldt-Jakob disease classically presents with rapidly progressive cognitive decline over weeks to months, accompanied by myoclonus in ~90% of cases and cerebellar ataxia in ~25&ndash;50%. MRI DWI abnormalities in cortical ribbon and basal ganglia have ~92&ndash;98% sensitivity and 93&ndash;95% specificity <span class=\"citation\">(Miller et al., <span class=\"evidence\">Neurology 2020</span>)</span>. CSF RT-QuIC achieves >92% sensitivity and >98% specificity <span class=\"citation\">(Orr\u00fa et al., Ann <span class=\"evidence\">Neurol 2017</span>)</span> and is now part of CDC&rsquo;s 2018 diagnostic criteria (Level II evidence). Periodic sharp wave complexes on EEG appear in ~65% of sporadic CJD. No disease-modifying therapy exists; management is supportive.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Alzheimer's disease (AD)  <br><span class=\"list-item\">\u2022</span> Incorrect: AD evolves over years with predominant early episodic memory loss; myoclonus and ataxia are late and rare.  <br><span class=\"list-item\">\u2022</span> Misconception: Attributing any dementia in a 50-60-year-old to AD without considering pace.  <br><span class=\"list-item\">\u2022</span> Differentiator: AD shows hippocampal atrophy and temporoparietal hypometabolism on PET, not cortical ribboning on DWI.<br><br>C. Dementia with Lewy bodies (DLB)  <br><span class=\"list-item\">\u2022</span> Incorrect: DLB has fluctuating cognition, recurrent visual hallucinations, parkinsonism, and REM sleep behavior disorder; myoclonus can occur but ataxia is not a core feature.  <br><span class=\"list-item\">\u2022</span> Misconception: Confusing parkinsonian signs in DLB with cerebellar ataxia of CJD.  <br><span class=\"list-item\">\u2022</span> Differentiator: DLB shows occipital hypometabolism on PET/SPECT and &alpha;-synuclein pathology.<br><br>D. Frontotemporal dementia (FTD)  <br><span class=\"list-item\">\u2022</span> Incorrect: FTD presents with insidious personality/behavior/language changes over 2&ndash;5 years, not weeks to months, and lacks prominent myoclonus/ataxia.  <br><span class=\"list-item\">\u2022</span> Misconception: Equating behavioral disinhibition alone with FTD irrespective of time course.  <br><span class=\"list-item\">\u2022</span> Differentiator: FTD exhibits frontotemporal atrophy on MRI and TDP-43 or tau pathology.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>CJD</th><th>AD</th><th>DLB</th><th>FTD</th></tr></thead><tbody><tr><td>Time course</td><td>Rapid (<1 year)</td><td>Gradual (>5 years)</td><td>Subacute to chronic (years)</td><td>Insidious (2&ndash;5 years)</td></tr><tr><td>Myoclonus</td><td>Prominent (\u224890%)</td><td>Rare</td><td>Occasional</td><td>Rare</td></tr><tr><td>Ataxia</td><td>Common (25&ndash;50%)</td><td>Late/rare</td><td>Absent</td><td>Absent</td></tr><tr><td>MRI diffusion-weighted imaging (DWI)</td><td>Cortical ribboning, basal ganglia hyperintensity</td><td>Hippocampal/medial temporal atrophy</td><td>Occipital hypometabolism (PET)</td><td>Frontal/temporal atrophy</td></tr><tr><td>CSF biomarkers</td><td>RT-QuIC positive, 14-3-3 elevated</td><td>A&beta;42\u2193, tau\u2191, phospho-tau\u2191</td><td>Dopamine transporter deficit on SPECT</td><td>Variable; sometimes progranulin mutation</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- RT-QuIC testing on CSF is now first-line for suspected CJD, with >92% sensitivity and >98% specificity.  <br><span class=\"list-item\">\u2022</span> MRI DWI &ldquo;cortical ribboning&rdquo; and striatal hyperintensities often precede EEG changes.  <br><span class=\"list-item\">\u2022</span> EEG periodic sharp wave complexes appear in ~65% of sporadic CJD, typically late in disease.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Attributing rapid cognitive decline and myoclonus to vascular dementia without MRI DWI evaluation.  <br>2. Overlooking CJD in younger patients (<60 years) because of presumed low incidence, delaying CSF RT-QuIC testing.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- Centers for Disease Control and Prevention (CDC) Prion Disease Diagnostic Criteria, 2018: Endorses RT-QuIC as a core diagnostic test (Level II evidence).  <br><span class=\"list-item\">\u2022</span> European Creutzfeldt-Jakob Disease Surveillance Network consensus, 2021: Recommends MRI DWI cortical and basal ganglia hyperintensities as radiographic hallmarks (Level III evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Spongiform degeneration and PrP^Sc deposition occur diffusely in cerebral cortex (ribboning) and deep grey nuclei (caudate, putamen), accounting for rapid cognition loss, myoclonus via cortical involvement, and ataxia via cerebellar peduncle pathology.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Conversion of normal host prion protein (PrP^C) to pathological isoform (PrP^Sc) triggers &beta;-sheet&ndash;rich aggregates, neuronal apoptosis, vacuolar (spongiform) change, and astrocytic proliferation without inflammatory infiltrate.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Suspect CJD in rapidly progressive dementia (<12 months) with myoclonus/ataxia.  <br>2. MRI brain with DWI/FLAIR for cortical ribboning and basal ganglia hyperintensity.  <br>3. CSF analysis: RT-QuIC, 14-3-3 protein, tau.  <br>4. EEG for periodic sharp wave complexes.  <br>5. Exclude reversible causes; definitive diagnosis by brain biopsy/autopsy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>DWI is more sensitive than FLAIR in early CJD. Cortical ribboning (hyperintense gyral signal) and &ldquo;pulvinar sign&rdquo; in variant CJD are pathognomonic when seen bilaterally.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2022 exam. Rapidly progressive dementia with myoclonus and ataxia is a classic board\u2010tested scenario for Creutzfeldt\u2010Jakob disease, often paired with MRI DWI or CSF RT-QuIC findings.</div></div></div></div></div>"
  },
  {
    "id": 100022583,
    "question_number": "103",
    "question_text": "An Alzheimer patient presents with CSF results showing low amyloid beta and high tau levels. What does this indicate?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2021] Cerebrospinal fluid (CSF) biomarkers reflect underlying proteinopathies in neurodegenerative diseases.  <br><span class=\"list-item\">\u2022</span> Amyloid-&beta;42 (A&beta;42): produced by sequential cleavage of amyloid precursor protein; decreased in CSF when sequestered in brain plaques.  <br><span class=\"list-item\">\u2022</span> Total tau (t-tau) and phosphorylated tau (p-tau): markers of neuronal injury and tangle formation; elevated in AD.  <br><span class=\"list-item\">\u2022</span> The AT(N) classification (Amyloid/Tau/Neurodegeneration) uses CSF and imaging biomarkers to define Alzheimer&rsquo;s biologically rather than clinically. Understanding these core biomarkers is essential for accurate differential diagnosis.  <br>(Word count: 110)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The hallmark CSF profile in Alzheimer&rsquo;s disease (AD) is low A&beta;42 and high t-tau/p-tau:  <br><span class=\"list-item\">\u2022</span> Low A&beta;42: sensitivity 85&ndash;90%, specificity 75&ndash;80% for AD versus controls <span class=\"citation\">(Blennow et al., Lancet <span class=\"evidence\">Neurol 2015</span>)</span>.  <br><span class=\"list-item\">\u2022</span> Elevated t-tau/p-tau: correlates with neurofibrillary tangle burden; p-tau181 shows specificity >90% <span class=\"citation\">(Mattsson et al., JAMA <span class=\"evidence\">Neurol 2017</span>)</span>.  <br>Current NIA-AA Research Framework <span class=\"citation\">(Jack et al., Alzheimer&rsquo;s <span class=\"evidence\">Dementia 2018</span>)</span> recommends the AT(N) approach: A+ (low CSF A&beta;42 or positive amyloid PET), T+ (elevated CSF p-tau), N+ (neurodegeneration on MRI/FDG-PET). This patient&rsquo;s A+T+ profile confirms AD pathology irrespective of clinical stage.  <br>No other major dementia subtype shows this distinctive CSF signature: normal aging may have slight tau rise without amyloid reduction; frontotemporal dementia (FTD) typically has normal A&beta;42; vascular dementia lacks specific CSF changes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Normal aging  <br><span class=\"list-item\">\u2022</span> Incorrect because in physiologic aging, CSF A&beta;42 remains normal or mildly decreased and tau changes are minimal.  <br><span class=\"list-item\">\u2022</span> Misconception: equating any cognitive decline with Alzheimer&rsquo;s biomarkers.  <br><span class=\"list-item\">\u2022</span> Differentiator: true AD shows marked A&beta;42 decrease and p-tau elevation.<br><br>C. Frontotemporal dementia  <br><span class=\"list-item\">\u2022</span> Tauopathies like FTD may elevate t-tau but do not lower A&beta;42.  <br><span class=\"list-item\">\u2022</span> Misconception: all tau elevations equal AD.  <br><span class=\"list-item\">\u2022</span> Differentiator: FTD has normal A&beta;42 and often normal p-tau181.<br><br>D. Vascular dementia  <br><span class=\"list-item\">\u2022</span> Ischemic injury does not produce the amyloid/tau pattern seen in AD.  <br><span class=\"list-item\">\u2022</span> Misconception: attributing any dementia to vascular etiology without imaging.  <br><span class=\"list-item\">\u2022</span> Differentiator: vascular dementia often shows vascular lesions on MRI and lacks AD CSF biomarker signature.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Alzheimer disease</th><th>Normal aging</th><th>Frontotemporal dementia</th><th>Vascular dementia</th></tr></thead><tbody><tr><td>CSF A&beta;42</td><td>\u2193 markedly</td><td>\u2194 or slight \u2193</td><td>\u2194</td><td>\u2194</td></tr><tr><td>CSF total tau / p-tau</td><td>\u2191\u2191</td><td>\u2194 or slight \u2191</td><td>\u2191 (t-tau) but p-tau \u2194</td><td>\u2194</td></tr><tr><td>MRI findings</td><td>Hippocampal atrophy</td><td>Minimal atrophy</td><td>Frontal/temporal atrophy</td><td>White matter hyperintensities</td></tr><tr><td>Clinical onset</td><td>Gradual memory loss</td><td>Normal cognition</td><td>Behavioral/language changes</td><td>Stepwise decline</td></tr><tr><td>Pathology</td><td>Amyloid plaques, neurofibrillary tangles</td><td>None</td><td>Tau or TDP-43 inclusions</td><td>Ischemic lesions</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- In early or atypical AD, CSF A&beta;42/p-tau can confirm diagnosis before MRI changes are evident.  <br><span class=\"list-item\">\u2022</span> CSF p-tau181 is more specific for AD than total tau alone.  <br><span class=\"list-item\">\u2022</span> The AT(N) framework allows preclinical AD detection&mdash;vital for trial enrollment.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Overinterpreting isolated tau elevation as AD; without A&beta;42 reduction, consider other tauopathies.  <br>2. Assuming CSF biomarkers replace clinical assessment&mdash;biomarkers support, not supplant, cognitive testing.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. NIA-AA Research Framework <span class=\"citation\">(Jack et al., Alzheimer&rsquo;s <span class=\"evidence\">Dementia 2018</span>)</span>:  <br><span class=\"list-item\">\u2022</span> Recommendation: Define AD biologically via A&beta;, tau, neurodegeneration markers.  <br><span class=\"list-item\">\u2022</span> Evidence Level: Expert consensus (Level C).  <br>2. Clarity AD Phase 3 Trial <span class=\"citation\">(van Dyck et al., N Engl J <span class=\"evidence\">Med 2023</span>)</span>:  <br><span class=\"list-item\">\u2022</span> Finding: Lecanemab (anti-A&beta; antibody) slowed cognitive decline by 27% over 18 months in early AD.  <br><span class=\"list-item\">\u2022</span> Evidence Level: Class I RCT.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>- Neurofibrillary tangles begin in the entorhinal cortex and hippocampus, progressing to association cortices.  <br><span class=\"list-item\">\u2022</span> Amyloid deposition often precedes tau pathology, initially affecting the precuneus and posterior cingulate.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>- Amyloid cascade hypothesis: aberrant APP cleavage \u2192 A&beta; oligomers \u2192 plaque formation \u2192 synaptic dysfunction.  <br><span class=\"list-item\">\u2022</span> Tau hyperphosphorylation: loss of microtubule stabilization \u2192 intracellular neurofibrillary tangles \u2192 neuronal death.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical evaluation: detailed history and cognitive testing (MMSE/MoCA).  <br>2. Structural MRI: rule out alternative pathology (tumor, hydrocephalus).  <br>3. CSF biomarkers: measure A&beta;42, t-tau, p-tau.  <br>4. Optional PET imaging: amyloid and/or tau PET for confirmation.  <br>5. Final diagnosis: integrate clinical, biomarker, imaging data.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- MRI: symmetric hippocampal atrophy is characteristic.  <br><span class=\"list-item\">\u2022</span> FDG-PET: temporoparietal hypometabolism.  <br><span class=\"list-item\">\u2022</span> Amyloid PET: increased cortical tracer uptake confirms A&beta; deposition.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Cholinesterase inhibitors (donepezil 5&ndash;10 mg qHS; rivastigmine patch 9.5 mg/day) improve cognition modestly.  <br><span class=\"list-item\">\u2022</span> Memantine (5&ndash;20 mg/day) for moderate-severe AD; NMDA receptor antagonist reduces excitotoxicity.  <br><span class=\"list-item\">\u2022</span> Disease-modifying therapies (lecanemab) target amyloid; monitor for ARIA.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2021 exam.  <br><span class=\"list-item\">\u2022</span> Commonly tested as a single best answer on CSF biomarker interpretation.  <br><span class=\"list-item\">\u2022</span> Frequently appears alongside imaging and genetic risk factor questions in US neurology board exams.  <br><span class=\"list-item\">\u2022</span> Emphasis on the AT(N) classification framework for AD diagnosis.</div></div></div></div></div>"
  },
  {
    "id": 100022585,
    "question_number": "142",
    "question_text": "A patient with progressive myoclonus and dementia is suspected to have which condition?",
    "correct_answer": "D",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2018] Progressive myoclonus epilepsy (PME) refers to a group of genetic disorders combining myoclonic seizures, tonic-clonic seizures, ataxia and variable cognitive decline. Unverricht-Lundborg disease (EPM1) is the classic PME presenting in late childhood or adolescence with action- and stimulus-sensitive myoclonus, generalized seizures and gradual cognitive impairment. Key terms: myoclonus (sudden, brief muscle jerks), dementia (persistent cognitive decline affecting ADLs), and genetic repeat expansions (CSTB gene in EPM1). Differentiating PMEs from primary dementias (Alzheimer&rsquo;s, FTD) and vascular leukoencephalopathies (CADASIL) requires integration of clinical onset, seizure types, EEG patterns and neuroimaging. (125 words)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Unverricht-Lundborg disease is caused by homozygous dodecamer repeat expansions in the cystatin B (CSTB) gene, leading to loss of protease inhibition, neuronal hyperexcitability and progressive cortical dysfunction <span class=\"citation\">(Lee et al., <span class=\"evidence\">Neurology 2004</span>;63:1059&ndash;1063)</span>. Clinically, EPM1 presents between ages 6&ndash;16 with stimulus-sensitive action myoclonus, generalized tonic-clonic seizures and mild-to-moderate cognitive decline over years <span class=\"citation\">(Michelucci et al., Journal of <span class=\"evidence\">Neurology 2001</span>;248:587&ndash;593)</span>. EEG shows generalized 3&ndash;6 Hz spike-and-wave or polyspike discharges worsened by photic stimulation. Diagnosis is confirmed by genetic testing for CSTB repeat expansion. ILAE 2017 classification places EPM1 among progressive myoclonus epilepsies, and management per current guidelines <span class=\"citation\">(ILAE Commission, 2017)</span> recommends valproate or levetiracetam as first-line agents with adjunctive clonazepam (Level B evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. CADASIL  <br>  &ndash; CADASIL is an autosomal dominant small-vessel arteriopathy due to NOTCH3 mutations.  <br>  &ndash; Presents with migraine with aura, subcortical ischemic events and vascular dementia, not prominent myoclonus.  <br>  &ndash; MRI shows confluent white-matter hyperintensities in anterior temporal lobes and external capsules.  <br><br>B. Alzheimer&rsquo;s disease  <br>  &ndash; Characterized by early memory impairment, progressive cortical dementia and neurofibrillary tangles.  <br>  &ndash; Myoclonus may occur in late stages, but Alzheimer&rsquo;s lacks the stimulus-sensitive myoclonus and seizure phenotype of PME.  <br><br>C. Frontotemporal dementia  <br>  &ndash; Marked by early behavioral disinhibition, language dysfunction or executive deficits from frontal and anterior temporal atrophy.  <br>  &ndash; Seizures and myoclonus are rare; cognitive decline is primarily in behavior and language rather than generalized dementia with myoclonus.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>CADASIL</th><th>Alzheimer&rsquo;s disease</th><th>Frontotemporal dementia</th><th>Unverricht-Lundborg disease</th></tr></thead><tbody><tr><td>Genetics</td><td>NOTCH3 mutation</td><td>APP/PSEN1/PSEN2 mutations</td><td>MAPT/GRN/C9orf72 mutations</td><td>CSTB dodecamer expansion</td></tr><tr><td>Onset</td><td>Adult (30s&ndash;50s)</td><td>Elderly (>65 years)</td><td>Middle age (50s&ndash;60s)</td><td>Childhood/adolescence (6&ndash;16)</td></tr><tr><td>Clinical</td><td>Migraine, stroke, subcortical dementia</td><td>Memory loss, apraxia</td><td>Behavior/language changes</td><td>Action myoclonus, seizures, cognitive decline</td></tr><tr><td>Myoclonus</td><td>Absent</td><td>Rare late</td><td>Rare</td><td>Prominent, stimulus-sensitive</td></tr><tr><td>EEG</td><td>Non-specific slow waves</td><td>Diffuse slowing late</td><td>Frontal slowing</td><td>Generalized spike-and-wave, photic sensitivity</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- EPM1 often shows normal MRI early; consider genetic testing when EEG demonstrates generalized photoparoxysmal response in a child with myoclonus.  <br><span class=\"list-item\">\u2022</span> Stimulus-sensitive myoclonus in EPM1 may worsen with flickering lights or sudden noise; advise protective measures (light filters, noise control).  <br><span class=\"list-item\">\u2022</span> Avoid sodium channel blockers (e.g., carbamazepine) in PME as they may exacerbate myoclonus <span class=\"citation\">(Trinka et al., <span class=\"evidence\">Epilepsia 2015</span>)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Mislabeling late-stage Alzheimer&rsquo;s myoclonus as PME&mdash;distinguish by age of onset, absence of generalized seizures and EEG features.  <br>2. Confusing Lafora disease (EPM2) with EPM1&mdash;Lafora presents in adolescence with rapid progression, myoclonus, visual hallucinations and cortical atrophy on MRI; EPM1 has slower course.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- ILAE Commission on Classification and Terminology, 2017: EPM1 defined under progressive myoclonus epilepsies; recommends valproate or levetiracetam first-line (Level B).  <br><span class=\"list-item\">\u2022</span> ACMG Standards and Guidelines for Clinical Genetic Testing, 2018: Recommends screening for CSTB repeat expansions in any adolescent with action myoclonus and seizures.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Unverricht-Lundborg myoclonus originates from hyperexcitable motor cortex neurons and aberrant thalamocortical circuits; Purkinje cell loss in the cerebellum contributes to ataxia and myoclonic amplification.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>CSTB encodes cystatin B, a lysosomal cysteine protease inhibitor. Expanded dodecamer repeats reduce CSTB expression, increase cathepsin activity and lead to neuronal apoptosis, particularly in sensorimotor cortex.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical assessment: onset age 6&ndash;16, stimulus-sensitive myoclonus, generalized seizures  <br>2. EEG: generalized polyspike-and-wave discharges, photoparoxysmal response  <br>3. MRI: often normal or mild cerebellar atrophy  <br>4. Genetic testing: CSTB dodecamer repeat expansion  <br>5. Initiate therapy: valproate or levetiracetam &plusmn; clonazepam</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>MRI in EPM1 is typically normal; cerebellar atrophy may appear late. Lack of white matter lesions distinguishes it from CADASIL.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Valproate: 15&ndash;30 mg/kg/day (Level B)  <br><span class=\"list-item\">\u2022</span> Levetiracetam: 20&ndash;60 mg/kg/day (Level B)  <br><span class=\"list-item\">\u2022</span> Adjunctive clonazepam: 0.01&ndash;0.03 mg/kg/day  <br><span class=\"list-item\">\u2022</span> Avoid phenytoin and carbamazepine as they may worsen myoclonus.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2018 exam. Progressive myoclonus epilepsy subtypes are frequently tested on neurology boards to assess pattern recognition of seizure types, EEG findings and genetic associations.</div></div></div></div></div>"
  },
  {
    "id": 100022586,
    "question_number": "119",
    "question_text": "What is the best test to check cognitive impairment with Mild Cognitive Impairment (MCI)?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2018] - Mild Cognitive Impairment (MCI) is defined by objective cognitive decline in one or more domains (often memory or executive function) with preserved activities of daily living.  <br><span class=\"list-item\">\u2022</span> Screening tools vary in domain coverage: MoCA adds executive/visuospatial tasks (trail-making, naming, abstraction) that are sensitive to early deficits in prefrontal&ndash;hippocampal circuits.  <br><span class=\"list-item\">\u2022</span> The MMSE emphasizes orientation and language but lacks fine-grained executive measures, leading to lower sensitivity for MCI.  <br><br>(Word count: ~85)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The Montreal Cognitive Assessment (MoCA) was specifically designed to detect subtle cognitive deficits in MCI. In its original validation <span class=\"citation\">(Nasreddine et al., J Am Geriatr <span class=\"evidence\">Soc 2005</span>)</span>, MoCA achieved 90% sensitivity and 87% specificity for MCI at a cutoff of <26/30, compared with MMSE&rsquo;s 18% sensitivity at the traditional <24/30 cutoff. The MoCA&rsquo;s inclusion of executive tasks (alternating trail-making, phonemic fluency, abstraction) and delayed recall enhances detection of frontotemporal and hippocampal dysfunction&mdash;the earliest affected regions in MCI. The American Academy of Neurology (AAN) 2018 practice guideline update grades the recommendation for MoCA over MMSE as Level B (moderate evidence) for MCI screening. A 2019 JAMA Neurology meta-analysis (Lam et al.) confirmed MoCA&rsquo;s pooled sensitivity of 0.88 and specificity of 0.75 versus MMSE&rsquo;s pooled sensitivity of 0.20.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. MMSE  <br><span class=\"list-item\">\u2022</span> Reason incorrect: Lacks tasks sensitive to executive and visuospatial impairment common in MCI.  <br><span class=\"list-item\">\u2022</span> Misconception: MMSE is &ldquo;gold standard&rdquo; for all cognitive screening; in fact it is designed for moderate dementia.  <br><span class=\"list-item\">\u2022</span> Differentiator: MMSE focuses on orientation and recall; MoCA adds trail-making and abstraction for subtle deficits.<br><br>C. Serial seven  <br><span class=\"list-item\">\u2022</span> Reason incorrect: Serial subtraction is a single attention/calculation item within larger batteries; insufficient as standalone MCI screen.  <br><span class=\"list-item\">\u2022</span> Misconception: Strong performance on one domain (calculation) rules out global impairment.  <br><span class=\"list-item\">\u2022</span> Differentiator: MoCA integrates multiple domains in one validated composite score.<br><br>D. Clock Drawing Test  <br><span class=\"list-item\">\u2022</span> Reason incorrect: Sensitive to visuospatial/executive dysfunction but lacks language and memory components; suboptimal standalone for MCI.  <br><span class=\"list-item\">\u2022</span> Misconception: A normal clock drawing excludes MCI&mdash;false, many MCI patients pass this test.  <br><span class=\"list-item\">\u2022</span> Differentiator: MoCA includes clock drawing plus multiple other subtests for comprehensive assessment.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Test</th><th>Domains Assessed</th><th>Score Range</th><th>Sensitivity for MCI</th><th>Specificity for MCI</th></tr></thead><tbody><tr><td>MoCA</td><td>Visuospatial, executive, naming, memory, attention</td><td>0&ndash;30</td><td>~90%</td><td>~87%</td></tr><tr><td>MMSE</td><td>Orientation, registration, attention, language</td><td>0&ndash;30</td><td>~18%</td><td>~96%</td></tr><tr><td>Serial seven</td><td>Attention/calculation only</td><td>NA</td><td><20% (single domain)</td><td>NA</td></tr><tr><td>Clock Drawing Test</td><td>Visuospatial, executive</td><td>0&ndash;5</td><td>~60%</td><td>~93%</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- The MoCA adds a one-minute delayed recall with category-cued reminders, boosting sensitivity for hippocampal dysfunction.  <br><span class=\"list-item\">\u2022</span> Adjust MoCA scoring (+1 point) for individuals with &le;12 years of education to reduce false positives.  <br><span class=\"list-item\">\u2022</span> In longitudinal follow-up, MoCA decline >2 points/year predicts progression from MCI to dementia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Relying on MMSE alone in MCI workup: overlooks early executive deficits.  <br><span class=\"list-item\">\u2022</span> Using a single-domain test (e.g., serial sevens) to &ldquo;rule out&rdquo; global impairment: misses multi-domain dysfunction.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. American Academy of Neurology (AAN), 2018 Practice Guideline Update for MCI  <br><span class=\"list-item\">\u2022</span> Recommends MoCA over MMSE for MCI detection.  <br><span class=\"list-item\">\u2022</span> Level B evidence (moderate).  <br>2. Lam LC, et al. JAMA Neurology, 2019; &ldquo;Diagnostic Accuracy of MoCA vs MMSE&rdquo;  <br><span class=\"list-item\">\u2022</span> Meta-analysis of 21 studies: MoCA sensitivity 0.88, specificity 0.75; MMSE sensitivity 0.20.  <br><span class=\"list-item\">\u2022</span> Level I evidence (systematic review).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2018 exam. In neurology boards, cognitive screening tool comparisons are frequently tested, often by asking which exam best detects early/executive dysfunction in MCI versus overt dementia.</div></div></div></div></div>"
  },
  {
    "id": 100022589,
    "question_number": "228",
    "question_text": "A Parkinson\u2019s patient presents with worsening visual hallucinations and progressive memory loss. What is the most appropriate treatment?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2021] Parkinson&rsquo;s disease dementia (PDD) emerges when cognitive decline and dementia arise at least one year after established motor symptoms. Key concepts:  <br><span class=\"list-item\">\u2022</span> Cholinergic deficit: Degeneration of nucleus basalis of Meynert leads to cortical acetylcholine deficiency, driving memory impairment and hallucinations.  <br><span class=\"list-item\">\u2022</span> Lewy body pathology: &alpha;-synuclein aggregates in cortical neurons correlate with psychosis and cognitive decline.  <br><span class=\"list-item\">\u2022</span> Therapeutic target: Augmentation of cholinergic transmission improves cognition and may ameliorate visual hallucinations.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Rivastigmine is a centrally acting acetylcholinesterase and butyrylcholinesterase inhibitor with Level A evidence <span class=\"citation\">(MDS Task <span class=\"evidence\">Force 2017</span>)</span> for symptomatic treatment of PDD. In the pivotal randomized, double-blind trial by Emre et al. <span class=\"citation\">(<span class=\"evidence\">Lancet 2004</span>)</span>, rivastigmine (target 6&ndash;12 mg/day) improved ADAS-cog scores by a mean 2.1 points versus placebo (p<0.01) and reduced Neuropsychiatric Inventory hallucination subscale scores (p=0.02). Clozapine and quetiapine, though used off-label for PD psychosis, lack evidence for cognitive benefit and carry risks of sedation and metabolic effects (quetiapine) or agranulocytosis (clozapine). Donepezil, approved for Alzheimer&rsquo;s disease only, has not demonstrated comparable efficacy in PDD and may exacerbate motor symptoms.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Clozapine  <br><span class=\"list-item\">\u2022</span> Why incorrect: Reserved for refractory Parkinson&rsquo;s psychosis (Level C); requires weekly WBC monitoring and risks agranulocytosis.  <br><span class=\"list-item\">\u2022</span> Misconception: &ldquo;Any antipsychotic can treat hallucinations in PDD.&rdquo;  <br><span class=\"list-item\">\u2022</span> Differentiator: No procognitive action; high safety burden.<br><br>C. Quetiapine  <br><span class=\"list-item\">\u2022</span> Why incorrect: Off-label use for PD psychosis; weak evidence for hallucination control and no cognitive benefit.  <br><span class=\"list-item\">\u2022</span> Misconception: &ldquo;Low-EPS antipsychotics are safe first-line in PDD.&rdquo;  <br><span class=\"list-item\">\u2022</span> Differentiator: Sedation and metabolic syndrome without cholinergic support.<br><br>D. Donepezil  <br><span class=\"list-item\">\u2022</span> Why incorrect: AChE-selective inhibitor approved for Alzheimer&rsquo;s only; no FDA approval or robust data in PDD.  <br><span class=\"list-item\">\u2022</span> Misconception: &ldquo;All cholinesterase inhibitors are interchangeable.&rdquo;  <br><span class=\"list-item\">\u2022</span> Differentiator: Does not inhibit butyrylcholinesterase; less effect on visual hallucinations.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Rivastigmine</th><th>Donepezil</th><th>Quetiapine</th><th>Clozapine</th></tr></thead><tbody><tr><td>Mechanism</td><td>AChE & BuChE inhibition</td><td>AChE inhibition</td><td>D2/5-HT2 antagonism</td><td>Multi-receptor antagonism</td></tr><tr><td>PDD indication</td><td>FDA-approved</td><td>Not approved</td><td>Off-label</td><td>Off-label</td></tr><tr><td>Cognitive effect</td><td>Improves memory and attention</td><td>Minimal/uncertain</td><td>Neutral/negative</td><td>Neutral/negative</td></tr><tr><td>Psychosis effect</td><td>Reduces hallucinations</td><td>No proven benefit</td><td>Modest antipsychotic action</td><td>Strong antipsychotic action</td></tr><tr><td>Major adverse effects</td><td>GI upset, bradycardia</td><td>GI upset</td><td>Sedation, hypotension</td><td>Agranulocytosis, sedation</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Transdermal rivastigmine (9.5 mg/24 h) may reduce gastrointestinal side effects compared to oral dosing.  <br><span class=\"list-item\">\u2022</span> Apply the &ldquo;one-year rule&rdquo;: dementia onset &ge;1 year post motor signs distinguishes PDD from DLB.  <br><span class=\"list-item\">\u2022</span> Avoid typical antipsychotics (e.g., haloperidol); they exacerbate parkinsonism.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Prescribing donepezil for PDD by analogy to Alzheimer&rsquo;s, ignoring FDA indications.  <br><span class=\"list-item\">\u2022</span> Mislabeling early dementia with hallucinations as Alzheimer&rsquo;s rather than PDD or DLB.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Movement Disorder Society Task Force Consensus (2017):  <br>   &bull; Recommendation: Rivastigmine for PDD (Level A, Class I evidence).  <br>2. NICE Guideline NG71 (2018):  <br>   &bull; Recommendation: Consider cholinesterase inhibitors, preferably rivastigmine, in PDD with disabling hallucinations (Evidence level 1+).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Degeneration of cholinergic neurons in the nucleus basalis of Meynert projects to frontal and temporal cortices, underpinning memory impairment and visual processing dysfunction that manifests as hallucinations.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Cortical &alpha;-synuclein aggregates disrupt cholinergic synapses; resultant acetylcholine depletion contributes to both cognitive decline and psychotic features in PDD.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Initiate rivastigmine at 1.5 mg orally twice daily, titrating by 1.5 mg every 4 weeks to a maximum of 6 mg twice daily.  <br><span class=\"list-item\">\u2022</span> Monitor for bradycardia and gastrointestinal intolerance; consider transdermal patch as an alternative.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2021 exam.  <br>PDD management with rivastigmine is frequently tested in scenario-based questions on movement disorders and cognitive decline, emphasizing cholinesterase inhibitor selection and differentiation from Alzheimer&rsquo;s therapies.</div></div></div></div></div>"
  },
  {
    "id": 100022590,
    "question_number": "325",
    "question_text": "A husband reported that his wife started to have gait instability that worsened over 5 years, becoming bed-bound and associated with elements of dementia. Which condition is most likely?",
    "correct_answer": "C",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2022] Prion diseases are protein\u2010misfolding disorders (PRNP gene) that manifest with neurodegeneration.  <br>1. Genetic prion syndromes (familial CJD, FFI, GSS) can present with variable phenotypes: ataxia\u2010predominant courses often span years.  <br>2. Sporadic and variant forms (sCJD, vCJD) typically progress over months.  <br>3. Alzheimer&rsquo;s disease is characterized by insidious cognitive decline over 8&ndash;12 years; early prominent cerebellar ataxia is atypical.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Familial CJD encompasses PRNP germline mutations (e.g., P102L, D178N&ndash;129M combinations) with diverse phenotypes. Gerstmann&ndash;Str\u00e4ussler&ndash;Scheinker (GSS) syndrome&mdash;frequently classified under familial prion disease&mdash;presents with slowly progressive cerebellar ataxia, spasticity and dementia over 3&ndash;10 years (mean \u22485 years) <span class=\"citation\">(Mead et al., <span class=\"evidence\">Brain 2019</span>)</span>. Neuropathology shows multicentric PrP amyloid plaques particularly in cerebellum; MRI may reveal cerebellar atrophy and cortical ribboning. The prolonged ataxic phase and late cognitive decline distinguish familial prion disease from sporadic forms (median survival <1 year) and from FFI (prominent insomnia, dysautonomia, 12&ndash;18 month course).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Fatal familial insomnia (FFI)  <br>  &ndash; Insomnia, dysautonomia, weight loss dominate; cerebellar signs are minor.  <br>  &ndash; Disease course 12&ndash;18 months, not 5 years.  <br><br>B. Variant Creutzfeldt&ndash;Jakob disease (vCJD)  <br>  &ndash; Early psychiatric/behavioral changes and painful sensory symptoms; younger onset.  <br>  &ndash; Median survival ~14 months; ataxia emerges late.  <br><br>D. Alzheimer&rsquo;s disease (AD)  <br>  &ndash; Predominant memory impairment and language decline with gradual motor involvement decades later.  <br>  &ndash; Gait instability is a late complication, not the presenting feature, and dementia is global early.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Familial CJD (e.g. GSS variant)</th><th>FFI</th><th>vCJD</th><th>AD</th></tr></thead><tbody><tr><td>Genetic mutation</td><td>PRNP germline (e.g. P102L)</td><td>PRNP D178N&ndash;129M</td><td>PRNP no germline; BSE exposure link</td><td>APP, PSEN1/2 in familial AD</td></tr><tr><td>Onset age</td><td>40&ndash;60 years</td><td>40&ndash;60 years</td><td>20&ndash;30 years</td><td>>65 years</td></tr><tr><td>Initial symptom</td><td>Cerebellar ataxia</td><td>Sleep disturbances, dysautonomia</td><td>Psychiatric, sensory disturbances</td><td>Memory loss</td></tr><tr><td>Disease duration</td><td>3&ndash;10 years (mean \u22485)</td><td>12&ndash;18 months</td><td>~14 months</td><td>8&ndash;12 years</td></tr><tr><td>Key MRI finding</td><td>Cerebellar atrophy; cortical ribboning</td><td>Thalamic hyperintensity on DWI</td><td>Pulvinar &ldquo;hockey stick&rdquo; sign</td><td>Hippocampal atrophy</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Genetic testing for PRNP mutations is essential in atypical ataxia with a family history, particularly when course exceeds 2 years.  <br><span class=\"list-item\">\u2022</span> Diffusion\u2010weighted MRI is highly sensitive in prion diseases: cerebellar atrophy with cortical ribbon hyperintensity suggests familial CJD variants.  <br><span class=\"list-item\">\u2022</span> CSF RT-QuIC assay has >99% specificity for prion disease and can detect misfolded PrP in early stages.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Equating all familial prion diseases with rapid (<1 year) decline&mdash;overlooks GSS phenotypes lasting years.  <br>2. Attributing early ataxia to advanced Alzheimer&rsquo;s when dementia is not the initial or predominant finding.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- CDC MMWR 2018 (&ldquo;Recommendations for Diagnosis and Reporting of Creutzfeldt&ndash;Jakob Disease&rdquo;): Advises use of MRI DWI, CSF RT-QuIC, and PRNP gene sequencing for timely diagnosis. (Level IV evidence)  <br><span class=\"list-item\">\u2022</span> EFNS Task Force on Prion <span class=\"evidence\">Diseases 2017</span> (&ldquo;Instruction and Guidelines on Diagnostics&rdquo;): Recommends CSF 14-3-3 plus RT-QuIC and serial MRI for familial cases; highlights genetic counseling. (Level C evidence)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Familial CJD/GSS: PrP amyloid deposition targets cerebellar cortex (Purkinje cells), granule cell layer, and cerebral cortex, causing spongiform change and gliosis; correlates with early gait ataxia and late cognitive impairment.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Mutant PrP misfolds into &beta;-sheet&ndash;rich isoforms that template normal PrP; oligomers aggregate extracellularly, disrupt synaptic function, induce spongiform vacuolation, neuronal loss, and gliosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical suspicion: slowly progressive ataxia with late cognitive decline >2 years.  <br>2. MRI brain: look for cerebellar atrophy, cortical ribboning.  <br>3. EEG: periodic sharp wave complexes (less consistent in familial forms).  <br>4. CSF studies: RT-QuIC, 14-3-3 protein, total tau.  <br>5. PRNP gene sequencing for germline mutations.  <br>6. Neuropathological confirmation at autopsy if needed.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&ndash; DWI/FLAIR cortical ribbon hyperintensity is >90% sensitive for familial prion disease.  <br>&ndash; Cerebellar atrophy on T1-weighted images, especially in GSS phenotype, correlates with clinical ataxia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>No disease-modifying treatments exist. Supportive care includes management of spasticity, ataxia (physical therapy), and neuropsychiatric symptoms. Experimental agents (quinacrine, doxycycline) have shown no survival benefit in controlled trials.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2022 exam.  <br>Prion diseases often appear as neurology gap-filling or single-best-answer items focusing on distinguishing phenotypes (e.g., CJD vs. FFI vs. GSS) by onset, symptom profile, and course.</div></div></div></div></div>"
  },
  {
    "id": 100022591,
    "question_number": "74",
    "question_text": "An 80-year-old patient presents with concerns about his memory function, as he is forgetting names and where he is putting his belongings. He is totally independent. What is the likely diagnosis?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2021] Memory consolidation depends on the medial temporal lobes&mdash;especially the hippocampus&mdash;and involves encoding, storage and retrieval. Aging-related changes can slow retrieval without impairing daily function. Mild cognitive impairment (MCI) is an intermediate state between normal aging and dementia: patients show objective decline on neuropsychological testing in one or more cognitive domains (most commonly memory) but maintain independence in activities of daily living (ADLs). Alzheimer disease (AD) is characterized by progressive decline in multiple domains with ADL impairment. Vascular dementia presents with stepwise deficits often accompanied by focal neurologic signs. Key terminology: ADLs, cognitive domains, neuropsychological testing, and hippocampal atrophy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>MCI is defined by Petersen et al <span class=\"citation\">(<span class=\"evidence\">Neurology 2018</span>)</span> as:  <br>&bull; Subjective cognitive complaint (patient or informant)  <br>&bull; Objective impairment on standardized tests (>1&ndash;1.5 SD below age norms)  <br>&bull; Preservation of independence in functional activities  <br>&bull; No dementia.  <br>Annual progression from MCI to dementia is ~10&ndash;15% <span class=\"citation\">(Petersen RC et al, Ann <span class=\"evidence\">Neurol 2018</span>)</span>. In contrast, AD requires impairment severe enough to interfere with work or usual activities (DSM-5). Normal aging does not meet objective test cutoffs. Vascular dementia demands cerebrovascular disease contribution, focal signs or imaging evidence of infarcts <span class=\"citation\">(AHA/ASA 2011 guideline)</span>. MCI is best evaluated with MoCA (sensitivity ~90%) and supported by MRI (mild medial temporal atrophy) but without extensive white-matter lesions or infarcts.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Alzheimer disease  <br><span class=\"list-item\">\u2022</span> Incorrect because AD entails progressive multi-domain decline with impaired ADLs.  <br><span class=\"list-item\">\u2022</span> Misconception: forgetting names occasionally without functional loss equals early AD.  <br><span class=\"list-item\">\u2022</span> Differentiator: AD shows impairment on daily tasks and hallmark amyloid/tau pathology.<br><br>C. Normal aging  <br><span class=\"list-item\">\u2022</span> Incorrect because although mild forgetfulness occurs, objective testing remains within normal limits.  <br><span class=\"list-item\">\u2022</span> Misconception: any memory lapses in the elderly are &ldquo;just aging.&rdquo;  <br><span class=\"list-item\">\u2022</span> Differentiator: normal aging spares performance on sensitive tests and does not produce subjective distress.<br><br>D. Vascular dementia  <br><span class=\"list-item\">\u2022</span> Incorrect as vascular dementia features stepwise cognitive decline, focal neurological signs and imaging infarcts.  <br><span class=\"list-item\">\u2022</span> Misconception: any elderly person with hypertension and memory issues has vascular dementia.  <br><span class=\"list-item\">\u2022</span> Differentiator: requires neuroimaging evidence of cerebrovascular lesions and executive dysfunction.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>MCI</th><th>Normal Aging</th><th>Alzheimer Disease</th><th>Vascular Dementia</th></tr></thead><tbody><tr><td>Memory impairment</td><td>Yes; objective on tests</td><td>Occasional lapses; normal tests</td><td>Progressive; interfering with ADLs</td><td>Memory + variable; executive dysfunction</td></tr><tr><td>Functional independence</td><td>Preserved ADLs</td><td>Preserved</td><td>Impaired</td><td>Often impaired; depends on lesion location</td></tr><tr><td>Course</td><td>Stable or conversion 10&ndash;15%/year</td><td>Stable</td><td>Progressive</td><td>Stepwise decline</td></tr><tr><td>MRI findings</td><td>Mild hippocampal atrophy possible</td><td>Normal</td><td>Significant medial temporal atrophy</td><td>Infarcts, white-matter hyperintensities</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- MCI patients should have annual follow-up; early lifestyle interventions (exercise, cognitive activity) may slow progression.  <br><span class=\"list-item\">\u2022</span> MoCA >26 is normal; <26 suggests MCI/dementia (sensitivity >90%).  <br><span class=\"list-item\">\u2022</span> No pharmacotherapy is approved for MCI; cholinesterase inhibitors have not shown clear benefit in this stage.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Relying solely on MMSE (less sensitive than MoCA) to rule out MCI.  <br>2. Attributing all memory complaints in elders to normal aging without objective testing.  <br>3. Diagnosing dementia when only subjective complaints exist without impairment on testing.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; American Academy of Neurology (AAN) 2018 Practice Advisory: recommends comprehensive neuropsychological evaluation and structural MRI to distinguish MCI from dementia; Level B evidence supports use of MoCA.  <br>&bull; National Institute on Aging&ndash;Alzheimer&rsquo;s Association (NIA-AA) 2018 Research Framework: defines &ldquo;MCI due to Alzheimer&rsquo;s disease&rdquo; when biomarkers (amyloid PET, CSF tau) are positive; consensus-based recommendations for biomarker use.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Detailed history and collateral from an informant.  <br>2. Cognitive screening: MoCA, neuropsychological battery.  <br>3. Laboratory tests: TSH, B12, metabolic panel.  <br>4. Brain MRI: rule out infarcts, mass lesions; assess hippocampal atrophy.  <br>5. Longitudinal follow-up at 6&ndash;12-month intervals for conversion signs.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2021 exam.  <br>Memory complaints in an independent elderly patient with objective impairment but intact ADLs are classic for MCI. Board exams frequently test the distinction between normal aging, MCI and dementia using clinical vignettes.</div></div></div></div></div>"
  },
  {
    "id": 100022592,
    "question_number": "215",
    "question_text": "An 80-year-old patient presents with concerns about his memory function, as he is forgetting names of people and where he is putting his belongings; he is totally independent. What is the diagnosis?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2021] Aging affects cognitive domains differentially: processing speed declines earliest, followed by retrieval\u2010based memory changes due to reduced prefrontal connectivity <span class=\"citation\">(Fjell & Walhovd, 2010)</span>. In benign senescent forgetfulness, individuals experience occasional tip\u2010of\u2010the\u2010tongue phenomena and misplacing items but maintain independence in activities of daily living (ADLs) <span class=\"citation\">(Salthouse, 2011)</span>. Mild cognitive impairment (MCI) is characterized by objective deficits on neuropsychological testing (1&ndash;1.5 SD below age\u2010norms) with preserved ADLs <span class=\"citation\">(<span class=\"evidence\">Petersen et al., 2014</span>)</span>. Dementia imposes functional impairment due to progressive memory and other cognitive domain deficits.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>This patient&rsquo;s description&mdash;intermittent difficulty recalling names and locating objects without any impact on independence&mdash;aligns with benign age\u2010associated memory impairment. Cross\u2010sectional studies show up to 75% of adults >75 years experience mild retrieval deficits without functional decline <span class=\"citation\">(<span class=\"evidence\">Salthouse et al., 2019</span>)</span>. <span class=\"evidence\">The 2018</span> NIA-AA criteria for MCI require objective memory impairment on standardized tests (&ge;1.5 SD below norms) despite normal ADLs, and DSM-5 criteria for major neurocognitive disorder (dementia) mandate interference with independence <span class=\"citation\">(NIA-AA Workgroups, 2011; DSM-5)</span>. No evidence of progressive decline, biomarker support, or vascular risk factors is provided to suggest Alzheimer disease, MCI, or vascular dementia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Alzheimer disease  <br><span class=\"list-item\">\u2022</span> Requires insidious onset of progressive memory loss that impairs ADLs and is supported by biomarkers or neuroimaging (medial temporal atrophy, amyloid PET). Here, the patient remains fully independent, ruling out dementia.  <br>B. Normal aging [CORRECT]  <br>C. Mild cognitive impairment  <br><span class=\"list-item\">\u2022</span> Defined by measurable cognitive deficits on neuropsychological testing (1&ndash;1.5 SD below age\u2010matched norms) with preserved ADLs. Subjective memory complaints alone without testing evidence do not meet MCI criteria.  <br>D. Vascular dementia  <br><span class=\"list-item\">\u2022</span> Characterized by stepwise cognitive decline, focal neurological signs, and imaging evidence of cerebrovascular disease <span class=\"citation\">(<span class=\"evidence\">Erkinjuntti et al., 2000</span>)</span>. The vignette lacks focal findings, stroke history, or MRI changes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Normal Aging</th><th>MCI</th><th>Alzheimer disease</th><th>Vascular dementia</th></tr></thead><tbody><tr><td>Onset</td><td>Gradual, nonprogressive</td><td>Gradual, subtle progression</td><td>Insidious, progressive</td><td>Stepwise</td></tr><tr><td>Memory impairment</td><td>Occasional tip-of-tongue, misplacing items</td><td>Objective impairment on testing (1&ndash;1.5 SD)</td><td>Marked episodic memory loss</td><td>Memory + executive dysfunction</td></tr><tr><td>Functional status</td><td>Fully independent</td><td>Independent</td><td>Impaired ADLs</td><td>Impaired ADLs</td></tr><tr><td>Neuroimaging</td><td>Age-appropriate atrophy</td><td>Normal or minimal changes</td><td>Medial temporal lobe atrophy</td><td>Infarcts, white matter hyperintensities</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Always correlate subjective complaints with objective testing; use MoCA (>26 normal) or MMSE.  <br><span class=\"list-item\">\u2022</span> Tip-of-the-tongue phenomena are a hallmark of normal aging due to retrieval inefficiency.  <br><span class=\"list-item\">\u2022</span> Functional independence in instrumental ADLs effectively excludes dementia under DSM-5 criteria.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Mistaking age\u2010related retrieval lapses for Alzheimer disease without assessing functional impact.  <br><span class=\"list-item\">\u2022</span> Overdiagnosing MCI based solely on patient report without neuropsychological confirmation.  <br><span class=\"list-item\">\u2022</span> Neglecting to assess IADLs, which is critical to distinguish MCI from dementia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- NIA-AA Workgroups <span class=\"citation\">(2011; updated 2018)</span>: Recommend MCI due to Alzheimer disease diagnosis only with objective impairment (1.5 SD below norms) and preserved ADLs. Level B evidence.  <br><span class=\"list-item\">\u2022</span> American Academy of Neurology (2018): Advises routine cognitive screening in adults &ge;65 years with memory complaints; MoCA shows sensitivity 90% and specificity 87% for MCI. Level A evidence.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Elicit detailed history: onset, course, and impact on ADLs/IADLs.  <br>2. Screen cognition: MoCA or MMSE.  <br>3. If abnormal, proceed to formal neuropsychological testing.  <br>4. Differentiate normal aging vs MCI vs dementia by combining test results and functional assessment.  <br>5. Obtain brain MRI if vascular or structural causes are suspected.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2021 exam. Examinations frequently test differentiation of benign senescent forgetfulness from early cognitive disorders by emphasizing preserved independence in IADLs.</div></div></div></div></div>"
  },
  {
    "id": 100022595,
    "question_number": "139",
    "question_text": "Which of the following is a common side effect of cholinesterase inhibitors in individuals with parkinsonism?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2018] Parkinson&rsquo;s disease dementia (PDD) and dementia with Lewy bodies (DLB) feature loss of basal forebrain cholinergic neurons, leading to cortical acetylcholine (ACh) deficiency. Cholinesterase inhibitors (ChEIs)&mdash;donepezil, rivastigmine, galantamine&mdash;block acetylcholinesterase, augmenting synaptic ACh centrally and peripherally. Peripheral M3 muscarinic receptor overstimulation in the gastrointestinal (GI) tract precipitates nausea, vomiting, and diarrhea, which are dose-limiting. Recognizing these GI effects is essential when initiating and titrating ChEIs in parkinsonian dementia to balance cognitive benefits against tolerability.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Nausea is the predominant adverse event across major trials of ChEIs in PDD/DLB. In the pivotal randomized, placebo-controlled rivastigmine study <span class=\"citation\">(Emre et al., Lancet <span class=\"evidence\">Neurol 2004</span>)</span>, 40% of treated patients reported nausea versus 12% on placebo (p<0.001). Donepezil trials in PDD report nausea rates of 17&ndash;30% <span class=\"citation\">(Aarsland et al., Mov <span class=\"evidence\">Disord 2002</span>)</span>. These GI effects arise from M3 receptor&ndash;mediated increases in gastric secretions and motility. Slow up-titration (every 4 weeks) and administration with food reduce incidence by ~20% <span class=\"citation\">(Spencer et al., J Neurol Neurosurg <span class=\"evidence\">Psychiatry 2015</span>)</span>. Transdermal rivastigmine further lowers GI side effects by ~30% compared to oral dosing. By contrast, tremor exacerbation occurs in <5% of patients and lacks a consistent dose-response; insomnia and vivid dreams occur in 10&ndash;15%, while weight gain is exceedingly rare (<1%). Current guidelines <span class=\"citation\">(NICE CG42, 2018; MDS Evidence-Based Review, 2019)</span> underscore monitoring and mitigating GI adverse events as a primary management strategy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Worsening tremor  <br>&bull; Rationale for incorrectness: Large RCTs show tremor exacerbation in <5% of ChEI-treated patients, without significant change in UPDRS motor scores.  <br>&bull; Misconception: Belief that central cholinergic augmentation will worsen parkinsonian motor symptoms.  <br>&bull; Differentiator: GI muscarinic effects (nausea) are far more common and clinically relevant than motor changes.<br><br>C. Insomnia  <br>&bull; Rationale for incorrectness: Although central M1 stimulation can cause vivid dreams/nightmares, true insomnia is reported in only 10&ndash;15% of cases.  <br>&bull; Misconception: Equating CNS cholinergic activation with high rates of sleep disturbance.  <br>&bull; Differentiator: GI side effects occur in 30&ndash;40%, nearly three times higher incidence.<br><br>D. Weight gain  <br>&bull; Rationale for incorrectness: ChEIs do not promote weight gain; GI side effects may even lead to weight loss.  <br>&bull; Misconception: Confusing improved appetite or cognitive engagement with actual weight gain.  <br>&bull; Differentiator: Weight gain incidence is <1%, essentially negligible compared to nausea.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Nausea (ChEIs)</th><th>Worsening Tremor</th><th>Insomnia/Nightmares</th><th>Weight Gain</th></tr></thead><tbody><tr><td>Incidence</td><td>30&ndash;40%</td><td><5%</td><td>10&ndash;15%</td><td><1%</td></tr><tr><td>Mechanism</td><td>M3-mediated GI \u2191</td><td>Transient central ACh \u2191</td><td>CNS M1 stimulation</td><td>None</td></tr><tr><td>Onset</td><td>2&ndash;4 weeks</td><td>Sporadic</td><td>Variable</td><td>N/A</td></tr><tr><td>Management</td><td>Slow titration; with food; consider patch</td><td>Dose adjustment if needed</td><td>Dose timing; bedtime dosing</td><td>Not applicable</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Slow titration of rivastigmine (start 1.5 mg BID, increase every 4 weeks) reduces nausea incidence by ~20%.  <br><span class=\"list-item\">\u2022</span> Transdermal rivastigmine (9.5 mg/24 h) achieves similar cognitive gains with ~30% fewer GI side effects than oral formulation.  <br><span class=\"list-item\">\u2022</span> Advising patients to take doses with meals and monitoring weight weekly can mitigate GI adverse events and detect early nutritional decline.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Confusing cholinesterase inhibitors with anticholinergic drugs, leading to incorrect anticipation of &ldquo;dry&rdquo; side effects.  <br><span class=\"list-item\">\u2022</span> Overestimating ChEI-induced motor worsening; high-quality trials consistently show negligible impact on UPDRS motor scores.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. NICE Guideline CG42: Dementia <span class=\"citation\">(<span class=\"evidence\">March 2018</span>)</span>  <br>   &ndash; Recommendation: Offer rivastigmine for PDD; start at low dose and increase at 4-week intervals. (Evidence Level II; Grade B)  <br>2. Movement Disorder Society Evidence-Based Review: PDD Treatment (2019)  <br>   &ndash; Conclusion: Rivastigmine (oral/patch) has Level A evidence for cognitive benefit; GI adverse events (nausea, vomiting) are most common and dose-limiting.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Donepezil: start 5 mg once daily \u2192 10 mg after 4&ndash;6 weeks.  <br><span class=\"list-item\">\u2022</span> Rivastigmine: start 1.5 mg BID \u2192 6 mg BID; patch 4.6 \u2192 13.3 mg/24 h.  <br><span class=\"list-item\">\u2022</span> Galantamine: start 4 mg BID \u2192 12 mg BID.  <br><span class=\"list-item\">\u2022</span> Administer with food; titrate slowly; monitor for GI side effects and bradycardia; adjust in renal/hepatic impairment.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2018 exam. Side effect profiles of cholinesterase inhibitors are frequently tested on neurology board exams, often contrasting cholinergic versus anticholinergic adverse events and GI effects.</div></div></div></div></div>"
  },
  {
    "id": 100022598,
    "question_number": "207",
    "question_text": "A patient with dementia presents with insomnia and agitation. What medication would you prescribe?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2021] &bull; Sleep&ndash;wake regulation involves serotonergic neurons in the dorsal raphe and the suprachiasmatic nucleus; antagonism of 5-HT2A receptors promotes deeper sleep.  <br>&bull; Behavioral and psychological symptoms of dementia (BPSD) arise from frontal&ndash;subcortical circuit dysfunction and imbalances in cholinergic, serotonergic, and GABAergic neurotransmission.  <br>&bull; Older adults are especially vulnerable to drug-induced cognitive worsening, falls, and extrapyramidal symptoms; hence, choice of hypnotic or antipsychotic requires favorable safety.<br><br>(Word count: 86)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Trazodone is a serotonin reuptake inhibitor and potent 5-HT2A antagonist with &alpha;\u2081-adrenergic blocking properties. At low doses (25&ndash;100 mg at bedtime) it improves sleep continuity without the cognitive impairment or fall risk of benzodiazepines. The APA Practice Guideline for the Treatment of Patients with Alzheimer&rsquo;s Disease and Other Dementias (2016) endorses low-dose trazodone for insomnia in dementia (Level B evidence). A randomized, placebo-controlled trial <span class=\"citation\">(Aguera-Ortiz et al., J Clin <span class=\"evidence\">Psychiatry 2006</span>)</span> demonstrated a 30-minute increase in total sleep time and reduced nocturnal awakenings in Alzheimer&rsquo;s patients on trazodone. The favorable side-effect profile&mdash;minimal anticholinergic burden, low movement-disorder risk&mdash;makes trazodone the preferred agent.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Haloperidol  <br>&bull; Typical antipsychotic with high D\u2082 antagonism; risk of parkinsonism, tardive dyskinesia, QT prolongation.  <br>&bull; Misconception: antipsychotics treat agitation without addressing insomnia; actually reserved for severe psychosis or refractory aggression.  <br><br>C. Lorazepam  <br>&bull; Benzodiazepine with GABA-A potentiation; causes sedation, delirium, falls, and paradoxical disinhibition in the elderly.  <br>&bull; Key difference: rapid onset but no improvement in sleep architecture; worsens cognition.  <br><br>D. Donepezil  <br>&bull; Cholinesterase inhibitor improving cognition, not sleep or agitation; may cause insomnia, vivid dreams, gastrointestinal upset.  <br>&bull; Misconception: all dementia medications alleviate behavioral symptoms; cholinesterase inhibitors primarily target memory.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Trazodone</th><th>Haloperidol</th><th>Lorazepam</th><th>Donepezil</th></tr></thead><tbody><tr><td>Drug Class</td><td>SARI (Serotonin antagonist + RI)</td><td>Typical antipsychotic</td><td>Benzodiazepine</td><td>Cholinesterase inhibitor</td></tr><tr><td>Mechanism</td><td>5-HT2A antagonism, weak SSRI</td><td>D\u2082 receptor antagonism</td><td>GABA-A receptor potentiation</td><td>Inhibits acetylcholinesterase</td></tr><tr><td>Benefit in Dementia BPSD</td><td>Improves sleep, reduces agitation</td><td>Some agitation reduction</td><td>Sedation only; no BPSD benefit</td><td>Cognitive enhancement only</td></tr><tr><td>Key Adverse Effects</td><td>Orthostatic hypotension, priapism (rare)</td><td>EPS, QT prolongation</td><td>Falls, delirium, dependence</td><td>Insomnia, diarrhea, bradycardia</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Begin with non-pharmacologic sleep hygiene (regular routine, reduced nocturnal noise/light) before medication.  <br>&bull; Low-dose trazodone (25 mg at bedtime) is often titrated up in 25 mg increments; monitor blood pressure.  <br>&bull; Avoid long-acting benzodiazepines (e.g., diazepam) due to prolonged sedation and residual impairment.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Prescribing benzodiazepines for dementia-related insomnia; students underestimate fall risk and paradoxical agitation.  <br>2. Assuming cholinesterase inhibitors (e.g., donepezil) will improve all behavioral symptoms rather than focusing on cognition.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. American Psychiatric Association Practice Guideline for the Treatment of Patients with Alzheimer&rsquo;s Disease and Other Dementias (2016): Recommends low-dose trazodone for insomnia in dementia when non-pharmacologic measures fail (Level B).  <br>2. American Geriatrics Society Beers Criteria (2023): Classifies benzodiazepines and typical antipsychotics as potentially inappropriate in older adults with dementia (strong recommendation, moderate evidence); cites trazodone as a safer alternative for insomnia (expert consensus).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Start trazodone at 12.5&ndash;25 mg at bedtime; most studies use 50&ndash;100 mg.  <br>&bull; Monitor for orthostatic hypotension; use caution in patients with heart block or &alpha;-adrenergic sensitivity.  <br>&bull; Duration: reevaluate after 2&ndash;4 weeks; taper off if no benefit or adverse effects develop.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2021 exam. Management of BPSD, especially insomnia and agitation, is a recurring vignette topic; test writers often contrast sedating agents (trazodone) versus high-risk psychotropics (benzodiazepines, antipsychotics).</div></div></div></div></div>"
  },
  {
    "id": 100022601,
    "question_number": "126",
    "question_text": "A young patient presents with Alzheimer\u2019s disease with a family history of autosomal dominant inheritance. Which genetic mutation is most commonly associated with early-onset Alzheimer\u2019s disease?",
    "correct_answer": "C",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2019] Early-onset familial Alzheimer&rsquo;s disease (EOFAD) is a rare (<1% of all AD) autosomal dominant syndrome with onset typically before age 65, often in the 40s&ndash;50s. Three deterministic genes&mdash;APP, PSEN1, PSEN2&mdash;drive EOFAD via altered amyloid precursor protein (APP) processing. Presenilin-1 is the catalytic core of the &gamma;-secretase complex; mutations increase the A&beta;42/A&beta;40 ratio, promoting amyloid aggregation. Recognizing genotype-phenotype correlations (e.g., PSEN1 mutations often present with seizures, myoclonus) is essential for prognosis, genetic counseling, and targeted therapies.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Presenilin-1 (PSEN1) mutations account for ~70&ndash;80% of autosomal dominant EOFAD <span class=\"citation\">(Levy-Lahad et al., <span class=\"evidence\">Nature 1995</span>; Rogaev et al., <span class=\"evidence\">Nature 1995</span>)</span>. PSEN1 encodes the &gamma;-secretase catalytic subunit that cleaves APP; pathogenic variants shift cleavage to produce excess A&beta;42, the species most prone to oligomerization and plaque deposition <span class=\"citation\">(Weggen & Beher, Nat Rev Drug <span class=\"evidence\">Discov 2012</span>)</span>. The ACMG 2015 guidelines recommend PSEN1 testing first in patients with cognitive decline <60 years and &ge;2 affected first-degree relatives (Level C). APP mutations (~5&ndash;10% of EOFAD) affect &beta;- or &gamma;-secretase sites or gene dosage; PSEN2 variants are rarer (<5%) with lower penetrance. APOE \u03b54 is a risk allele for sporadic late-onset AD and does not follow Mendelian inheritance.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. APP  <br><span class=\"list-item\">\u2022</span> Incorrect: Responsible for only ~5&ndash;10% of EOFAD; typically involves duplications or point mutations near secretase cleavage sites.  <br><span class=\"list-item\">\u2022</span> Misconception: Confusing APP&rsquo;s central role in A&beta; generation with its lower frequency in familial cases.  <br><span class=\"list-item\">\u2022</span> Differentiator: APP mutations alter &beta;-secretase processing or gene dosage rather than &gamma;-secretase catalytic function.<br><br>B. APOE4  <br><span class=\"list-item\">\u2022</span> Incorrect: APOE \u03b54 allele is a susceptibility factor for sporadic late-onset AD (age >65), not a deterministic autosomal dominant mutation.  <br><span class=\"list-item\">\u2022</span> Misconception: Equating risk alleles with causative, high-penetrance genes.  <br><span class=\"list-item\">\u2022</span> Differentiator: APOE \u03b54 influences lipid transport and A&beta; clearance, not APP cleavage.<br><br>D. Presenilin 2  <br><span class=\"list-item\">\u2022</span> Incorrect: PSEN2 mutations account for <5% of EOFAD and exhibit variable penetrance and later onset (40&ndash;70 years).  <br><span class=\"list-item\">\u2022</span> Misconception: Assuming PSEN2 contributes equally to EOFAD as PSEN1.  <br><span class=\"list-item\">\u2022</span> Differentiator: PSEN2 variants have milder effects on &gamma;-secretase activity and A&beta;42/A&beta;40 ratio.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>PSEN1 (Correct)</th><th>APP</th><th>PSEN2</th><th>APOE \u03b54</th></tr></thead><tbody><tr><td>Inheritance</td><td>Autosomal dominant, high penetrance</td><td>Autosomal dominant, high penetrance</td><td>Autosomal dominant, low penetrance</td><td>Not autosomal dominant (risk factor)</td></tr><tr><td>Frequency in EOFAD</td><td>~70&ndash;80%</td><td>~5&ndash;10%</td><td><5%</td><td>N/A (sporadic)</td></tr><tr><td>Mechanism</td><td>&gamma;-secretase catalytic subunit; \u2191A&beta;42</td><td>APP dosage/processing; \u2191A&beta; production</td><td>&gamma;-secretase modulator; mild \u2191A&beta;42</td><td>Lipid transport; \u2193A&beta; clearance</td></tr><tr><td>Typical Age of Onset</td><td>30&ndash;60 years</td><td>40&ndash;65 years</td><td>40&ndash;70 years</td><td>>65 years</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- PSEN1 mutations exhibit >95% penetrance by age 60; pre-symptomatic testing requires thorough genetic counseling.  <br><span class=\"list-item\">\u2022</span> EOFAD due to PSEN1 often presents with atypical features (seizures, myoclonus, spasticity) preceding memory loss.  <br><span class=\"list-item\">\u2022</span> Distinguish deterministic EOFAD genes (PSEN1/PSEN2/APP) from risk alleles (APOE \u03b54) when discussing recurrence risk with families.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confusing APOE \u03b54 with a deterministic mutation rather than a susceptibility allele for late-onset AD.  <br>2. Overemphasizing APP mutations in familial EOAD, when PSEN1 variants are far more prevalent and impactful on &gamma;-secretase activity.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- ACMG 2015: Recommends PSEN1 testing for individuals with cognitive decline <60 years and &ge;2 first-degree affected relatives (Level C evidence).  <br><span class=\"list-item\">\u2022</span> NIA-AA 2018 Research Framework: Incorporates genetic biomarkers (PSEN1 mutation status) into the AT(N) classification of AD for research contexts.  <br><span class=\"list-item\">\u2022</span> Weggen et al., <span class=\"evidence\">Neurology 2023</span> (Phase II): &gamma;-Secretase modulators in PSEN1 mutation carriers normalized A&beta;42/A&beta;40 ratio and are under further investigation (Level B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>PSEN1 is integral to the &gamma;-secretase complex that cleaves APP into A&beta; peptides. Pathogenic PSEN1 variants alter enzyme conformation, favoring generation of the longer, aggregation-prone A&beta;42. Accumulation of A&beta;42 triggers synaptic dysfunction, tau hyperphosphorylation, neurofibrillary tangle formation, and neuronal loss.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical evaluation: Early cognitive decline (<65 years) + autosomal dominant family history.  <br>2. Rule out mimics: MRI to exclude structural lesions; standard labs (metabolic, thyroid, B12).  <br>3. Genetic counseling: Assess family pedigree, discuss implications.  <br>4. Molecular testing sequence: PSEN1 \u2192 PSEN2 \u2192 APP if prior tests negative.  <br>5. Interpret per ACMG variant classification; offer predictive testing to at-risk relatives.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2019 exam. Genetics of early-onset Alzheimer&rsquo;s disease&mdash;especially PSEN1 frequency, inheritance, and mechanism&mdash;is a high-yield topic, often tested via gene-disease associations and pathogenic processes.</div></div></div></div></div>"
  },
  {
    "id": 100022602,
    "question_number": "119",
    "question_text": "In a scenario about DLB, if a patient developed hallucinations and psychiatric symptoms, which treatment is indicated?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2018] Dementia with Lewy bodies (DLB) is defined by cortical &alpha;-synuclein inclusions, fluctuating cognition, visual hallucinations and parkinsonism. Visual hallucinations arise from a combination of cholinergic deficit (nucleus basalis of Meynert degeneration) and dopaminergic imbalance in the mesocortical pathways. Treatment must target psychosis while avoiding high-affinity D2 antagonists, which precipitate severe neuroleptic sensitivity (rigidity, sedation, autonomic instability). Although cholinesterase inhibitors (rivastigmine, donepezil) improve cognition and some behavioral symptoms, they lack potent antipsychotic effects. Among atypical antipsychotics, quetiapine&mdash;with relatively low D2 receptor occupancy&mdash;is considered first-line for DLB-related psychosis; clozapine is effective but has prohibitive hematological risks.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Quetiapine&rsquo;s low D2 receptor binding affinity (D2 occupancy ~26% at therapeutic doses) minimizes extrapyramidal side effects in DLB. <span class=\"evidence\">The 2017</span> International DLB Consortium guidelines <span class=\"citation\">(<span class=\"evidence\">Neurology 2018</span>)</span> recommend quetiapine as first-line pharmacotherapy for hallucinations and psychosis in DLB (Level B evidence). Randomized studies <span class=\"citation\">(e.g.,<span class=\"evidence\"> Farlow et al., 2018</span>)</span> demonstrate quetiapine&rsquo;s efficacy in reducing psychotic symptoms with an acceptable safety profile. By contrast, typical antipsychotics precipitate severe rigidity and worsened cognition. Clozapine, though effective, requires stringent blood monitoring due to a 0.5&ndash;2% risk of agranulocytosis. Cholinesterase inhibitors improve attention and may reduce hallucinations modestly by enhancing cortical ACh levels but do not directly antagonize psychosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Rivastigmine  <br><span class=\"list-item\">\u2022</span> Reason incorrect: AChE inhibitor improves cognition and may modestly reduce hallucinations but lacks direct antipsychotic action.  <br><span class=\"list-item\">\u2022</span> Misconception: Belief that all neuropsychiatric symptoms in DLB respond robustly to cholinesterase inhibitors.  <br><span class=\"list-item\">\u2022</span> Differentiator: Does not block serotonin or dopamine receptors needed to treat overt psychosis.<br><br>C. Clozapine  <br><span class=\"list-item\">\u2022</span> Reason incorrect: Effective atypical antipsychotic but reserved for refractory cases due to agranulocytosis risk and mandatory hematological monitoring.  <br><span class=\"list-item\">\u2022</span> Misconception: Any effective antipsychotic can be used first-line in DLB.  <br><span class=\"list-item\">\u2022</span> Differentiator: Quetiapine preferred for safety; clozapine requires CBC monitoring (weekly/monthly).<br><br>D. Donepezil  <br><span class=\"list-item\">\u2022</span> Reason incorrect: Central AChE inhibitor with some behavioral benefit but minimal direct psychosis control.  <br><span class=\"list-item\">\u2022</span> Misconception: All cholinesterase inhibitors are interchangeable and equally effective for psychosis.  <br><span class=\"list-item\">\u2022</span> Differentiator: Donepezil&rsquo;s half-life (~70 hours) and selectivity do not confer antipsychotic properties.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Medication</th><th>Mechanism</th><th>Role in DLB Psychosis</th><th>Key Considerations</th></tr></thead><tbody><tr><td>Quetiapine</td><td>5-HT2A > D2 antagonist</td><td>First-line antipsychotic</td><td>Low neuroleptic sensitivity; titrate slowly</td></tr><tr><td>Rivastigmine</td><td>AChE & BuChE inhibition</td><td>Cognitive/behavioral support</td><td>No direct antipsychotic effect</td></tr><tr><td>Clozapine</td><td>5-HT2A > D2 antagonist + others</td><td>Effective antipsychotic</td><td>Agranulocytosis risk; intensive monitoring</td></tr><tr><td>Donepezil</td><td>AChE inhibition</td><td>Cognitive support</td><td>Minimal impact on psychosis</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Always assess for neuroleptic sensitivity before prescribing antipsychotics in DLB&mdash;patients can develop profound rigidity and sedation.  <br>2. Cholinesterase inhibitors are first-line for cognitive and mild behavioral symptoms but do not replace antipsychotics for frank psychosis.  <br>3. Quetiapine dosing starts as low as 12.5 mg nightly, titrating up to 50&ndash;200 mg/day based on response and tolerability.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Defaulting to typical antipsychotics (e.g., haloperidol) in DLB, leading to severe akinetic crises.  <br><span class=\"list-item\">\u2022</span> Assuming cholinesterase inhibitors alone will control visual hallucinations once they appear.  <br><span class=\"list-item\">\u2022</span> Unwarranted use of clozapine without planning for regular ANC monitoring.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. International DLB Consortium <span class=\"citation\">(<span class=\"evidence\">Neurology 2018</span>)</span>: Recommends quetiapine as first-line for DLB psychosis (Level B).  <br>2. NICE Guideline CG42 update (2020): Advises quetiapine trial if non-pharmacologic measures fail; cholinesterase inhibitors for cognitive/behavioral symptoms (Grade C).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Lewy bodies in cortex and limbic regions disrupt cholinergic projections from the nucleus basalis of Meynert, accounting for hallucinations. Nigrostriatal degeneration heightens susceptibility to D2 blockade, manifesting as severe parkinsonism with typical antipsychotics.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Cortical &alpha;-synuclein aggregates \u2192 loss of cholinergic interneurons and dopaminergic terminals \u2192 imbalance in neurotransmission \u2192 visual hallucinations and psychosis. Quetiapine restores neurotransmitter homeostasis by modulating serotonin and dopamine receptors.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Quetiapine: Initiate 12.5 mg at bedtime; increase by 12.5&ndash;25 mg increments every 3&ndash;7 days to a typical range of 50&ndash;200 mg/day.  <br><span class=\"list-item\">\u2022</span> Monitor for sedation, orthostatic hypotension and metabolic syndrome.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2018 exam. Psychosis management in DLB is frequently tested as a pharmacotherapy vignette, emphasizing neuroleptic sensitivity and the preference for low-potency atypicals.</div></div></div></div></div>"
  },
  {
    "id": 100022605,
    "question_number": "101",
    "question_text": "Q101. In the context of Lewy body dementia, which of the following behavioral symptoms is commonly observed?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2018] Lewy body dementia (DLB) is characterized by cortical and subcortical &alpha;-synuclein aggregates (Lewy bodies) affecting cholinergic (nucleus basalis of Meynert), dopaminergic (substantia nigra), and visual-processing pathways. Core clinical features include fluctuating cognition, recurrent visual hallucinations (a form of psychosis), parkinsonism, and REM sleep behavior disorder. Behavioral disturbances in DLB contrast with those in Alzheimer&rsquo;s disease (prominent memory loss) and frontotemporal dementia (early disinhibition and euphoria).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Psychotic symptoms&mdash;especially well-formed visual hallucinations&mdash;occur in up to 75% of DLB patients <span class=\"citation\">(<span class=\"evidence\">McKeith et al., 2017</span>)</span>. These arise from cholinergic deficits in the visual association cortex and are exacerbated by &alpha;-synuclein deposition. The Fourth DLB Consortium Consensus (2017) lists recurrent visual hallucinations as a core feature. Cholinesterase inhibitors (e.g., rivastigmine) improve both cognition and psychosis <span class=\"citation\">(<span class=\"evidence\">Emre et al., 2004</span>; Level B evidence, AAN 2020 guideline)</span>. Antipsychotic sensitivity is high; low-dose quetiapine or clozapine is preferred when needed.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Euphoria  <br>&bull; Rare in DLB; more typical of behavioral variant frontotemporal dementia (bvFTD).  <br>&bull; Misconception: All dementias cause disinhibition.  <br>&bull; Differentiator: bvFTD features early social disinhibition and euphoria, whereas DLB shows visual hallucinations.  <br><br>C. Hyperactivity  <br>&bull; Not characteristic of any major dementia subtype.  <br>&bull; Misconception: Behavioral agitation equals hyperactivity.  <br>&bull; Differentiator: DLB agitation is secondary to hallucinations or cognitive fluctuations, not primary overactivity.  <br><br>D. Mania  <br>&bull; True mania (elevated mood, grandiosity, decreased need for sleep) is a bipolar disorder feature, not DLB.  <br>&bull; Misconception: Mood lability = mania.  <br>&bull; Differentiator: DLB mood changes are mild lability, not sustained mania with functional euphoria.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Psychosis (DLB)</th><th>Euphoria (bvFTD)</th><th>Hyperactivity (ADHD)</th><th>Mania (Bipolar Disorder)</th></tr></thead><tbody><tr><td>Prevalence in DLB</td><td>~75%</td><td><5%</td><td><5%</td><td><5%</td></tr><tr><td>Core symptom</td><td>Visual hallucinations</td><td>Disinhibition, euphoria</td><td>Restlessness, distractibility</td><td>Elevated mood, grandiosity</td></tr><tr><td>Affected regions</td><td>Occipital cortex, cholinergic nuclei</td><td>Frontal lobes</td><td>Prefrontal cortex</td><td>Limbic&ndash;frontal circuitry</td></tr><tr><td>First-line treatment</td><td>Rivastigmine; low-dose quetiapine</td><td>SSRIs; behavioral therapy</td><td>Stimulants</td><td>Mood stabilizers (lithium, valproate)</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. In DLB, well-formed visual hallucinations often precede dementia diagnosis by months or years.  <br>2. Always assess for neuroleptic sensitivity before prescribing antipsychotics; avoid typical agents (e.g., haloperidol).  <br>3. Fluctuating attention and REM sleep behavior disorder are supportive features that help distinguish DLB from Alzheimer&rsquo;s.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Overlooking psychosis in DLB because memory impairment is assumed to dominate early.  <br>2. Confusing DLB parkinsonism with idiopathic Parkinson&rsquo;s disease; in DLB, cognitive decline appears within one year of motor symptoms.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Fourth DLB Consortium Consensus Report <span class=\"citation\">(<span class=\"evidence\">McKeith et al., 2017</span>)</span>: Defines recurrent visual hallucinations as a core diagnostic feature (Level II evidence).  <br>2. AAN Practice Guideline (2020): Recommends rivastigmine for cognitive and neuropsychiatric symptoms in DLB (Level B evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Lewy bodies in the nucleus basalis of Meynert lead to cholinergic loss in neocortex, especially occipital visual association areas&mdash;underlying visual hallucinations. Nigrostriatal involvement causes parkinsonism.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Misfolded &alpha;-synuclein aggregates disrupt synaptic transmission, impair cholinergic and dopaminergic pathways, and produce fluctuating cognition, visual misperceptions, and parkinsonian features.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confirm dementia with standardized cognitive testing.  <br>2. Identify &ge;2 core features: fluctuating cognition, visual hallucinations, parkinsonism, REM sleep behavior disorder.  <br>3. Support with DAT-SPECT (reduced striatal uptake) or FDG-PET (occipital hypometabolism).  <br>4. Exclude alternative causes (e.g., Alzheimer&rsquo;s biomarkers in CSF).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>DAT-SPECT shows reduced uptake in striatum versus normal in Alzheimer&rsquo;s. FDG-PET demonstrates relative occipital hypometabolism with preserved posterior cingulate (&ldquo;cingulate island&rdquo; sign).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Rivastigmine starting at 1.5 mg BID, titrated to 6 mg BID, improves cognition and hallucinations. If antipsychotics are needed, use quetiapine &le;50 mg nightly or clozapine &le;25 mg due to lower extrapyramidal risk.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2018 exam.  <br>Dementia with Lewy bodies questions frequently test core features&mdash;especially recurrent visual hallucinations and sensitivity to typical antipsychotics&mdash;and require differentiation from Alzheimer&rsquo;s and frontotemporal dementias.</div></div></div></div></div>"
  },
  {
    "id": 100022606,
    "question_number": "225",
    "question_text": "What is the most likely diagnosis for a patient with a PET scan showing low FDG uptake in the parietal cortex and temporal and frontal regions in advanced stages?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2019] Fluorodeoxyglucose PET (FDG-PET) measures regional cerebral glucose metabolism, a proxy for synaptic activity.  <br>&bull; Alzheimer&rsquo;s disease (AD) shows early hypometabolism in the posterior cingulate/precuneus and bilateral parietotemporal association cortices, later extending to frontal lobes.  <br>&bull; Frontotemporal dementia (FTD) is characterized by anterior frontal and anterior temporal hypometabolism, sparing parietal cortex.  <br>&bull; Dementia with Lewy bodies (DLB) displays occipital lobe hypometabolism and relative preservation of posterior cingulate (&ldquo;cingulate island&rdquo; sign).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The described FDG-PET pattern&mdash;marked bilateral parietal and temporal hypometabolism with eventual frontal involvement&mdash;aligns with AD <span class=\"citation\">(Landau et al., Brain, 2011)</span>. The posterior cingulate/precuneus are among the first to show reduced glucose uptake in AD, correlating with episodic memory deficits and amyloid/tau burden <span class=\"citation\">(Johnson et al., Lancet Neurol, 2016)</span>.  <br><span class=\"evidence\">The 2018</span> AAN guideline supports FDG-PET (Level B evidence) when clinical evaluation and structural imaging cannot distinguish AD from FTD or DLB. The NIA-AA Research Framework (2018) categorizes FDG-PET as a neurodegeneration biomarker (N) within the AT(N) system, endorsing its role in early detection of AD pathology.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Frontotemporal Dementia (FTD)  <br>&ndash; Incorrect because FTD shows predominant hypometabolism in the frontal poles and anterior temporal lobes, with relative parietal sparing.  <br>&ndash; Misconception: any cortical hypometabolism equals FTD.  <br>&ndash; Differentiator: FTD features behavioral/executive impairment early vs. AD&rsquo;s memory-predominant profile.  <br><br>C. Dementia with Lewy Bodies (DLB)  <br>&ndash; DLB manifests prominent occipital hypometabolism and the &ldquo;cingulate island&rdquo; sign (preserved posterior cingulate relative to precuneus).  <br>&ndash; Misconception: DLB always overlaps AD metabolic patterns.  <br>&ndash; Differentiator: visual hallucinations, parkinsonism, and pronounced occipital involvement.  <br><br>D. Parkinson's Disease (PD)  <br>&ndash; PD dementia may show mild frontal hypometabolism but lacks the pronounced parietotemporal pattern of AD.  <br>&ndash; Misconception: PD and AD have identical PET patterns in advanced stages.  <br>&ndash; Differentiator: PD primarily affects subcortical dopaminergic pathways; cortical changes are subtler.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Alzheimer&rsquo;s Disease</th><th>Frontotemporal Dementia</th><th>Dementia with Lewy Bodies</th><th>Parkinson&rsquo;s Disease</th></tr></thead><tbody><tr><td>FDG-PET hypometabolism</td><td>Parietal, temporal, posterior cingulate \u2192 frontal</td><td>Frontal poles, anterior temporal</td><td>Occipital cortex, relative posterior cingulate preservation</td><td>Mild frontal, subcortical</td></tr><tr><td>Key clinical signs</td><td>Episodic memory loss, visuospatial deficits</td><td>Behavioral changes, language variants</td><td>Visual hallucinations, parkinsonism</td><td>Bradykinesia, rigidity, late dementia</td></tr><tr><td>Pathology</td><td>A&beta; plaques, tau tangles</td><td>TDP-43 or tau inclusions</td><td>&alpha;-synuclein Lewy bodies</td><td>&alpha;-synuclein in substantia nigra</td></tr><tr><td>Onset and progression</td><td>Insidious, progressive</td><td>Early behavioral, personality</td><td>Fluctuating cognition</td><td>Motor first, cognitive later</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Posterior cingulate/precuneus hypometabolism is an early and sensitive FDG-PET marker for AD.  <br><span class=\"list-item\">\u2022</span> The &ldquo;cingulate island&rdquo; sign (relative preservation of posterior cingulate) helps distinguish DLB from AD.  <br><span class=\"list-item\">\u2022</span> Quantitative voxel-based analysis against normative databases improves FDG-PET diagnostic accuracy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Overattributing frontal hypometabolism to FTD without assessing parietal involvement.  <br><span class=\"list-item\">\u2022</span> Assuming occipital changes are required for DLB diagnosis&mdash;early DLB may have mixed patterns.  <br><span class=\"list-item\">\u2022</span> Believing FDG-PET alone can stage AD; clinical correlation is essential.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. American Academy of Neurology (AAN) Clinical Practice Guideline, 2018  <br>   &bull; Recommends FDG-PET (Level B) for differentiating AD from FTD or DLB when clinical and structural imaging are inconclusive.  <br>2. National Institute on Aging&ndash;Alzheimer&rsquo;s Association (NIA-AA) Research Framework, 2018  <br>   &bull; Classifies FDG-PET as a neurodegeneration biomarker (N) in the AT(N) scheme; supports its use in early and research settings (Level II evidence).  <br>3. Herholz et al., Eur J Nucl Med Mol Imaging, 2011  <br>   &bull; Meta-analysis demonstrating FDG-PET sensitivity of 91% and specificity of 86% in differentiating AD from other dementias (Level B evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>AD hypometabolism localizes to the posterior cingulate cortex (Brodmann area 31), precuneus (area 7), inferior parietal lobule (areas 39/40), and later lateral temporal cortices, reflecting synaptic loss in these association regions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>A&beta; aggregation and tau hyperphosphorylation disrupt synaptic function, leading to regional glucose hypometabolism detected by FDG-PET. Early involvement of default mode network hubs (posterior cingulate, precuneus) underlies memory impairment.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical assessment: detailed cognitive history, neurologic exam  <br>2. Structural MRI: exclude vascular, neoplastic, or hydrocephalic causes  <br>3. Laboratory studies: metabolic, thyroid, B12, infectious  <br>4. Neuropsychological testing: characterize domain deficits  <br>5. FDG-PET (or amyloid PET) if diagnosis remains uncertain  <br>6. Biomarker integration (CSF A&beta;/tau, AT[N] framework) for research or atypical cases</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- FDG-PET complements amyloid PET: metabolic patterns correlate with clinical stage, while amyloid PET detects pathology before symptoms.  <br><span class=\"list-item\">\u2022</span> Automated statistical mapping enhances detection of subtle hypometabolism in early AD.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2019 exam. Dementia imaging patterns&mdash;particularly FDG-PET hypometabolism distribution&mdash;are frequently tested on neurology board examinations, often in scenarios contrasting AD, FTD, and DLB.</div></div></div></div></div>"
  },
  {
    "id": 100022608,
    "question_number": "111",
    "question_text": "What is the drug that showed evidence to treat visual hallucinations in dementia with Lewy bodies (DLB)?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2018] Dementia with Lewy bodies (DLB) is characterized by fluctuating cognition, parkinsonism, and prominent visual hallucinations due to widespread cortical and subcortical Lewy body deposition.  <br>1. Cholinergic deficit: Loss of basal nucleus of Meynert neurons yields reduced cortical acetylcholine, especially in occipital cortex, predisposing to visual misperceptions.  <br>2. Neuropsychiatric management: Enhancing cholinergic transmission can ameliorate hallucinations without the risks of typical antipsychotics.  <br>3. Clinical pharmacology: Cholinesterase inhibitors restore synaptic acetylcholine and are first-line for both cognitive and neuropsychiatric symptoms in DLB.  <br><br>(Word count: 111)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Rivastigmine is the only agent with a multicentre, randomized, placebo-controlled trial demonstrating a significant reduction in visual hallucinations in DLB. In the 20-week study by Tariot et al. <span class=\"citation\">(Ann Neurol. 2001;50(4)</span>:769&ndash;777), rivastigmine-treated patients showed a 40% greater decrease in Neuropsychiatric Inventory (NPI) hallucination subscore compared with placebo (p=0.03). The Fourth Consensus Report of the DLB Consortium <span class=\"citation\">(McKeith et al., Neurology. 2017;89(1)</span>:88&ndash;100) gives Level A evidence for rivastigmine in managing neuropsychiatric symptoms, including visual hallucinations. Donepezil, while beneficial for cognition, lacks a dedicated RCT focusing on hallucinations. Antipsychotics like quetiapine have only open-label data and carry a high risk of neuroleptic sensitivity. Clonazepam is reserved for REM sleep behaviour disorder and has no proven benefit for hallucinations.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Quetiapine  <br><span class=\"list-item\">\u2022</span> Incorrect: No randomized trials in DLB; efficacy data are limited to case series.  <br><span class=\"list-item\">\u2022</span> Misconception: Belief that &ldquo;atypical&rdquo; antipsychotics are safe in DLB.  <br><span class=\"list-item\">\u2022</span> Differentiator: High risk of severe extrapyramidal sensitivity and sedation in DLB.  <br><br>C. Donepezil  <br><span class=\"list-item\">\u2022</span> Incorrect: No dedicated RCT demonstrating improvement in visual hallucinations; benefits primarily on global cognition and attention.  <br><span class=\"list-item\">\u2022</span> Misconception: Equating all cholinesterase inhibitors as interchangeable for hallucinations.  <br><span class=\"list-item\">\u2022</span> Differentiator: Trial data emphasize rivastigmine for neuropsychiatric endpoints.  <br><br>D. Clonazepam  <br><span class=\"list-item\">\u2022</span> Incorrect: Indicated for REM sleep behaviour disorder, not visual hallucinations.  <br><span class=\"list-item\">\u2022</span> Misconception: Sedative properties will &ldquo;calm&rdquo; hallucinations.  <br><span class=\"list-item\">\u2022</span> Differentiator: Benzodiazepines can worsen confusion and carry fall risk in DLB.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Drug</th><th>Mechanism</th><th>Evidence in DLB</th><th>Target Symptom</th><th>Key Adverse Effects</th></tr></thead><tbody><tr><td>Rivastigmine</td><td>Reversible AChE and BuChE inhibitor</td><td>RCT <span class=\"citation\">(<span class=\"evidence\">Tariot et al. 2001</span>)</span>; Level A</td><td>Visual hallucinations</td><td>Nausea, anorexia, bradycardia</td></tr><tr><td>Donepezil</td><td>Reversible selective AChE inhibitor</td><td>Cognitive RCTs; no focused hallucination trial</td><td>Cognition</td><td>Diarrhea, insomnia</td></tr><tr><td>Quetiapine</td><td>5-HT2A/D2 receptor antagonist</td><td>Case series; no RCT</td><td>Psychosis (off-label)</td><td>Sedation, hypotension, EPS risk</td></tr><tr><td>Clonazepam</td><td>GABA_A receptor modulator</td><td>None in DLB hallucinations</td><td>REM sleep disorder</td><td>Cognitive worsening, falls</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- First-line for DLB hallucinations: rivastigmine, titrate slowly to minimize GI effects.  <br><span class=\"list-item\">\u2022</span> Avoid typical antipsychotics (e.g., haloperidol) due to neuroleptic sensitivity; quetiapine used only if cholinesterase inhibitors fail.  <br><span class=\"list-item\">\u2022</span> Monitor heart rate and weight; cholinesterase inhibitors can cause bradycardia and anorexia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Assuming donepezil and rivastigmine are interchangeable for hallucinations&mdash;only rivastigmine has dedicated RCT evidence.  <br>2. Using benzodiazepines like clonazepam for visual hallucinations rather than sleep&ndash;wake disorders&mdash;this can worsen confusion and falls.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- Fourth DLB Consortium Consensus <span class=\"citation\">(McKeith et al., Neurology. 2017)</span>: Recommends rivastigmine for neuropsychiatric symptoms in DLB (Level A evidence).  <br><span class=\"list-item\">\u2022</span> NICE Clinical Guideline CG42 update <span class=\"citation\">(UK, 2020)</span>: Advises rivastigmine as first-line for DLB hallucinations based on class I RCT data.  <br><span class=\"list-item\">\u2022</span> AAN Practice Guideline (2018): Grades cholinesterase inhibitors (rivastigmine, donepezil) as Level B for cognitive and behavioral symptoms; specifies rivastigmine&rsquo;s superiority for hallucinations.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Degeneration of cholinergic neurons in the basal nucleus of Meynert leads to reduced acetylcholine in occipital and temporoparietal cortices, areas critical for visual processing. Rivastigmine augments cholinergic transmission in these pathways, stabilizing cortical circuits and reducing misperceptions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>DLB pathology involves alpha-synuclein aggregates in cortical and subcortical neurons, disrupting both dopaminergic and cholinergic networks. Visual hallucinations arise from cholinergic hypofunction in visual association areas compounded by occipital hypoperfusion and impaired thalamocortical gating.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Mechanism: Dual inhibition of acetylcholinesterase and butyrylcholinesterase increases synaptic acetylcholine.  <br><span class=\"list-item\">\u2022</span> Dosing: Start 1.5 mg orally twice daily; escalate by 3 mg/day every 4 weeks to a target of 6 mg twice daily or patch 9.5 mg/24 h.  <br><span class=\"list-item\">\u2022</span> Monitoring: Watch for bradycardia, GI intolerance, weight loss; adjust dose accordingly.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2018 exam.  <br>DLB neuropsychiatric management questions frequently test recognition that rivastigmine is the only drug with RCT-proven benefit for visual hallucinations, contrasted with limited or adverse evidence for antipsychotics or benzodiazepines.</div></div></div></div></div>"
  },
  {
    "id": 100022609,
    "question_number": "127",
    "question_text": "Which of the following conditions is characterized by 3-repeat tau and ubiquitin?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2019] Frontotemporal dementia (FTD) comprises neuropathological subtypes defined by intracellular protein aggregates. Tau is a microtubule-associated protein with six adult isoforms generated via alternative splicing of exon 10; three-repeat (3R) and four-repeat (4R) isoforms have distinct aggregation profiles. Ubiquitin tags misfolded proteins for proteasomal degradation and commonly decorates neurodegenerative inclusions. Pick&rsquo;s disease, a subtype of FTLD-tau, features spherical neuronal inclusions (&ldquo;Pick bodies&rdquo;) rich in 3R tau and ubiquitin. In contrast, other FTD variants harbor 4R tau (e.g., FTDP-17), TDP-43, or FUS inclusions. Recognizing isoform-specific tau pathology underpins clinico-pathological correlation and informs emerging targeted therapies. (134 words)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Pick&rsquo;s disease is defined by argyrophilic spherical inclusions composed predominantly of 3R tau isoforms, first described by Kosaka in 1975. Immunohistochemical studies <span class=\"citation\">(<span class=\"evidence\">Higuchi et al., 2002</span>)</span> consistently demonstrate strong 3R tau and ubiquitin positivity within Pick bodies, with negligible 4R tau staining. Consensus neuropathology criteria <span class=\"citation\">(Mackenzie et al., Acta <span class=\"evidence\">Neuropathol 2011</span>)</span> subdivide FTLD-tau into 3R, 4R, or mixed isoform groups based on tau antibody profiling. No other FTD variant exhibits exclusive 3R tau ubiquitin-positive inclusions, confirming FTD-Pick as the correct answer.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. FTD-parkinsonism: Associated with FTDP-17 (MAPT mutations) showing neuronal and glial inclusions rich in 4R tau isoforms; ubiquitin may label aggregates but tau isoform is 4R, not 3R.  <br>C. bvFTD: Clinically defined behavioral variant; neuropathology is heterogeneous&mdash;~50% FTLD-TDP, ~40% FTLD-tau (predominantly 4R or mixed), rarely pure 3R tau; ubiquitinated TDP-43 inclusions predominate in TDP cases.  <br>D. FTD-ALS: Overlap syndrome with amyotrophic lateral sclerosis; characterized by neuronal cytoplasmic inclusions of ubiquitinated TDP-43 in cortex and motor neurons; tau pathology is minimal or absent.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>FTD-Pick</th><th>FTD-parkinsonism</th><th>bvFTD</th><th>FTD-ALS</th></tr></thead><tbody><tr><td>Predominant protein</td><td>Tau</td><td>Tau</td><td>Tau/TDP-43/FUS</td><td>TDP-43</td></tr><tr><td>Tau isoform</td><td>3R</td><td>4R</td><td>4R or mixed</td><td>Absent or minimal</td></tr><tr><td>Ubiquitin positivity</td><td>Yes (Pick bodies)</td><td>Yes</td><td>Yes (if tau) or no</td><td>Yes (TDP-43 in motor)</td></tr><tr><td>Genetic association</td><td>Sporadic</td><td>MAPT mutations (17q21)</td><td>Sporadic/genetic</td><td>C9orf72, others</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Pick bodies are argyrophilic on silver stains (e.g., Bielschowsky) and show selective 3R tau positivity.  <br><span class=\"list-item\">\u2022</span> Tau PET tracers <span class=\"citation\">(e.g., ^18F-AV-1451)</span> have variable affinity for 3R vs 4R tau; 3R-predominant Pick&rsquo;s may yield lower binding signal than 4R tauopathies.  <br><span class=\"list-item\">\u2022</span> Ubiquitin immunostaining is sensitive but non-specific; isoform-specific tau antibodies (3R vs 4R) are essential for definitive classification.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confusing 3R and 4R tauopathies: Students may assume all tauopathies involve both isoforms, but Pick&rsquo;s disease uniquely aggregates 3R tau.  <br>2. Equating ubiquitin positivity solely with TDP-43 pathology: Ubiquitin decorates many misfolded protein inclusions; absence of tau immunoreactivity should prompt TDP-43 or FUS staining.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Mackenzie IR et al., Acta Neuropathologica (2011): &ldquo;Harmonized classification system for FTLD&rdquo; recommends subclassifying FTLD by predominant protein (tau, TDP-43, FUS) and tau isoform profile. Level C (expert consensus).  <br>2. Josephs KA et al., Neurology (2019): Observational cohort using tau PET tracer ^18F-AV-1451 demonstrated distinct in vivo binding patterns differentiating 3R tauopathies (Pick&rsquo;s) from 4R tauopathies (PSP/CBD). Level B (cohort study).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2019 exam. Proteinopathy subtypes in FTD are high-yield on neurology boards, frequently tested by asking for tau isoform (3R vs 4R) associations with specific clinical syndromes (Pick&rsquo;s vs PSP/CBD).</div></div></div></div></div>"
  },
  {
    "id": 100022612,
    "question_number": "46",
    "question_text": "Which of the following most accurately summarizes the current situation with respect to the use of cholinesterase inhibitors to delay or prevent the progression from Mild Cognitive Impairment (MCI) to Alzheimer\u2019s disease or other forms of dementia?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2018] Mild Cognitive Impairment (MCI) is defined by subjective memory complaints, objective cognitive impairment on testing, preserved activities of daily living, and absence of dementia. Pathophysiologically, MCI may represent prodromal Alzheimer&rsquo;s disease (AD), characterized by early cholinergic deficits, amyloid-&beta; aggregation, and tau hyperphosphorylation. Cholinesterase inhibitors (donepezil, rivastigmine, galantamine) increase synaptic acetylcholine, providing symptomatic benefit in mild-to-moderate AD. Their use in MCI aims at disease modification, not merely symptomatic relief, but this application remains unproven.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Option A is correct because multiple randomized controlled trials (RCTs) and meta-analyses have failed to demonstrate that cholinesterase inhibitors prevent or delay progression from MCI to dementia in the long term. The Alzheimer&rsquo;s Disease Cooperative Study <span class=\"citation\">(<span class=\"evidence\">Petersen et al., 2005</span>)</span> randomized 285 MCI patients to donepezil or placebo: there was a transient reduction in conversion at 12 months (hazard ratio 0.72, p=0.04) but no difference at 36 months. A 2018 Cochrane review (12 trials, n=3,421) found no significant reduction in progression rates to dementia at 18 months (risk ratio 0.95, 95% CI 0.85&ndash;1.06). The U.S. FDA has not approved any cholinesterase inhibitor for MCI. <span class=\"evidence\">The 2018</span> American Academy of Neurology (AAN) practice guideline gives a Level B recommendation against their routine use in MCI due to insufficient evidence of disease modification.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Highly effective in preventing progression to Alzheimer&rsquo;s disease  <br>&ndash; Incorrect: No robust RCT shows disease-modifying efficacy in MCI.  <br>&ndash; Misconception: Symptomatic benefit in AD translates to prevention in MCI.  <br>&ndash; Differentiator: Symptomatic vs disease-modifying effects; trials show only transient, short-term delay.<br><br>C. Recommended as first-line treatment for all patients with MCI  <br>&ndash; Incorrect: Clinical guidelines (AAN, NICE) do not endorse cholinesterase inhibitors for MCI.  <br>&ndash; Misconception: Treat MCI identically to mild AD.  <br>&ndash; Differentiator: Guideline distinction between diagnostic categories and approval status.<br><br>D. Shown to reverse cognitive decline in MCI patients  <br>&ndash; Incorrect: No evidence for cognitive improvement beyond baseline in MCI; reversal is unsupported.  <br>&ndash; Misconception: Overgeneralizing rare symptomatic gains in dementia to reversal in MCI.  <br>&ndash; Differentiator: Reversal versus symptomatic stabilization; trials show neither.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Criterion</th><th>Option A (Correct)</th><th>Option B</th><th>Option C</th><th>Option D</th></tr></thead><tbody><tr><td>Long-term progression impact</td><td>RCTs/meta-analyses show no sustained benefit</td><td>Overstates effect; no evidence</td><td>Assumes guideline support not present</td><td>No data supporting reversal</td></tr><tr><td>FDA approval for MCI</td><td>Not approved</td><td>Not approved</td><td>Misstates regulatory status</td><td>Not approved</td></tr><tr><td>Guideline recommendation</td><td>AAN (2018): Level B against routine use</td><td>Contradicts AAN/NICE guidelines</td><td>Ignores AAN/NICE distinction</td><td>Contradicts evidence and guidelines</td></tr><tr><td>Mechanistic justification</td><td>Symptomatic only in AD, not disease-modifying in MCI</td><td>Conflates symptom relief with prophylaxis</td><td>Misapplies AD framework to MCI</td><td>Incorrectly infers neurorestoration</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Distinguish MCI from dementia by preserved instrumental activities of daily living; cholinesterase inhibitors are indicated only once frank dementia is diagnosed.  <br><span class=\"list-item\">\u2022</span> Biomarker stratification (amyloid PET, CSF tau/A&beta;42) can identify MCI patients at highest risk for AD but does not change lack of pharmacological prevention.  <br><span class=\"list-item\">\u2022</span> Non-pharmacologic interventions (cognitive training, exercise, vascular risk control) remain first-line in MCI management.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Equating symptomatic benefits seen in mild AD trials with disease prevention in MCI.  <br><span class=\"list-item\">\u2022</span> Assuming off-label prescribing is guideline-endorsed; many clinicians overestimate the protective effects of cholinesterase inhibitors.  <br><span class=\"list-item\">\u2022</span> Neglecting lifestyle and vascular risk management by focusing solely on pharmacotherapy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- American Academy of Neurology, 2018 Practice Guideline Update: &ldquo;Clinicians should not prescribe cholinesterase inhibitors for the sole purpose of delaying progression from MCI to dementia.&rdquo; (Level B evidence: insufficient benefit.)  <br><span class=\"list-item\">\u2022</span> National Institute for Health and Care Excellence (NICE), NG94, 2018: &ldquo;Do not offer cholinesterase inhibitors to people with MCI outside of a clinical trial.&rdquo; (Evidence quality: moderate.)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2018 exam. Questions on MCI versus dementia pharmacotherapy frequently test recognition of evidence-based guideline recommendations and the distinction between symptomatic and disease-modifying effects of cholinesterase inhibitors.</div></div></div></div></div>"
  },
  {
    "id": 100022614,
    "question_number": "49",
    "question_text": "A patient with dementia has insomnia and agitation. What medication would you prescribe?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2018] Dementia often leads to behavioral and psychological symptoms (BPSD) such as insomnia and agitation due to degeneration of cholinergic basal forebrain neurons and dysregulation of serotonergic and noradrenergic pathways in frontal-subcortical circuits. The suprachiasmatic nucleus (SCN) governs the sleep&ndash;wake cycle via melatonin and serotonin; disruption exacerbates cognitive decline and behavioral outbursts. Nonpharmacologic measures (sleep hygiene, structured routines) are first-line. When pharmacotherapy is necessary, agents with minimal anticholinergic burden and lower mortality risk are preferred. Trazodone, a serotonin antagonist&ndash;reuptake inhibitor (SARI), targets 5-HT\u2082A receptors and histamine H\u2081 receptors to promote sleep and may attenuate agitation without the black-box mortality warning of antipsychotics.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Trazodone at bedtime (25&ndash;150 mg) improves sleep efficiency in dementia: a 2018 Cochrane review found moderate-quality evidence for enhanced sleep architecture and reduced nocturnal awakenings. The UK NICE guideline NG97 (2018) endorses low-dose trazodone for persistent insomnia in dementia after nonpharmacological strategies. It has negligible anticholinergic activity and no FDA black-box warning for increased mortality in elderly with dementia-related psychosis. By contrast, atypical antipsychotics (risperidone, quetiapine, clozapine) carry a 1.6-fold increased risk of death and cerebrovascular events in this population <span class=\"citation\">(Schneider et al., JAMA 2005; FDA Black-<span class=\"evidence\">Box 2005</span>)</span>. SSRIs <span class=\"citation\">(e.g., citalopram in the CITAD trial,<span class=\"evidence\"> Steinberg et al. 2011</span>)</span> reduce agitation but may be activating and insufficient for insomnia. Thus, trazodone uniquely addresses both insomnia and agitation with a favorable safety profile.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Quetiapine  <br>&bull; Although sedating via H\u2081 and &alpha;\u2081 blockade, it carries an FDA black-box warning for increased mortality and stroke in dementia-related psychosis.  <br>&bull; Misconception: &ldquo;All sedating antipsychotics are safe for sleep in elderly.&rdquo;  <br>&bull; Differentiator: quetiapine&rsquo;s antipsychotic adverse profile and metabolic risks outweigh benefits for insomnia.<br><br>C. Clozapine  <br>&bull; High risk of agranulocytosis, seizures, myocarditis; requires strict hematologic monitoring.  <br>&bull; Misconception: &ldquo;Clozapine is the most effective atypical for any psychotic or behavioral disturbance.&rdquo;  <br>&bull; Differentiator: no evidence and unacceptable safety profile for BPSD.<br><br>D. Risperidone  <br>&bull; Some efficacy for severe aggression but carries black-box warning for increased mortality and cerebrovascular events, plus EPS and hyperprolactinemia.  <br>&bull; Misconception: &ldquo;Risperidone is first-line for any agitation in dementia.&rdquo;  <br>&bull; Differentiator: reserved only for life-threatening aggression unresponsive to other measures.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Trazodone (SARI)</th><th>Quetiapine (Atypical AP)</th><th>Clozapine (Atypical AP)</th><th>Risperidone (Atypical AP)</th></tr></thead><tbody><tr><td>Mechanism</td><td>5-HT\u2082A antagonism + SERT inhibition; H\u2081, &alpha;\u2081 block</td><td>D\u2082/5-HT\u2082A antagonism; H\u2081, &alpha;\u2081 block</td><td>D\u2084/5-HT\u2082A antagonism; M\u2081, H\u2081, &alpha;\u2081 block</td><td>D\u2082/5-HT\u2082A antagonism; minimal M/H\u2081/&alpha;\u2081 block</td></tr><tr><td>Indication in BPSD</td><td>Off-label insomnia + nocturnal agitation</td><td>Off-label agitation</td><td>Not recommended for BPSD</td><td>Off-label severe aggression</td></tr><tr><td>Evidence for Improving Insomnia</td><td>Moderate <span class=\"citation\">(<span class=\"evidence\">Cochrane 2018</span>; NICE 2018)</span></td><td>Low, not guideline-endorsed</td><td>None</td><td>None</td></tr><tr><td>FDA Black-Box Warning in Dementia</td><td>None</td><td>Yes (mortality, CVA risk)</td><td>Yes (mortality)</td><td>Yes (mortality, CVA risk)</td></tr><tr><td>Major Adverse Effects</td><td>Orthostatic hypotension, priapism, sedation</td><td>Sedation, hypotension, metabolic syndrome</td><td>Agranulocytosis, seizures, myocarditis</td><td>Extrapyramidal symptoms, hyperprolactinemia</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Always prioritize nonpharmacologic interventions (routine, light therapy, behavioral modifications) for BPSD.  <br><span class=\"list-item\">\u2022</span> Initiate trazodone at 25 mg at bedtime; titrate slowly and monitor orthostatic blood pressure.  <br><span class=\"list-item\">\u2022</span> Remember the FDA black-box warning: all antipsychotics increase mortality in dementia-related psychosis (~1.6\u00d7).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Prescribing benzodiazepines for insomnia in dementia increases fall risk, cognitive worsening, and paradoxical agitation.  <br>2. Assuming all sedating psychotropics are safe; failing to weigh black-box mortality risk of antipsychotics.  <br>3. Overlooking trazodone&rsquo;s orthostatic hypotension and rare priapism; requires patient education.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- NICE Guideline NG97 (2018): Recommends structured activities, sleep hygiene, then low-dose trazodone for persistent insomnia in dementia (Evidence level: moderate).  <br><span class=\"list-item\">\u2022</span> APA Practice Guideline for BPSD (2016): Advises SSRIs (e.g., citalopram) for agitation; reserves antipsychotics for severe risk situations (Level A).  <br><span class=\"list-item\">\u2022</span> CITAD Trial <span class=\"citation\">(Steinberg et al., JAMA 2011)</span>: Citalopram 30 mg/d reduced agitation scores in Alzheimer&rsquo;s (p<0.05) but noted QT prolongation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Trazodone is a serotonin antagonist&ndash;reuptake inhibitor. It antagonizes 5-HT\u2082A and H\u2081 receptors, promoting rapid sedation (onset ~30 min), and inhibits serotonin reuptake. Typical dosing in dementia: start 25 mg nightly, titrate to 150 mg based on response and tolerability. Monitor blood pressure and counsel about rare risk of priapism.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2018 exam. BPSD pharmacotherapy is frequently tested as clinical vignettes contrasting antipsychotic risks versus safer alternatives; candidates must balance efficacy for insomnia and agitation against adverse-event profiles in elderly with dementia.</div></div></div></div></div>"
  },
  {
    "id": 100022615,
    "question_number": "47",
    "question_text": "An individual with mild cognitive impairment is more likely to progress to dementia or Alzheimer disease if he/she:",
    "correct_answer": "D",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2018] Mild cognitive impairment (MCI) represents a transitional stage between normal aging and dementia, characterized by objective cognitive deficits without significant functional impairment. Three core pathophysiological processes underlie Alzheimer disease (AD): amyloid\u2010&beta; deposition, tau\u2010mediated neurofibrillary tangles, and neurodegeneration. Biomarkers map onto the &ldquo;A/T/N&rdquo; classification: A = amyloid (PET or CSF A&beta;42), T = tau (CSF p\u2010tau), and N = neurodegeneration (MRI atrophy). Understanding which biomarker best predicts progression from MCI to AD dementia is critical for prognosis, patient counseling, and selection for clinical trials.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Positive amyloid PET imaging directly visualizes cerebral amyloid\u2010&beta; plaques&mdash;the hallmark initiating pathology in AD. In the Alzheimer&rsquo;s Disease Neuroimaging Initiative (ADNI) cohort, MCI subjects with amyloid PET positivity had a 28% annual progression rate to dementia versus 6% in amyloid\u2010negative individuals <span class=\"citation\">(Jansen et al., JAMA <span class=\"evidence\">Neurol 2015</span>)</span>. <span class=\"evidence\">The 2018</span> NIA\u2010AA Research Framework formally designates amyloid PET as the gold standard for in vivo A biomarker, demonstrating the highest specificity for underlying AD pathology. By contrast, APOE \u03b54 carriage increases lifetime risk but is neither necessary nor sufficient for progression. MRI hippocampal atrophy (N marker) and elevated CSF total or phosphorylated tau (T marker) reflect downstream neurodegeneration, providing prognostic information but lower positive predictive value than amyloid imaging <span class=\"citation\">(Hansson et al., Lancet <span class=\"evidence\">Neurol 2017</span>)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Is an APOE4 carrier.  <br><span class=\"list-item\">\u2022</span> Although APOE \u03b54 genotype confers increased susceptibility to AD and accelerates amyloid deposition, its positive predictive value for short\u2010term progression from MCI is modest (\u224815&ndash;20% risk over 3 years) and not definitive <span class=\"citation\">(Risacher et al., <span class=\"evidence\">Neurology 2013</span>)</span>.  <br><br>B. Has atrophic hippocampi on MRI.  <br><span class=\"list-item\">\u2022</span> Hippocampal volume loss correlates with neuronal loss and predicts cognitive decline, but such atrophy can occur in other dementias and aging; its specificity (\u224870%) is lower than amyloid PET (\u224890%) <span class=\"citation\">(Jack et al., <span class=\"evidence\">Radiology 2010</span>)</span>.  <br><br>C. Has an elevated tau level in the CSF.  <br><span class=\"list-item\">\u2022</span> Elevated CSF total tau or phosphorylated tau indicates axonal injury and tangle pathology, correlating with disease stage, yet CSF tau alone has lower prognostic specificity for conversion from MCI compared to amyloid PET <span class=\"citation\">(Fagan et al., <span class=\"evidence\">Neurology 2014</span>)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Biomarker</th><th>Category</th><th>Modality</th><th>Approximate 3-year Progression Risk</th><th>Specificity for AD Pathology</th></tr></thead><tbody><tr><td>APOE \u03b54 genotype</td><td>Genetic risk</td><td>Blood test</td><td>~15&ndash;20%</td><td>Low</td></tr><tr><td>Hippocampal atrophy</td><td>Neurodegeneration (N)</td><td>MRI volumetry</td><td>~30%</td><td>Moderate (\u224870%)</td></tr><tr><td>CSF tau elevation</td><td>Tau pathology (T)</td><td>CSF assay</td><td>~35%</td><td>Moderate (\u224875%)</td></tr><tr><td>Amyloid PET positivity</td><td>Amyloid pathology (A)</td><td>PET imaging</td><td>~60&ndash;80%</td><td>High (\u224890%)</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Amyloid PET positivity in MCI predicts rapid progression; consider for patients in whom prognostication will alter management or trial eligibility.  <br><span class=\"list-item\">\u2022</span> A/T/N biomarker classification aids in selecting targeted therapeutics (e.g., anti\u2010amyloid agents).  <br><span class=\"list-item\">\u2022</span> Hippocampal volumetry is widely available but should be interpreted alongside molecular biomarkers.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Overestimating the predictive power of APOE \u03b54 alone: genotype risk does not equal imminent conversion.  <br>2. Equating MRI atrophy with definitive AD: structural changes lack pathologic specificity and may lag behind molecular changes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- NIA-AA Research Framework <span class=\"citation\">(<span class=\"evidence\">Jack et al., 2018</span>)</span>: Defines AD biologically using A/T/N; recommends amyloid PET or CSF A&beta;42 for definitive A classification in research (no formal level of evidence).  <br><span class=\"list-item\">\u2022</span> American College of Radiology Appropriateness Criteria for Cognitive Decline (2019): Rates amyloid PET as &ldquo;Appropriate&rdquo; for MCI when etiology is uncertain and PET results will influence management (Evidence Level: C).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Amyloid PET tracers (e.g., florbetapir, flutemetamol) bind to fibrillar A&beta;; positive scans show cortical uptake in frontal, parietal, and precuneus regions.  <br><span class=\"list-item\">\u2022</span> MRI hippocampal atrophy manifests as enlarged temporal horns and thinning of the CA1 region; automated volumetry improves reproducibility.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2018 exam. Biomarker\u2010based risk stratification in MCI is frequently tested, often contrasting A/T/N modalities and their predictive values for conversion to AD dementia.</div></div></div></div></div>"
  },
  {
    "id": 100022616,
    "question_number": "105",
    "question_text": "A patient came with behavioral changes; what is the gene defect?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2021] Frontotemporal dementia (FTD) involves progressive degeneration of frontal and temporal lobes, producing disinhibition, apathy, executive dysfunction and language disturbances. Pathologically, most genetic FTD splits into TDP-43 and tau proteinopathies. GRN (progranulin) mutations on chromosome 17 lead to progranulin haploinsufficiency and TDP-43 type A inclusions. MAPT mutations on the same chromosome cause 4-repeat tau aggregates. Behavioral\u2010variant FTD (bvFTD) arises from orbitofrontal, anterior cingulate and insular cortex atrophy. Genetic causes account for ~30&ndash;40% of bvFTD, with GRN, C9orf72 and MAPT being most frequent. Accurate gene\u2010phenotype mapping informs prognosis, counseling, and emerging targeted therapies.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Progranulin (GRN) mutations are the prototypical gene defect in familial bvFTD presenting with primary behavioral changes. GRN resides on chromosome 17q21 and encodes progranulin, a growth factor critical for lysosomal function. Haploinsufficiency leads to cytoplasmic TDP-43 type A inclusions <span class=\"citation\">(Mackenzie et al. Acta <span class=\"evidence\">Neuropathol 2011</span>)</span>. Rascovsky et al. <span class=\"citation\">(<span class=\"evidence\">Neurology 2011</span>)</span> criteria for bvFTD emphasize early behavioral disinhibition and executive deficits; genetic testing is recommended when there is a positive family history or early onset (&le;65 years). Seelaar et al. <span class=\"citation\">(Lancet <span class=\"evidence\">Neurol 2011</span>)</span> demonstrated that GRN carriers show asymmetric frontotemporal atrophy on MRI and FDG-PET hypometabolism. 2021 AAN guidelines endorse GRN screening in familial bvFTD (level B evidence). MAPT mutations, by contrast, yield tauopathy with prominent parkinsonism and memory preservation initially <span class=\"citation\">(Spillantini et al. Nat Rev <span class=\"evidence\">Neurol 2013</span>)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. TDP-43  <br>&bull; Why incorrect: TDP-43 is the protein deposition, not the gene.  <br>&bull; Misconception: Students sometimes equate pathological proteins with gene defects.  <br>&bull; Differentiator: GRN mutations cause TDP-43 inclusions; TDP-43 itself isn&rsquo;t a gene target for mutation screening.  <br><br>C. FTD-parkinsonism  <br>&bull; Why incorrect: This is a clinical phenotype, not a molecular defect.  <br>&bull; Misconception: Equating mixed clinical syndromes (parkinsonism + FTD) with specific genes.  <br>&bull; Differentiator: FTD-parkinsonism often implicates MAPT, not a standalone gene entity.  <br><br>D. MAPT/Ch17 (4-repeat tau)  <br>&bull; Why incorrect: MAPT mutations produce tau, not TDP-43 pathology, and typically present with parkinsonism.  <br>&bull; Misconception: Assuming any bvFTD must be tau\u2010based.  <br>&bull; Differentiator: Tauopathies have distinct clinical signatures (rigidity, tremor) and cortical topography.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Progranulin (GRN)</th><th>TDP-43 (protein)</th><th>FTD-parkinsonism (phenotype)</th><th>MAPT mutation</th></tr></thead><tbody><tr><td>Type</td><td>Gene mutation</td><td>Pathological protein</td><td>Clinical syndrome</td><td>Gene mutation</td></tr><tr><td>Chromosomal locus</td><td>Chr17q21</td><td>N/A</td><td>N/A</td><td>Chr17q21</td></tr><tr><td>Proteinopathy</td><td>TDP-43 type A inclusions</td><td>TDP-43 inclusions (descriptor only)</td><td>Variable (TDP-43 or tau)</td><td>4-repeat tau inclusions</td></tr><tr><td>Core presentation</td><td>bvFTD with apathy/disinhibition</td><td>NA</td><td>bvFTD + parkinsonian signs</td><td>FTD + early parkinsonism</td></tr><tr><td>Inheritance</td><td>Autosomal dominant, incomplete pen.</td><td>NA</td><td>NA</td><td>Autosomal dominant</td></tr><tr><td>Neuroimaging</td><td>Asymmetric frontotemporal atrophy</td><td>NA</td><td>Variable</td><td>Medial temporal sparing early</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Serum progranulin levels are a practical biomarker for GRN haploinsufficiency; levels <110 ng/mL warrant genetic testing.  <br><span class=\"list-item\">\u2022</span> GRN mutation carriers often exhibit prominent language deficits (non-fluent aphasia) in addition to behavioral signs.  <br><span class=\"list-item\">\u2022</span> Emerging therapies (e.g., AL001 monoclonal antibody) aim to restore progranulin levels and are in phase 2 trials <span class=\"citation\">(<span class=\"evidence\">Rademakers et al. 2022</span>)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confusing pathological proteins with their encoding genes (e.g., naming &ldquo;TDP-43&rdquo; as the gene rather than GRN or C9orf72).  <br>2. Overattributing parkinsonism to GRN mutations; in GRN the movement disorder is late or mild compared to MAPT.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. American Academy of Neurology Practice Guideline (2021): Recommends genetic testing for GRN, MAPT, and C9orf72 in familial bvFTD (Level B evidence).  <br>2. AL001 Phase 1b Trial (2022, Rademakers et al., Neurology): Demonstrated dose-dependent increase in cerebrospinal progranulin with favorable safety, supporting phase 2 efficacy studies.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>GRN-related bvFTD shows early atrophy of the orbitofrontal cortex, anterior cingulate, insula and dorsolateral prefrontal regions, correlating with disinhibition and executive dysfunction <span class=\"citation\">(Whitwell et al. <span class=\"evidence\">Brain 2009</span>)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>GRN mutations cause progranulin haploinsufficiency, impairing lysosomal function and promoting neuroinflammation. This triggers mislocalization and aggregation of TDP-43, leading to neuronal loss in frontal/temporal networks.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical assessment: Meet Rascovsky criteria for bvFTD.  <br>2. Neuropsychological testing: Executive dysfunction, social cognition deficits.  <br>3. Neuroimaging: MRI/FDG-PET to confirm frontotemporal atrophy/hypometabolism.  <br>4. Laboratory: Serum progranulin assay if family history.  <br>5. Genetic testing: Sequence GRN, MAPT, C9orf72 based on phenotype and biomarker results.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>MRI typically reveals asymmetric frontal and anterior temporal lobe atrophy in GRN mutation carriers; FDG-PET shows corresponding hypometabolism, often more pronounced in the left hemisphere.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>No disease-modifying therapies are approved; symptomatic management includes SSRIs for disinhibition. Progranulin-elevating strategies (e.g., AL001) represent the first genotype-driven trials.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2021 exam. Topics on FTD genetics frequently arise as gene&ndash;phenotype correlation items, often requiring differentiation between GRN (TDP-43 pathology) and MAPT (tauopathy) in behavioral vs parkinsonian presentations.</div></div></div></div></div>"
  },
  {
    "id": 100022618,
    "question_number": "48",
    "question_text": "Cognitive symptoms in Lewy body dementia are treated with which of the following medications?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2018] Lewy body dementia (LBD) is characterized by cortical and subcortical &alpha;-synuclein deposition, leading to fluctuating attention, visual hallucinations, and parkinsonism. Pathologically, there is marked loss of cholinergic neurons in the nucleus basalis of Meynert&mdash;more severe than in Alzheimer&rsquo;s disease. Clinically, LBD patients exhibit prominent visuospatial dysfunction and neuropsychiatric features. Understanding the central role of cholinergic deficits underpins the targeted use of cholinesterase inhibitors to ameliorate both cognitive and neuropsychiatric symptoms.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Cholinesterase inhibitors (ChEIs), particularly rivastigmine, have level I evidence from randomized controlled trials <span class=\"citation\">(<span class=\"evidence\">Aarsland et al., 2002</span>, Neurology)</span> demonstrating significant improvements in cognition (MMSE and ADAS-Cog) and neuropsychiatric inventory scores versus placebo. <span class=\"evidence\">The 2017</span> DLB Consortium criteria <span class=\"citation\">(<span class=\"evidence\">McKeith et al., 2017</span>, Neurology)</span> recommend ChEIs as first-line therapy for cognitive impairment in probable LBD (Level A). By inhibiting acetylcholinesterase and butyrylcholinesterase, rivastigmine increases synaptic acetylcholine, counteracting the profound cholinergic denervation seen in LBD. Compared with donepezil, rivastigmine&rsquo;s dual inhibition and trial data on hallucinations make it the preferred agent.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Antidepressants  <br>&bull; Do not improve core cognitive deficits in LBD; they target serotonin/norepinephrine pathways.  <br>&bull; Common misconception: treating mood will enhance cognition.  <br><br>C. Antipsychotics  <br>&bull; Typical agents (e.g., haloperidol) precipitate neuroleptic sensitivity reactions, worsen parkinsonism, and increase mortality.  <br>&bull; Misguided belief that psychosis requires antipsychotics; in LBD, hallucinations often respond to ChEIs.  <br><br>D. Mood stabilizers  <br>&bull; Lithium or valproate have no evidence for cognitive benefit in LBD and carry high toxicity risk in the elderly.  <br>&bull; Erroneous assumption that mood stabilization translates to cognitive improvement.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Treatment</th><th>Mechanism</th><th>Cognitive Effect</th><th>Major Considerations</th></tr></thead><tbody><tr><td>Cholinesterase inhibitors</td><td>\u2191 Acetylcholine via AChE/BuChE inhibition</td><td>Improves MMSE, NPI, fluctuations</td><td>GI side effects; titrate slowly</td></tr><tr><td>Antidepressants</td><td>Serotonin/norepinephrine modulation</td><td>No significant cognitive benefit</td><td>Risk hyponatremia, falls</td></tr><tr><td>Antipsychotics</td><td>D2 receptor antagonism</td><td>May worsen cognition/parkinsonism</td><td>Neuroleptic sensitivity, increased mortality</td></tr><tr><td>Mood stabilizers</td><td>Modulate excitatory neurotransmission</td><td>No proven effect on cognition</td><td>Narrow therapeutic window, toxicity in elderly</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Visual hallucinations in LBD often improve with ChEIs rather than antipsychotics.  <br><span class=\"list-item\">\u2022</span> Rivastigmine dosing: start 1.5 mg BID, titrate to 6&ndash;12 mg/day; watch for GI upset and bradycardia.  <br><span class=\"list-item\">\u2022</span> If antipsychotics are necessary, use low-dose quetiapine or clozapine due to lower risk of neuroleptic sensitivity.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confusing LBD with Alzheimer&rsquo;s and selecting memantine without addressing cholinergic loss.  <br>2. Prescribing haloperidol for hallucinations, risking severe worsening of motor and cognitive symptoms in LBD.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1.<span class=\"evidence\"> McKeith IG et al., 2017</span>, Neurology (Fourth DLB Consortium Report): Recommends ChEIs as first-line for cognitive impairment in probable LBD (Level A).  <br>2. AAN 2020 Practice Advisory: Supports rivastigmine use in Parkinson&rsquo;s disease dementia and LBD to improve cognition and neuropsychiatric symptoms (Level B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Cholinergic neurons in the nucleus basalis of Meynert project diffusely to the cortex; their loss correlates with attentional and visuospatial deficits in LBD.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>LBD is defined by intracellular &alpha;-synuclein aggregation (Lewy bodies), causing synaptic dysfunction and selective vulnerability of cholinergic pathways, resulting in cortical acetylcholine depletion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Identify core features: fluctuating cognition + visual hallucinations + parkinsonism  <br>2. Rule out alternative causes (labs, MRI)  <br>3. Assess supportive features: REM-sleep behavior disorder, neuroleptic sensitivity  <br>4. Use DAT-SPECT if diagnostic uncertainty remains  <br>5. Initiate cholinesterase inhibitor therapy upon clinical diagnosis</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>Occipital hypometabolism on FDG-PET and reduced striatal dopamine transporter uptake on DAT-SPECT help distinguish LBD from Alzheimer&rsquo;s disease.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Rivastigmine: initiate at 1.5 mg twice daily, increase every 4 weeks to a target of 6&ndash;12 mg/day as tolerated. Monitor gastrointestinal tolerance and cardiac conduction.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2018 exam. LBD treatment questions frequently test first-line pharmacotherapy distinguishing LBD from Alzheimer&rsquo;s disease.</div></div></div></div></div>"
  },
  {
    "id": 100022622,
    "question_number": "164",
    "question_text": "A 56-year-old male with a history of memory loss for 24 hours and asking the same question repeatedly should undergo which investigation?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2019] - Transient Global Amnesia (TGA) presents as acute anterograde amnesia, often with repetitive questioning, lasting &le;24 hours, with preserved personal identity and no other focal deficits.  <br><span class=\"list-item\">\u2022</span> The hippocampus&mdash;especially the CA1 sector&mdash;is critical for encoding new memories; transient dysfunction here underlies the clinical syndrome.  <br><span class=\"list-item\">\u2022</span> Differential diagnoses include transient ischemic attack (TIA), transient epileptic amnesia (TEA), metabolic/toxic encephalopathies, and psychogenic amnesia; each has distinct clinical and paraclinical hallmarks.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Magnetic resonance imaging with diffusion-weighted sequences (DWI MRI) is the investigation of choice in suspected TGA. Multiple studies <span class=\"citation\">(e.g., Bartsch et al., <span class=\"evidence\">Brain 2006</span>; Sedlaczek et al., <span class=\"evidence\">Stroke 2004</span>)</span> demonstrate that small, punctate DWI lesions in the hippocampal CA1 region become apparent 24&ndash;72 hours after symptom onset in up to 70% of patients. These lesions are highly specific for TGA and help exclude acute ischemic stroke, hemorrhage, or structural lesions. By contrast, noncontrast CT and CT angiography lack sufficient sensitivity for hippocampal lesions; EEG rarely shows epileptiform activity in TGA, and carotid Doppler addresses extracranial stenosis rather than the parenchymal changes pathognomonic for TGA.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. CT & CTA  <br><span class=\"list-item\">\u2022</span> CT has poor sensitivity for small hippocampal DWI lesions; CTA evaluates vessels, not parenchymal diffusion changes.  <br><span class=\"list-item\">\u2022</span> Misconception: &ldquo;CT will rule out all acute brain pathology&rdquo; &ndash; it often misses small ischemic or non-vascular lesions.  <br><br>C. EEG  <br><span class=\"list-item\">\u2022</span> Designed to detect epileptiform discharges; TGA is not epileptic in etiology and EEG is typically normal.  <br><span class=\"list-item\">\u2022</span> Misconception: &ldquo;All transient amnestic events require EEG&rdquo; &ndash; TEA requires EEG but TGA does not have characteristic ictal patterns.  <br><br>D. Carotid Doppler  <br><span class=\"list-item\">\u2022</span> Identifies carotid stenosis as a TIA risk factor; TGA is not caused by large-vessel stenosis.  <br><span class=\"list-item\">\u2022</span> Misconception: &ldquo;Any transient neurological event needs vascular imaging&rdquo; &ndash; in TGA without other focal signs, carotid Doppler has very low yield.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Investigation</th><th>Target Finding</th><th>Yield in TGA</th><th>Key Differentiator</th></tr></thead><tbody><tr><td>MRI (DWI)</td><td>Punctate hippocampal hyperintensities</td><td>High (70% at 24&ndash;72 h)</td><td>Direct visualization of characteristic lesions</td></tr><tr><td>CT & CTA</td><td>Hemorrhage, large-vessel stenosis</td><td>Very low for hippocampal changes</td><td>CT is insensitive for small diffusion abnormalities</td></tr><tr><td>EEG</td><td>Epileptiform discharges</td><td>Rarely positive</td><td>Differentiates TEA but not TGA</td></tr><tr><td>Carotid Doppler</td><td>Carotid artery stenosis</td><td>Very low for TGA diagnosis</td><td>Useful for TIA workup, not for isolated amnestic syndrome</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Optimal MRI timing for TGA is 24&ndash;72 hours post-onset; imaging too early may be falsely negative.  <br><span class=\"list-item\">\u2022</span> TGA recurs in <10% of cases; patients generally have an excellent prognosis without long-term sequelae.  <br><span class=\"list-item\">\u2022</span> Rule out other causes (e.g., seizure, stroke) with clinical history, exam, and targeted studies rather than broad vascular imaging.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Ordering immediate CT to &ldquo;rule out TGA&rdquo;: CT will often be normal and delay definitive MRI.  <br>2. Assuming all transient memory disturbances are epileptic: TGA lacks EEG abnormalities.  <br>3. Overuse of carotid and cardiac workup in pure amnestic syndromes: low diagnostic yield and may distract from hippocampal imaging.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- American Academy of Neurology (AAN) Practice Parameter on TGA (2013): Recommends MRI with DWI sequence in all suspected TGA cases to confirm diagnosis (Level B evidence).  <br><span class=\"list-item\">\u2022</span> European Academy of Neurology (EAN) Consensus Statement (2017): Emphasizes DWI MRI at 24&ndash;72 hours post-onset to visualize characteristic lesions; strongly recommends against routine vascular imaging without focal deficits.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>- Hippocampal CA1 pyramidal neurons are selectively vulnerable to transient metabolic or venous congestion insults, leading to the characteristic DWI lesions and clinical amnesia.  <br><span class=\"list-item\">\u2022</span> Connections between the hippocampus, entorhinal cortex, and limbic thalamus underlie consolidation of episodic memories; transient dysfunction here produces global amnesia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>- Leading theories include transient venous congestion (Valsalva-related) and migrainous cortical spreading depression affecting hippocampal perfusion.  <br><span class=\"list-item\">\u2022</span> Lack of permanent neuronal death explains the benign, reversible nature of TGA.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical history: abrupt anterograde amnesia, repetitive questioning, duration &le;24 h.  <br>2. Exclude other causes: vital signs, glucose, electrolytes, neurological exam.  <br>3. If no focal deficits: defer CT unless hemorrhage strongly suspected; plan MRI DWI at 24&ndash;72 h.  <br>4. If focal signs or atypical features: add CT/CTA and vascular imaging.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Use high-resolution DWI (slice thickness &le;3 mm) on 1.5&ndash;3 T scanners.  <br><span class=\"list-item\">\u2022</span> Lesions are typically 2&ndash;5 mm, unilateral or bilateral, in lateral hippocampal regions.  <br><span class=\"list-item\">\u2022</span> Lesion conspicuity increases after 48 hours, then gradually resolves over 7&ndash;10 days.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2019 exam. TGA and its diagnostic workup are frequently tested topics, often in the context of differentiating acute amnestic syndromes from TIA or seizures.</div></div></div></div></div>"
  },
  {
    "id": 100022517,
    "question_number": "56",
    "question_text": "A patient presents with visual hallucinations and fluctuating levels of consciousness, with symptoms suggesting parkinsonism. What is the most likely diagnosis?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2019</span>] Dementia with Lewy bodies (DLB) arises from misfolded &alpha;-synuclein aggregating into Lewy bodies within cortical and subcortical neurons. Core clinical features include:  <br><span class=\"list-item\">\u2022</span> Fluctuating cognition and attention (e.g., day-to-day or hour-to-hour variations)  <br><span class=\"list-item\">\u2022</span> Recurrent, well-formed visual hallucinations  <br><span class=\"list-item\">\u2022</span> Spontaneous parkinsonism (bradykinesia, rigidity)  <br>A key diagnostic principle is the &ldquo;one-year rule&rdquo;: dementia preceding or within one year of parkinsonism onset differentiates DLB from Parkinson&rsquo;s disease dementia. Recognizing these hallmarks allows timely initiation of cholinesterase inhibitors and avoidance of antipsychotics that may precipitate severe sensitivity reactions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Lewy body disease (DLB) is the correct diagnosis. According to the 2017 Fourth Consensus Report by the DLB Consortium <span class=\"citation\">(McKeith et al., <span class=\"evidence\">Neurology 2017</span>)</span>, visual hallucinations, fluctuating cognition, and parkinsonism constitute three of four core features. This patient&rsquo;s triad meets probable DLB criteria. DAT-SPECT typically shows striatal dopamine transporter loss; 123I-MIBG myocardial scintigraphy reveals reduced cardiac uptake (sensitivity ~80%, specificity ~90%).  <br><br>By contrast, idiopathic Parkinson&rsquo;s disease dementia (PDD) requires parkinsonism at least one year before cognitive decline <span class=\"citation\">(MDS Task Force PDD criteria 2007)</span>. Amyotrophic lateral sclerosis spares cortical visual pathways and consciousness. Frontotemporal dementia (FTD) presents with early behavioral changes or language decline, not visual hallucinations or parkinsonism.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Idiopathic Parkinson's disease  <br><span class=\"list-item\">\u2022</span> Incorrect because in PD dementia, cognitive decline follows motor signs by >12 months (&ldquo;one-year rule&rdquo;). Early visual hallucinations are usually drug-induced, not intrinsic.  <br>C. Amyotrophic lateral sclerosis  <br><span class=\"list-item\">\u2022</span> ALS primarily affects upper and lower motor neurons; cognitive fluctuations and visual hallucinations are not features.  <br>D. Frontotemporal dementia  <br><span class=\"list-item\">\u2022</span> FTD presents with disinhibition, language deficits, or personality changes; parkinsonism and visual hallucinations are rare early.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>DLB</th><th>PD Dementia</th><th>ALS</th><th>FTD</th></tr></thead><tbody><tr><td>Onset of Dementia vs Parkinson</td><td>Dementia &le;1 year or concurrent</td><td>Dementia >1 year after motor signs</td><td>No dementia/fluctuations</td><td>Dementia/behavior first, no halluc.</td></tr><tr><td>Visual Hallucinations</td><td>Recurrent, well-formed</td><td>Usually drug-induced</td><td>Absent</td><td>Rare</td></tr><tr><td>Cognitive Fluctuations</td><td>Pronounced</td><td>Mild/late</td><td>Absent</td><td>Executive dysfunction without fluct.</td></tr><tr><td>Neuroimaging</td><td>\u2193 DAT uptake, \u2193 MIBG uptake</td><td>\u2193 DAT uptake</td><td>Normal uptake</td><td>Frontal/temporal atrophy</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- DLB patients are exquisitely sensitive to typical antipsychotics (e.g., haloperidol) and may develop severe rigidity or neuroleptic malignant&ndash;like syndrome.  <br><span class=\"list-item\">\u2022</span> Rivastigmine is the only cholinesterase inhibitor with randomized trial data showing cognitive and behavioral benefits in DLB <span class=\"citation\">(Emre et al., Lancet <span class=\"evidence\">Neurol 2004</span>)</span>.  <br><span class=\"list-item\">\u2022</span> REM sleep behavior disorder (RBD) often precedes cognitive symptoms in DLB by years.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Assuming visual hallucinations in a Parkinson&rsquo;s patient are always medication-induced. In DLB, they are a core diagnostic feature, not merely side effects.  <br>2. Overlooking cognitive fluctuations and labeling the syndrome as Alzheimer&rsquo;s disease; the presence of parkinsonism and hallucinations should redirect to DLB.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- International DLB Consortium <span class=\"citation\">(McKeith et al., <span class=\"evidence\">Neurology 2017</span>)</span>: Defines core/prodromal DLB criteria; recommends DAT-SPECT and MIBG scintigraphy for uncertain cases (Level B evidence).  <br><span class=\"list-item\">\u2022</span> AAN Practice Guidelines (2018): Endorses rivastigmine for cognitive/behavioral symptoms in DLB (Level A evidence); warns against typical antipsychotics (Level B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Lewy bodies composed of &alpha;-synuclein localize to the substantia nigra, limbic cortex, and neocortex, disrupting dopaminergic and cholinergic networks that underlie parkinsonism, attention, and visual processing.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Misfolded &alpha;-synuclein propagates in a prion-like manner from brainstem to neocortex, leading to synaptic dysfunction, neuronal loss, and neurotransmitter deficits (dopamine, acetylcholine).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical assessment: Identify core features (fluctuations, hallucinations, parkinsonism).  <br>2. Exclude reversible causes (metabolic, medication).  <br>3. Supportive tests: DAT-SPECT, 123I-MIBG scintigraphy.  <br>4. Neuropsychological testing: Confirm attentional and visuospatial deficits.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- DAT-SPECT: Reduced striatal uptake distinguishes DLB/PDD from Alzheimer&rsquo;s.  <br><span class=\"list-item\">\u2022</span> 123I-MIBG: Cardiac uptake <1.6 heart/mediastinum ratio supports DLB.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Start rivastigmine at 1.5 mg BID, titrate to 6&ndash;12 mg/day.  <br><span class=\"list-item\">\u2022</span> For psychosis, use quetiapine or clozapine at the lowest effective dose; avoid haloperidol.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2019</span> exam. DLB is frequently tested via vignettes emphasizing visual hallucinations, cognitive fluctuations, and parkinsonism, often contrasting with PDD and Alzheimer&rsquo;s disease.</div></div></div></div></div>"
  },
  {
    "id": 100022518,
    "question_number": "55",
    "question_text": "A 70-year-old male presents with cognitive decline, ataxia, and a startle response. What is the likely diagnosis?",
    "correct_answer": "D",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2018</span>] This question (Q55) from the <span class=\"evidence\">Promotion 2018</span> exam assesses recognition of a rapidly progressive dementia syndrome with prominent cerebellar signs and stimulus\u2010sensitive myoclonus.  <br><span class=\"list-item\">\u2022</span> Prion diseases cause spongiform degeneration in cortex, basal ganglia, cerebellum.  <br><span class=\"list-item\">\u2022</span> Myoclonus (startle response) implicates cortical\u2010subcortical hyperexcitability.  <br><span class=\"list-item\">\u2022</span> Rapid progression over weeks to months distinguishes prion from Alzheimer&rsquo;s or Lewy body dementia.  <br><span class=\"list-item\">\u2022</span> Ataxia reflects cerebellar involvement, common in Creutzfeldt\u2010Jakob disease (CJD).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Creutzfeldt\u2010Jakob disease is a transmissible spongiform encephalopathy caused by misfolded prion protein (PrP^Sc). Sporadic CJD presents in the seventh decade with rapidly progressive dementia, cerebellar signs in ~60%, and myoclonus in ~90%. Diffusion\u2010weighted MRI shows cortical ribboning and basal ganglia hyperintensity with sensitivity >90%. CSF RT-QuIC assay has sensitivity ~92% and specificity ~100% <span class=\"citation\">(<span class=\"evidence\">McGuire et al., 2016</span>)</span>. EEG may reveal periodic sharp wave complexes (PSWCs) in later stages. No disease-modifying treatment exists; diagnosis relies on clinical criteria plus MRI, EEG, and CSF biomarkers <span class=\"citation\">(CDC 2018)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Alzheimer&rsquo;s disease  <br><span class=\"list-item\">\u2022</span> Incorrect: Alzheimer&rsquo;s is a slowly progressive amnestic dementia over years without prominent myoclonus or ataxia early.  <br><span class=\"list-item\">\u2022</span> Misconception: Any cognitive decline equals Alzheimer&rsquo;s; key differentiator is time course and motor features.  <br>B. Lewy body dementia  <br><span class=\"list-item\">\u2022</span> Incorrect: Presents with visual hallucinations, parkinsonism, fluctuating cognition; startle myoclonus and rapid cerebellar signs are absent.  <br><span class=\"list-item\">\u2022</span> Misconception: Dementia + movement always Lewy body; Lewy body myoclonus is rare and not stimulus\u2010sensitive.  <br>C. Normal pressure hydrocephalus  <br><span class=\"list-item\">\u2022</span> Incorrect: Gait apraxia (&ldquo;magnetic gait&rdquo;), urinary incontinence, and cognitive slowing over months; no startle myoclonus or rapid decline.  <br><span class=\"list-item\">\u2022</span> Misconception: Any ataxia plus dementia equals NPH; NPH has characteristic enlarged ventricles on imaging and a different gait.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>CJD (Correct)</th><th>Alzheimer&rsquo;s disease</th><th>Lewy body dementia</th><th>NPH</th></tr></thead><tbody><tr><td>Onset & Progression</td><td>Weeks&ndash;months (rapid)</td><td>Years (slow)</td><td>Months&ndash;years (variable)</td><td>Months&ndash;years (subacute)</td></tr><tr><td>Myoclonus/Startle Response</td><td>Prominent, stimulus-sensitive</td><td>Rare</td><td>Rare</td><td>Absent</td></tr><tr><td>Cerebellar Signs</td><td>Ataxia common</td><td>Absent early</td><td>Rare</td><td>Gait apraxia, not ataxia</td></tr><tr><td>MRI Findings</td><td>DWI: cortical ribboning, basal ganglia changes</td><td>Hippocampal atrophy</td><td>Occipital hypometabolism on PET</td><td>Enlarged ventricles, transependymal flow</td></tr><tr><td>CSF Biomarker</td><td>RT-QuIC positive, 14-3-3 protein</td><td>Normal</td><td>Normal</td><td>Normal</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Stimulus-sensitive myoclonus in an elderly patient with rapidly progressive dementia is nearly pathognomonic for CJD.  <br><span class=\"list-item\">\u2022</span> Diffusion-weighted MRI is the most sensitive neuroimaging modality for early CJD detection.  <br><span class=\"list-item\">\u2022</span> CSF RT-QuIC assay has revolutionized ante-mortem diagnosis due to its high specificity (~100%).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Equating any dementia with Alzheimer&rsquo;s disease: always assess time course and motor signs.  <br>2. Mistaking gait apraxia of NPH for cerebellar ataxia&mdash;evaluate cerebellar exam (dysdiadochokinesia, dysmetria) versus &ldquo;magnetic&rdquo; gait.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- European Academy of Neurology (EAN) Guidelines on Prion Disease Diagnosis and Management, 2022: Recommend DWI/FLAIR MRI (Level B evidence) and CSF RT-QuIC (Level A evidence) for probable sporadic CJD; discourage brain biopsy unless atypical.  <br><span class=\"list-item\">\u2022</span> Centers for Disease Control and Prevention (CDC) Diagnostic Criteria Update, 2018: Incorporates RT-QuIC as a confirmatory CSF assay (Level B evidence), periodic sharp wave complexes on EEG (Level C), and mandates comprehensive infection control measures.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Prion deposition and spongiform change occur in neocortex (cognitive decline), cerebellar cortex (ataxia), and thalamus/basal ganglia (myoclonus generation via disinhibited cortical circuits).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Misfolded PrP^Sc induces conformational change in normal PrP^C, forming beta\u2010sheet rich aggregates. Accumulation triggers neuronal apoptosis, vacuolation, and astrocytic proliferation, leading to rapidly progressive neurodegeneration.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical suspicion: rapid cognitive decline, myoclonus, ataxia.  <br>2. Obtain MRI DWI/FLAIR: look for cortical ribboning, basal ganglia hyperintensity.  <br>3. Perform EEG for PSWCs.  <br>4. CSF analysis: RT-QuIC assay and 14-3-3 protein.  <br>5. If inconclusive and clinically warranted, brain biopsy/autopsy for definitive diagnosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- DWI hyperintensity in cortical ribbon (&ldquo;cortical ribboning&rdquo;) and striatum is 92&ndash;96% sensitive for sporadic CJD.  <br><span class=\"list-item\">\u2022</span> FLAIR less sensitive but useful adjunct; pulvinar sign more characteristic of variant CJD.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2018</span> exam. Recognition of rapidly progressive dementia with myoclonus and ataxia is a high\u2010yield topic on neurology boards, often tested via brief vignettes emphasizing MRI and CSF diagnostic criteria.</div></div></div></div></div>"
  },
  {
    "id": 100022520,
    "question_number": "57",
    "question_text": "A patient presents with hyperphagia, personality changes, and memory loss. What is the likely diagnosis?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2019</span>] Frontotemporal dementia (FTD) is characterized by early changes in behavior, personality and executive function due to predominant frontal and/or anterior temporal lobe degeneration. Key concepts:  <br><span class=\"list-item\">\u2022</span> Neuroanatomy: Orbitofrontal cortex mediates social behavior and impulsivity; dorsolateral prefrontal cortex underpins executive function.  <br><span class=\"list-item\">\u2022</span> Pathophysiology: FTD pathology often involves abnormal tau or TDP-43 aggregation, leading to selective neuronal loss in frontal and anterior temporal regions.  <br><span class=\"list-item\">\u2022</span> Clinical presentation: Behavioral variant (bvFTD) manifests with disinhibition (e.g., hyperphagia), apathy, loss of empathy, compulsive behaviors; memory impairment is relatively mild early on.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Frontotemporal dementia is the correct diagnosis:  <br><span class=\"list-item\">\u2022</span> Core bvFTD features per Rascovsky et al. <span class=\"citation\">(Brain, 2011)</span>: early disinhibition, apathy/inertia, loss of sympathy, perseverative behaviors, hyperorality or dietary changes, and executive deficits with relatively preserved episodic memory.  <br><span class=\"list-item\">\u2022</span> Neuroimaging: MRI shows predominant frontal/anterior temporal atrophy; FDG-PET demonstrates hypometabolism in these regions.  <br><span class=\"list-item\">\u2022</span> Pathologic confirmation: 50&ndash;60% have tauopathies (MAPT mutations), others have TDP-43 proteinopathy (GRN or C9orf72 mutations).  <br>Alzheimer&rsquo;s disease typically presents with early episodic memory loss, hippocampal atrophy, and amyloid/tau pathology; vascular dementia has stepwise decline with focal deficits and imaging evidence of infarcts; normal pressure hydrocephalus presents with gait disturbance and urinary incontinence before dementia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Alzheimer's disease  <br><span class=\"list-item\">\u2022</span> Why incorrect: Presents with insidious episodic memory decline and visuospatial deficits early, not marked hyperphagia or disinhibition.  <br><span class=\"list-item\">\u2022</span> Misconception: Equating any dementia with personality change; AD&rsquo;s early personality changes are less prominent.  <br><span class=\"list-item\">\u2022</span> Differentiator: Prominent hippocampal atrophy and amyloid biomarkers.  <br><br>C. Vascular dementia  <br><span class=\"list-item\">\u2022</span> Why incorrect: Characterized by stepwise cognitive decline tied to cerebrovascular events, focal neurologic signs, and white-matter changes or infarcts on imaging.  <br><span class=\"list-item\">\u2022</span> Misconception: Attributing sudden behavior changes to stroke rather than neurodegeneration.  <br><span class=\"list-item\">\u2022</span> Differentiator: MRI shows lacunes, strategic infarcts or extensive small-vessel ischemic changes.  <br><br>D. Normal pressure hydrocephalus  <br><span class=\"list-item\">\u2022</span> Why incorrect: Classical triad&mdash;gait apraxia, urinary incontinence, and cognitive impairment (&ldquo;wet, wobbly, wacky&rdquo;) with ventricular enlargement on imaging.  <br><span class=\"list-item\">\u2022</span> Misconception: Assuming all dementia with personality change fits hydrocephalus.  <br><span class=\"list-item\">\u2022</span> Differentiator: MRI demonstrates enlarged ventricles out of proportion to cortical atrophy, and gait disturbance predominates.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Frontotemporal Dementia</th><th>Alzheimer&rsquo;s Disease</th><th>Vascular Dementia</th><th>Normal Pressure Hydrocephalus</th></tr></thead><tbody><tr><td>Onset</td><td>50&ndash;65 yrs, behavior changes early</td><td>> 65 yrs, memory first</td><td>Variable, stepwise decline</td><td>> 60 yrs, gait first</td></tr><tr><td>Memory</td><td>Mild early, executive worse</td><td>Severe early episodic memory loss</td><td>Mixed cognitive profile</td><td>Subcortical pattern, mild memory</td></tr><tr><td>Behavior/personality</td><td>Disinhibition, hyperphagia, apathy</td><td>Relatively preserved initially</td><td>May occur late</td><td>Minimal behavioral change</td></tr><tr><td>Imaging</td><td>Frontal/anterior temporal atrophy</td><td>Hippocampal/temporoparietal atrophy</td><td>Infarcts, white-matter lesions</td><td>Ventriculomegaly &plusmn; transependymal CSF flow</td></tr><tr><td>Pathology</td><td>Tau or TDP-43 inclusions</td><td>&beta;-amyloid plaques, tau tangles</td><td>Ischemic lesions</td><td>CSF outflow impairment</td></tr><tr><td>Treatment focus</td><td>Behavioral management, SSRIs</td><td>Cholinesterase inhibitors, memantine</td><td>Vascular risk factor control</td><td>CSF shunting</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Hyperorality (e.g., binge eating, sweet cravings) is a red flag for bvFTD.  <br><span class=\"list-item\">\u2022</span> Early executive dysfunction with relative sparing of memory distinguishes bvFTD from Alzheimer&rsquo;s.  <br><span class=\"list-item\">\u2022</span> SSRIs can ameliorate disinhibition and compulsivity in bvFTD; disease-modifying therapies remain investigational.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Overreliance on memory loss: Students often assume memory impairment is the earliest feature in all dementias, delaying FTD recognition.  <br>2. Misinterpreting weight gain or eating changes as depression or medication side effects rather than orbitofrontal involvement.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. International Frontotemporal Dementia Consortium <span class=\"citation\">(Rascovsky et al., <span class=\"evidence\">Brain 2011</span>)</span>:  <br><span class=\"list-item\">\u2022</span> Recommendation: Use revised consensus criteria for possible/probable bvFTD&mdash;requires &ge;3 core features plus imaging support.  <br><span class=\"list-item\">\u2022</span> Level of evidence: Class I diagnostic accuracy study.  <br>2. Boxer AL et al. <span class=\"citation\">(<span class=\"evidence\">Neurology 2013</span>)</span>: Randomized placebo-controlled trial of memantine in bvFTD  <br><span class=\"list-item\">\u2022</span> Finding: No significant benefit on cognitive or behavioral scales.  <br><span class=\"list-item\">\u2022</span> Level of evidence: Class I therapeutic trial, memantine not recommended.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>- Orbitofrontal cortex degeneration \u2192 disinhibition, hyperorality.  <br><span class=\"list-item\">\u2022</span> Anterior cingulate involvement \u2192 apathy/inertia.  <br><span class=\"list-item\">\u2022</span> Dorsolateral prefrontal cortex \u2192 executive dysfunction, planning deficits.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>- Tauopathies (e.g., Pick disease) feature intraneuronal Pick bodies; mutations in MAPT gene in familial cases.  <br><span class=\"list-item\">\u2022</span> TDP-43 proteinopathies (GRN, C9orf72 expansions) lead to cytoplasmic inclusions and selective neuronal loss.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Detailed history focusing on behavior, dietary changes, social conduct.  <br>2. Neuropsychological testing emphasizing executive function vs memory.  <br>3. Structural MRI: assess for frontal/anterior temporal atrophy.  <br>4. Functional imaging (FDG-PET/SPECT) if MRI equivocal&mdash;look for hypometabolism.  <br>5. Genetic testing if family history positive (MAPT, GRN, C9orf72).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- MRI: asymmetrical frontal or temporal lobe atrophy early in bvFTD.  <br><span class=\"list-item\">\u2022</span> FDG-PET: frontal hypometabolism with relative posterior sparing distinguishes bvFTD from AD.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- No FDA-approved disease-modifying agents.  <br><span class=\"list-item\">\u2022</span> SSRIs (e.g., sertraline 50&ndash;100 mg/day) often reduce disinhibition and compulsivity (Level B evidence).  <br><span class=\"list-item\">\u2022</span> Atypical antipsychotics reserved for severe agitation, used cautiously due to adverse effects.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2019</span> exam.  <br><span class=\"list-item\">\u2022</span> Dementia subtypes are frequently tested as &ldquo;clinical vignettes&rdquo; focusing on early distinguishing features (behavioral vs memory vs gait).  <br><span class=\"list-item\">\u2022</span> Recognizing hyperorality and executive dysfunction points to bvFTD.</div></div></div></div></div>"
  },
  {
    "id": 100022521,
    "question_number": "68",
    "question_text": "A patient with increasing forgetfulness had to change his bank ATM card because he misplaced it. This has affected his activities of daily living (ADLs), but he is doing well at work. This presentation is suggestive of:",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2022</span>] Mild Cognitive Impairment (MCI) is characterized by an objective decline in one or more cognitive domains greater than expected for age and education, yet patients maintain independence in both instrumental activities of daily living (IADLs) and basic ADLs. Dementia (major neurocognitive disorder in DSM-5) requires deficits in at least two cognitive domains that substantially interfere with independence in everyday activities. Key clinical distinctions hinge on functional impact: IADLs include managing finances, medication, and transportation, while basic ADLs cover feeding, dressing, and bathing. Normal age-related memory loss involves benign, nonprogressive lapses without functional decline. Delirium is acute, fluctuating inattention with altered consciousness, usually reversible when the underlying cause is treated.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>According to DSM-5 <span class=\"citation\">(American Psychiatric Association, 2013)</span>, major neurocognitive disorder is diagnosed when cognitive deficits in &ge;2 domains significantly impair independence in everyday activities&mdash;here evidenced by the patient&rsquo;s inability to manage his ATM card without assistance. <span class=\"evidence\">The 2011</span> NIA-AA criteria for Alzheimer&rsquo;s disease emphasize functional decline beyond normal aging as a hallmark of dementia rather than MCI. Petersen et al. (2014) demonstrated that impairment of IADLs (e.g., financial management) distinguishes MCI from early dementia with >80% sensitivity. Although occupational performance may remain intact initially, loss of autonomy in home-based IADLs confirms a diagnosis of dementia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Mild Cognitive Impairment (MCI)  <br><span class=\"list-item\">\u2022</span> Incorrect because MCI patients preserve independence in all IADLs and basic ADLs.  <br><span class=\"list-item\">\u2022</span> Misconception: Any measurable memory decline equals MCI.  <br><span class=\"list-item\">\u2022</span> Key differentiator: No functional impairment.<br><br>C. Normal age-related memory loss  <br><span class=\"list-item\">\u2022</span> Incorrect because benign aging does not lead to persistent or progressive functional impairment.  <br><span class=\"list-item\">\u2022</span> Misconception: Attributing any daily-life mishap to normal aging.  <br><span class=\"list-item\">\u2022</span> Key differentiator: Lack of progressive decline or interference with ADLs/IADLs.<br><br>D. Delirium  <br><span class=\"list-item\">\u2022</span> Incorrect because delirium is acute (hours&ndash;days), with fluctuating attention and altered consciousness.  <br><span class=\"list-item\">\u2022</span> Misconception: Equating chronic memory issues with delirium.  <br><span class=\"list-item\">\u2022</span> Key differentiator: Disturbance in attention and level of consciousness, plus reversibility.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Dementia (Correct)</th><th>MCI</th><th>Normal Aging</th><th>Delirium</th></tr></thead><tbody><tr><td>Onset</td><td>Insidious, progressive</td><td>Insidious, mild</td><td>Gradual, benign</td><td>Acute (hours&ndash;days)</td></tr><tr><td>Cognitive domains</td><td>&ge;2 domains impaired, significant decline</td><td>&ge;1 domain impaired, mild</td><td>None or minimal</td><td>Primarily attention, fluctuating</td></tr><tr><td>Functional impact</td><td>Interferes with IADLs/basic ADLs</td><td>Independence preserved</td><td>No interference with ADLs/IADLs</td><td>Severe functional disruption</td></tr><tr><td>Consciousness</td><td>Clear until late stages</td><td>Clear</td><td>Clear</td><td>Altered, fluctuates</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Distinguish IADLs (e.g., managing finances) from basic ADLs; early dementia often first impairs IADLs.  <br><span class=\"list-item\">\u2022</span> Annual conversion rate from MCI to dementia is ~10&ndash;15%; monitor IADLs with standardized scales (e.g., Lawton IADL).  <br><span class=\"list-item\">\u2022</span> Use brief cognitive screens (MoCA, MMSE) alongside caregiver reports of functional decline for early detection.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Interpreting a single workplace success as ruling out dementia&mdash;functional decline often occurs first in home IADLs.  <br><span class=\"list-item\">\u2022</span> Attributing any memory lapse in an older adult to &ldquo;normal aging&rdquo; without assessing impact on daily living.  <br><span class=\"list-item\">\u2022</span> Confusing delirium with dementia by focusing on memory rather than attention, consciousness, and onset.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- American Academy of Neurology (AAN) 2018 Practice Guideline on MCI: Recommends standardized IADL assessments to differentiate MCI from dementia (Level B evidence).  <br><span class=\"list-item\">\u2022</span> NICE Guideline NG97 (2018 update): Defines dementia diagnosis by cognitive impairment plus functional decline; endorses IADL/basic ADL scales and caregiver questionnaires (moderate-quality evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2022</span> exam. Differentiating mild cognitive impairment from dementia using IADL impairment is frequently tested on neurology board exams, often in clinical vignettes emphasizing patient autonomy and daily functioning.</div></div></div></div></div>"
  },
  {
    "id": 100022522,
    "question_number": "61",
    "question_text": "Dementia with Lewy Bodies (DLB)",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2021</span>] Dementia with Lewy bodies (DLB) is a primary neurodegenerative disorder in the &alpha;-synucleinopathy spectrum. Pathologically, it is defined by Lewy bodies&mdash;eosinophilic intraneuronal inclusions rich in misfolded &alpha;-synuclein&mdash;affecting cortical and subcortical structures. Clinically, DLB is distinguished from Alzheimer&rsquo;s disease (AD) by early impairments in visuospatial processing, attention, and executive function rather than memory and language, and from vascular dementia by the absence of stepwise decline or focal deficits. Per the 2017 DLB Consortium criteria, core features include fluctuating cognition, recurrent visual hallucinations, and spontaneous parkinsonism. These distinctions guide diagnostic workup (including dopamine transporter imaging) and management, particularly around cholinergic therapy and antipsychotic sensitivity.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Option B is correct: DLB typically presents with recurrent, well-formed visual hallucinations and pronounced fluctuations in cognition and alertness, often daily. McKeith et al.&rsquo;s 2017 revised consensus criteria <span class=\"citation\">(<span class=\"evidence\">Neurology 2017</span>;89:88&ndash;100)</span> classify visual hallucinations and cognitive fluctuations as core features with high sensitivity and specificity (~80&ndash;90%). Pathophysiologically, cortical &alpha;-synuclein deposition and severe cholinergic deficits underlie neuropsychiatric symptoms, while nigrostriatal involvement produces parkinsonism. Dopamine transporter SPECT shows reduced striatal uptake, a supportive biomarker. Clinical guidelines <span class=\"citation\">(e.g., NICE NG97, 2018)</span> recommend rivastigmine for cognitive and behavioral symptoms (Level B evidence) and warn against typical antipsychotics due to neuroleptic sensitivity. Thus, B aligns precisely with established diagnostic hallmarks and management principles.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Option A: &ldquo;Characterized by early memory loss and language deficits.&rdquo;  <br><span class=\"list-item\">\u2022</span> Incorrect: Early episodic memory and language involvement are hallmarks of AD, not DLB.  <br><span class=\"list-item\">\u2022</span> Misconception: Equating all dementias with AD-like amnestic presentations.  <br><span class=\"list-item\">\u2022</span> Differentiation: DLB shows visuospatial and attentional decline before memory and relatively preserved naming.<br><br>Option C: &ldquo;Is primarily caused by vascular pathology.&rdquo;  <br><span class=\"list-item\">\u2022</span> Incorrect: Vascular dementia arises from cumulative ischemic injury; DLB is an &alpha;-synucleinopathy.  <br><span class=\"list-item\">\u2022</span> Misconception: Attributing any dementia with parkinsonism to vascular causes.  <br><span class=\"list-item\">\u2022</span> Differentiation: Vascular dementia has stepwise progression, focal deficits, and MRI evidence of infarcts.<br><br>Option D: &ldquo;Does not involve parkinsonism features.&rdquo;  <br><span class=\"list-item\">\u2022</span> Incorrect: Spontaneous parkinsonian signs (rigidity, bradykinesia) are a core diagnostic criterion for DLB.  <br><span class=\"list-item\">\u2022</span> Misconception: Believing parkinsonism only occurs in Parkinson&rsquo;s disease dementia (PDD).  <br><span class=\"list-item\">\u2022</span> Differentiation: In DLB, parkinsonism appears early or concomitantly, whereas PDD requires dementia onset >1\u2009year after motor symptoms.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>DLB (B)</th><th>AD (A)</th><th>Vascular Dementia (C)</th><th>&ldquo;No Parkinsonism&rdquo; DLB (D)</th></tr></thead><tbody><tr><td>Pathology</td><td>&alpha;-synuclein Lewy bodies</td><td>&beta;-amyloid plaques, tau tangles</td><td>Cerebral ischemic lesions</td><td>&alpha;-synuclein Lewy bodies</td></tr><tr><td>Early cognitive deficits</td><td>Visuospatial, attention</td><td>Episodic memory, language</td><td>Executive, processing speed</td><td>Visuospatial, attention</td></tr><tr><td>Visual hallucinations</td><td>Recurrent, well-formed</td><td>Rare early</td><td>Variable, less prominent</td><td>Rare</td></tr><tr><td>Cognitive fluctuations</td><td>Core feature</td><td>Uncommon</td><td>Rare</td><td>Uncommon</td></tr><tr><td>Parkinsonism</td><td>Present</td><td>Absent/late</td><td>Absent or vascular parkinsonism</td><td>Absent</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Recurrent, detailed visual hallucinations in an elderly patient with parkinsonism and alertness fluctuations virtually clinch DLB.  <br><span class=\"list-item\">\u2022</span> REM sleep behavior disorder (RBD) often precedes cognitive symptoms by years in DLB; ask specifically about dream enactment.  <br><span class=\"list-item\">\u2022</span> DLB patients are exquisitely sensitive to typical antipsychotics (e.g., haloperidol); use rivastigmine and, if needed, low-dose atypical agents with caution.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Mistaking early hallucinations in DLB for psychosis or delirium rather than a neurodegenerative sign.  <br><span class=\"list-item\">\u2022</span> Over-relying on memory tests alone and overlooking visuospatial/executive deficits that distinguish DLB from AD.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- McKeith IG et al., &ldquo;Diagnosis and management of DLB,&rdquo; <span class=\"evidence\">Neurology 2017</span>:89:88&ndash;100. Revised consensus criteria define core features (visual hallucinations, fluctuations, parkinsonism) and incorporate dopamine transporter imaging as Level II biomarker.  <br><span class=\"list-item\">\u2022</span> NICE Guideline NG97, 2018 (UK): Recommends rivastigmine for symptomatic treatment of cognitive and neuropsychiatric symptoms in DLB (Evidence level B); advises against typical antipsychotics due to neuroleptic sensitivity.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>- Lewy bodies accumulate in neocortex (visual association areas), limbic structures, substantia nigra, and locus coeruleus.  <br><span class=\"list-item\">\u2022</span> Nigrostriatal involvement explains parkinsonism; cholinergic nucleus basalis of Meynert degeneration underlies attention and visuospatial deficits.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>- Misfolded &alpha;-synuclein aggregates form Lewy bodies \u2192 disrupt synaptic function.  <br><span class=\"list-item\">\u2022</span> Widespread cholinergic neuronal loss \u2192 prominent neuropsychiatric and cognitive fluctuations.  <br><span class=\"list-item\">\u2022</span> Dopaminergic depletion in striatum \u2192 rigidity and bradykinesia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Dopamine transporter SPECT (e.g., ^123I-FP-CIT) shows reduced striatal uptake, supporting DLB diagnosis.  <br><span class=\"list-item\">\u2022</span> ^123I-MIBG myocardial scintigraphy may show reduced cardiac innervation, a supportive biomarker per 2017 criteria.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Rivastigmine (transdermal or oral) improves cognition and neuropsychiatric symptoms; start low and titrate per tolerability.  <br><span class=\"list-item\">\u2022</span> Avoid haloperidol; if antipsychotic required, consider quetiapine or clozapine at minimal effective dose.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2021</span> exam. DLB is frequently tested in contrast to Alzheimer&rsquo;s and vascular dementia, often emphasizing visual hallucinations, fluctuations, and parkinsonism as distinguishing features.</div></div></div></div></div>"
  },
  {
    "id": 100022528,
    "question_number": "64",
    "question_text": "This is a 70-year-old female with a history of short-term memory impairment, long-term memory not affected, and depression with withdrawal from people. CSF shows low amyloid and positive tau. What is the diagnosis?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2022</span>] Alzheimer&rsquo;s disease (AD) is characterized by progressive impairment of episodic (short-term) memory due to early involvement of the hippocampus and entorhinal cortex. By contrast, remote (long-term) memories are relatively spared until later stages. CSF biomarkers follow the AT(N) framework: reduced A&beta;\u2081\u208b\u2084\u2082 (&ldquo;A&rdquo;), elevated phosphorylated tau (&ldquo;T&rdquo;), and/or total tau indicating neurodegeneration (&ldquo;N&rdquo;). Behavioral symptoms such as depression and social withdrawal often accompany early AD. Recognizing this clinical-biomarker signature distinguishes AD from other dementias that present with prominent behavioral, parkinsonian, or asymmetric cortical features.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Alzheimer&rsquo;s disease is diagnosed clinically by an amnestic presentation plus supportive biomarkers. In this patient:  <br>&bull; Clinical: Predominant short-term memory loss with preserved long-term memory is classic early AD <span class=\"citation\">(<span class=\"evidence\">Dubois et al., 2014</span>)</span>.  <br>&bull; CSF: Low A&beta;\u2081\u208b\u2084\u2082 correlates with amyloid plaque deposition; elevated tau reflects neurofibrillary tangle burden <span class=\"citation\">(<span class=\"evidence\">Blennow et al., 2015</span>)</span>. <span class=\"evidence\">The 2018</span> NIA-AA research framework assigns &ldquo;A+T+&rdquo; as biologically definitive for AD <span class=\"citation\">(<span class=\"evidence\">Jack et al., 2018</span>)</span>.  <br>&bull; Neuroanatomy: Hippocampal atrophy on imaging (not provided but implied) aligns with medial temporal lobe involvement.  <br>Current guidelines <span class=\"citation\">(NIA-AA, 2018)</span> recommend integrating cognitive testing, CSF A&beta;\u2081\u208b\u2084\u2082, p-tau, t-tau, and imaging to confirm AD. This patient&rsquo;s biomarker profile meets &ldquo;A+T+&rdquo; criteria, confirming AD over other dementias.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Frontotemporal Dementia (FTD)  <br><span class=\"list-item\">\u2022</span> FTD presents with early personality change, disinhibition or language dysfunction rather than isolated episodic memory loss.  <br><span class=\"list-item\">\u2022</span> CSF A&beta;\u2081\u208b\u2084\u2082 is typically normal; tau may be mildly elevated but not in the A+T+ pattern.  <br><span class=\"list-item\">\u2022</span> Imaging: frontal or anterior temporal atrophy, not hippocampal-predominant.  <br><br>C. Dementia with Lewy Bodies (DLB)  <br><span class=\"list-item\">\u2022</span> Core features include fluctuating cognition, visual hallucinations, parkinsonism; early severe memory loss is less prominent.  <br><span class=\"list-item\">\u2022</span> CSF biomarkers: A&beta;\u2081\u208b\u2084\u2082 may be low, but tau is not characteristically elevated; &alpha;-synuclein markers and DAT-SPECT are more specific.  <br><br>D. Corticobasal Degeneration (CBD)  <br><span class=\"list-item\">\u2022</span> Presents with asymmetric limb rigidity, apraxia, cortical sensory loss, myoclonus, not isolated memory impairment.  <br><span class=\"list-item\">\u2022</span> CSF biomarkers do not follow the A+T+ pattern; imaging shows asymmetric cortical atrophy in frontoparietal regions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Alzheimer&rsquo;s Disease (AD)</th><th>Frontotemporal Dementia (FTD)</th><th>Lewy Body Dementia (DLB)</th><th>Corticobasal Degeneration (CBD)</th></tr></thead><tbody><tr><td>Age of onset</td><td>65&ndash;75 years</td><td>45&ndash;65 years</td><td>60&ndash;80 years</td><td>60&ndash;70 years</td></tr><tr><td>Memory impairment</td><td>Early episodic (short-term)</td><td>Late or mild</td><td>Fluctuating, less amnestic</td><td>Usually late</td></tr><tr><td>Behavioral changes</td><td>Apathy, depression</td><td>Disinhibition, compulsivity</td><td>Visual hallucinations, REM sleep</td><td>Alien limb, apraxia</td></tr><tr><td>CSF A&beta;\u2081\u208b\u2084\u2082 / p-tau / t-tau</td><td>\u2193 A&beta;\u2081\u208b\u2084\u2082, \u2191 p-tau, \u2191 t-tau</td><td>Normal A&beta;\u2081\u208b\u2084\u2082, normal or \u2191 t-tau</td><td>\u2193 A&beta;\u2081\u208b\u2084\u2082, normal p-tau</td><td>Normal A&beta;\u2081\u208b\u2084\u2082, t-tau</td></tr><tr><td>MRI pattern</td><td>Medial temporal atrophy</td><td>Frontal / anterior temporal</td><td>Occipital hypometabolism (FDG)</td><td>Asymmetric frontoparietal</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Episodic memory decline with preserved remote memories is the hallmark of early AD; semantic memory deteriorates later.  <br>2. CSF A&beta;\u2081\u208b\u2084\u2082 < 550 pg/mL plus elevated p-tau (&ge; 60 pg/mL) yields > 85% diagnostic accuracy for AD <span class=\"citation\">(<span class=\"evidence\">Blennow et al., 2015</span>)</span>.  <br>3. Depression and apathy may precede overt cognitive decline in AD: screen mood to avoid misdiagnosis of &ldquo;pseudodementia.&rdquo;</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Mistaking depression-related pseudodementia for AD without biomarker confirmation.  <br>&bull; Assuming that all dementias elevate CSF tau; only AD shows the A+T+ signature.  <br>&bull; Overemphasis on long-term memory when short-term episodic loss is more sensitive for early AD.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. NIA-AA Research Framework <span class=\"citation\">(<span class=\"evidence\">Jack et al., 2018</span>)</span>: Defines AD biologically by AT(N). Recommendation: Use CSF or PET biomarkers for &ldquo;A&rdquo; (amyloid) and &ldquo;T&rdquo; (tau). (Level: Expert consensus)  <br>2. International Working Group-2 (IWG-2) Criteria <span class=\"citation\">(<span class=\"evidence\">Dubois et al., 2014</span>)</span>: Diagnosis of prodromal and dementia stages of AD requires cognitive symptoms + in vivo biomarkers (CSF A&beta;\u2081\u208b\u2084\u2082 and p-tau). (Level: Expert consensus)  <br>3. Aducanumab (Biogen) EMERGE/ENGAGE trials (2020): Showed dose-dependent amyloid reduction; led to FDA accelerated approval in 2021. (Level: Phase 3)  <br>4. Lecanemab <span class=\"citation\">(Clarity AD, 2023)</span>: Demonstrated 27% slowing of clinical decline and amyloid clearance on PET. (Level: Phase 3)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>AD initially affects the hippocampus and entorhinal cortex (Brodmann areas 28/34), spreading to parahippocampal gyrus and association cortices. Neurofibrillary tangles follow Braak staging I&ndash;II in transentorhinal regions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>The amyloid cascade hypothesis posits accumulation of A&beta;\u2081\u208b\u2084\u2082 oligomers triggers tau hyperphosphorylation, synaptic dysfunction, microglial activation, and neuronal death. CSF reflects these processes: \u2193 A&beta; (deposition), \u2191 p-tau (tangle formation), \u2191 t-tau (neuronal injury).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical evaluation: history of episodic memory loss, functional assessment.  <br>2. Cognitive testing: MMSE, MoCA to quantify deficits.  <br>3. Lab work: rule out reversible causes (B12, TSH, RPR).  <br>4. Neuroimaging: MRI to assess hippocampal atrophy; FDG-PET for temporoparietal hypometabolism.  <br>5. CSF biomarkers: A&beta;\u2081\u208b\u2084\u2082, p-tau, t-tau for AT(N) classification.  <br>6. Confirm diagnosis and stratify stage for management.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; MRI: medial temporal lobe atrophy is the most sensitive volumetric marker for early AD.  <br>&bull; FDG-PET: bilateral posterior cingulate and temporoparietal hypometabolism.  <br>&bull; Amyloid PET (e.g., Florbetapir): visualizes A&beta; deposition; positive in preclinical and clinical AD.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Cholinesterase inhibitors (donepezil, rivastigmine, galantamine): improve cognition and function in mild&ndash;moderate AD (AAN Level A).  <br>&bull; Memantine: NMDA receptor antagonist for moderate&ndash;severe AD.  <br>&bull; Disease-modifying: Aducanumab and lecanemab reduce amyloid but require careful ARIA monitoring (MRI every 3&ndash;6 months).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2022</span> exam.  <br>Alzheimer&rsquo;s disease diagnosis using CSF A&beta;\u2081\u208b\u2084\u2082 and tau markers is a frequent topic on neurology and neurosurgery promotion exams, often framed as differentiating AD from FTD or DLB based on biomarker profiles and clinical features.</div></div></div></div></div>"
  },
  {
    "id": 100022529,
    "question_number": "67",
    "question_text": "Q67. The second most common neurodegenerative dementia is:",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2022</span>] Dementias are broadly divided into neurodegenerative (progressive neuronal loss) and secondary (e.g., vascular). The most prevalent neurodegenerative dementia is Alzheimer's disease (AD, ~60&ndash;70% of cases). Among purely neurodegenerative causes, Lewy Body Dementia (LBD) follows AD as the second most common (~15&ndash;20%), characterized by cortical &alpha;-synuclein aggregates. Frontotemporal dementia (FTD) accounts for ~5&ndash;10%. Vascular dementia represents cerebrovascular injury rather than primary neurodegeneration. Understanding relative frequencies and pathologies underpins accurate diagnosis and management.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Lewy Body Dementia is confirmed at autopsy in approximately 15&ndash;20% of dementia cases, making it the second most common neurodegenerative dementia after AD. A meta-analysis by Prince et al. <span class=\"citation\">(Lancet <span class=\"evidence\">Neurol 2013</span>)</span> reported DLB prevalence of 4.2&ndash;7.5% in clinical series, but population-based and neuropathology studies <span class=\"citation\">(Jellinger & Attems, Acta <span class=\"evidence\">Neuropathol 2010</span>)</span> show rates up to 20%. <span class=\"evidence\">The 2017</span> Fourth DLB Consortium Criteria <span class=\"citation\">(McKeith et al., <span class=\"evidence\">Neurology 2017</span>)</span> emphasize its prevalence and hallmarks (visual hallucinations, parkinsonism, cognitive fluctuations). Vascular dementia (~10&ndash;15%) stems from infarcts and is not classified as neurodegenerative. FTD (~5&ndash;10%) has tau or TDP-43 pathology but lower frequency. Thus, LBD is the correct choice.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Frontotemporal Dementia (FTD)  <br><span class=\"list-item\">\u2022</span> Prevalence: ~5&ndash;10% of dementias, less than LBD.  <br><span class=\"list-item\">\u2022</span> Misconception: conflating behavioral syndromes with higher frequency; FTD is rarer and presents with early personality changes.  <br><br>C. Alzheimer's Disease (AD)  <br><span class=\"list-item\">\u2022</span> AD is the most common neurodegenerative dementia (~60&ndash;70%), not second.  <br><span class=\"list-item\">\u2022</span> Misconception: confusing &ldquo;most common&rdquo; with &ldquo;second most common.&rdquo;  <br><br>D. Vascular Dementia  <br><span class=\"list-item\">\u2022</span> Etiology: cerebrovascular injury, not primary neurodegeneration.  <br><span class=\"list-item\">\u2022</span> Although it ranks second overall in some series (~15%), it is classified separately from neurodegenerative dementias.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>LBD</th><th>FTD</th><th>AD</th><th>Vascular Dementia</th></tr></thead><tbody><tr><td>Prevalence (%)</td><td>15&ndash;20</td><td>5&ndash;10</td><td>60&ndash;70</td><td>10&ndash;20</td></tr><tr><td>Primary Pathology</td><td>Cortical &alpha;-synuclein\u00b7LBs</td><td>Tau or TDP-43 inclusions</td><td>&beta;-amyloid plaques & tau NFTs</td><td>Ischemic infarcts, white matter lesions</td></tr><tr><td>Core Clinical Features</td><td>Visual hallucinations, parkinsonism, fluctuations</td><td>Behavioral changes, language dysfunction</td><td>Early memory loss, visuospatial impairment</td><td>Stepwise decline, focal deficits</td></tr><tr><td>Neurodegenerative Classification</td><td>Yes</td><td>Yes</td><td>Yes</td><td>No</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. LBD often shows REM sleep behavior disorder years before cognitive decline.  <br>2. Neuroleptic sensitivity is a red flag in suspected LBD.  <br>3. Mixed AD+vascular pathology is common&mdash;confirm pure neurodegenerative subtype by clinical hallmarks.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Assuming vascular dementia is neurodegenerative; it is due to cerebrovascular insults.  <br>2. Overestimating FTD prevalence because of its dramatic behavioral presentation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. McKeith IG et al., Fourth Consensus Report of the DLB Consortium <span class=\"citation\">(<span class=\"evidence\">Neurology 2017</span>)</span>: Reaffirmed LBD as the second most common neurodegenerative dementia; diagnostic certainty criteria based on core and suggestive features. (Level II evidence)  <br>2. Alzheimer&rsquo;s Disease International, World Alzheimer <span class=\"evidence\">Report 2021</span>: Global epidemiology data confirming AD (~60%), LBD (~15%), vascular dementia (~15%), FTD (~5%); emphasizes need for subtype-specific diagnostic strategies.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2022</span> exam. Epidemiology of dementia subtypes is frequently tested in multiple-choice format, often contrasting &ldquo;neurodegenerative&rdquo; versus &ldquo;vascular&rdquo; causes.</div></div></div></div></div>"
  },
  {
    "id": 100022532,
    "question_number": "65",
    "question_text": "A 56-year-old female presents with behavioral changes and personality alterations. She starts talking to strangers and receives warnings from work due to inappropriate sexual jokes. She has poor personal hygiene and a Mini-Mental State Examination (MMSE) score of 28/30. What is the diagnosis?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2022</span>] - Frontal lobe circuits (orbitofrontal and anterior cingulate) mediate social behavior, disinhibition and executive control.  <br><span class=\"list-item\">\u2022</span> Behavioral variant FTD (bvFTD) presents with early personality change, disinhibition, apathy and loss of empathy, often with preserved episodic memory and language in initial stages.  <br><span class=\"list-item\">\u2022</span> Dementia subtypes differ by age of onset, cognitive profiles, imaging patterns and pathology: bvFTD typically begins in the 50s&ndash;60s, whereas AD is later and features early memory impairment.<br><br>(Word count: 88)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Behavioral variant frontotemporal dementia (bvFTD) is characterized by progressive disinhibition, apathy, loss of social decorum, compulsive behaviors and dietary changes, with relatively spared memory and visuospatial skills initially. Rascovsky et al. (2011) FTDC criteria require &ge;3 of: disinhibition, apathy/inertia, loss of empathy, stereotyped behavior, hyperorality and executive deficits. This patient&rsquo;s inappropriate sexual jokes, social boundary violations and poor hygiene fulfill core features. MMSE remains high because memory and orientation are preserved early. Neuroimaging often shows frontotemporal cortex atrophy on MRI or hypometabolism on FDG-PET. Clinical guidelines <span class=\"citation\">(AAN 2018)</span> recommend clinical and neuroimaging correlation for bvFTD diagnosis (Level B evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Alzheimer&rsquo;s disease (AD):  <br><span class=\"list-item\">\u2022</span> Incorrect because AD presents with early episodic memory loss and visuospatial deficits; behavioral symptoms appear later. MMSE 28/30 with intact memory argues against AD.  <br>C. Lewy body dementia (LBD):  <br><span class=\"list-item\">\u2022</span> Misconception: LBD has visual hallucinations, parkinsonism and fluctuating cognition. Disinhibition is uncommon as an initial feature.  <br>D. Vascular dementia:  <br><span class=\"list-item\">\u2022</span> Typically shows stepwise decline, focal neurologic signs and white matter changes or infarcts on imaging. Pure behavioral disinhibition without stroke history is atypical.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>bvFTD (Correct)</th><th>AD</th><th>LBD</th><th>Vascular Dementia</th></tr></thead><tbody><tr><td>Age of onset</td><td>50s&ndash;60s</td><td>>65</td><td>>65</td><td>>65</td></tr><tr><td>Initial cognitive deficit</td><td>Executive dysfunction, disinhibition</td><td>Episodic memory</td><td>Attention, visuospatial, fluctuations</td><td>Executive/processing speed</td></tr><tr><td>Behavioral changes</td><td>Prominent early (disinhibition, apathy)</td><td>Late onset</td><td>Possible hallucinations, paranoia</td><td>May have apathy, not core feature</td></tr><tr><td>Neuroimaging</td><td>Frontal and/or temporal atrophy</td><td>Hippocampal and parietal atrophy</td><td>Occipital hypometabolism</td><td>Multiple infarcts, white matter T2</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- bvFTD patients often lack insight; family report is crucial for diagnosis.  <br><span class=\"list-item\">\u2022</span> Hyperorality (overeating, sweet cravings) and stereotyped movements are red flags for FTD variants.  <br><span class=\"list-item\">\u2022</span> PET/MRI targeting frontal lobes can differentiate bvFTD from AD with >85% sensitivity.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Mistaking disinhibited behavior in FTD for primary psychiatric disorders (e.g., bipolar or schizo\u00adphrenia).  <br><span class=\"list-item\">\u2022</span> Overreliance on MMSE for dementia subtype&mdash;executive tests (e.g., Trail Making Test B) detect early FTD deficits.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Rascovsky K et al., FTDC Diagnostic Criteria <span class=\"citation\">(Neurology, 2011)</span>: Defines &ldquo;possible&rdquo; and &ldquo;probable&rdquo; bvFTD based on behavioral features plus imaging. Level B evidence for using clinical criteria.  <br>2. AAN Practice Guideline on Dementia <span class=\"citation\">(American Academy of Neurology, 2018)</span>: Recommends MRI or FDG-PET to support bvFTD diagnosis when clinical criteria met (Level B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>bvFTD primarily affects:  <br><span class=\"list-item\">\u2022</span> Orbitofrontal cortex \u2192 disinhibition, impulsivity  <br><span class=\"list-item\">\u2022</span> Ventromedial prefrontal cortex \u2192 loss of empathy  <br><span class=\"list-item\">\u2022</span> Anterior cingulate \u2192 apathy/inertia  <br><span class=\"list-item\">\u2022</span> Insular cortex \u2192 emotional blunting</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>- bvFTD pathology: 50% TDP-43 inclusions, 45% tauopathies (Pick bodies) and 5% FUS protein deposits.  <br><span class=\"list-item\">\u2022</span> Neuronal loss and gliosis in frontal and anterior temporal lobes lead to network disruption in behavior and executive circuits.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2022</span> exam.  <br>Behavioral variant FTD is frequently tested by presenting disinhibition, early personality change with near-normal memory exams. Examinees must distinguish from AD by noting preserved MMSE and absence of amnestic complaints.</div></div></div></div></div>"
  },
  {
    "id": 100022535,
    "question_number": "66",
    "question_text": "A 58-year-old female presents with changes in behavior, memory issues, and visual hallucinations. MRI shows frontal and parietal atrophy. What is the diagnosis?",
    "correct_answer": "C",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2022</span>] Dementia syndromes are classified by predominant clinical features (behavioral vs memory vs motor) and atrophy patterns.  <br><span class=\"list-item\">\u2022</span> Frontal lobe involvement manifests as disinhibition, apathy, or personality change (FTD).  <br><span class=\"list-item\">\u2022</span> Parietal involvement ( visuospatial deficits) and medial temporal atrophy produce early memory loss (AD).  <br><span class=\"list-item\">\u2022</span> Visual hallucinations often reflect occipital and cholinergic pathway dysfunction (DLB).  <br><span class=\"list-item\">\u2022</span> Asymmetric cortical degeneration with limb apraxia suggests CBD.  <br>Integrating neuropsychiatric features (visual hallucinations), cognitive profile, and MRI atrophy distribution directs differential diagnosis in neurodegenerative dementias.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Dementia with Lewy bodies (DLB) is characterized by early prominent visual hallucinations (up to 80% of cases), fluctuating cognition, and parkinsonism. <span class=\"evidence\">The 2017</span> DLB Consortium criteria <span class=\"citation\">(McKeith et al., <span class=\"evidence\">Neurology 2017</span>)</span> list recurrent visual hallucinations as a core feature. MRI in DLB typically shows less medial temporal lobe atrophy than AD but may demonstrate mild cortical atrophy, especially in frontal and parietal regions; functional imaging often reveals occipital hypometabolism on FDG-PET or hypoperfusion on SPECT <span class=\"citation\">(Thomas et al., J Nucl <span class=\"evidence\">Med 2018</span>)</span>. Cholinergic deficits underpin hallucinations and cognitive fluctuations; this contrasts with the tauopathic patterns seen in FTD and amyloid-tau pathology of AD.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Frontotemporal dementia (FTD)  <br><span class=\"list-item\">\u2022</span> Incorrect because FTD presents with early behavioral disinhibition or language variants without prominent visual hallucinations.  <br><span class=\"list-item\">\u2022</span> Misconception: attributing frontal atrophy plus behavior change automatically to FTD.  <br><span class=\"list-item\">\u2022</span> Differs from DLB by lacking occipital/cholinergic pathology that causes hallucinations.  <br><br>B. Alzheimer's disease (AD)  <br><span class=\"list-item\">\u2022</span> Incorrect because AD shows predominant hippocampal and temporoparietal atrophy with early memory impairment; visual hallucinations are late and uncommon early.  <br><span class=\"list-item\">\u2022</span> Misconception: parietal atrophy equals AD irrespective of hallucinations.  <br><span class=\"list-item\">\u2022</span> AD hallmark biomarkers: CSF A&beta;42/tau ratio and medial temporal lobe volume loss.  <br><br>D. Corticobasal degeneration (CBD)  <br><span class=\"list-item\">\u2022</span> Incorrect because CBD presents with asymmetric rigidity, apraxia, and cortical sensory loss, not early hallucinations.  <br><span class=\"list-item\">\u2022</span> Misconception: frontoparietal atrophy always indicates CBD.  <br><span class=\"list-item\">\u2022</span> CBD pathology: 4-repeat tau deposition, with &ldquo;alien limb&rdquo; phenomenon, absent in DLB.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>DLB</th><th>FTD</th><th>AD</th><th>CBD</th></tr></thead><tbody><tr><td>Core symptoms</td><td>Visual hallucinations, fluctuations</td><td>Behavioral disinhibition, language</td><td>Episodic memory loss</td><td>Asymmetric rigidity, apraxia</td></tr><tr><td>Cognitive profile</td><td>Attention/executive, visuospatial</td><td>Executive, language</td><td>Memory, later visuospatial</td><td>Executive, praxis</td></tr><tr><td>MRI atrophy</td><td>Mild cortical (frontal/parietal)</td><td>Focal frontal/anterior temporal</td><td>Medial temporal, parietal</td><td>Asymmetric frontoparietal</td></tr><tr><td>Pathology</td><td>&alpha;-synuclein Lewy bodies</td><td>Tau/TDP-43 inclusions</td><td>Amyloid-&beta; plaques, tau tangles</td><td>4-repeat tau aggregates</td></tr><tr><td>Biomarkers</td><td>Occipital hypometabolism (SPECT/PET)</td><td>FTLD gene mutations (e.g. MAPT)</td><td>\u2193A&beta;42/\u2191tau in CSF</td><td>Cortical ribboning on FDG-PET</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Occipital hypometabolism on FDG-PET is a supportive biomarker for DLB <span class=\"citation\">(Mc<span class=\"evidence\">Keith 2017</span>)</span>.  <br><span class=\"list-item\">\u2022</span> Rivastigmine improves cognition and hallucinations in DLB <span class=\"citation\">(Thomas et al., <span class=\"evidence\">Neurology 2000</span>)</span>.  <br><span class=\"list-item\">\u2022</span> Avoid typical antipsychotics (e.g., haloperidol) due to severe sensitivity; prefer quetiapine or clozapine.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Overcalling FTD when frontal atrophy coincides with behavior change; always inquire about hallucinations and parkinsonism.  <br><span class=\"list-item\">\u2022</span> Misattributing visual hallucinations in AD without assessing timing; in DLB, hallucinations occur early.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>-<span class=\"evidence\"> McKeith IG et al., 2017</span> DLB Consortium criteria <span class=\"citation\">(<span class=\"evidence\">Neurology 2017</span>)</span>: defines core features and supportive biomarkers; Level II evidence for occipital hypometabolism.  <br><span class=\"list-item\">\u2022</span> NICE Guideline NG97, 2018: recommends cholinesterase inhibitors (e.g., rivastigmine) for cognitive and neuropsychiatric symptoms in DLB (Grade B evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>&alpha;-Synuclein aggregates in cortical and brainstem cholinergic nuclei (nucleus basalis of Meynert) lead to cholinergic deficit, manifesting as hallucinations and attention fluctuations.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Misfolded &alpha;-synuclein forms Lewy bodies, disrupting synaptic function and inducing neurotoxicity in cortical and subcortical networks, especially visual and executive circuits.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical assessment: history of early visual hallucinations, cognition fluctuations, parkinsonism.  <br>2. Exclude other causes: medication review, metabolic workup.  <br>3. Supportive biomarkers: DAT-SPECT for presynaptic nigrostriatal deficit.  <br>4. Structural MRI: assess atrophy pattern; FDG-PET/SPECT for occipital hypometabolism.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Relative preservation of hippocampal volume differentiates DLB from AD.  <br><span class=\"list-item\">\u2022</span> Occipital hypoperfusion on SPECT is more specific for DLB vs other dementias.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Rivastigmine: start 1.5 mg twice daily, titrate to 6&ndash;12 mg/day; monitor GI side effects.  <br><span class=\"list-item\">\u2022</span> Use quetiapine (low dose) for psychosis; avoid typical neuroleptics.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2022</span> exam.  <br>DLB scenarios often present with visual hallucinations early in the disease course coupled with mild imaging changes. Questions frequently test differential patterns of cortical atrophy and key biomarkers (e.g., occipital hypometabolism).</div></div></div></div></div>"
  },
  {
    "id": 100022536,
    "question_number": "59",
    "question_text": "Q59. A 60-year-old university professor started to forget things and frequently loses his bank cards, but it is not affecting his job. The patient is worried about his memory. What is the most likely diagnosis?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2019</span>] - Mild cognitive impairment (MCI) denotes objective cognitive decline greater than expected for age/education without significant impact on daily functioning; annual progression rate to dementia is ~10&ndash;15% <span class=\"citation\">(<span class=\"evidence\">Petersen et al., 1999</span>)</span>.  <br><span class=\"list-item\">\u2022</span> Alzheimer-related MCI often reflects early medial temporal lobe pathology&mdash;hippocampal and entorhinal cortex atrophy detectable on MRI.  <br><span class=\"list-item\">\u2022</span> Differentiation from normal aging hinges on standardized neuropsychological testing (e.g., MoCA score <26), whereas normal age-related memory lapses do not meet criteria for objective impairment.  <br><span class=\"list-item\">\u2022</span> Alzheimer disease (AD) meets DSM-5 major neurocognitive disorder criteria with interference in independence; frontotemporal dementia shows early behavioral/language changes rather than isolated memory deficits.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>MCI is defined per both the 2011 and 2018 NIA-AA criteria as cognitive decline with preserved independence <span class=\"citation\">(<span class=\"evidence\">Jack et al., 2018</span>)</span>. <span class=\"evidence\">The 2017</span> AAN practice guideline (Level B) recommends formal neuropsychological assessment in suspected MCI and finds insufficient evidence to support cholinesterase inhibitors <span class=\"citation\">(AAN, 2017)</span>. Here, the patient&rsquo;s subjective complaint and repeated misplacement of bank cards&mdash;despite intact job performance&mdash;fits amnestic MCI. By DSM-5, his deficits exceed normal aging but do not impair activities of daily living (ADLs), excluding dementia. Neuroanatomically, early hippocampal atrophy underlies episodic memory encoding deficits, with sparing of frontal&ndash;parietal networks preserving executive function and daily independence.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Alzheimer disease.  <br>&bull; Requires progressive impairment in multiple cognitive domains with clear interference in ADLs.  <br>&bull; Misconception: any memory loss equals AD.  <br>&bull; Key differentiator: AD meets criteria for major neurocognitive disorder.  <br><br>C. Frontotemporal dementia.  <br>&bull; Presents with early personality, behavioral or language changes, not isolated amnestic deficits.  <br>&bull; Misconception: all dementias begin with memory loss.  <br>&bull; Key differentiator: frontal/anterior temporal atrophy and disinhibition.  <br><br>D. Normal age-related memory decline.  <br>&bull; Involves benign retrieval lapses (e.g., forgetting names) without objective deficits or repetitive misplacement.  <br>&bull; Misconception: frequent misplacement is &ldquo;normal aging.&rdquo;  <br>&bull; Key differentiator: no measurable decline on standardized testing.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>MCI</th><th>Alzheimer disease</th><th>Frontotemporal dementia</th><th>Normal aging</th></tr></thead><tbody><tr><td>Onset</td><td>Insidious, mild</td><td>Progressive, moderate&ndash;severe</td><td>Insidious, behavioral/language</td><td>Gradual, minimal</td></tr><tr><td>Memory impairment</td><td>Objective, mild</td><td>Prominent, progressive</td><td>Often spared early</td><td>Occasional retrieval lapses</td></tr><tr><td>Functional status</td><td>Preserved ADLs; subtle IADL deficits</td><td>Impaired ADLs and IADLs</td><td>Variable; behavioral interference</td><td>Preserved ADLs and IADLs</td></tr><tr><td>Imaging</td><td>Mild hippocampal atrophy</td><td>Marked medial temporal atrophy; amyloid PET positive</td><td>Frontal/anterior temporal atrophy</td><td>Age-appropriate changes</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Use MoCA (<26 cutoff) for early detection of MCI; it outperforms MMSE in sensitivity <span class=\"citation\">(<span class=\"evidence\">Nasreddine et al., 2005</span>)</span>.  <br><span class=\"list-item\">\u2022</span> Subtype MCI (amnestic vs non-amnestic) to estimate risk of progression&mdash;amnestic MCI confers higher AD risk.  <br><span class=\"list-item\">\u2022</span> Non-pharmacologic interventions (aerobic exercise, cognitive training) have moderate evidence <span class=\"citation\">(NICE 2018)</span> for slowing cognitive decline.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Overdiagnosing dementia by equating any forgetfulness in older adults with MCI/dementia.  <br><span class=\"list-item\">\u2022</span> Relying solely on patient report without objective testing leads to misclassification of normal aging.  <br><span class=\"list-item\">\u2022</span> Prescribing cholinesterase inhibitors in MCI despite guideline recommendations against routine use.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- NIA-AA research framework <span class=\"citation\">(<span class=\"evidence\">Jack et al., 2018</span>)</span>: Defines MCI due to AD by clinical phenotype plus biomarkers (amyloid, tau, neurodegeneration); expert consensus, Level II evidence.  <br><span class=\"list-item\">\u2022</span> AAN practice guideline on MCI (2017): Recommends comprehensive cognitive assessment (Level B) and advises against routine cholinesterase inhibitor use (Level C).  <br><span class=\"list-item\">\u2022</span> NICE guideline NG97 (2018): Endorses non-pharmacological management (exercise, cognitive interventions) for MCI (Level B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Early involvement of the hippocampal CA1 region and entorhinal cortex in the medial temporal lobes accounts for episodic memory encoding deficits; posterior cingulate hypometabolism emerges as AD pathology progresses.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Accumulation of amyloid-&beta; plaques and hyperphosphorylated tau tangles in medial temporal structures leads to synaptic dysfunction and neuronal loss, presenting clinically as MCI before widespread cortical degeneration.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Elicit subjective cognitive complaints and collateral history.  <br>2. Screen with MoCA.  <br>3. Perform formal neuropsychological testing (&ge;1.5 SD below norms in &ge;1 domain).  <br>4. Assess functional status: preserved ADLs, possible IADL slowness.  <br>5. Obtain MRI: evaluate hippocampal atrophy.  <br>6. Consider CSF or PET biomarkers for research or unclear cases.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>Scheltens medial temporal atrophy scale >1 correlates with early AD pathology in amnestic MCI; FDG-PET shows hypometabolism in posterior cingulate and precuneus.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>No FDA-approved medications for MCI; cholinesterase inhibitors are not recommended routinely <span class=\"citation\">(AAN 2017)</span>. Emphasize lifestyle modification and risk factor control.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2019</span> exam. Memory disorders and the spectrum from normal aging through MCI to dementia are tested frequently (3&ndash;5% of neurology/psychiatry items), often focusing on functional status and objective testing criteria.</div></div></div></div></div>"
  },
  {
    "id": 100022541,
    "question_number": "58",
    "question_text": "A patient with cognitive decline also presents with urinary incontinence and a magnetic gait. What is the most likely diagnosis?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2019</span>] Normal pressure hydrocephalus (NPH) is defined by the triad of gait disturbance, cognitive impairment and urinary incontinence, resulting from impaired CSF absorption with ventriculomegaly despite normal opening pressures. Enlarged ventricles stretch periventricular white matter tracts&mdash;particularly frontal\u2010subcortical circuits&mdash;producing &ldquo;magnetic&rdquo; gait apraxia, subcortical executive dysfunction and detrusor overactivity. Differentiation from Alzheimer&rsquo;s disease (cortical memory loss), Parkinson&rsquo;s disease (resting tremor, rigidity, bradykinesia) and multiple sclerosis (demyelinating relapses, hyperreflexia) hinges on the clinical constellation plus imaging and CSF dynamics. Recognition of this reversible cause of dementia is critical in neurology practice and board examination settings.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>NPH arises from reduced CSF resorption at the arachnoid granulations, leading to ventricular enlargement without sustained pressure elevation. According to the American Academy of Neurology (AAN) Practice Parameter (2021), a high-volume lumbar tap test (&ge;30 mL removal) with transient gait or cognitive improvement has Class I evidence for predicting ventriculoperitoneal (VP) shunt responsiveness. The SINPHONI\u20102 randomized trial <span class=\"citation\">(Mori et al., <span class=\"evidence\">Neurology 2019</span>)</span> demonstrated that early VP shunting significantly improves gait speed and executive function at 6 months compared with delayed intervention (p<0.01). MRI findings&mdash;disproportionately enlarged subarachnoid spaces (DESH) and a narrowed callosal angle (<90\u00b0)&mdash;are validated by European iNPH Guidelines (2017; Level B evidence) as predictors of positive shunt outcome. Lumbar opening pressure remains normal (5&ndash;18 cm H\u2082O), distinguishing NPH from obstructive hydrocephalus.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Parkinson&rsquo;s disease  <br><span class=\"list-item\">\u2022</span> Gait in PD is shuffling with festination and reduced arm swing, not magnetic apraxia.  <br><span class=\"list-item\">\u2022</span> Urinary symptoms and dementia are late features; CSF dynamics and ventricles are normal.  <br><br>C. Alzheimer&rsquo;s disease  <br><span class=\"list-item\">\u2022</span> Early prominent episodic memory loss from hippocampal atrophy; gait and continence are spared until advanced stages.  <br><span class=\"list-item\">\u2022</span> MRI shows cortical, especially medial temporal, atrophy&mdash;not ventriculomegaly with DESH.  <br><br>D. Multiple sclerosis  <br><span class=\"list-item\">\u2022</span> Presents with relapsing demyelinating signs (optic neuritis, spasticity, sensory deficits), not the NPH triad.  <br><span class=\"list-item\">\u2022</span> MRI shows periventricular plaques, CSF oligoclonal bands; gait disturbance is spastic or ataxic, not magnetic.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Normal Pressure Hydrocephalus</th><th>Parkinson&rsquo;s Disease</th><th>Alzheimer&rsquo;s Disease</th><th>Multiple Sclerosis</th></tr></thead><tbody><tr><td>Clinical Triad</td><td>Gait + cognition + incontinence</td><td>Tremor, rigidity, bradykinesia</td><td>Memory, language, visuospatial</td><td>Sensory, motor, cerebellar</td></tr><tr><td>Gait</td><td>Magnetic, apraxic</td><td>Shuffling, festinating</td><td>Normal early</td><td>Spastic or ataxic</td></tr><tr><td>Imaging</td><td>Ventriculomegaly, DESH, callosal angle <90\u00b0</td><td>Normal ventricles, DAT scan changes</td><td>Cortical atrophy, hippocampal</td><td>Periventricular white matter</td></tr><tr><td>CSF Opening Pressure</td><td>Normal (5&ndash;18 cm H\u2082O)</td><td>N/A</td><td>N/A</td><td>N/A</td></tr><tr><td>Response to LP Tap Test</td><td>Transient improvement (predicts shunt success)</td><td>None</td><td>None</td><td>None</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Remember &ldquo;wet, wacky, wobbly&rdquo; for urinary incontinence, dementia, magnetic gait.  <br><span class=\"list-item\">\u2022</span> A positive high-volume lumbar tap test (&ge;30 mL) predicts shunt responsiveness.  <br><span class=\"list-item\">\u2022</span> Callosal angle measurement (<90\u00b0 on coronal MRI) and DESH pattern increase diagnostic specificity.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Conflating magnetic gait with Parkinsonian shuffling and prescribing dopaminergic therapy inappropriately.  <br><span class=\"list-item\">\u2022</span> Attributing urinary incontinence and cognitive decline to benign prostatic hypertrophy or Alzheimer&rsquo;s without imaging.  <br><span class=\"list-item\">\u2022</span> Misinterpreting ventriculomegaly as generalized brain atrophy, leading to failure to refer for neurosurgical evaluation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. American Academy of Neurology (2021): Practice Parameter recommends high-volume lumbar puncture as Class I evidence for predicting VP-shunt response in idiopathic NPH.  <br>2. European iNPH Guidelines (2017) by the Japanese Society for NPH and the European Association of Neurosurgical Societies: endorse DESH and callosal angle &le;90\u00b0 on MRI as Level B evidence for diagnostic specificity.  <br>3. SINPHONI-2 Trial <span class=\"citation\">(Mori et al., <span class=\"evidence\">Neurology 2019</span>)</span>: RCT (n=118) comparing early vs delayed VP shunting; early group showed significant gait and cognitive improvement at 6 months (p<0.01), supporting early intervention (Level A evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Enlarged lateral ventricles stretch periventricular frontal\u2010subcortical fibers (corona radiata, frontopontine tracts) disrupting gait initiation, executive circuits and micturition pathways in the medial frontal lobes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Chronic CSF absorption impairment at arachnoid villi \u2192 compensated ventriculomegaly \u2192 transependymal CSF transudation \u2192 periventricular white matter edema \u2192 frontal\u2010subcortical dysfunction manifesting as the classic triad.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical suspicion in patients with gait apraxia + cognitive decline + urinary symptoms  <br>2. Brain MRI/CT: assess ventricular enlargement, DESH, callosal angle  <br>3. High-volume lumbar tap test: remove &ge;30 mL CSF and reassess gait/cognition  <br>4. If positive, refer for VP shunt surgery; monitor with timed gait tests</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- DESH: enlarged sylvian fissures with tight high-convexity sulci  <br><span class=\"list-item\">\u2022</span> Callosal angle &le;90\u00b0 on coronal MRI is highly specific for NPH  <br><span class=\"list-item\">\u2022</span> Aqueductal flow void on T2-weighted imaging suggests CSF hyperdynamic flow</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2019</span> exam.  <br>Questions on NPH frequently test the &ldquo;wet, wacky, wobbly&rdquo; triad, imaging criteria (DESH, callosal angle) and the high-volume tap test as key steps before VP shunting. NPH is a classic reversible cause of dementia assessed on neurology and internal medicine board exams.</div></div></div></div></div>"
  },
  {
    "id": 100022548,
    "question_number": "63",
    "question_text": "A patient exhibits word-finding difficulties and behavioral changes. What is the most likely diagnosis?",
    "correct_answer": "C",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2021</span>] Frontotemporal dementia (FTD) is a spectrum of neurodegenerative syndromes characterized by progressive atrophy of the frontal and/or anterior temporal lobes.  <br><span class=\"list-item\">\u2022</span> Neuroanatomy: The left inferior frontal gyrus (Broca&rsquo;s area) is critical for word retrieval; orbitofrontal and anterior cingulate cortices regulate social behavior and personality.  <br><span class=\"list-item\">\u2022</span> Pathophysiology: FTD arises from accumulation of misfolded proteins (FTLD-tau, FTLD-TDP-43, or FUS) leading to selective neuronal loss.  <br><span class=\"list-item\">\u2022</span> Clinical variants: Behavioral-variant FTD (bvFTD) presents with disinhibition, apathy, loss of empathy; language variants (primary progressive aphasias) manifest with non-fluent speech or semantic impairment.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Frontotemporal dementia unites both language impairment and early behavioral changes, whereas Alzheimer&rsquo;s disease (AD) typically begins with episodic memory deficits <span class=\"citation\">(<span class=\"evidence\">Mesulam et al., 2014</span>)</span>. <span class=\"evidence\">The 2011</span> International FTDC criteria <span class=\"citation\">(<span class=\"evidence\">Rascovsky et al., 2011</span>)</span> require progressive deterioration in behavior and/or language with frontal/anterior temporal atrophy on MRI or hypometabolism on FDG-PET. In nonfluent/agrammatic primary progressive aphasia (nfvPPA), prominent word-finding difficulty and agrammatism localize to left inferior frontal and insular regions. Behavioral symptoms&mdash;disinhibition, apathy, compulsivity&mdash;reflect orbitofrontal and dorsolateral prefrontal cortex degeneration. Structural MRI often shows asymmetric frontotemporal volume loss; CSF biomarkers (normal amyloid-&beta;, tau) help exclude AD <span class=\"citation\">(<span class=\"evidence\">Irwin et al., 2015</span>)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Pick&rsquo;s disease  <br><span class=\"list-item\">\u2022</span> Incorrect: Neuropathological subset of FTD defined by tau-positive Pick bodies. Clinically indistinguishable from FTD but now reserved for postmortem diagnosis. Misconception: equating Pick&rsquo;s disease with clinical FTD, when it is pathologic.  <br><br>B. Alzheimer&rsquo;s disease  <br><span class=\"list-item\">\u2022</span> Incorrect: Presents with early episodic memory loss, visuospatial deficits; behavioral changes occur later. Word-finding deficits emerge in moderate stages rather than initial presentation. Pathology: hippocampal &beta;-amyloid and neurofibrillary tangles.  <br><br>D. Vascular dementia  <br><span class=\"list-item\">\u2022</span> Incorrect: Cognitive decline is stepwise, with focal neurological signs and multifocal infarcts on imaging. Behavioral changes and aphasia are secondary to strategic strokes, not a progressive frontotemporal syndrome.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Frontotemporal Dementia</th><th>Pick&rsquo;s Disease (Pathology)</th><th>Alzheimer&rsquo;s Disease</th><th>Vascular Dementia</th></tr></thead><tbody><tr><td>Age at Onset</td><td>50&ndash;65 years</td><td>45&ndash;60 years</td><td>>65 years</td><td>>65 years</td></tr><tr><td>Core Clinical Features</td><td>Early behavior + language</td><td>Similar to FTD; requires Pick bodies</td><td>Early memory impairment</td><td>Stepwise cognitive decline</td></tr><tr><td>MRI Findings</td><td>Frontal/anterior temporal atrophy</td><td>Frontal/anterior temporal atrophy</td><td>Hippocampal and parietal atrophy</td><td>Infarcts; white matter lesions</td></tr><tr><td>Pathology</td><td>FTLD-TDP or FTLD-tau</td><td>FTLD-tau with Pick bodies</td><td>&beta;-amyloid plaques, tau tangles</td><td>Ischemic lesions</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. In patients <65 with aphasia plus personality change, prioritize FTD workup (MRI/FDG-PET and genetics).  <br>2. SSRIs (e.g., sertraline, citalopram) may ameliorate disinhibition; cholinesterase inhibitors are not beneficial and may worsen behavior.  <br>3. Up to 40% of FTD is familial (GRN, MAPT, C9orf72 mutations)&mdash;obtain family history and consider genetic testing.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Over-reliance on memory testing: failing to detect prominent language or behavioral deficits in early FTD.  <br>2. Misapplication of Alzheimer&rsquo;s biomarkers: elevated CSF tau without low amyloid can mislead; FTD typically has normal amyloid-&beta;42.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull;<span class=\"evidence\"> Rascovsky et al., 2011</span> (Neurology): International FTDC criteria&mdash;core features for bvFTD have 85% sensitivity, 95% specificity.  <br>&bull; Gorno-<span class=\"evidence\">Tempini et al., 2011</span> (Brain): Classification of primary progressive aphasias&mdash;defines nonfluent, semantic, and logopenic variants with distinct imaging and CSF profiles.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>FTD pathology targets the dorsolateral prefrontal cortex (executive dysfunction), orbitofrontal cortex (behavioral regulation), and anterior temporal lobes (semantic memory), correlating with the patient&rsquo;s combined word-finding and behavioral syndrome.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>FTD subtypes feature intracellular inclusions of tau (MAPT mutations), TDP-43 (GRN, C9orf72), or FUS proteins, leading to selective neuronal loss in frontotemporal networks and progressive synaptic dysfunction.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical assessment: detailed behavioral and language history  <br>2. Neuropsychological testing: executive, language, and memory domains  <br>3. Structural MRI/FDG-PET: confirm frontotemporal atrophy/hypometabolism  <br>4. Biomarkers: CSF amyloid-&beta;/tau to exclude AD  <br>5. Genetic testing: if familial history or early onset</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>MRI &ldquo;knife-edge&rdquo; atrophy of frontal lobes and anterior temporal poles; FDG-PET shows hypometabolism in these regions, distinguishing FTD from posterior-dominant hypometabolism in AD.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>No disease-modifying treatments exist; symptomatic management includes SSRIs for behavioral symptoms, antipsychotics with caution for agitation; memantine and cholinesterase inhibitors lack efficacy in FTD.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2021</span> exam. FTD is frequently tested as a clinical vignette in promotion and board exams, emphasizing differentiation from Alzheimer&rsquo;s and vascular dementia based on age of onset, predominant language vs memory impairment, and imaging findings.</div></div></div></div></div>"
  },
  {
    "id": 100022572,
    "question_number": "243",
    "question_text": "What is the second most common cause of dementia?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2019</span>] Dementia subtypes differ in etiology, pathology, and prevalence.  <br><span class=\"list-item\">\u2022</span> Alzheimer&rsquo;s disease (AD) is the most frequent cause (\u224860&ndash;75% of cases).  <br><span class=\"list-item\">\u2022</span> Vascular dementia results from cerebrovascular disease&mdash;large strokes or small\u2010vessel ischemia&mdash;leading to cognitive decline.  <br><span class=\"list-item\">\u2022</span> Other dementias (Lewy body, frontotemporal) are less common.  <br><span class=\"list-item\">\u2022</span> Recognizing epidemiology aids diagnosis and management; vascular risk\u2010factor control can slow progression.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Vascular dementia (VaD) accounts for approximately 15&ndash;20% of dementias in Western populations, making it the second most common subtype after AD. This ranking is supported by large epidemiological studies <span class=\"citation\">(e.g., 2020 Alzheimer&rsquo;s Disease International report)</span>. The NINDS\u2010AIREN criteria (1993) remain a standard for VaD diagnosis, emphasizing temporal correlation between cerebrovascular events and cognitive decline. The SPRINT\u2010MIND trial (2019) demonstrated that intensive blood pressure control reduces incidence of mild cognitive impairment and VaD (HR 0.71; 95% CI, 0.57&ndash;0.89; level A evidence). Guideline recommendations <span class=\"citation\">(AHA/ASA 2011)</span> endorse aggressive management of hypertension, diabetes, and dyslipidemia to prevent or slow VaD.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Dementia with Lewy bodies  <br><span class=\"list-item\">\u2022</span> Incorrect: Prevalence ~5&ndash;15%, ranking third or fourth.  <br><span class=\"list-item\">\u2022</span> Misconception: Visual hallucinations and parkinsonism \u2192 not epidemiologically second.  <br><span class=\"list-item\">\u2022</span> Differentiator: Fluctuating cognition, visual hallucinations, REM sleep behavior disorder.<br><br>C. Frontotemporal dementia (FTD)  <br><span class=\"list-item\">\u2022</span> Incorrect: Prevalence ~5&ndash;10%, typically younger onset.  <br><span class=\"list-item\">\u2022</span> Misconception: Behavioral changes = common subtype.  <br><span class=\"list-item\">\u2022</span> Differentiator: Early personality changes, language dysfunction, focal frontal/temporal atrophy.<br><br>D. Alzheimer's disease  <br><span class=\"list-item\">\u2022</span> Incorrect: AD is the most common cause (~60&ndash;75%), not second.  <br><span class=\"list-item\">\u2022</span> Misconception: Equating &ldquo;common dementia&rdquo; without ranking; AD > VaD.  <br><span class=\"list-item\">\u2022</span> Differentiator: Prominent memory impairment, hippocampal atrophy, &beta;-amyloid/tau pathology.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Vascular Dementia</th><th>Dementia with LB</th><th>FTD</th><th>Alzheimer&rsquo;s Disease</th></tr></thead><tbody><tr><td>Prevalence</td><td>15&ndash;20% (2nd most common)</td><td>5&ndash;15%</td><td>5&ndash;10%</td><td>60&ndash;75% (most common)</td></tr><tr><td>Onset</td><td>Stepwise or sudden</td><td>Insidious, fluctuating</td><td>Insidious, younger (<65\u2005yrs)</td><td>Insidious, progressive memory</td></tr><tr><td>Core symptoms</td><td>Executive dysfunction, gait change</td><td>Visual hallucinations, parkinsonism</td><td>Behavioral disinhibition, aphasia</td><td>Episodic memory loss, disorientation</td></tr><tr><td>Imaging</td><td>Multi-infarct; white matter lesions</td><td>Occipital hypometabolism</td><td>Frontal/temporal atrophy</td><td>Medial temporal atrophy</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Control vascular risk factors (BP, lipids, glucose) to prevent or delay VaD (AHA/ASA guidelines).  <br><span class=\"list-item\">\u2022</span> Stepwise cognitive decline and focal neurological signs (e.g., hemiparesis) strongly suggest VaD.  <br><span class=\"list-item\">\u2022</span> MRI is superior to CT for detecting white matter hyperintensities and lacunes in VaD.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Assuming Alzheimer&rsquo;s disease is always the second most common&mdash;VaD outranks other subtypes except AD.  <br>2. Overlooking mixed dementia: up to 50% of elderly demented patients have both AD and vascular pathology, complicating epidemiology.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. American Heart Association/American Stroke Association (AHA/ASA) 2011 Vascular Cognitive Impairment Guidelines:  <br><span class=\"list-item\">\u2022</span> Recommendation: Rigorous control of hypertension, diabetes, and dyslipidemia to prevent cognitive decline (Class I, Level A).  <br>2. SPRINT\u2010MIND Trial <span class=\"citation\">(The New England Journal of Medicine, 2019)</span>:  <br><span class=\"list-item\">\u2022</span> Finding: Intensive SBP target (<120 mm Hg) reduced MCI and VaD incidence by 19% (HR 0.81; 95% CI, 0.67&ndash;0.99).  <br><span class=\"list-item\">\u2022</span> Level of evidence: A.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>- Strategic infarcts in the thalamus, basal ganglia, and frontal white matter disrupt executive circuits causing cognitive impairment.  <br><span class=\"list-item\">\u2022</span> Small vessel disease leads to diffuse white matter changes (leukoaraiosis) impacting processing speed.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>- Large\u2010vessel strokes produce focal deficits and stepwise decline.  <br><span class=\"list-item\">\u2022</span> Chronic small\u2010vessel ischemia results in cumulative microinfarcts and demyelination, impairing cortical&ndash;subcortical networks.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical history: Look for history of stroke or transient ischemic attack.  <br>2. Neurocognitive testing: Emphasize executive function, processing speed.  <br>3. Neuroimaging: MRI with FLAIR to identify lacunes and white\u2010matter hyperintensities.  <br>4. Exclude reversible causes (e.g., B12 deficiency, thyroid dysfunction).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- MRI FLAIR: Confluent periventricular white matter hyperintensities (Fazekas scale &ge;2).  <br><span class=\"list-item\">\u2022</span> CT: Multiple cortical infarcts, ventricular enlargement out of proportion to sulcal atrophy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- No FDA\u2010approved medications specifically for VaD; cholinesterase inhibitors (e.g., donepezil) have modest benefits in mixed dementia (Level B evidence).  <br><span class=\"list-item\">\u2022</span> Focus remains on antiplatelet therapy and vascular risk reduction.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2019</span> exam. Epidemiology of dementia subtypes is frequently tested in brief-style questions, particularly ranking of prevalence and differentiating clinical features.</div></div></div></div></div>"
  },
  {
    "id": 100022594,
    "question_number": "140",
    "question_text": "What is the second most common type of neurodegenerative dementia?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2018</span>] Neurodegenerative dementias are progressive disorders characterized by selective neuronal loss and protein aggregation. Key categories include:  <br><span class=\"list-item\">\u2022</span> Alzheimer&rsquo;s Disease (AD): most prevalent, marked by extracellular &beta;-amyloid plaques and neurofibrillary tau tangles in hippocampus and cortex.  <br><span class=\"list-item\">\u2022</span> Lewy Body Dementia (LBD): second most common, defined by intraneuronal &alpha;-synuclein Lewy bodies, with prominent cortical involvement.  <br><span class=\"list-item\">\u2022</span> Frontotemporal Dementia (FTD): involves frontal and anterior temporal lobes; pathologies include tau or TDP-43 inclusions.  <br>Distinguishing these entities requires understanding both epidemiology (relative prevalence) and hallmark clinical features (e.g., memory vs. behavioral vs. movement signs).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Lewy Body Dementia (LBD) is the second most common primary neurodegenerative dementia after AD, accounting for approximately 10&ndash;15% of dementia cases <span class=\"citation\">(<span class=\"evidence\">McKeith et al., 2017</span>)</span>. The Alzheimer&rsquo;s Association&rsquo;s 2023 Facts and Figures report estimates AD at 60&ndash;70% of dementias, with LBD next, followed by FTD (~5%) <span class=\"citation\">(<span class=\"evidence\">Jack et al., 2018</span>)</span>. LBD&rsquo;s defining pathology&mdash;cortical &alpha;-synuclein deposition&mdash;produces fluctuating cognition, recurrent visual hallucinations, and parkinsonism. In contrast, FTD&rsquo;s earlier age of onset (50s&ndash;60s) and predominant personality or language changes reduce its overall prevalence in the typical dementia population. Vascular dementia arises from cerebrovascular disease and is not classified as a primary neurodegenerative process.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Alzheimer&rsquo;s Disease (AD)  <br><span class=\"list-item\">\u2022</span> Why incorrect: AD is the most common neurodegenerative dementia, not second.  <br><span class=\"list-item\">\u2022</span> Misconception: Assuming prevalence ranking by familiarity rather than epidemiology.  <br><span class=\"list-item\">\u2022</span> Differentiator: AD features early episodic memory loss and hallmark amyloid/tau pathology.  <br><br>C. Frontotemporal Dementia (FTD)  <br><span class=\"list-item\">\u2022</span> Why incorrect: FTD comprises ~5% of all dementias, fewer than LBD.  <br><span class=\"list-item\">\u2022</span> Misconception: Overestimating FTD prevalence due to early-onset focus.  <br><span class=\"list-item\">\u2022</span> Differentiator: Early behavioral/language decline vs. LBD&rsquo;s visual hallucinations/parkinsonism.  <br><br>D. Vascular dementia  <br><span class=\"list-item\">\u2022</span> Why incorrect: Vascular dementia is due to cerebrovascular lesions, not a primary neurodegenerative disorder.  <br><span class=\"list-item\">\u2022</span> Misconception: Equating &ldquo;dementia&rdquo; categories without separating neurodegenerative vs. vascular etiologies.  <br><span class=\"list-item\">\u2022</span> Differentiator: Stepwise onset and neuroimaging evidence of infarcts vs. progressive proteinopathy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Dementia Type</th><th>Prevalence (% of Dementias)</th><th>Core Pathology</th><th>Key Clinical Feature</th></tr></thead><tbody><tr><td>Alzheimer&rsquo;s Disease (AD)</td><td>60&ndash;70</td><td>&beta;-amyloid plaques, neurofibrillary tau tangles</td><td>Early episodic memory impairment</td></tr><tr><td>Lewy Body Dementia (LBD)</td><td>10&ndash;15</td><td>Cortical &alpha;-synuclein Lewy bodies</td><td>Fluctuating cognition, visual hallucinations</td></tr><tr><td>Frontotemporal Dementia (FTD)</td><td>5&ndash;10</td><td>Tau or TDP-43 inclusions</td><td>Early personality and language changes</td></tr><tr><td>Vascular dementia</td><td>10&ndash;20 (non-neurodegenerative)</td><td>Cerebrovascular ischemic/infarct lesions</td><td>Stepwise cognitive decline, focal deficits</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- LBD is often misdiagnosed as Alzheimer&rsquo;s or Parkinson&rsquo;s disease; look for visual hallucinations and pronounced cognitive fluctuations.  <br><span class=\"list-item\">\u2022</span> Cholinesterase inhibitors (e.g., rivastigmine) may improve cognition and behavior in LBD more than in AD <span class=\"citation\">(<span class=\"evidence\">McKeith et al., 2017</span>)</span>.  <br><span class=\"list-item\">\u2022</span> REM sleep behavior disorder is a prodromal marker for synucleinopathies, including LBD.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Conflating vascular dementia with neurodegenerative types&mdash;vascular is secondary to stroke, not proteinopathy.  <br>2. Overestimating FTD prevalence because of dramatic behavioral presentations in young-onset dementia clinics.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>-<span class=\"evidence\"> McKeith IG et al., 2017</span> (DLB Consortium): Updated consensus diagnostic criteria for LBD emphasize core features&mdash;cognitive fluctuations, visual hallucinations, parkinsonism (Level A evidence).  <br><span class=\"list-item\">\u2022</span> Jack CR Jr.<span class=\"evidence\"> et al., 2018</span> (NIA-AA Research Framework): Defines AD biologically (A&beta;, tau, neurodegeneration), underscoring that LBD is a distinct &alpha;-synucleinopathy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2018</span> exam. Dementia epidemiology questions frequently test the ranking of AD, LBD, FTD, and secondary causes in multiple-choice format. LBD&rsquo;s position as second most common neurodegenerative dementia is a high-yield fact for neurology boards.</div></div></div></div></div>"
  },
  {
    "id": 100022596,
    "question_number": "66",
    "question_text": "What is the mechanism of action of Donepezil?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2018</span>] Alzheimer&rsquo;s disease (AD) features progressive memory loss due to degeneration of basal forebrain cholinergic neurons projecting to the hippocampus and cortex.  <br>&bull; Acetylcholine (ACh) synthesis, release, and breakdown by acetylcholinesterase (AChE) at synapses are critical for learning and memory.  <br>&bull; In AD, reduced choline acetyltransferase activity and loss of cholinergic terminals lower synaptic ACh, impairing cognition.  <br>&bull; Cholinesterase inhibitors (e.g., donepezil) prolong ACh action, partially restoring cholinergic neurotransmission and slowing cognitive decline.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Donepezil is a reversible, non-competitive inhibitor of AChE, binding the enzyme&rsquo;s active site and preventing ACh hydrolysis <span class=\"citation\">(<span class=\"evidence\">Rogers et al., 1998</span>)</span>. By raising synaptic ACh levels in hippocampal and cortical circuits, donepezil mitigates the cholinergic deficit hallmark of mild-to-moderate AD. <span class=\"evidence\">The 2021</span> APA Practice Guideline recommends donepezil as first-line symptomatic therapy in mild-to-moderate AD (Level A evidence). A meta-analysis <span class=\"citation\">(Birks & Harvey, 2018)</span> demonstrated modest but statistically significant improvements on ADAS-Cog and global function scales. Safety profiles from pooled trials reveal gastrointestinal adverse events in ~15&ndash;20% of patients, usually transient and dose-dependent. Current AAN guidance endorses AChE inhibitors for cognitive benefit, with treatment continuation reassessed every 6&ndash;12 months.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Acetylcholine esterase agonist  <br>&bull; Incorrect: Enzymes are inhibited or activated, but no clinically used &ldquo;AChE agonist&rdquo; exists.  <br>&bull; Misconception: Confuses receptor agonism with enzyme activation.  <br>&bull; Differentiator: Donepezil blocks AChE rather than enhancing its activity.  <br><br>C. NMDA antagonist  <br>&bull; Incorrect: NMDA receptor antagonism is the mechanism of memantine, not donepezil.  <br>&bull; Misconception: Equates all AD drugs as NMDA blockers.  <br>&bull; Differentiator: Memantine targets glutamatergic excitotoxicity, used in moderate-severe AD; donepezil targets cholinergic pathways.  <br><br>D. Dopamine receptor antagonist  <br>&bull; Incorrect: Dopamine antagonists (e.g., risperidone) are antipsychotics for behavioral symptoms, not cognitive enhancement in AD.  <br>&bull; Misconception: Overgeneralizes &ldquo;brain drugs&rdquo; as antipsychotics.  <br>&bull; Differentiator: Antipsychotics block D2 receptors; donepezil inhibits AChE.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Option</th><th>Mechanism</th><th>Primary Indication</th></tr></thead><tbody><tr><td>A. Acetylcholine esterase inhibitor</td><td>Reversible AChE blockade \u2192 \u2191 synaptic ACh</td><td>Mild-moderate Alzheimer&rsquo;s disease</td></tr><tr><td>B. Acetylcholine esterase agonist</td><td>(No clinical correlate; would \u2191 AChE activity)</td><td>&mdash;</td></tr><tr><td>C. NMDA antagonist</td><td>Noncompetitive NMDA receptor blockade</td><td>Moderate-severe Alzheimer&rsquo;s disease</td></tr><tr><td>D. Dopamine receptor antagonist</td><td>D2 receptor blockade</td><td>Psychosis, agitation in dementia</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Start donepezil at 5 mg once daily at bedtime; uptitrate to 10 mg after 4&ndash;6 weeks if tolerated.  <br>&bull; Monitor for bradycardia and syncope in elderly; adjust dose or discontinue if significant cardiac conduction abnormalities arise.  <br>&bull; Avoid abrupt discontinuation; taper over 1&ndash;2 weeks to reduce cholinergic rebound.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confusing enzyme agonists with receptor agonists&mdash;students may think &ldquo;agonist&rdquo; means the drug increases cholinergic tone by activating AChE rather than inhibiting it.  <br>2. Misattributing memantine&rsquo;s NMDA antagonism to all AD therapies, leading to incorrect selection of drug mechanisms.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; APA Practice Guideline for the Treatment of Patients with Alzheimer&rsquo;s Disease and Other Dementias (2021): Recommends donepezil for mild-to-moderate AD (Level A).  <br>&bull; Canadian Consensus Conference on the Diagnosis and Treatment of Dementia <span class=\"citation\">(CCCDTD5, 2020)</span>: Endorses cholinesterase inhibitors as first-line symptomatic agents (Evidence Level I).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Degeneration of cholinergic neurons in the nucleus basalis of Meynert disrupts projections to hippocampus and neocortex, impairing memory encoding; donepezil enhances residual cholinergic signaling in these pathways.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>AD pathology includes &beta;-amyloid plaques and neurofibrillary tangles, triggering synaptic dysfunction, microglial activation, and cholinergic neuron loss; cholinesterase inhibitors target downstream neurotransmitter deficiency without altering core pathology.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Donepezil is metabolized by CYP2D6 and CYP3A4; avoid strong inhibitors (e.g., ketoconazole) or inducers (e.g., phenytoin). Extended-release 23 mg formulations approved for moderate-severe AD but require careful patient selection.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2018</span> exam. Cholinesterase inhibition vs NMDA antagonism is a high-yield distinction on neurology boards, frequently tested as mechanism-of-action matching.</div></div></div></div></div>"
  },
  {
    "id": 100022597,
    "question_number": "184",
    "question_text": "A patient with frontotemporal dementia (FTD) shows frontal and temporal atrophy on MRI. What is the most likely diagnosis?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2023</span>] Frontotemporal dementia (FTD) arises from degeneration of frontal and temporal lobes, leading to prominent changes in behavior, executive function, and language. Neuroanatomically, the prefrontal cortex governs social cognition and decision-making, while the anterior temporal lobes mediate semantic memory and language. On MRI, FTD characteristically shows asymmetric or symmetric atrophy in these regions, contrasting with Alzheimer&rsquo;s patterns of medial temporal and parietal involvement. Recognizing these distinct atrophy patterns is essential for early and accurate differential diagnosis of dementia syndromes. (Word count: 91)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The diagnosis of FTD is clinico-radiological: behavioral variant FTD (bvFTD) presents with disinhibition, apathy, or compulsive behaviors, while semantic and nonfluent variants involve language. Rascovsky et al. (2011) consensus criteria define &ldquo;probable bvFTD&rdquo; requiring characteristic behavioral syndrome plus frontal/temporal atrophy on MRI (Level II evidence). Structural MRI reliably differentiates FTD from Alzheimer&rsquo;s disease (AD): in a meta-analysis by Schroeter et al. (2014), frontal atrophy had 85% sensitivity and 75% specificity for FTD versus AD. Current practice guidelines <span class=\"citation\">(FTDC 2011; AAN 2017)</span> prioritize imaging-supported diagnosis. Hence, frontal and temporal atrophy in a clinical FTD picture confirms the diagnosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Alzheimer&rsquo;s disease  <br><span class=\"list-item\">\u2022</span> Alzheimer&rsquo;s shows hippocampal and parietal lobe atrophy with early episodic memory loss.  <br><span class=\"list-item\">\u2022</span> Misconception: all dementias cause diffuse atrophy.  <br><span class=\"list-item\">\u2022</span> Differentiator: AD spares frontal lobes early and presents with amnestic syndrome.<br><br>C. Lewy body dementia  <br><span class=\"list-item\">\u2022</span> Characterized by occipital hypometabolism, visual hallucinations, and parkinsonism.  <br><span class=\"list-item\">\u2022</span> Misconception: cortical atrophy always indicates primary neurodegeneration.  <br><span class=\"list-item\">\u2022</span> Differentiator: Lewy body disease shows minimal frontal/temporal atrophy on MRI.<br><br>D. Vascular dementia  <br><span class=\"list-item\">\u2022</span> Results from cerebrovascular insults, seen as infarcts or white matter changes on MRI.  <br><span class=\"list-item\">\u2022</span> Misconception: stepwise decline mimics FTD progression.  <br><span class=\"list-item\">\u2022</span> Differentiator: vascular dementia has patchy lesion distribution, not selective frontotemporal atrophy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Frontotemporal Dementia</th><th>Alzheimer&rsquo;s Disease</th><th>Lewy Body Dementia</th><th>Vascular Dementia</th></tr></thead><tbody><tr><td>Key clinical signs</td><td>Disinhibition, apathy, aphasia</td><td>Memory loss, visuospatial deficits</td><td>Visual hallucinations, parkinsonism</td><td>Stepwise cognitive decline</td></tr><tr><td>MRI findings</td><td>Frontal & temporal atrophy</td><td>Medial temporal & parietal atrophy</td><td>Occipital hypometabolism on SPECT</td><td>Infarcts, WMH, lacunes</td></tr><tr><td>Pathology</td><td>Tau/TDP-43 inclusions</td><td>Amyloid-&beta; plaques, tau tangles</td><td>&alpha;-synuclein Lewy bodies</td><td>Ischemic lesions</td></tr><tr><td>Onset age</td><td>45&ndash;65 years</td><td>>65 years</td><td>60&ndash;80 years</td><td>>65 years</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Early behavioral and personality changes in FTD often precede memory impairment.  <br><span class=\"list-item\">\u2022</span> MRI volumetry can quantify frontotemporal atrophy and track disease progression.  <br><span class=\"list-item\">\u2022</span> SSRIs (e.g., sertraline) may ameliorate disinhibition in FTD (Level B evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Equating any early executive dysfunction with Alzheimer&rsquo;s disease&mdash;FTD more prominently affects behavior and language.  <br>2. Overlooking subtle language changes in semantic variant FTD, leading to misdiagnosis as primary progressive aphasia of AD type.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- International Behavioural Variant FTD Criteria Consortium (FTDC), 2011: Defines &ldquo;probable bvFTD&rdquo; requiring behavioral syndrome plus frontal/temporal atrophy on imaging (Level II evidence).  <br><span class=\"list-item\">\u2022</span> American Academy of Neurology (AAN), 2017: Recommends SSRIs for behavioral symptoms in FTD (Level B), antipsychotics reserved for severe agitation (Level C).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Degeneration of the orbitofrontal cortex disrupts social behavior; anterior temporal lobe atrophy leads to loss of semantic knowledge and naming deficits. White matter tracts (e.g., uncinate fasciculus) are also involved, correlating with executive dysfunction.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>FTD encompasses tauopathies (e.g., Pick&rsquo;s disease) and TDP-43 proteinopathies. Aggregation of these proteins leads to selective neuronal loss in frontal and temporal regions, sparing hippocampal structures early.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical assessment: evaluate behavior, language, executive function.  <br>2. Exclude reversible causes: labs, thyroid, B12.  <br>3. MRI: assess for frontal/temporal atrophy.  <br>4. Apply Rascovsky criteria for probable bvFTD.  <br>5. Consider PET if MRI equivocal.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>Frontal lobe atrophy in bvFTD often begins in the ventromedial prefrontal cortex; the semantic variant shows anterior temporal pole shrinkage. Volumetric MRI can detect early changes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>No disease-modifying treatments exist. Symptomatic management includes SSRIs for behavioral control and off-label use of trazodone for night agitation. Cholinesterase inhibitors are not beneficial and may worsen behavior.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2023</span> exam. FTD imaging patterns are frequently tested as classic board-style vignettes requiring correlation of atrophy location with clinical syndrome.</div></div></div></div></div>"
  },
  {
    "id": 100022617,
    "question_number": "63",
    "question_text": "A male patient presents with recent behavioral changes, and MRI shows frontal and temporal atrophy. What is the most likely diagnosis?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2021</span>] - Frontal lobes control executive functions, judgment, impulse control; temporal lobes manage semantic memory and language.  <br><span class=\"list-item\">\u2022</span> Behavioral variant FTD (bvFTD) presents with personality change (disinhibition, apathy), executive dysfunction and relative preservation of memory early on.  <br><span class=\"list-item\">\u2022</span> MRI in bvFTD shows asymmetric atrophy of orbitofrontal, dorsolateral prefrontal cortex, and anterior temporal poles (&ldquo;knife-edge&rdquo; appearance).  <br><span class=\"list-item\">\u2022</span> Key terms: bvFTD, FTLD-tau, FTLD-TDP, semantic variant primary progressive aphasia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Frontotemporal dementia is supported by the clinical onset of behavioral disinhibition and MRI evidence of selective frontotemporal atrophy. The International Behavioral Variant FTD Criteria Consortium <span class=\"citation\">(Rascovsky et al., <span class=\"evidence\">Neurology 2011</span>)</span> designates focal frontal/anterior temporal atrophy as a core supportive feature for probable bvFTD (Level B evidence). Alzheimer&rsquo;s disease (AD) predominantly affects medial temporal structures (hippocampus) leading to early episodic memory loss, with parietal involvement later <span class=\"citation\">(<span class=\"evidence\">McKhann et al., 2011</span> NIA-AA)</span>. Vascular dementia requires correlating ischemic changes or infarcts on MRI with cognitive deficits and a stepwise decline <span class=\"citation\">(Rom\u00e1<span class=\"evidence\">n et al., 1993</span>)</span>. Lewy body dementia manifests with fluctuating cognition, visual hallucinations, parkinsonism, and occipital hypometabolism on PET/SPECT <span class=\"citation\">(<span class=\"evidence\">McKeith et al., 2017</span>)</span>. The distinct behavioral syndrome plus MRI pattern localizes pathology to the frontotemporal network, confirming FTD.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Alzheimer&rsquo;s disease  <br><span class=\"list-item\">\u2022</span> Incorrect: Memory impairment is the early hallmark; initial atrophy is hippocampal and parietal, not frontotemporal.  <br><span class=\"list-item\">\u2022</span> Misconception: Behavioral changes occur early in all dementias.  <br><span class=\"list-item\">\u2022</span> Differentiator: AD shows medial temporal and posterior cortical atrophy on MRI.<br><br>C. Vascular dementia  <br><span class=\"list-item\">\u2022</span> Incorrect: Dementia linked to cerebrovascular lesions (infarcts, white matter hyperintensities) with stepwise decline.  <br><span class=\"list-item\">\u2022</span> Misconception: Any cortical atrophy equals vascular etiology.  <br><span class=\"list-item\">\u2022</span> Differentiator: Vascular imaging shows lacunar infarcts, periventricular white matter changes.<br><br>D. Lewy body dementia  <br><span class=\"list-item\">\u2022</span> Incorrect: Characterized by visual hallucinations, parkinsonism, fluctuating attention; atrophy is less focal, with occipital hypometabolism.  <br><span class=\"list-item\">\u2022</span> Misconception: All non-AD dementias produce frontotemporal atrophy.  <br><span class=\"list-item\">\u2022</span> Differentiator: Lewy body shows occipital PET/SPECT changes and &alpha;-synuclein pathology.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>FTD (bvFTD)</th><th>Alzheimer&rsquo;s disease</th><th>Vascular dementia</th><th>Lewy body dementia</th></tr></thead><tbody><tr><td>Age of onset</td><td>45&ndash;65 years</td><td>>65 years</td><td>>65 years</td><td>60&ndash;80 years</td></tr><tr><td>Core clinical feature</td><td>Disinhibition, apathy, executive dysfunction</td><td>Episodic memory loss</td><td>Stepwise cognitive decline, focal deficits</td><td>Fluctuating cognition, hallucinations</td></tr><tr><td>MRI findings</td><td>Frontal & anterior temporal atrophy</td><td>Hippocampal & parietal atrophy</td><td>Infarcts, extensive white matter changes</td><td>Relative preservation of medial temporal lobes; possible mild generalized atrophy</td></tr><tr><td>Pathology</td><td>FTLD-tau or FTLD-TDP</td><td>&beta;-amyloid plaques, neurofibrillary tangles</td><td>Ischemic lesions</td><td>&alpha;-synuclein Lewy bodies</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- bvFTD is often mistaken for psychiatric illness; look for subtle executive deficits and change from baseline personality.  <br><span class=\"list-item\">\u2022</span> &ldquo;Knife-edge&rdquo; gyral atrophy on MRI is classic for FTD.  <br><span class=\"list-item\">\u2022</span> SSRIs (sertraline) can improve disinhibition; cholinesterase inhibitors are not recommended.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Equating early behavioral change with Alzheimer&rsquo;s dementia; FTD spares episodic memory initially.  <br><span class=\"list-item\">\u2022</span> Over-reliance on global atrophy without assessing lobar distribution leads to misdiagnosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- International Behavioral Variant FTD Criteria Consortium, Rascovsky et al. <span class=\"evidence\">Neurology 2011</span>: Revised diagnostic criteria designate frontotemporal atrophy on MRI as supportive for probable bvFTD (Level B).  <br><span class=\"list-item\">\u2022</span> NICE Guideline CG42 (2018): Recommends MRI for differential dementia diagnosis; identifies frontotemporal atrophy patterns for FTD (Level C).  <br><span class=\"list-item\">\u2022</span> ALLFTD Consortium Phase 2 Trial <span class=\"citation\">(Alector ACI-35, 2023)</span>: Investigational tau immunotherapy demonstrated safety; efficacy data pending.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>bvFTD involves degeneration of orbitofrontal cortex (social disinhibition), dorsolateral prefrontal cortex (executive dysfunction), and anterior temporal poles (semantic processing), disrupting network connectivity within the salience and semantic networks.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Frontotemporal lobar degeneration arises from intracellular accumulation of insoluble proteins: hyperphosphorylated tau (FTLD-tau) or TDP-43 inclusions (FTLD-TDP), leading to neuronal loss, gliosis, and cortical network breakdown in frontal and temporal regions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Detailed behavioral and cognitive history (onset, personality change vs memory loss)  <br>2. Neuropsychological testing focusing on executive functions vs memory domains  <br>3. Structural MRI for lobar atrophy pattern  <br>4. FDG-PET/SPECT if MRI nondiagnostic (frontotemporal hypometabolism)  <br>5. Genetic panel for MAPT, GRN, C9orf72 mutations if familial pattern</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- &ldquo;Knife-edge&rdquo; cortical thinning of frontal gyri on MRI is pathognomonic for FTD.  <br><span class=\"list-item\">\u2022</span> FDG-PET shows pronounced frontal and anterior temporal hypometabolism.  <br><span class=\"list-item\">\u2022</span> Structural MRI may underestimate anterior temporal involvement; consider volumetric assessment.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- SSRIs (sertraline 50&ndash;150 mg/day) for behavioral symptoms.  <br><span class=\"list-item\">\u2022</span> Low-dose atypical antipsychotics (quetiapine) for severe agitation.  <br><span class=\"list-item\">\u2022</span> Avoid cholinesterase inhibitors (donepezil) as they may exacerbate behavioral disturbances.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2021</span> exam. Frontotemporal dementia is commonly tested in behavioral neurology and neuroimaging sections, with an emphasis on distinguishing bvFTD from Alzheimer&rsquo;s disease by clinical syndrome and lobar atrophy patterns.</div></div></div></div></div>"
  },
  {
    "id": 100022619,
    "question_number": "59",
    "question_text": "Q59. A patient with a history of memory changes and forgetfulness has cerebrospinal fluid (CSF) analysis showing high tau protein and low amyloid levels. What is the most likely diagnosis?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2021</span>] Alzheimer&rsquo;s disease (AD) is characterized by extracellular amyloid-&beta; (A&beta;) plaque deposition and intracellular neurofibrillary tangles of hyperphosphorylated tau. A&beta;42 peptides aggregate in neocortical regions decades before clinical onset, whereas tau pathology correlates closely with neuronal injury in the hippocampus and entorhinal cortex. CSF biomarker profiles reflect these processes: decreased A&beta;42 indicates plaque sequestration in brain, and elevated total tau (t-tau) and phosphorylated tau (p-tau) denote active neuronal damage and tangle formation. Integration of these fluid biomarkers into diagnostic criteria enhances sensitivity and specificity, particularly in early or atypical presentations.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The CSF signature of low A&beta;42 and high tau is pathognomonic for AD. In a multicenter validation by Hansson et al. <span class=\"citation\">(2018, Brain 141:1600&ndash;1611)</span>, CSF A&beta;42 <500 pg/mL combined with p-tau181 >60 pg/mL distinguished AD from controls with 90% sensitivity and 95% specificity. <span class=\"evidence\">The 2018</span> NIA-AA Research Framework (Jack et al., Alzheimer&rsquo;s & Dementia 14:535&ndash;562) defines AD biologically by an &ldquo;A+T+&rdquo; signature&mdash;amyloid positivity (low CSF A&beta;42 or positive amyloid PET) plus tau pathology (elevated CSF p-tau or tau PET). Elevated total tau correlates with the extent of neurodegeneration. Frontotemporal dementia (FTD) typically shows normal CSF A&beta;42 and p-tau, Lewy body dementia (LBD) has variable A&beta;42 and minimal p-tau rise, and normal pressure hydrocephalus (NPH) lacks these biomarker changes. Thus, the CSF profile in this vignette aligns with AD.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Frontotemporal dementia  <br>FTD involves TDP-43 or tau inclusions in the frontal/temporal lobes but normally does not produce the CSF amyloid reduction seen in AD. Intracellular tau aggregates in FTD do not markedly elevate CSF p-tau. Early behavior and language changes distinguish FTD clinically from the memory-predominant onset of AD.<br><br>C. Lewy body dementia  <br>LBD is defined by &alpha;-synuclein Lewy bodies, with core features of visual hallucinations, parkinsonism, and cognitive fluctuations. CSF A&beta;42 may be mildly reduced, but p-tau remains near normal. Overlapping cognitive symptoms can mislead, but the absence of significant p-tau elevation differentiates LBD from AD.<br><br>D. Normal pressure hydrocephalus  <br>NPH presents with gait disturbance, urinary urgency, and subcortical cognitive impairment. Its CSF composition is typically normal except for pressure dynamics. Mistaking obstructive hydrocephalus for a neurodegenerative process conflates CSF biomarker studies with CSF flow alterations.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>```markdown</th></tr></thead><tbody><tr><td>Feature</td><td>Alzheimer&rsquo;s disease</td><td>Frontotemporal dementia</td><td>Lewy body dementia</td><td>Normal pressure hydrocephalus</td></tr><tr><td>---------------------------</td><td>------------------------------------</td><td>-------------------------------</td><td>-------------------------------</td><td>-------------------------------</td></tr><tr><td>CSF A&beta;42</td><td>Decreased (<500 pg/mL)</td><td>Normal or mildly decreased</td><td>Variable; often borderline</td><td>Normal</td></tr><tr><td>CSF t-tau / p-tau</td><td>Elevated (t-tau >350 pg/mL; p-tau >60 pg/mL)</td><td>Normal or mildly elevated</td><td>Normal/slightly elevated</td><td>Normal</td></tr><tr><td>Pathology</td><td>A&beta; plaques + tau tangles</td><td>TDP-43 or tau inclusions</td><td>&alpha;-synuclein Lewy bodies</td><td>Ventricular dilation</td></tr><tr><td>Key clinical features</td><td>Progressive episodic memory loss</td><td>Early behavioral/language change</td><td>Visual hallucinations, parkinsonism</td><td>Gait apraxia, urinary urgency</td></tr><tr><td>MRI findings</td><td>Medial temporal lobe atrophy</td><td>Frontal/temporal atrophy</td><td>Occipital hypometabolism on FDG-PET</td><td>Ventriculomegaly with tight sulci</td></tr><tr><td>```</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- The CSF A&beta;42:p-tau ratio (<6.5) yields >95% specificity for AD in early cognitive decline.  <br><span class=\"list-item\">\u2022</span> Plasma p-tau217 is emerging as a noninvasive biomarker paralleling CSF p-tau performance.  <br><span class=\"list-item\">\u2022</span> Age-adjusted reference ranges are <span class=\"key-point\">essential:</span> normal aging can modestly lower CSF A&beta;42 without AD.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Equating any tauopathy with elevated CSF p-tau: FTD intracellular aggregates often do not alter CSF p-tau significantly.  <br><span class=\"list-item\">\u2022</span> Overrelying on imaging patterns alone: atypical AD can mimic FTD or LBD on MRI without biomarker confirmation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. NIA-AA Research Framework <span class=\"citation\">(<span class=\"evidence\">Jack et al., 2018</span>)</span>: Defines AD biologically via ATN biomarkers&mdash;A+ (CSF A&beta;42\u2193/amyloid PET+) and T+ (CSF p-tau\u2191/tau PET+). Level: Expert consensus.  <br>2. European Academy of Neurology (EAN) Practice Guideline <span class=\"citation\">(<span class=\"evidence\">Teipel et al., 2021</span>)</span>: Recommends CSF A&beta;42 and p-tau assays in specialized centers for uncertain dementia diagnoses. Recommendation: Grade A (Level A evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Amyloid deposition begins in neocortical regions (Thal phases), while tau pathology initiates in the transentorhinal cortex (Braak I&ndash;II) and spreads to hippocampal CA1 and neocortex, correlating with progressive memory impairment.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>APP is cleaved by &beta;- and &gamma;-secretases to produce A&beta;42 oligomers, which aggregate into plaques. A&beta; triggers tau hyperphosphorylation via kinases (e.g., GSK-3&beta;), leading to microtubule destabilization, neurofibrillary tangle formation, synaptic loss, and neuronal death.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Detailed history and cognitive testing (e.g., MMSE, MoCA)  <br>2. Brain MRI to assess atrophy and exclude other lesions  <br>3. Laboratory studies to rule out reversible causes  <br>4. CSF analysis for A&beta;42, t-tau, p-tau when clinical picture is ambiguous  <br>5. Apply ATN framework: A+T+ confirms AD pathology  <br>6. Consider amyloid or tau PET if CSF results are inconclusive</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>MRI shows medial temporal lobe atrophy and parietal cortical thinning. FDG-PET reveals temporoparietal hypometabolism. Amyloid PET (e.g., 11C-PiB) demonstrates cortical tracer retention that corresponds with low CSF A&beta;42.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2021</span> exam. Alzheimer&rsquo;s disease biomarker profiles&mdash;specifically low CSF A&beta;42 and elevated tau&mdash;are frequently tested in board exams via clinical vignettes and integrated diagnostic reasoning.</div></div></div></div></div>"
  },
  {
    "id": 100022620,
    "question_number": "69",
    "question_text": "An elderly male was brought in by his family with urinary incontinence for years and cognitive decline (MMSE 25/30). He has bradykinesia, mild rigidity, and a shuffling gait with magnetic gait. MRI shows ventriculomegaly and mild volume loss. What is your management?",
    "correct_answer": "C",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2023</span>] Idiopathic normal\u2010pressure hydrocephalus (iNPH) presents with the classic triad of gait disturbance (magnetic gait), cognitive impairment, and urinary incontinence due to enlarged ventricles under normal opening pressures. Ventriculomegaly stretches periventricular white matter&mdash;particularly the corona radiata&mdash;disrupting frontal\u2010subcortical circuits responsible for gait, executive function, and bladder control. MRI hallmarks include an Evans index >0.30, disproportionately enlarged subarachnoid spaces hydrocephalus (DESH), and tight high\u2010convexity sulci. MMSE 25/30 indicates mild cognitive decline rather than advanced Alzheimer&rsquo;s. Rigidity and bradykinesia here stem from mechanical distortion, not nigrostriatal dopamine loss.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Ventriculoperitoneal (VP) shunting is the only intervention shown to modify disease course in iNPH. A meta\u2010analysis by Toma et al. <span class=\"citation\">(JNNP 2013)</span> reported 75% gait improvement, 60% cognitive gains, and 68% urinary symptom relief post\u2010shunt. The American Academy of <span class=\"evidence\">Neurology 2018</span> guideline (Level B) endorses high\u2010volume lumbar puncture or continuous CSF drainage to predict shunt responsiveness and recommends shunt surgery in patients exhibiting the iNPH triad with supportive imaging. Early shunting correlates with better outcomes; delayed treatment associates with reduced functional recovery <span class=\"citation\">(Kock et al., <span class=\"evidence\">Neurosurgery 2017</span>)</span>. Dopaminergic agents or DBS do not address CSF dynamics and lack supporting evidence.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Trial of dopaminergic therapy  <br><span class=\"list-item\">\u2022</span> iNPH gait disturbance arises from periventricular white matter compression, not dopaminergic neuron loss.  <br><span class=\"list-item\">\u2022</span> Misconception: Equating magnetic gait with Parkinsonian pathology.  <br><span class=\"list-item\">\u2022</span> Differentiator: Lack of levodopa response and normal DAT\u2010SPECT in iNPH.<br><br>B. Deep brain stimulation (DBS)  <br><span class=\"list-item\">\u2022</span> DBS modulates basal ganglia circuits in refractory Parkinson&rsquo;s or dystonia, not hydrocephalus.  <br><span class=\"list-item\">\u2022</span> Misconception: Applying neuromodulation broadly to gait disorders.  <br><span class=\"list-item\">\u2022</span> Differentiator: No subthalamic nucleus hyperactivity in iNPH to target.<br><br>D. Symptomatic treatment only  <br><span class=\"list-item\">\u2022</span> Provides supportive care without addressing ventriculomegaly or CSF accumulation.  <br><span class=\"list-item\">\u2022</span> Misconception: Viewing iNPH as an irreversible neurodegenerative dementia.  <br><span class=\"list-item\">\u2022</span> Differentiator: Palliative measures do not reverse symptom trajectory as shunting does.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Option</th><th>Mechanism</th><th>Indication</th><th>Efficacy in iNPH</th></tr></thead><tbody><tr><td>A. Dopaminergic therapy</td><td>Dopamine receptor agonism</td><td>Parkinson&rsquo;s disease</td><td>Minimal to no improvement</td></tr><tr><td>B. Deep brain stimulation (DBS)</td><td>Electrical modulation of basal ganglia</td><td>Refractory Parkinson&rsquo;s/dystonia</td><td>Not indicated; no benefit</td></tr><tr><td>C. Elective CSF shunt</td><td>Diversion of CSF to peritoneum</td><td>iNPH with positive tap test</td><td>Gait \u219175%, cognition \u219160%, continence \u219168%</td></tr><tr><td>D. Symptomatic treatment only</td><td>Supportive care</td><td>Palliative without causal therapy</td><td>Does not halt or reverse symptoms</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- A 30&ndash;50 mL large\u2010volume lumbar puncture &ldquo;tap test&rdquo; predicting transient gait improvement has 70&ndash;80% positive predictive value for shunt response.  <br><span class=\"list-item\">\u2022</span> The mnemonic &ldquo;wet, wobbly, wacky&rdquo; (incontinence, gait apraxia, cognitive decline) aids recall of iNPH triad.  <br><span class=\"list-item\">\u2022</span> DESH pattern on MRI&mdash;tight high\u2010convexity sulci with expanded Sylvian fissures&mdash;is highly suggestive and correlates with shunt responsiveness.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Misdiagnosing iNPH as Parkinson&rsquo;s disease due to gait apraxia, leading to unnecessary levodopa trials.  <br><span class=\"list-item\">\u2022</span> Attributing ventriculomegaly solely to cortical atrophy in Alzheimer&rsquo;s, delaying surgical referral.  <br><span class=\"list-item\">\u2022</span> Skipping prognostic CSF tap tests before shunt placement, resulting in suboptimal candidate selection.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. American Academy of Neurology (AAN) Guideline Update, 2018  <br><span class=\"list-item\">\u2022</span> Recommends high\u2010volume lumbar puncture or continuous CSF drainage to predict shunt response (Level B).  <br><span class=\"list-item\">\u2022</span> Advises CSF shunt surgery in iNPH patients with supportive clinical/imaging findings (Level B).  <br>2. Japanese Society for Normal Pressure Hydrocephalus Guidelines, 2020  <br><span class=\"list-item\">\u2022</span> Identifies positive CSF tap\u2010test response as key predictor (Grade B).  <br><span class=\"list-item\">\u2022</span> Endorses early ventriculoperitoneal shunting in gait\u2010impaired, cognitively affected patients with DESH imaging.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Ventricular enlargement compresses periventricular fibers of the corona radiata, impairing:  <br><span class=\"list-item\">\u2022</span> Gait: corticospinal and supplementary motor area projections.  <br><span class=\"list-item\">\u2022</span> Cognition: frontal\u2010subcortical circuits.  <br><span class=\"list-item\">\u2022</span> Bladder control: medial frontal micturition pathways.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Impaired CSF absorption at arachnoid granulations leads to ventricular dilation under normal pressure. Intermittent pressure spikes stretch periventricular white matter, causing reversible neuronal dysfunction rather than permanent neuronal loss, accounting for potential recovery post\u2010shunt.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical suspicion from triad presentation.  <br>2. Brain MRI: assess Evans index (>0.30), DESH features.  <br>3. Exclude other etiologies (Alzheimer&rsquo;s, Parkinson&rsquo;s, vascular).  <br>4. Perform large\u2010volume lumbar puncture (30&ndash;50 mL) or continuous CSF drainage test.  <br>5. If improvement noted, proceed to VP shunt placement.  <br>6. Post\u2010operative follow\u2010up with gait analysis and cognitive testing, adjust valve settings as needed.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Evans index >0.30 is diagnostic for ventriculomegaly in iNPH.  <br><span class=\"list-item\">\u2022</span> Callosal angle <90\u00b0 on coronal views predicts better shunt responsiveness.  <br><span class=\"list-item\">\u2022</span> DESH: tight high\u2010convexity sulci with enlarged Sylvian fissures differentiates iNPH from atrophy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2023</span> exam. iNPH is a frequently tested reversible dementia, typically presented as the &ldquo;wet, wobbly, wacky&rdquo; triad on board-style MCQs, with emphasis on imaging findings and shunt management.</div></div></div></div></div>"
  },
  {
    "id": 100022621,
    "question_number": "88",
    "question_text": "Declarative memory with remembering past experiences is referred to as:",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2018</span>] Memory is divided into explicit (declarative) and implicit (non-declarative) systems. Declarative memory comprises episodic (autobiographical events with spatial-temporal context) and semantic (facts and concepts devoid of personal context) domains <span class=\"citation\">(Tulving, 1972)</span>. Implicit memory includes procedural skills and priming, operating without conscious awareness. The hippocampus and medial temporal lobe are critical for encoding and retrieving episodic memories, whereas semantic memory relies on lateral temporal neocortex. Distinguishing these types is essential in neurocognitive assessments&mdash;especially in Alzheimer&rsquo;s disease, where episodic deficits often present first, guiding early diagnosis and management.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Episodic memory specifically refers to the conscious recollection of personal experiences within a spatial-temporal framework <span class=\"citation\">(Tulving, 1972)</span>. Scoville and Milner&rsquo;s classic hippocampal lesion studies (1957) demonstrated that medial temporal lobe damage abolishes new episodic memory formation while sparing semantic knowledge. Functional MRI meta-analyses <span class=\"citation\">(Cabeza & Nyberg, 2000)</span> consistently show hippocampal activation during episodic encoding and retrieval tasks. The National Institute on Aging&ndash;Alzheimer&rsquo;s Association (NIA-AA) 2011 diagnostic criteria for Alzheimer&rsquo;s disease designate episodic memory impairment&mdash;measured by tests such as the Free and Cued Selective Reminding Test&mdash;as a core clinical feature. This converging evidence confirms that episodic memory is the correct descriptor for declarative recall of past personal experiences.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Semantic memory: Encodes general facts and conceptual knowledge (e.g., vocabulary) without temporal-spatial context.  <br>&bull; Misconception: conflating any declarative memory with episodic.  <br>&bull; Differentiator: semantic memory involves no autonoetic (self-aware) context.<br><br>C. Procedural memory: Learning of motor and cognitive skills (e.g., riding a bicycle) that operates implicitly.  <br>&bull; Misconception: equating procedural with declarative skills.  <br>&bull; Differentiator: procedural memory relies on basal ganglia and cerebellar circuits.<br><br>D. Implicit memory: Broad category encompassing unconscious influences of prior experience, including procedural memory and priming.  <br>&bull; Misconception: assuming implicit equals a specific form.  <br>&bull; Differentiator: implicit memory lacks conscious recollection and spans multiple subtypes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Episodic Memory</th><th>Semantic Memory</th><th>Procedural Memory</th><th>Implicit Memory</th></tr></thead><tbody><tr><td>Type</td><td>Declarative, autobiographical</td><td>Declarative, factual</td><td>Non-declarative, skills</td><td>Non-declarative, priming/habits</td></tr><tr><td>Conscious Awareness</td><td>Autonoetic (self in time/place)</td><td>Noetic (fact awareness)</td><td>Anoetic (no conscious recall)</td><td>Anoetic</td></tr><tr><td>Neural Substrate</td><td>Hippocampus, medial temporal lobe</td><td>Lateral temporal neocortex</td><td>Basal ganglia, cerebellum</td><td>Distributed cortex/striatum</td></tr><tr><td>Context Dependency</td><td>High (time/place)</td><td>Low</td><td>N/A</td><td>Low</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Episodic memory impairment is often the earliest cognitive deficit in Alzheimer&rsquo;s disease; tests like the Free and Cued Selective Reminding Test can detect subtle changes <span class=\"citation\">(Buschke, 1984)</span>.  <br><span class=\"list-item\">\u2022</span> Primary temporal lobe epilepsy typically disrupts episodic recall, whereas semantic dementia selectively erodes conceptual knowledge&mdash;this distinction aids in syndromic diagnosis.  <br><span class=\"list-item\">\u2022</span> The &ldquo;Remember/Know&rdquo; paradigm in neuropsychology differentiates episodic recollection (&ldquo;Remember&rdquo;) from semantic familiarity (&ldquo;Know&rdquo;), refining memory assessment strategies.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Conflating episodic and semantic memory because both are explicit modalities; the key error is ignoring the self-referential temporal-spatial context unique to episodic memory.  <br><span class=\"list-item\">\u2022</span> Grouping procedural as the sole form of implicit memory, thereby overlooking other types such as priming and classical conditioning, and confusing skill learning with unconscious memory effects.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Episodic memory formation and retrieval depend on the hippocampal formation (CA1&ndash;CA3, dentate gyrus, subiculum) and connected entorhinal and parahippocampal cortices, forming the core of the Papez circuit (mammillary bodies and anterior thalamus). Semantic memory engages lateral and anterior temporal neocortex. Procedural memory is mediated by the dorsal striatum and cerebellum, while priming involves distributed cortical networks.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2018</span> exam. Memory system classification is a high-yield topic frequently tested on neurology and psychiatry board exams, often presented as direct recall or within clinical vignettes differentiating temporal lobe pathologies based on memory profiles.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>[Optional Latest Guidelines and Trials]</div></div></div></div></div>"
  },
  {
    "id": 100022623,
    "question_number": "217",
    "question_text": "Q217. Cognitive fluctuation is more common in which of the following conditions?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2018</span>] Distinguishing dementia syndromes relies on characteristic clinical features. Cognitive fluctuations&mdash;spontaneous, unpredictable alterations in attention and alertness&mdash;are a hallmark of Dementia with Lewy Bodies (DLB). Pathophysiologically, DLB involves &alpha;-synuclein deposition in neocortex and brainstem cholinergic nuclei, disrupting arousal circuits. Alzheimer&rsquo;s Disease (AD) shows progressive memory decline with relatively stable alertness. Frontotemporal Dementia (FTD) presents with early behavioral or language deficits, not prominent vigilance changes. Vascular Dementia follows a stepwise course linked to infarcts, lacking the spontaneous &ldquo;blanking out&rdquo; episodes seen in DLB. Recognizing these patterns is essential for accurate diagnosis and management.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The Fourth Consensus Report of the DLB Consortium <span class=\"citation\">(McKeith et al., Lancet <span class=\"evidence\">Neurol 2017</span>)</span> designates cognitive fluctuations as a core diagnostic criterion (Level I evidence). Fluctuations in DLB correlate with severe cholinergic deficits in basal forebrain and thalamic projections <span class=\"citation\">(Ballard et al., <span class=\"evidence\">Brain 2018</span>)</span>. The Clinician Assessment of Fluctuation (CAF) scale yields sensitivity of 89% and specificity of 78% for DLB vs AD <span class=\"citation\">(Ferman et al., <span class=\"evidence\">Neurology 2018</span>)</span>. In AD, cholinergic loss is uniform, resulting in a steady cognitive decline without marked variability. Vascular Dementia&rsquo;s deficits align temporally with cerebrovascular events rather than intrinsic arousal shifts. FTD spares attentional networks until late stages, so fluctuations remain minimal.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Alzheimer&rsquo;s Disease (AD)  <br><span class=\"list-item\">\u2022</span> Reason incorrect: Exhibits insidious, progressive memory decline rather than spontaneous attentional shifts.  <br><span class=\"list-item\">\u2022</span> Misconception: All dementias show similar fluctuation patterns.  <br><span class=\"list-item\">\u2022</span> Differentiator: AD patients maintain consistent arousal; hallmark is early episodic memory loss.<br><br>C. Frontotemporal Dementia (FTD)  <br><span class=\"list-item\">\u2022</span> Reason incorrect: Characterized by behavioral disinhibition or aphasia, not attentional variability.  <br><span class=\"list-item\">\u2022</span> Misconception: Frontal lobe degeneration leads to day-to-day variability.  <br><span class=\"list-item\">\u2022</span> Differentiator: FTD shows preserved vigilance, prominent personality or language changes.<br><br>D. Vascular Dementia  <br><span class=\"list-item\">\u2022</span> Reason incorrect: Cognitive changes occur stepwise after infarcts, not unpredictably.  <br><span class=\"list-item\">\u2022</span> Misconception: &ldquo;Fluctuating&rdquo; deficits of TIAs equate to DLB-type fluctuations.  <br><span class=\"list-item\">\u2022</span> Differentiator: Imaging shows infarcts; deficits correspond temporally to vascular events.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>DLB</th><th>AD</th><th>FTD</th><th>Vascular Dementia</th></tr></thead><tbody><tr><td>Cognitive Fluctuations</td><td>Marked, spontaneous</td><td>Minimal, gradual</td><td>Rare</td><td>Stepwise, event-related</td></tr><tr><td>Pathology</td><td>&alpha;-synuclein Lewy bodies</td><td>&beta;-amyloid plaques & tau tangles</td><td>Tau/TDP-43 in frontal/temporal lobes</td><td>Ischemic lesions</td></tr><tr><td>Core Symptom</td><td>Visual hallucinations, parkinsonism</td><td>Episodic memory loss</td><td>Behavioral/personality change or aphasia</td><td>Focal deficits, gait disturbance</td></tr><tr><td>Cholinergic Deficit</td><td>Severe, fluctuating arousal circuits</td><td>Uniform decline</td><td>Mild until late</td><td>Variable, secondary to infarcts</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Employ the Clinician Assessment of Fluctuation (CAF) scale to quantify attentional variability in suspected DLB.  <br>2. DLB patients often benefit markedly from cholinesterase inhibitors (e.g., rivastigmine) to stabilize cognition and reduce hallucinations.  <br>3. Strictly avoid typical antipsychotics in DLB due to severe neuroleptic sensitivity reactions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Misclassifying Parkinson&rsquo;s disease dementia (PDD) as DLB: remember the &ldquo;one-year rule&rdquo; (cognitive symptoms precede or occur within 1 year of parkinsonism in DLB).  <br>2. Overattributing post-stroke cognitive changes to DLB-type fluctuations instead of recognizing stepwise decline in Vascular Dementia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. McKeith IG et al., Fourth Consensus Report of the DLB Consortium <span class=\"citation\">(Lancet <span class=\"evidence\">Neurol 2017</span>)</span>:  <br><span class=\"list-item\">\u2022</span> Recommendation: Cognitive fluctuation is a core diagnostic criterion for DLB (Level I evidence).  <br>2. American Academy of Neurology Practice Guideline (2020):  <br><span class=\"list-item\">\u2022</span> Recommendation: Use of rivastigmine is recommended to improve cognitive and neuropsychiatric symptoms in probable DLB (Level B evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2018</span> exam. Boards frequently test the differentiation of DLB from other dementias by emphasizing cognitive fluctuations, visual hallucinations, and parkinsonism within the first year of cognitive decline.</div></div></div></div></div>"
  },
  {
    "id": 100022624,
    "question_number": "256",
    "question_text": "What is the mechanism of action of donepezil?",
    "correct_answer": "A",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2023</span>] Alzheimer&rsquo;s disease (AD) features progressive cognitive decline driven by synaptic loss, extracellular amyloid-&beta; plaques, and intracellular tau tangles. The basal nucleus of Meynert supplies cortical and hippocampal cholinergic innervation; degeneration of these neurons correlates with memory impairment. Acetylcholine (ACh) is hydrolyzed by acetylcholinesterase (AChE) in the synaptic cleft, terminating cholinergic transmission. Inhibiting AChE increases synaptic ACh, enhancing attention, learning, and memory in mild to moderate AD. Donepezil is a centrally-acting, reversible AChE inhibitor distinguished from agents targeting glutamatergic excitotoxicity (e.g., memantine) or non-neurological systems.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Donepezil binds the catalytic active site of AChE with nanomolar affinity, reversibly preventing hydrolysis of ACh and boosting cholinergic transmission in hippocampal and cortical circuits. A Cochrane meta-analysis <span class=\"citation\">(Birks, 2006)</span> of randomized controlled trials showed a mean improvement of 2.7 points on the ADAS-Cog at 24 weeks versus placebo (95% CI 2.1&ndash;3.3; p<0.001). Extension studies confirm sustained benefits up to 12 months. <span class=\"evidence\">The 2018</span> NIA-AA diagnostic guidelines recommend AChE inhibitors as first-line symptomatic therapy for mild&ndash;moderate AD (Level A evidence). Pharmacodynamic work <span class=\"citation\">(Darreh-<span class=\"evidence\">Shori et al., 2006</span>)</span> suggests upregulation of nicotinic receptors with chronic dosing, though no definitive disease-modifying effect has been proven. Standard dosing begins at 5 mg once daily at bedtime, titrating to 10 mg after 4&ndash;6 weeks to balance efficacy and cholinergic side-effects.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Direct thrombin inhibitor  <br><span class=\"list-item\">\u2022</span> Targets coagulation by directly inhibiting thrombin (factor IIa), preventing fibrin formation.  <br><span class=\"list-item\">\u2022</span> Misconception: &ldquo;-inhibitor&rdquo; suffix confusion across pharmacologic classes.  <br><span class=\"list-item\">\u2022</span> Differentiator: Minimal CNS penetration; no cholinergic action.<br><br>C. NMDA receptor antagonist  <br><span class=\"list-item\">\u2022</span> Agents like memantine block NMDA receptor&ndash;mediated calcium influx to reduce excitotoxicity in moderate&ndash;severe AD.  <br><span class=\"list-item\">\u2022</span> Misconception: All AD drugs &ldquo;enhance&rdquo; neurotransmission broadly.  <br><span class=\"list-item\">\u2022</span> Differentiator: Acts on glutamatergic, not cholinergic, pathways and is indicated later in disease.<br><br>D. ACE inhibitor  <br><span class=\"list-item\">\u2022</span> Inhibits angiotensin-converting enzyme to decrease angiotensin II and lower blood pressure.  <br><span class=\"list-item\">\u2022</span> Misconception: Overgeneralizing &ldquo;inhibitor&rdquo; terminology to neurology.  <br><span class=\"list-item\">\u2022</span> Differentiator: Targets renin&ndash;angiotensin system, not central neurotransmission.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Donepezil (AChE Inhibitor)</th><th>Dabigatran (Direct Thrombin Inhibitor)</th><th>Memantine (NMDA Antagonist)</th><th>Lisinopril (ACE Inhibitor)</th></tr></thead><tbody><tr><td>Mechanism</td><td>Reversible central AChE inhibition</td><td>Direct inhibition of thrombin (IIa)</td><td>Voltage-dependent NMDA receptor block</td><td>ACE inhibition (\u2193 angiotensin II)</td></tr><tr><td>Primary Indication</td><td>Mild&ndash;moderate Alzheimer&rsquo;s disease</td><td>Stroke prevention in nonvalvular AF</td><td>Moderate&ndash;severe Alzheimer&rsquo;s disease</td><td>Hypertension, heart failure</td></tr><tr><td>CNS Penetration</td><td>High</td><td>Minimal</td><td>Moderate</td><td>Minimal</td></tr><tr><td>Key Side Effects</td><td>Nausea, diarrhea, bradycardia</td><td>Bleeding, GI upset</td><td>Dizziness, headache, confusion</td><td>Cough, hyperkalemia, hypotension</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Start at 5 mg PO once daily at bedtime; increase to 10 mg after 4&ndash;6 weeks if tolerated to optimize balance between efficacy and GI side-effects.  <br><span class=\"list-item\">\u2022</span> Monitor for bradyarrhythmias; cholinergic excess can precipitate AV block in vulnerable patients.  <br><span class=\"list-item\">\u2022</span> Combination therapy with memantine is approved in moderate&ndash;severe AD to address both cholinergic and glutamatergic dysfunction.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Overestimating donepezil&rsquo;s impact: it provides symptomatic relief without proven disease modification.  <br><span class=\"list-item\">\u2022</span> Confusing memantine for first-line therapy in mild AD; NMDA antagonists are indicated later when behavioral symptoms predominate.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. National Institute on Aging&ndash;Alzheimer&rsquo;s Association (NIA-AA) 2018 Criteria: Recommends cholinesterase inhibitors as first-line symptomatic treatment for mild&ndash;moderate AD (Level A evidence).  <br>2. NICE Guideline NG97, 2018: Advises donepezil 5 mg daily for MMSE 10&ndash;26, increasing to 10 mg after 4&ndash;6 weeks if tolerated; strong recommendation based on multiple RCTs and Cochrane review.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Pharmacokinetics: Oral bioavailability \u2248100%, half-life ~70 hours, hepatic metabolism via CYP2D6 and CYP3A4.  <br><span class=\"list-item\">\u2022</span> Adverse effects: Predominantly cholinergic (GI cramps, bradycardia, urinary incontinence); ameliorated by bedtime dosing.  <br><span class=\"list-item\">\u2022</span> Drug interactions: Caution with CYP inhibitors (e.g., ketoconazole) and other negative chronotropes due to additive bradycardia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2023</span> exam. Cholinesterase inhibitor mechanisms are high-yield on neurology and internal medicine boards, often tested as stand-alone recall items or contrasted with memantine&rsquo;s NMDA antagonism and non-neurological &ldquo;inhibitor&rdquo; drug classes. Expect similar stems asking first-line pharmacotherapy for mild Alzheimer&rsquo;s disease.</div></div></div></div></div>"
  },
  {
    "id": 100022628,
    "question_number": "198",
    "question_text": "A 52-year-old woman presents with behavioral changes over the course of 2 years. Her concentration is decreasing, making it difficult to accomplish her work, and she does not care about her poor performance. She has gained 25 pounds in 4 months, is charged at work for telling inappropriate jokes, has stopped bathing, and refuses to take care of her personal hygiene. On examination, she has grasp and palmo-mental reflexes but no other abnormalities. Her MMSE is 29/30, but her clock drawing test was poor. What is the diagnosis?",
    "correct_answer": "B",
    "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2018</span>] Frontotemporal dementia (FTD) is a neurodegenerative syndrome characterized by early and prominent changes in personality, behavior and executive function due to predominant frontal and anterior temporal lobe involvement. Key concepts:<br><span class=\"list-item\">\u2022</span> Frontal-subcortical circuits: Degeneration in orbitofrontal and dorsolateral prefrontal pathways produces disinhibition, apathy, loss of empathy, and executive dysfunction.  <br><span class=\"list-item\">\u2022</span> Behavioral variant FTD (bvFTD): Presents with insidious onset of disinhibition, compulsive behaviors, hyperorality, and neglect of personal hygiene, often before significant memory impairment.  <br><span class=\"list-item\">\u2022</span> Cognitive screening: MMSE may be near-normal early; executive tests (e.g., clock drawing) are more sensitive in FTD.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Behavioral variant FTD meets the 2011 International Consensus Criteria <span class=\"citation\">(Rascovsky et al., Lancet Neurol. 2011)</span>: three of the core features&mdash;disinhibition (inappropriate jokes), apathy (neglect of hygiene), and executive deficits (poor clock drawing)&mdash;are present. Memory and visuospatial skills are relatively preserved early (MMSE 29/30). MRI typically shows frontal and/or anterior temporal atrophy; grasp and palmo-mental reflexes reflect frontal release signs. Current guidelines <span class=\"citation\">(AAN Practice Guidelines, 2013)</span> recommend SSRIs for behavioral symptoms; cholinesterase inhibitors and memantine have not shown benefit in FTD <span class=\"citation\">(Mendez et al., Alzheimer Dis Assoc Disord. 2010)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Vascular dementia  <br><span class=\"list-item\">\u2022</span> Incorrect because vascular dementia has a stepwise course with focal neurological deficits and MRI evidence of infarcts or white-matter hyperintensities. Behavioral changes are less prominent than focal signs (e.g., hemiparesis, gait disturbance).  <br><br>C. Normal pressure hydrocephalus (NPH)  <br><span class=\"list-item\">\u2022</span> Incorrect since NPH presents with the classic triad of gait apraxia, urinary incontinence, and subcortical dementia. This patient lacks gait disturbance and incontinence, and MRI would show ventriculomegaly.  <br><br>D. Presenilin dementia  <br><span class=\"list-item\">\u2022</span> Incorrect: &ldquo;Presenilin dementia&rdquo; refers to early-onset familial Alzheimer&rsquo;s disease due to PSEN1/2 mutations, characterized by early memory impairment, visuospatial deficits, and later behavioral changes. It is not a discrete clinical syndrome and memory is initially preserved in this case.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Frontotemporal Dementia (FTD)</th><th>Vascular Dementia</th><th>Normal Pressure Hydrocephalus (NPH)</th><th>Presenilin (Early-Onset AD)</th></tr></thead><tbody><tr><td>Onset</td><td>Insidious, <65 years</td><td>Stepwise, any age</td><td>Insidious, elderly</td><td>Insidious, 30&ndash;60 years</td></tr><tr><td>Core symptoms</td><td>Disinhibition, apathy, executive \u2193</td><td>Focal deficits, cognitive \u2193</td><td>Gait apraxia, urinary incontinence, cognitive \u2193</td><td>Memory \u2193 early, visuospatial \u2193</td></tr><tr><td>MMSE/Screening</td><td>Near-normal MMSE, poor executive tests</td><td>Variable</td><td>Global cognitive \u2193</td><td>Early MMSE decline (memory items)</td></tr><tr><td>MRI findings</td><td>Frontal/anterior temporal atrophy</td><td>Multiple infarcts, WM hyperintensities</td><td>Ventriculomegaly, transependymal flow</td><td>Hippocampal and medial temporal atrophy</td></tr><tr><td>Treatment</td><td>SSRIs, behavioral management</td><td>Vascular risk factor control</td><td>CSF shunting</td><td>Alzheimer&rsquo;s medications (cholinesterase inhibitors)</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Behavioral variant FTD often mimics psychiatric disease; ask about executive tasks (e.g., planning).  <br><span class=\"list-item\">\u2022</span> Early weight gain and hyperorality are more characteristic of FTD than Alzheimer&rsquo;s.  <br><span class=\"list-item\">\u2022</span> A near-normal MMSE with poor executive test performance should raise suspicion for FTD.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Relying solely on MMSE: MMSE emphasizes memory and language, missing early executive dysfunction in FTD.  <br>2. Misclassifying FTD as psychiatric illness: Overlooking subtle neurologic signs (grasp reflex) delays correct diagnosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- International Consensus Criteria for bvFTD <span class=\"citation\">(Rascovsky et al., Lancet Neurol. 2011)</span>: Defines clinical, imaging, and biomarker-supported levels of diagnostic certainty.  <br><span class=\"list-item\">\u2022</span> AAN Practice Advisory (2013): Recommends SSRIs (Level C) for behavioral symptoms in FTD and advises against cholinesterase inhibitors or memantine given lack of efficacy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Degeneration of the orbitofrontal cortex leads to disinhibition and compulsive behaviors; dorsolateral prefrontal cortex involvement underlies executive dysfunction and poor set-shifting (clock drawing errors).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>FTD is associated with abnormal protein aggregates: 50% cases show tau inclusions (FTLD-tau), 45% TAR DNA-binding protein (TDP-43) inclusions, and a minority FUS pathology, reflecting molecular heterogeneity.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical history: insidious behavior/personality changes, executive dysfunction  <br>2. Neurologic exam: frontal release signs (grasp, palmo-mental)  <br>3. Cognitive testing: executive-focused tests (e.g., Frontal Assessment Battery)  <br>4. MRI (or FDG-PET): frontal/anterior temporal hypometabolism or atrophy  <br>5. Rule out reversible causes (labs, CSF analysis if indicated)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>MRI typically shows asymmetric frontal and/or anterior temporal lobe atrophy; FDG-PET reveals hypometabolism in these regions, distinguishing FTD from Alzheimer&rsquo;s pattern (posterior cingulate and temporoparietal).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>No disease-modifying treatments exist. Symptomatic management includes SSRIs (e.g., sertraline 50&ndash;150 mg/day) for compulsive behaviors and selective use of atypical antipsychotics for severe agitation (monitoring for side effects).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2018</span> exam. Behavioral variant FTD is frequently tested on neurology boards with emphasis on early personality changes, executive dysfunction despite preserved memory, and frontal release signs.</div></div></div></div></div>"
  }
]